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ABSTRACT 
 
MOLECULAR DYNAMICS SIMULATION STUDIES OF DNA AND PROTEINS:  
FORCE FIELD PARAMETER DEVELOPMENT FOR SMALL LIGANDS AND 
CONVERGENCE ANALYSIS FOR SIMULATIONS OF BIOMOLECULES 
 
 
By 
Anne Elizabeth Loccisano 
December 2007 
 
 
Dissertation Supervised by: Dr. Jeffrey D. Evanseck 
In the first part of this dissertation, CHARMM force field parameters for DNA 
minor groove-binding polyamides were developed.  The parameterization involved the 
subdivision of the polyamides into model compounds, which were calibrated against 
MP2/6-31G(d) data.  To test the new parameters, fourteen 10 ns molecular dynamics 
crystal simulations have been carried out on a DNA/polyamide complex at low (113K) 
and high (300K) temperatures.  Of the 18 helical parameters examined, only one 
(stagger) is found to be statistically significant from the crystal structure with a t-test at 
the 95% confidence level.  For the high temperature, stagger is non-significant at the 97% 
confidence level, which underscores the importance of running multiple trajectories.  It is 
observed that when the simulations are run at 300K, the DNA fragment begins to distort; 
however, better sampling is achieved.  Competition between water and polyamides for 
hydrogen bonding to DNA is found to explain weak or unpredictable binding.    
 v
In the second part, force field parameters for retinoids were developed.  The 
retinoids were divided into model compounds and calibrated against MP2/6-31G(d) data.  
To test the parameters, five molecular dynamics crystal simulations of reported x-ray 
structures of protein/retinoid complexes were performed.  The structural and geometric 
analysis of these simulations compares well to experiment, and some dynamics that could 
be important to ligand binding were discovered.  The new parameters can now be used in 
simulations of retinoid-binding proteins to better understand these systems and in drug 
design to make new retinoids with therapeutic and anticancer potential.   
The last part explores the convergence of structural parameters in biomolecular 
systems.  A simple statistical test was applied to the different parameters from a few long 
and many short simulations to observe which strategy is best.  For the protein, both the 
long and short simulations gave similar results with respect to convergence.  For the 
DNA, it was found that fraying effects penetrate four base pairs in from the ends of the 
helix. Structural parameters converge more quickly for the middle four bases than for all 
bases, and the long simulations yielded better results with respect to convergence than the 
short simulations. 
 vi
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Chapter 1  
 
 
Introduction 
 
1.1 Historical Perspective on Simulation 
 
 The first molecular dynamics simulation of a biomolecular system was 
published in 1977.1  The simulation was of bovine pancreatic trypsin inhibitor 
(BPTI), and although the system was small (58 residues; 885 atoms), the simulation 
was performed in vacuum, the force field was primitive, and the simulation only 
lasted 9.2 ps, it showed that proteins exhibit substantial fluctuations on the 
picosecond timescale.1  The first molecular dynamics simulations of DNA followed 
in 1983 and were performed on a 12- and 24-base pair fragment in vacuum and 
without accounting for electrostatic forces.2 Since then, a wide range of protein and 
nucleic acid motions and structure features have been discovered and explored 
through molecular dynamics simulations.3-11 Advances in computer hardware, 
software, force fields, improvement in simulation methodology, and also the 
tremendous progress in experimental structure determination have allowed the field 
of MD simulation to grow at a rapid rate.  Since the first BPTI simulation in 1977 in 
vacuum on a short timescale, these advances now enable large (104-106 atoms) and 
complicated systems3, 12 (such as a membrane-bound protein with explicit lipid and 
 2
water molecules) to be simulated on longer timescales (hundreds of nanoseconds to 
microseconds) with a more realistic representation of the solvent and surroundings.   
 Molecular dynamics simulations can provide the methodology to model, in 
ultimate detail, the internal atomic motions and fluctuations of a biomolecular system 
as a function of time.  MD simulations allow for observation of phenomena and 
properties of systems that cannot be observed with experimental techniques.  
Although MD simulations have been widely used to give insight into the underlying 
natural dynamics, observe functionally important motions, make predictions, and 
facilitate experimental structure determination, the dynamics of many biomolecular 
systems are poorly or not understood.12-14 In addition, in order to compute and extract 
accurate information from the modeled system, the models used must be as realistic 
as possible (e.g., the force field used must be parameterized for the molecules of 
interest).  Also, the various properties of interest that are calculated need to have 
reached satisfactory levels of convergence; the properties must be stabilized if 
analysis is to be performed on them.15, 16   
1.2 Force Field Development 
 
In molecular dynamics and molecular mechanics, the intra- and intermolecular 
forces between the atoms are described by an empirical force field (the CHARMM 
force field, which is used in this dissertation, is discussed in Chapter 2).  The 
mathematical terms in empirical force fields that are used to describe the intra- and 
intermolecular forces in biomolecules are relatively simple, and force fields assume 
that an atom is the smallest particle in the system of interest, rather than considering 
nuclei and electrons explicitly as in quantum mechanics.3, 17  Both of these factors 
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allow for the computational demands of biomolecular simulation studies to be 
fulfilled.  However, the force field parameters must be developed correctly in order to 
obtain accurate and reliable results and predictions.   
The quality and accuracy obtained from a calculation performed with a 
particular force field is obviously based on the methods and target data used to 
optimize the parameters.  Several considerations should be taken into account when 
parameterizing a force field for a new class of compounds.18 The first is the issue of 
transferability; this refers to the ability to take parameters optimized for a specific set 
of target data and then apply those parameters to molecules that are not included in 
the target data.  In a transferable force field, the dihedral parameters that are 
optimized for rotation about the C-C bond of ethane could then be used for butane.  In 
a nontransferable force field, the dihedrals present in butane but not in ethane (C-C-
C-C) must be optimized specifically by using target data for butane.  However, how 
transferable parameters are depends on the similarity of the molecules, and what 
parameters are actually transferable and which are not is not well-defined.18  Any new 
compounds to be used with the force field must be tested in order to ensure that they 
are treated correctly and the required accuracy is obtained.  Generally, the extent of 
transferability is considered to be minimal, and new parameters must be generated for 
each new class of molecules to be used with the force field.18  
Since new parameters must usually be generated and optimized, a second 
consideration is the selection of target data that is to be used to optimize the new 
parameters.  The form of the CHARMM force field is discussed in Chapter 2; 
therefore, the terms will not be described and shown here.  The parameters needed to 
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extend the force field for a new class of compounds will fit into the different terms of 
the force field, and these are generally optimized using different sources.  The 
internal parameters such as equilibrium bond lengths, equilibrium angle values, and 
dihedral multiplicity are often optimized to reproduce gas-phase geometric data 
obtained from quantum mechanical calculations, electron diffraction, or microwave 
experiments.  The internal force constants, such as the bond and angle force 
constants, are usually optimized using vibrational spectra, which contain individual 
frequencies and their assignments.  The external parameter optimization is usually 
more difficult than the internal parameter optimization; the amount of target data 
relative to the amount of needed parameters is decreased compared to the internal 
parameters.18  Upon the development of the OPLS force field, optimization of van der 
Waals terms improved.19 Heats of vaporization of pure solvents were computed 
through Monte Carlo simulations, and this data was then used to refine the van der 
Waals parameters.19 This same approach has also been applied to the CHARMM and 
AMBER force fields.20, 21 Van der Waals parameters have also been optimized using 
the calculated heats of sublimation of crystals.22  The approaches for optimization of 
electrostatic parameters are mostly dominated by the reproduction of target data from 
QM calculations.18  One method is based on optimizing partial atomic charges to 
reproduce the electrostatic potential (ESP) around a molecule calculated with QM 
methods.  A popular variation of this method is called the RESP method,23 where the 
charges on atoms that are minimally exposed to solvent are restrained. The goal of 
both methods is to produce the partial atomic charges that reproduce the electrostatic 
field created by the molecule.24   
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When parameterizing the force field for a new set of compounds, it is 
important to remember that the force field is “empirical”.  The choice of method and 
target data and even the form of the potential energy function is the decision of the 
developer of the force field.18  Even if the same form of the potential energy function 
is used, if developers have used different target data, the quality and results of the 
force field can differ.  A great amount of correlation exists between all the different, 
individual parameters of the force field, and therefore, a number of different 
combinations of parameters can reproduce a given set of target data.18  Therefore, the 
optimization process is extremely important to the quality and results of the force 
field.  Automatic parameterization procedures have been attempted;25-27 however, a 
significant amount of manual work is generally required.18 
A third consideration is the procedure used in which to optimize the force 
field.  When a force field is selected for use, the information that one wishes to 
extract must be considered.  For example, if one is interested in examining the atomic 
details of water interactions with protein residues, the proper force field to use would 
be an all-atom force field (as opposed to an extended atom force field where 
hydrogens are not explicitly represented but treated as part of the atom to which they 
are bound) designed specifically for biomolecules that allows for explicit 
representation of water molecules.  In this case, the AMBER or CHARMM force 
fields would be a suitable choice; however, they may not be of sufficient accuracy for 
a particular study.18  If the study mentioned above also involved different but 
structurally similar ligands being bound to the protein, the AMBER or CHARMM 
force field must be extended to treat the new class of compounds.  The optimization 
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method used must be consistent with the method used for the original development of 
the force field.  Chapters 3 and 4 of this dissertation contain the details of how the 
CHARMM force field was parameterized and tested for two new sets of compounds, 
polyamides and retinoids.   
1.3 Project Overviews 
 
This dissertation focuses on the three issues mentioned above: force field 
parameterization, gaining insight into dynamics of the systems using the new force 
field parameters, and analyzing biomolecular systems for convergence.  The first part 
of the force field parameterization focuses on the polyamides, which are a class of 
DNA minor groove binders.28  The molecules have potential as DNA sequence-
specific recognition agents; however, why some show poor binding affinity for their 
target sites and why some sites are more difficult than others to target is not well 
understood.  Force field parameters for the polyamides were created, and through 
testing the parameters with molecular dynamics simulations in the crystal 
environment, a new conceptual idea as to why polyamides are weak binders emerged 
as well as an interesting phenomenon concerning the sampling of DNA helical 
parameters.  The second part of the force field parameterization focuses on retinoids.  
Attempts to model π-conjugated systems have been difficult to implement29-31 or the 
compounds have not been explicitly parameterized.26, 32   New parameters were made 
for conjugated systems with a focus on retinoids.  Retinoids are an attractive class of 
compounds in anticancer therapy now; however, toxicity limits their use.33, 34  
Through testing the parameters with crystal simulations, interesting details were 
uncovered with respect to ligand motions that could be important in ligand binding 
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and dynamics.  These motions enable better understanding of how the ligand behaves 
in the binding site of the protein, and this can aid in the future design of less toxic 
retinoids for use as anticancer agents.  The last part of this dissertation focuses on the 
convergence of structural/geometric parameters in two biomolecular systems, DNA 
and a small protein.  Multiple trajectories are commonly run in order to improve 
sampling of conformational space,35-37 and this approach was used in this study.  A 
set of a few long simulations and a set of many short simulations were run, the 
parameters of interest were measured, and a statistical test was applied to the different 
parameters from the sets of simulations to observe which simulation strategy works 
best.   
1.4 DNA Minor Groove-Binding Polyamides 
  
The sequence specific recognition of DNA by small, organic molecules is an 
area of intense research due to the ability of these agents to interfere with critical 
biochemical processes involving DNA.  Pioneering work by Dervan,38-57 
Dickerson,58-63 and Lown64-70 on analogues of the natural products distamycin and 
netropsin (which are made up of three and two N-methylpyrrole (Py) rings, 
respectively) has led to the development of compounds that are capable of 
recognizing any base pair combination found in DNA.  These compounds, termed 
polyamides or lexitropsins, have functional groups that are complementary to the 
distinct pattern and position of hydrogen bond donors and acceptors found in the 
minor groove of DNA.28, 39, 41, 45, 71-73  The polyamides are made up of five-membered 
(and recently, six-membered) heterocyclic amino acids linked by amide bonds that 
can be combined as antiparallel ring pairs in the minor groove of DNA to recognize 
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predetermined sequences of DNA, with affinities and specificities comparable to 
those of DNA-binding proteins (i.e., Kd < 1nM).41  
The heterocycle pairs used in polyamides are pieced together with the 
intervening amide bonds in order to recognize a predetermined DNA sequence based 
on hydrogen bond donors and acceptors, molecular shape, and electrostatic potential 
of the minor groove. The Dervan group has established a code describing this 
relationship.40, 74-77  It was first discovered that a Py/Py pair could distinguish an AT 
or TA pair from CG or GC pairs (AT/TA pairs are fairly symmetrical compared to the 
unsymmetrical nature of GC/CG pairs due to the exocyclic NH2 group of G); shortly 
after, it was found that an imidazole (Im)/Py pair could distinguish GC from the other 
three base pairs (due to a linear hydrogen bond between the Im nitrogen and the 
exocyclic NH2 group of G).  It took more time to distinguish AT from TA; it was 
finally discovered that the Py/hydroxypyrrole (Hp) pair could distinguish AT from 
TA, due to the hydrogen bond formed between the hydroxyl group and the O2 of 
thymine.  Thus, the basic Dervan pairing code is as follows: Im/Py pair binds GC, a 
Py/Im pair binds CG, a Py/Py pair binds AT or TA, and an Hp/Py pair and a Py/Hp 
pair distinguish TA and AT, respectively.40, 41, 74 All polyamides contain a positively 
charged group at the tail end (dimethylaminopropyamine (Dp)), which interacts with 
the negatively charged phosphate backbone and increases affinity.  
Polyamides can bind to DNA in either 1:1 or 2:1 stoichiometries; however, 
less is understood about polyamide recognition in the 1:1 mode.78  It is known that in 
the 1:1 binding mode, polyamides can form bifurcated hydrogen bonds between bases 
on either one of the two strands in DNA.  Also, because DNA sequences containing a 
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run of purine bases has a particularly narrow minor groove79 and cannot 
accommodate two polyamides in the groove, the 1:1 motif shows promise in targeting 
these types of sequences.78, 80 
In the 2:1 binding mode, which is the most common binding mode, the 
heterocycles of two polyamide molecules are paired and stack on top of each other 
when bound to the minor groove of DNA.  In this mode, one polyamide is capable of 
reading one strand of DNA, while the other polyamide recognizes the second strand.  
In addition to forming hydrogen bonds to the DNA, the interaction is stabilized by the 
DNA-polyamide van der Waals interactions and π-stacking interactions formed 
between the ring pairs of the polyamides. Figure 1.1 shows a 3-D representation of 
how two antiparallel polyamides bind in the minor groove of DNA (left) and a 
schematic diagram of how the paired heterocycles recognize the hydrogen bond 
donor-acceptor pattern of the minor groove (right).   
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Figure 1.1 On the left: 3-D representation of polyamides bound 2:1 in the minor groove of DNA (PDB81 
id 1CVY73). DNA is shown as blue sticks, and the polyamides are shown in van der Waals representation 
(imidazoles in red, pyrroles in yellow, amide bonds in cyan, β-alanine linker in orange, and cationic tail in 
green).  The structure contains the sequence 5’-CCAGATCTGG-3’ complexed with two polyamides of 
sequence ImPyPyPy-β-Dp. On the right: Schematic diagram of how the paired heterocycles recognize the 
hydrogen bond donors and acceptor of the minor groove.  The “ladder” in the middle is the DNA binding 
site, the dashed lines are the hydrogen bonds, the circles with the dots are the lone pairs on O2 of T and C 
and N3 of A and G, and circles with an H are the Hs of the exocyclic NH2 of G.  The tail is made up of two 
parts: β-alanine, which targets A, T bases and the cationic Dp, which interacts with the phosphate backbone 
(figure adapted from Dervan, et al., 200571).  
 
In the 2:1 binding mode, the heterocycles are usually paired by the covalent 
linkage of two antiparallel polyamide strands; the covalent linkage results in 
increased affinity and specifity (100-fold higher affinity than their unlinked 
counterparts).28 The standard motif for polyamides is a hairpin containing eight 
heterocycles, where two strands containing four heterocycles each are linked by a γ-
aminobutyric acid linker.  Called a γ-turn, it shows preference for binding AT/TA 
pairs over GC/CG pairs (due to steric clashes with the exocyclic NH2 group of G82), 
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and it connects the carboxylic end of one polyamide to the amino end of the other 
polyamide (thus, the polyamides are antiparallel).  The γ-turn stabilizes the register of 
the heterocycle pairings with the DNA bases, which is most likely the reason for the 
higher affinity and specificity.83  Hairpin polyamides align themselves with the DNA 
so that the amino end of the polyamide is oriented toward the 5’ direction of the 
adjacent DNA strand, and the carboxylic end oriented toward the 3’ direction of the 
adjacent DNA strand.84   
Although the normal eight-ring hairpin motif binds with high affinity and 
specificity, this motif binds only six base pairs of DNA.  In order for the polyamides 
to be useful in biology or medicine, specifically recognizing a very long stretch of 
DNA is important; longer sequences would be expected to occur less frequently in 
large genome.28, 71 However, expanding the binding site size simply by adding extra 
heterocycles to the polyamides has been shown to decrease affinity and specificity 
because the curvature of the polyamides is tighter than that of the curvature of the 
DNA groove.85 Actually, beyond five heterocycles, the polyamide shape is no longer 
complementary to the DNA groove.47 In order to allow more conformational freedom 
in the polyamides, a flexible β-alanine residue is used.  The β-alanine residue is used 
as a replacement for Py, so β/Py and β/Im pairs function as Py/Py and Py/Im pairs 
and simultaneously relaxe the curvature of the polyamide, restoring complementarity 
to the DNA groove.86  Polyamides with β-alanine have been used to target 
successfully up to 16 base pairs with high affinity and specificity. 52 
Although most polyamide research has focused on the five-membered 
heterocycles, other heterocycles have recently been shown to bind to DNA.28, 71  
 12
These heterocycles are based on the benzimidazole (Bi) ring system, which consists 
of a 6-5 bicyclic ring structure.  Different substituents can be added to the six-
membered ring, and polyamides with the benzimidazole derivatives have a curvature 
that is more complementary to the DNA than the traditional five-membered ring 
polyamides.87, 88 The benzimidazole derivatives (imidazopyridine (Ip) and 
hydroxybenzimidazole (Hz)) have been incorporated into the eight-ring hairpin 
polyamides and have been found to be as effective as the five-membered ring 
polyamides at recognizing the minor groove of DNA; the hydrogen bonding contacts 
between the DNA and polyamide are preserved.55  Of particular interest are the Hz/Py 
and Py/Hz pairing.  This pair can replace Hp/Py and Py/Hp pairs, and because Hp-
containing polyamides have been found to degrade over time and the Hz polyamides 
are chemically stable, the Hz/Py pair is a candidate to replace the Hp/Py pair.28 
However, because the benzimidazole system is more hydrophobic and has a greater 
surface area, this may alter the DNA-polyamide van der Waals interactions and the π-
stacking interactions between the polyamide ring pairs.28 
Polyamides utilized in this dissertation are composed of three most common 
five-membered ring heterocycle types joined by an amide functional group.  The NH 
group of the amide bonds is critical for binding as it forms specific hydrogen bonds 
with the bases when bound to the DNA.  The three heterocycles, N-methylpyrrole 
(Py), N-methylimidazole (Im), and N-methyl-4-hydroxypyrrole (Hp) and the amide 
linkages are shown in Figure 1.2.  
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Figure 1.2 Schematic diagram of Im-Py-Hp polyamide fragment.  
 
 The Dervan pairing rules have been used to design literally hundreds of 
synthetic ligands that do bind their predetermined DNA target sequences with the 
high affinity and specificity comparable to DNA binding proteins.  The polyamides 
have been shown to affect both transcriptional activation (by inhibiting repressor 
proteins and thus activating a particular gene)43, 89-93 and repression (by inhibiting 
assembly of transcriptional proteins on DNA and thus downregulating a particular 
gene) in vitro and in cell cultures.39, 42, 69, 94-98  Polyamides labeled with fluorescent 
dyes have also been shown to be taken up by cells, although nuclear uptake is 
dependent on cell type.38, 44, 99  However, even though the polyamides bind to B-DNA 
and have been found to perform the functions mentioned above, there are limitations 
regarding targeted DNA sequences.  Sequence dependent structural variations of the 
DNA minor groove affect the energetics of binding, a number of DNA sequences 
remain difficult to target (especially purine tracts), and binding affinity and specificity 
at some sequences is weak and/or unpredictable.  Variation in the DNA minor groove 
width, curvature, flexibility, hydration, and the relative positions of hydrogen bond 
donors/acceptors could all possibly influence polyamide binding and affinity for a 
particular sequence.71  Because molecular dynamics simulations allow for an 
atomistic view and examination of the DNA minor groove, this is an ideal tool for 
better understanding of the interactions of the polyamides with the DNA.   
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Computational studies are important for the description on how distamycin A, 
netropsin, and related polyamides bind to DNA.72, 76, 78, 83, 86, 100-121  For example, 
molecular dynamics simulations have been used to aid in the refinement of NMR 
structures of DNA/distamycin and DNA/polyamide complexes.72, 78, 83, 100, 102-104, 121 
Free energy perturbation studies have been utilized to understand binding affinities of 
DNA/polyamide complexes,103, 109 and unrestrained molecular dynamics have been 
employed to understand features of the complex such as hydrogen bonding, 
hydration, and structural distortions on the DNA induced by the polyamides.108, 110-112, 
114-120 Finally, quantum mechanical studies have been applied to understand the 
electronic and geometric properties of novel polyamides, and to interpret the results 
of experimental binding studies.76, 101, 106  
The quality of the force fields implemented to treat polyamides varies greatly 
between studies.   Close examination of the force field parameters utilized 
underscores the need for parameter development.  For example, treatments of DNA 
complexes with an isopropyl-thiazole polyamide,100 lexitropsin,103 CPI-lexitropsin,102 
distamycin A,104, 107-109, 121 netropsin,109, 114, 117, 118, 122 2-imidazoledistamycin,107 
carbocyclic analogs of netropsin and distamycin,110, 111 carbocyclic derivatives of 
distamycin with a chlorambucil moiety,112 ImHpPyPy-β-Dp,115, 116, 119 ImPyPy-γ-
PyPyDp,112 ImPy-β-Im-β-ImPy-β-Dp,78 Ac-ImPyPy-γ-PyPyPy-Gly-Dp,72 and 
ImPyPy-γ-PyPyPy-Gly-Dp72 have used default force field parameters that are best 
guesses or extrapolations from similar functionality.  Force field development based 
upon the recruitment of similar terms and parameters may be successful in some 
cases;18 however, in the case of polyamides made up of Im, Py, and Hp, serious errors 
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in the torsional terms, multiplicity, phase shift, and force constant magnitude have 
been found. The simulation results could lead to artificial behavior that could impact 
the interpretation of structure, dynamics, and properties of polyamides and their 
complexes.   
 Zhang and coworkers created polyamide parameters in the AMBER force 
field21 to determine the structure of a DNA/cyclic polyamide complex by NMR.105 
Energy minimization and molecular dynamics with the AMBER force field were used 
to aid in structure refinement; their results for the structure indicate distortion of the 
DNA in the polyamide binding site and altered stacking of the ligand rings relative to 
noncyclic polyamides.105 A number of specific bonds, angles, and torsional terms 
were calibrated against B3LYP/6-31G(d) data.  However, a majority of the terms 
were derived by comparison with other functionalities, and no comparison was made 
back to experimental structures.  It is well known that density functional methods, 
such as B3LYP, do not account for the effects of dispersion.123-131 Dispersion effects 
are important in the development of polyamide force fields because polyamides are 
cresent-shaped, which complements the shape of the narrow minor groove and 
improves binding by promoting van der Waals interactions.132 Also, in the case of the 
2:1 binders, the rings of the polyamides must stack on top of one another in the minor 
groove, which is stabilized mainly by nonbond interactions.132  
  Pang developed force field parameters for AMBER21 to study the formation 
of DNA/polyamide complexes.120 The results suggest that three and four ring 
polyamides have the same tendency for forming the same dimer conformations in 
water as they do in their ternary complexes with DNA and that the “pre-dimerization” 
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of polyamides in water assists in generating a tighter and more selective binding to 
DNA.120 The majority of bonds, angle, and dihedral terms were calibrated against 
HF/6-31G(d), and no comparison was made back to any experimental structures.   In 
a separate study, Topham and Smith made parameters for the CHARMM force field 
for distamycin and netropsin.113   Netropsin and distamycin were divided into smaller 
model compounds, and potential energy surfaces for specific torsions were generated 
using HF/6-31G(d).  The energy-minimized model of netropsin had an RMSD of 0.28 
Å with the crystal structure.  It is known that Hartree-Fock does not account for the 
effects of electron correlation.133  
Wellenzohn, et al. performed simulation studies with the AMBER force field21 on 
DNA/netropsin114, 118 and other DNA/polyamide complexes.21, 115-117, 119  The 
netropsin molecule and other polyamides were not explicitly parameterized for the 
force field.  Only the partial charges on the atoms of the molecules were explicitly 
derived; the other parameters for these molecules were taken from analogous existing 
functionality and molecules in the force field.  Generally, the extent of transferability 
of force field parameters is considered to be minimal, and new parameters must be 
generated for each new class of molecules to be used with the force field.18 No 
comparison back to experiment was reported.  
Given the problem of interest in polyamide/DNA simulation and the lack of 
accurate force field parameters to perform molecular dynamics simulations, we have 
developed parameters for the polyamides for the CHARMM force field.20   
Parameterization is accomplished by first dividing the polyamides into six model 
compounds and carrying out energy minimization using MP2/6-31G(d), which 
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includes the effects of electron correlation and dispersive interactions.  The bond, 
angle, torsional, and improper terms were modified to match the quantum mechanical 
results. The parameters were tested by performing molecular dynamics crystal 
simulations of the reported x-ray crystal structures of a netropsin crystal, a 2:1 
polyamide/DNA complex, a netropsin/DNA complex, a distamycin/DNA complex, 
and DNA without bound polyamides. The new parameters can be used for improved 
simulations of polyamides and their nucleic acid complexes.  
1.5 Retinoids and π-Conjugated Systems 
 
Retinoids make up a large group of naturally occurring and synthetic 
compounds related to retinol, otherwise known as vitamin A.134 135 136   
Physiologically occuring retinoids consist of a β-ionene ring, a chain of conjugated 
double bonds (that includes the ring), and a polar functional group at the end of the 
chain.  The figure below illustrates the general retinoid skeleton with two naturally 
occurring retinoids, retinol (1) and retinal (2), and two synthetic retinoids, 
axerophthene (3), and fenretinide (4).  
 
Figure 1.3  Structures of four retinoids.  1, retinol; 2, retinal; 3, axerophthene; 4, 
fenretinide. 
 
OH H
O
N
H
O
OH
CH3
1 2
3 4
 18
 
Retinoids are essential in a number of vertebrate physiological processes; they 
play vital roles in cell growth,137 reproduction (spermatogenesis, conception, and 
placental formation),138 embryogenesis,138 vision,136, 139 learning and memory,140 and 
resistance to and recovery from infection.136  Retinol (also known as vitamin A) and 
its active metabolites (the most active is retinoic acid) also control the differentiation, 
proliferation, and apoptosis of many different types of cells from conception to 
death,138, 141 including epithelial cells in the digestive tract, respiratory system, skin, 
bone, and the central nervous system.136, 142, 143  Retinol cannot be synthesized de 
novo by the human body, so it is an essential part of the diet.134  Dietary retinol is 
taken in as retinyl esters (obtained from animal products primarily as retinyl 
palmitate) or as β-carotene (obtained from vegetables).144  The retinyl esters and β-
carotene are then metabolized into the various retinoids found in the body, including 
retinol, retinoic acid, and retinal.  Retinyl palmitate is thought to be hydrolyzed to 
form retinol and a carboxylic acid in the intestine before being transported to the 
liver.  In the liver, which is the main storage site of vitamin A, retinol is esterified 
again to maintain the storage levels.  β-carotene is thought to be cleaved to form two 
retinal molecules in the intestine.  The retinal can then be reduced by retinaldehyde 
reductase to yield retinoic acid or it can be esterified to retinyl esters for storage.33, 138 
The stored retinyl esters in the liver are hydrolyzed to all-trans retinol, which 
is the major circulating retinoid, for release into blood circulation.144  The carrier 
protein for all-trans retinol in the blood to various target tissues is binding protein 
(RBP), which controls the plasma levels of retinol. Retinoids have low solubility in 
their uncomplexed form in aqueous medium so they must be protected, solubilized, 
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and transported in the blood and in the cell by specific retinoid binding proteins.135, 
145-147  In circulation, holo RBP is bound to transthyretin (TTR), which consists of 
four subunits.  Formation of the complex is thought to prevent filtration of the 
relatively small RBP through the kidneys and is hypothesized to be the complex that 
interacts with cell surface receptors that mediate the uptake of retinol.148, 149    
Once inside the cells of target tissues, retinol can be metabolized by various 
enzymes to retinal and retinoic acid or converted back to the ester form for storage; 
all forms (alcohol, acid, aldehyde and ester) can be present in the cell and are 
interconvertible.150  Cytoplasmic retinol-binding proteins (CRBP I and CRBP II) and 
cytoplasmic retinoic acid-binding proteins (CRABP I and CRABP II) bind retinol and 
retinoic acid with high affinity, respectively, inside the cell.151 Other than the obvious 
binding of retinoids in the cell, the functions of these cytoplasmic retinoid-binding 
proteins remain to be defined; however, they are thought to modulate intracellular 
retinoid metabolism by influencing the amount of ligand available to nuclear 
receptors.135, 151, 152  The regulation of retinoid metabolism in the cell is crucial 
because a shortage or excess or retinoic acid can affect retinoid-signaling pathways 
and is known to result in developmental defects.33, 150, 153 However, it is known that 
retinol bound to CRBP I is the substrate of enzymes that synthesize retinyl esters or 
oxidize retinol to retinoic acid.  Retinoic acid bound to CRABP I or II is then 
delivered to the nuclear receptors, which direct and regulate the expression of specific 
retinoic-acid inducible genes.143  CRBPs and CRABPs show a specific tissue 
distribution in adult and developing animals, which suggests that these proteins each 
serve different functions.151  Visual tissues contain other specific binding proteins for 
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11-cis retinal and 11-cis retinol (known to function only in vision), cellular 
retinaldehyde-binding protein (CRALBP) and interphotoreceptor retinol binding 
protein (IRBP).138, 154 
Two classes of nuclear receptors mediate the biological activities of retinoids, 
retinoic acid receptors (RARs) and retinoid X receptors (RXRs), both of which have 
three subtypes (α, β, and γ).34, 134, 140  RARs bind and are activated by all-trans 
retinoic acid and 9-cis retinoic acid with similar affinity but bind 13-cis retinoic acid 
only weakly; RXRs bind and are activated by only 9-cis retinoic acid.34 RARs and 
RXRs are transcription factors that bind to specific DNA sequence-retinoic acid 
response elements as RAR-RXR heterodimers and RXR homodimers, acting as 
ligand-dependent transcriptional regulators for retinoic acid responsive genes.34, 155, 156 
Because retinoids play essential roles in cell differentiation, growth, 
proliferation, and apoptosis in all stages of life in vertebrates, their pharmaceutical 
and chemopreventative properties have been exploited.  The many effects that 
retinoids have on cells have made this class of compounds an attractive candidate for 
use in cancer therapy and other diseases.34, 155, 157, 158  Both naturally occurring and 
synthetic retinoids are used to treat various skin disorders (acne, psoriasis, and 
ageing),155 they have been in used to augment treatments of other diseases, such as 
type II diabetes,159 and they show promise for the treatment of several cancers,142, 158, 
160, 161 HIV infection,162 and late-onset Alzheimer’s disease.140 These agents have 
targeted the RARs and RXRs; however, the scope of retinoid therapy is limited due to 
high toxicity (only a few retinoids are used routinely for treatment of skin 
disorders163-165),34 and the design of less toxic retinoids is necessary for further 
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clinical use. Because vitamin A and its derivatives play a multitude of roles in all 
stages of life through activation of widely expressed RARs and RXRs, administration 
of additional retinoids (natural or synthetic) causes toxic side effects that are 
characteristic of excess levels of vitamin A.33 Current efforts in retinoid development 
involve increasing the selectivity of synthetic retinoids to decrease the toxic side 
effects.155, 166 
Because of their biological importance and potential theraputic uses, it is of 
interest to understand the interactions and dynamics of retinoids with the various 
proteins that bind them at the molecular level.  Molecular dynamics simulations are a 
powerful tool for elucidating the atomistic details of biomolecular systems; however, 
the empirical force field parameters used must be optimized so that they accurately 
treat the class of compounds that one is attempting to model. Previous attempts have 
been made to treat conjugated systems properly, which are fundamental to retinoids. 
The first attempts were made independently by Warshel and Karplus29 and Allinger 
and Sprague,30 where both involved a combined quantum mechanical/molecular 
mechanical approach.   
The method of Warshel and Karplus was based on the formal separation of σ 
and π electrons, where the σ electrons were treated using an empirical force field (the 
consistent force field, or CFF167), and π electrons with Pariser-Parr-Pople 
semiempirical theory168, 169 corrected for orbital overlap. The total energy of a 
molecule was then expressed as the sum of σ and π electron contributions.  The goal 
of the method was to treat the equilibrium conformations and vibrational spectra of 
the ground and excited states of conjugated molecules.  Experimental data from 
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ethylene, butadiene, benzene, and propylene were used to fit the σ and π parameters 
used in their method.29 The method was tested against the ground and excited states 
of several conjugated molecules, including 1,3-butadiene, 1,3-cyclohexadiene, and 
1,3,5-hexatriene.  The results were in good agreement with experimental geometries 
and vibrational frequencies; however, it was never generally used and thus never 
made widely available because at that time it required excessive computer resources, 
and it was not easily extended for large systems of interest.   
Allinger also developed a combined quantum and molecular mechanical 
approach that separated the σ and π electrons.30 Allinger treated the σ electrons with 
the MMP1 force field,170 and the π electrons were treated with a variable-
electronegativity self-consistent field (VESCF) calculation.  The method was tested 
against the experimental geometries (x-ray crystallographic and electron diffraction 
structures) and heats of formation for a representative group of 65 compounds.  The 
computed results yielded satisfactory agreement with experiment over the range of 
compounds with the largest difference between experiment and computation being 
2.0 kcal/mol for the heats of formation.  The program was never widely used by the 
scientific community due to the same issues limiting the Warshel and Karplus 
method.     
A more recent method by Treboux for calculating geometries and vibrational 
frequencies of ground state and excited conjugated hydrocarbons also utilized the 
combined quantum mechanics and molecular mechanics methods.31 This method 
again partitioned the total energy into σ and π parts.  In order to reduce the 
computational time involved with the iterative SCF algorithm utilized in the last two 
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methods described, this method makes use of a Heisenberg Hamiltonian for the π 
electrons.31 The geometries and energy barriers calculated from various conjugated 
systems were in good agreement with experimental data; however, the authors made 
note of the fact that it could be practically applied to only 20 carbon atoms at the time 
the method was devised, which was in 1995.31 
 The most recent approach for treating a general class of large biomolecules, 
which include conjugated systems, was based completely on molecular mechanics.  
Both CHARMM and AMBER force fields were designed to be general purpose force 
fields to describe a wide variety of organic molecules, specifically, moieties that are 
commonly found in pharmaceuticals.20, 26, 32 Neither CHARMM nor AMBER were 
parameterized explicitly for conjugated systems.   
The limitations of force fields to treat conjugated systems, such as retinoids, 
have been recognized.  Numerous molecular dynamics studies involving retinal-
binding proteins have been performed, primarily with the goal of understanding 
different aspects of the bacteriorhodopsin or rhodopsin photocycle.171-174 175-185  Some 
studies involved the parameterization of the retinal ligand using quantum mechanical 
calculations; however, the quantum mechanical calculations used to parameterize the 
retinal were performed using Hartree-Fock176, 177, 186 or B3LYP,180, 183, 187, 188 which do 
not account for the effects of electron correlation and dispersion interactions, 
respectively.  Many other studies used parameters for the retinal ligand that were 
simply adapted from other atoms or molecules in the force field being used in the 
study.171-175, 178, 179, 181 
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In order to understand the interactions and dynamics of retinoid binding 
proteins and design new retinoid ligands with therapeutic potential using molecular 
dynamics simulations, this class of compounds has been explicitly parameterized for 
this dissertation.  New force field parameters have been developed for the CHARMM 
force field for retinoids, which properly account for the alternating single and double 
bonds present in the conjugated systems of these compounds.  The new force field 
has been evaluated against x-ray crystallographic data and quantum mechanical 
structures and energies.  Through testing the parameters with crystal simulations, 
some ligand motions were also discovered that could be important in ligand binding 
and dynamics or interaction of the protein/ligand complex with other molecules.  The 
observed motions aid in understanding more about how the ligands move internally 
within the protein, which can be used in design of new ligands.  The parameters can 
now be used in simulations of retinoid binding proteins to better understand their 
structure, dynamics, and how they interact with other proteins and for the design of 
new retinoids that show promise as therapeutic and anticancer agents.    
1.6 Convergence Analysis of Biomolecular Simulations 
 
Understanding DNA and protein dynamics is critical not only for expanding 
our knowledge of DNA and protein structure in itself, but for understanding DNA and 
protein interactions and dynamics with other proteins, nucleic acids, and ligands. 
Therefore, it is crucial to build a knowledge base of DNA and protein dynamics, 
which is not currently available, especially for DNA. The energy landscapes of 
biomolecules are rough and rugged, containing many accessible local minima 
(corresponding to similar but slightly different conformations) separated by energy 
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barriers, and transitions between these minima take time.15, 35, 36, 189, 190  On the current 
time scale of MD simulations (hundreds of nanoseconds), the simulation can get 
stuck in the many minima on the potential energy surface, and thus not allow for 
complete sampling of all possible conformations of even a small (8-10 base pairs) 
DNA duplex or small protein (46 residues).191  Slow motions, such as large 
conformational changes, ion channel gating motions, or other functionally relevant 
motions, often occur on timescales that not easily accessible and thus are not well-
characterized with simulations (microseconds to milliseconds).37, 191  Furthermore, 
simulated biomolecular systems commonly contain a complex mixture of nucleic 
acids or proteins, water, and counterions (such as sodium, chlorine, or magnesium), 
and in some systems, lipid bilayers, which cause the convergence to occur more 
slowly, resulting from less efficient sampling.192-196  
Sampling of minima is essential for the conformational flexibility of 
biomolecules, and therefore, to their function.35, 197, 198 Thus, if the biomolecular 
system of interest is not properly sampled, the properties measured from the 
simulation will not be representative of its true behavior, and predictions made could 
be incorrect.  The results and predictions from simulation studies depend on proper 
sampling of the molecule’s conformational space.   
Simulations of biomolecular systems must address the issue of the ergodic 
hypothesis, which a problem for any system with multiple minima on its potential 
energy surface.35  The system may not cross all of the energy barriers sufficiently in 
the time that the simulation is run to sample properly all states accessible to it.  The 
ergodic hypothesis states that average of a property over the entire simulation 
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trajectory is equal to an average over all states accessible to the system.15, 35  The 
hypothesis is difficult to prove for any system; however, it is easier and possible to 
evaluate a necessary criterion for the ergodic hypothesis to be valid:  At equilibrium, 
independent trajectories over an ergodic system must be self-averaging.15  This means 
that a property measured from two or more independent trajectories should be equal if 
the system dynamics are ergodic.  In other words, if two independent simulations do 
not converge to equal values, the system is nonergodic on the timescale that the 
simulations were run.15  Obviously, different properties of the system will exhibit 
different convergence behavior (some will converge more quickly than others), so 
multiple properties should be examined in order to address ergodicity and 
convergence.35, 199 
Because of the complexity of biomolecular systems and the need for adequate 
sampling, one of the primary issues with MD simulations is convergence: How long 
does the simulation need to be run in order to extract reliable information?  Acquiring 
reliable and accurate information on dynamics from MD simulations requires us to 
know how much sampling is required for the convergence of all of the properties of 
interest.  Attaining convergence is obviously going depend on the system under study 
and the properties of interest, and it is a difficult question to answer.  For effective 
sampling and therefore ergodicity, the simulations must correctly sample the regions 
of phase space that are accessible to the system under the given conditions (e.g., 
temperature and pressure).  If only a single long simulation is run, the system can get 
stuck in one of the many minima and thus not sample effectively.  Multiple shorter 
trajectories have been found to be more effective at sampling phase space than a 
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single long one,35-37, 200-204 and this is the approach that is utilized in this dissertation 
for the convergence studies.  
Rigid convergence of a system can never be proved, because there is no 
guarantee that the past dynamics of the system will predict the future dynamics, and 
in principle, new events or conformations of a system may be discovered with more 
extensive sampling.32, 37, 191, 192  However, efforts can be made to ensure that the 
various properties calculated from simulations have reached a level of satisfactory 
convergence, and different approaches have been used to do this.  Some methods are 
relatively simple and commonly used, such as monitoring the RMSD of the 
simulation structures over time with respect to the starting structure and calculating 
correlation times among different properties.32, 196, 205-208  However, the RMSD is not 
always a good indicator of convergence;191, 209 we have found in this study that DNA 
simulations started from different atomic coordinates result in RMSDs that converge 
at different rates or fluctuate at different points when the simulation has run for a 
considerable amount of time (>100 ns).  In other words, the RMSD failed to settle 
down to a constant value; the system appears to be moving between various substates 
(see Chapter 5).  This is not surprising for a flexible biomolecule like DNA, but it 
indicates that this method cannot determine when the simulation has converged.  
Also, if correlation times (time over which a particular property value takes to 
become independent from the previous values) longer than the overall trajectory 
length exist for the system, then the proper correlation time will not be observed; the 
correlation times will also depend on what part of the protein (a loop vs. a helix) or 
DNA (entire fragment vs. selected base pairs) is being examined.37, 191, 209 Another 
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commonly used method is block averaging.32, 195, 210  With block averaging, the total 
trajectory is broken up into independent, equally sized blocks, and the averages are 
then calculated and compared over the blocks.  However, in order obtain independent 
blocks, the relaxation time of the property of interest must determined to figure out 
what length of block can be considered independent.32  This, as with correlation 
times, will present a problem if the trajectory has not been run sufficiently long 
enough for the property to relax.  
Other more advanced methods, such as principal components analysis 
(PCA),198, 206, 211-216 cluster population analysis, 37, 191, 199, 217-219 or energy-based 
methods189, 220, 221 have also been used to diagnose sampling and convergence.  PCA, 
also called essential dynamics,211, 222 has been to applied biomolecular simulations to 
visualize large-scale motions.198, 206, 211-216, 223, 224 225, 226 It is assumed that the 
dynamics of the large-scale motions analyzed by PCA are converged on the timescale 
of the simulation.37 However, this may not be the case; several studies have found 
that the motion visualized from PCA were not consistent among individual 
simulations.37, 227-230  Although these studies showed that portions of a single 
trajectory or that individual simulations yield different results when PCA is applied, 
they do show that the simulation times examined are not long enough to sample 
properly the structure and fluctuations of the systems studied.   
Cluster population analysis37, 191, 199, 217-219 has been used to examine the 
relative populations of substates on the potential energy surface of the simulated 
system.  This method aims to classify the structures generated from trajectories into 
clusters based on the RMSD between the trajectory structures and a reference 
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structure.  In practice, sampling is limited so there are statistical variations among the 
cluster probability distributions; the magnitude of the variations is then considered a 
measure of the degree of convergence among the simulations.  However, interpreting 
the cluster population variance can be difficult,37 and as a result, the whole procedure 
requires time and processing of data.  Despite the time investment, this method has 
been used, and results suggest the same as those of PCA: the simulation times used 
were not long enough to produce ergodic behavior of the systems studied.37, 191 
The energy-base method (also called the “ergodic measure”189 and not limited 
to energy-based quantities) developed by Straub, Thirumalai, and Mountain189, 220, 221 
examines the fluctuations of some quantity averaged over independent simulations, 
and the timescale required for that quantity to be ergodic is determined.  However, a 
thorough sampling of the conformational space of the system’s structures is required 
for convergence, and many structures are close in energy but not structurally similar, 
and energy-based methods will not be sensitive to this.191, 209   
In order to understand more about sampling and convergence in simulations 
of DNA and protein systems, we have approached the problem using several long-
time simulations (4 simulations of 150 ns each for DNA; 10 simulations of 45 ns each 
for the protein crambin) and many short-time simulations (20 simulations of 2 ns each 
for both the DNA and crambin) and a simple statistical test.  The statistical test used 
is called the potential scale reduction test,231 and it is a popular convergence 
diagnostic used by statisticians in order to monitor convergence in multiple Markov 
chain Monto Carlo simulations.232-235  Approximate convergence of a particular 
parameter measured from the simulations is assumed when the variance between the 
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different simulations for a particular parameter is no larger than the variance seen in 
that particular parameter from an individual simulation.235  This approach enables us 
to know which methodology is better (several long simulations or many short 
simulations) for achieving convergence of several geometric parameters.  Eighteen 
helical parameters236 were measured from the DNA simulations and 16 parameters, 
including radius of gyration and hydrogen bonding distances, were measured from the 
crambin simulations.  This approach will also give insight as to which parameters 
may take longer to stabilize over multiple simulations and how long they take to 
stabilize (effectively telling us how long we need to run the simulations in order to 
achieve convergence of a particular parameter thus obtain reliable results).  To our 
knowledge, the potential scale reduction test has never been applied to biomolecular 
systems in order to assess convergence.  Like other approaches, this test cannot 
diagnose absolute convergence, but the approach is very simple.  All that is required 
are the values of the properties of interest over time; the statistical test (see Chapter 5 
for details and formula) can easily be implemented in any statistical program.   
In addition to gaining knowledge of the convergence of different properties, 
we have also discovered interesting and important information about which base pairs 
of the simulated DNA fragment should be included in the analysis of DNA 
simulations. For example, we have found that the effects of fraying (a well-known 
phenomenon where the end base pairs open and close rapidly)237-240 penetrate beyond 
the end base pairs of the DNA.  An understanding of sampling and convergence in 
biomolecular simulations will enable us to better model these systems and thus use 
 31
computational techniques to examine structural and dynamic features that cannot be 
observed by experiment.   
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Chapter 2  
 
 
Methods 
 
 
 This chapter discusses the background, methods, and procedures used for 
computations.  The theoretical background of molecular dynamics is described in Section 
2.1, the statistical tests used for analysis are described in Section 2.2, the theoretical 
background of quantum mechanical methods used is described in Section 2.3, and 
descriptions of the computations performed are in Section 2.4.   
 
2.1 Molecular Dynamics 
 
 Molecular dynamics simulation provides a method for examination of molecular 
motion at the level of the atom and thus is a useful tool in chemistry and physics.1  MD is 
a classical simulation method, meaning that the motions of the particles in the system 
obey Newton’s laws of motion and that electronic degrees of freedom are not explicitly 
described.  Thus, one of the most important limitations of MD is that it cannot be used to 
describe phenomena involving bond breaking/formation events, excited states, or 
isomerizations.1  MD simulations enable the time dependence of properties of a 
molecular system (structural, dynamic, and thermodynamic) to be studied by numerically 
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solving Newton’s equations of motion.   A simple description of a simulation can be 
summarized by the following four steps:2   
 1. Initial coordinates are obtained (in the case of biomolecules, these are usually 
obtained from the Brookhaven Protein Data Bank3or from the Rutgers Nucleic Acid 
Database4. Initial velocities are then assigned to the initial coordinates (usually assigned 
from some sort of distribution—Gaussian, Maxwell, etc.).   
  2. Compute the forces on acting on every particle in the system.  This is the most 
time-consuming part of most simulations because the contribution of to the force on 
every particle due to all of its neighbors must be considered.  If the system contains N 
particles, and if no techniques are employed in order to speed up the evaluation of short- 
or long-range forces (use of nonbond cutoffs), the force evaluation scales as N2.  
 3. Integrate Newton’s equations of motion.  After all forces are computed, 
Newton’s equations of motion are integrated by breaking the calculation down into small 
time steps.  Integration of Newton’s equations is described in further detail below.  Steps 
2 and 3 make up the bulk of the simulation; they repeated until the time evolution of the 
system has been computed for the specified amount of time.   
 4. Determine desired averages and properties of the system.  When the calculation 
is complete, the desired structural, dynamic, and thermodynamic properties can then be 
computed.   
2.1.1 CHARMM Force Field.  In molecular dynamics and molecular mechanics, 
the intra- and intermolecular forces between the atoms are described by an empirical 
force field.  Empirical force fields use atomistic models, where atoms are the smallest 
particles in the system, rather than the electrons and nuclei used in quantum mechanics.  
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The empirical force field, as known as a potential energy function, allows for the 
potential energy (V) of the system to be calculated as a function of the 3-D structure of 
the system (R).  The potential energy function consists of harmonic approximations of 
intramolecular (bond stretching, angle bending, and torsion interaction) terms and 
intermolecular (Coulombic and Van der Waals) terms (Eqn.2.1).  
  
The harmonic approximations used in the force field are sufficient for biomolecular 
simulations.  Simulations of biomolecules are typically performed at temperatures where 
bond lengths and angles usually stay near their equilibrium values.  Also, since there is 
no bond breakage/formation occurring in an MD simulation, a harmonic potential can 
accurately describe any bond and angle distortions.  
The CHARMM force field, which is used in this dissertation, has the following 
form (Eqn.2.2).  
 
 
 
The first five terms are the intramolecular terms, and the last two terms are the 
intermolecular terms.  The parameters Kb, KUB, Kθ, Kχ, and Kimp are the force constants 
and are usually determined experimentally or from quantum mechanical calculations.5  
The terms in parentheses (e.g., b-b0) describe the deviation (b) of the parameter value 
from the equilibrium value (b0).  For example, (b-b0) describes the deviation of the 
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current bond length from the equilibrium bond length (the other terms are analogous).  
The UB term is the Urey-Bradley term which describes 1,3-nonbonded interactions.  In 
the dihedral term, χ is the torsion angle value, δ is the phase shift, and n is the 
multiplicity.  The first intermolecular term is the Lennard-Jones term, where Rmin,ij is the 
minimum interaction radius (this is dependent on the atoms interacting and is determined 
by experiment), ε is the Lennard-Jones well depth, 1/r6 describes the attractive 
interactions, and 1/r12 describes the repulsive interactions. The second intermolecular 
term is the Coulombic term, where qi and qj are the partial charges on the interacting 
atoms, rij is the distance between the interacting atoms, and ε1 is the dielectric constant, 
which is generally treated as equal to 1 (permittivity of vacuum).   
 The 3-D structure (usually Cartesian coordinates obtained from the PDB or NDB 
in the case of biomolecules) and all parameters required in the force field are needed in 
order to begin the simulation.  Once these are known, the energy of the system can then 
be calculated using Eqn.2.2.  The first derivative of the energy with respect to the 
positions of the atoms yields the forces acting on the atoms, which is then used for the 
MD simulation (Eqn.2.3),  
  
 
where x are the coordinates (xi is the coordinate for the ith particle and N is the number of 
particles in the system).  
There are currently a variety of existing force fields, and choice for which to use 
depends on the nature of the system.  In this dissertation, the CHARMM force field is 
used for MD simulations, which is designed for use with biomolecular systems.6-8 
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2.1.2 Integration of Newton’s equations. Once the 3-D coordinates are obtained, 
velocities are assigned to each particle in the system (these are usually assigned from a 
Gaussian or Maxwell distribution). The motion of the system is then simulated by 
integrating Newton’s second law of motion,   
  
where F is the force acting on a particle (this is obtained from the potential energy 
function in Eqn.2.2), m is the mass of the particle, and a is its acceleration. The force can 
also be expressed as the gradient of the potential energy.  
  
Since acceleration is the second derivative of position with respect to time, this can be 
substituted in and Eqns. 2.4 and 2.5 can be combined to yield 
  
Newton’s equation of motion can then relate the derivative of the potential energy to the 
changes in position as a function of time. 
The potential energy is a function of all coordinates of all particles in the system.    
Numerical treatment is accomplished by using finite difference methods, which break the 
integration down into small timesteps (∆t). The timestep for the simulation must be 
chosen so that the algorithm will accurately describe the fastest degrees of freedom 
(highest frequency motions) of the system.  For biomolecular systems, the fastest motions 
are the stretching vibrations of hydrogens covalently bound to heavy atoms (this occurs 
on a timescale of ~1 fs; therefore, the integration is only accurate for a timestep of ~1-2 
fs).   In order to use a timestep of 2 fs, the SHAKE algorithm9 is applied to covalent 
F ma=
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hydrogen bonds in molecular dynamics simulations.  SHAKE holds the covalent 
hydrogen bonds (e.g. C-H) constrained, eliminating the high frequency motions, and thus 
allows for a larger timestep.  From the force, the accelerations of the particles can be 
calculated, and those are then combined with the positions and velocities at time t to 
calculate the new positions and velocities at time t + ∆t.  The forces on the particles in 
the new positions are then calculated, which gives new positions and velocities at time  
t + 2∆t, etc.   
 There are several algorithms which are commonly used for integrating Newton’s 
equations using finite difference methods.  All of them assume that the positions, 
velocities, and accelerations of the particles in the system can be approximated by a 
Taylor series expansion.  The most commonly used algorithm in simulations of 
biomolecules is the Verlet algorithm, which is based on two Taylor series expansions, a 
forward expansion (t + ∆t) and a backward (t – ∆t) expansion:  
  
  
where rn indicates the position at step n, n +1 indicates the position at the next step, and 
O(∆tn) is the term of order ∆tn or smaller.  These two expansions can be summed 
together, which gives an algorithm for propagating the positions:  
  
 
The Verlet algorithm is carried out in two steps: use the current position rn to calculate 
the current force Fn and then use the current and previous positions rn and rn+1 together 
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with the current force Fn to obtain the position in the next step, rn+1.  These two steps are 
repeated for every timestep for every particle in the system.   
 Because the velocities do not explicitly appear in the Verlet algorithm for 
computing the new positions, subtracting Eqn. 2.8 from Eqn. 2.7 yields an algorithm for 
propagating the velocities:  
  
 
In this dissertation, the leap-frog integrator is used.  The leap-frog integrator is a 
variation on the Verlet integrator; the modification was made to improve upon the large 
velocity errors of the velocity propagation of the Verlet algorithm.  In the leap-frog 
integrator, velocities are determined at the mid-point of the position evaluation.   
The algorithm is written as:  
  
  
 
where vn±1/2 is the velocity at the mid-step time, t ± (1/2)∆t.  The leap-frog integrator 
involves three steps: use the current position rn to calculate the current force Fn, use the 
current force and previous mid-step velocity vn –1/2 to calculate the next mid-step velocity 
vn +1/2, and finally use the current position and the next mid-step velocity to obtain the 
position in the next step rn+1.   
2.1.3 Nonbond Calculations.  The expensive part of an MD simulation is the 
evaluation of nonbond forces.  The number of bond, angle, and dihedral terms in the 
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force field are proportional to the number of particles in the system (the number of 
internal coordinates is 3N-6, which is linear in N); however, the number of nonbond 
terms increases on the order of N2 (nonbond forces must be calculated between every pair 
of atoms in system).  The non-bond attractive and repulsive terms of the Lennard-Jones 
potential decay quickly with distance; at 2.5σ (σ is the distance at which the force 
between the two interacting particles is zero) the Lennard-Jones potential has only 1% of 
its value at σ.10  However, charge-charge interactions do not decay as rapidly with 
distance; the electrostatic energy is ~1/r for two point charges.  In both instances, various 
algorithms are employed in order to reduce computational time.1, 11   
2.1.3.1. Use of Cutoffs.  The most common way of reducing computational time 
and effort in the calculation of nonbond interactions is the use of nonbond cutoffs.  These 
methods generally work by explicitly calculating the interaction energies between all 
pairs of particles within a specified distance (this is known as the cutoff distance and is 
usually set to 10-12 Å for biomolecular systems) and approximating the contributions 
from the particles beyond the cutoff distance.   
 Abruptly truncating interactions at the cutoff distance causes discontinuities in the 
potential energy and in the force near the cutoff distance.10  This is obviously a problem, 
and methods have been developed to reduce the discontinuities.  Two commonly used 
algorithms are known as switching and shifting functions.  Both methods set the nonbond 
energies at zero beyond some distance value; however, the values for interactions at less 
than the cutoff distance, r, are treated differently.  For a switching function S(r), S(r) is a 
polynomial of r that alters the nonbond energies smoothly and gradually over a buffer 
region [a,b] so that the energy at b = 0 and the energies at r ≤ a are not changed (the 
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buffer region is typically 1-2 Å).11 Shifting functions alter the nonbond energies more 
gradually over a larger region than switching function.  This method underestimates 
short-range forces and alters the nonbond energies over the region r ≤ b, rather than the 
smaller region that is affected in switching functions.11 
2.1.3.2. Ewald Summation.  Because long-range electrostatic interactions do not 
decay as rapidly as other nonbond interactions, long-range electrostatics can be 
problematic in MD. Until recently, cutoffs were applied to electrostatics (just like they 
were to other, more rapidly decaying nonbond interactions) in order to cut back on 
computational time.  However, it was noticed that when cutoffs were used for 
electrostatic interactions, artifacts were introduced to the system, especially when the 
system contained many localized charges, as in the case of DNA.12, 13  For example, it 
was found that even when explicit counterions were used in DNA simulations with 
periodic boundary conditions and cutoffs, substantial distortions were observed for the 
DNA structure.14   In simulations of polypeptides, the size of the cutoff distance was 
found to affect the stability of an α-helix.15   
 Because of the artifacts caused by cutoffs, use of the Ewald summation, which is 
a more rigorous treatment of electrostatics, is required for highly charged systems, such 
as DNA.12, 16  Studies have shown that use of the Ewald summation has led to more stable 
trajectories of DNA, RNA, and proteins.17-20  The Ewald summation is a technique for 
calculating the electrostatic energy of a system using periodic boundary conditions 
(simulated system is placed in a unit cell and is considered to have infinite images of 
itself in space).  The method uses a combination of real and reciprocal space sums of 
interaction energies in order to evaluate long-range electrostatic energies.  In 
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crystallography, the reciprocal lattice is an orthogonal system related to the orthogonal 
system associated with the atoms of the unit cell, which is the real space lattice.  In the 
Ewald sum, two terms arise from the calculation of electrostatic energy; one term from 
pairs of atoms in the direct lattice (central simulation cell) and the other term from atom 
pairs corresponding to interactions with images of the central cell atoms.  The Ewald sum 
is a periodic method; it includes a complete representation of electrostatic energies from 
an infinite number of images.  Because it is a periodic method, the Ewald sum avoids the 
truncation effects in energy forces observed when using cutoff methods (and also requires 
use of periodic boundary conditions).   
In the Ewald method, a particle interacts with all other particles in the simulation 
cell and with all of their images in the periodic system.  There is thus a contribution to the 
total energy from interactions in the central simulation box along with the interactions 
between the central box and the periodic image boxes.  The electrostatic contribution to 
the potential energy for all pairs of charges in the central simulation cell is written  
  
 
where qi is the partial charge on particle i, ε0 is the dielectric constant, N is the number of 
particles in the system, rij is the minimum distance between particles i and j, and ½ is in 
front to avoid double-counting.  The charge-charge contribution between the particles in 
the central cell and all the images of all the particles in the periodic system is written as  
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where n is a vector whose components are integral multiples of the length, L, of the 
central simulation box (n = nxL, nyL, nzL).  The sum in Eqn. 2.14 is very slow to 
converge, so the Ewald sum converts the summation to two series, both of which 
converge much more quickly.  The split must take into account the slow decay of 
Coulomb interactions when r is a large distance and also the variation Coulomb 
interactions when r is a short distance.  The split is of the form 
  
 
where f(r) must be a function to take both problems with Coulomb interaction into 
account.  The first term is for real space and is short-ranged, and the second term is for 
reciprocal space and is a long-ranged term (this term can be Fourier-transformed).  The 
Ewald sum uses the complementary error function (erfc(r)) for f(r). 
  
 
In the Ewald sum, each charge is considered to be surrounded by a neutralizing charge 
distribution which is of equal magnitude but opposite in sign to the charge.  This is 
normally a Gaussian distribution of the form 
  
 
The sum is now the sum of the interactions between charges and the neutralizing 
Gaussians.  This is the real space part of the Ewald sum.   
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The summation with the prime indicates that the series does not include the interaction  
i = j at n = 0.  The new summation that uses the error function now converges quickly 
(and beyond some cutoff distance, the value is considered negligible).  The rate of 
convergence depends on α, the width of the neutralizing Gaussians, and the wider the 
Gaussian, the faster the sum converges.   
 Another charge distribution is then added to the system to counteract the first 
neutralizing distribution.  This is the reciprocal space sum (k are reciprocal vectors) and 
is a Fourier series.  
  
 
The reciprocal space sum, like the real space sum, also converges much more quickly 
than the original sum.  However, unlike the real space sum, the reciprocal space sum 
converges more quickly for a small α (narrower Gaussian).  The number of terms that 
must be included in the reciprocal sum increases as α increases, which results in more 
time required for evaluation.   
 The sum of the neutralizing Gaussians in real space includes the interaction of 
each Gaussian with itself.  Therefore, a term must be subtracted from the Ewald sum:  
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The sums described are convergent; however, they are convergent only for a system with 
a net charge of zero.  If the system has a non-zero net charge, then an extra term must be 
added.  
  
 
The full Ewald summation is shown in Eqn. 2.22.  
  
 
The Ewald method is computationally expensive to implement (it scales as N2); 
however, methods have been devised to cut back on computational time.14, 16  By 
optimizing α, the relative rates of convergence of the real and reciprocal space sums can 
be adjusted to suit the system under study.  The optimal balance between the sums will 
enable the Ewald sum to scale as N3/2, which is still a considerable amount of 
computational time for large biomolecular systems.  The particle mesh Ewald sum (PME) 
developed by Darden and coworkers reduces the Ewald sum to N log(N).16  In the PME 
method, the trigonometric function values of the Fourier series present in the reciprocal 
space sum are evaluated by a smooth approximation of the potential over a grid, or mesh.   
The smoothing function is known as the Euler spline, which expresses the value of the 
trigonometric function at the actual charge coordinates in terms of the charge value at 
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neighboring grid points.  The resulting sums over the grid points are then evaluated 
efficiently by a fast Fourier transform.  This dissertation uses the PME for all 
simulations; in the case of net-charged systems, a neutralizing background is used by 
default in the standard Ewald calculation.21 
 The Ewald sum was developed by P.P.Ewald in the 1920s,22 long before the 
advent of computers, in order to compute the electrostatic energy of crystal.  In the 1970s, 
it was applied to computer simulations of particles for precisely the same reason: to 
calculate efficiently the electrostatic energy of a periodic system (effectively, a crystal).   
2.1.4. Boundaries.  The treatment of boundaries and their effects is important to 
MD simulations because it allows macroscopic properties to be simulated using a 
relatively small number of particles.  To be realistic, biomolecular simulations have to 
include some sort of description of a solvent environment.  This modeling of bulk solvent 
is accomplished through the use of boundary conditions.  There are various approaches to 
doing this, which include continuum boundary conditions, finite boundary conditions, 
and periodic boundary conditions.  
With continuum boundary conditions, the solute (protein or DNA) is treated as a 
macroscopic object surrounded by a continuum which represents the solvent (water 
molecules are represented explicitly). With finite boundary conditions, the solute is 
surrounded by a layer of explicit water molecules while the bulk solvent molecules are 
modeled by some form of boundary potential at the solvent/vacuum border. 1, 12  These 
methods have the advantage of decreasing the number of particles that are explicitly 
represented and thus decrease computational expense; however, they have drawbacks.  
With continuum solvent methods, explicit interaction of the solute with water molecules 
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at the atomic level cannot be observed (e.g., interaction of specific water molecules with 
amino acids in a protein).12, 23  With finite boundary conditions, water molecules cannot 
diffuse naturally due to the finite size of the system, and movements of water molecules 
can only be observed in the interior parts of the protein, such as binding cavities.12, 23  
Periodic boundary conditions allow simulations to be performed using a relatively 
small number of particles so that the particles in the system experience forces as if they 
were in bulk solvent.  The simulated system (the solute and the solvent) is placed in a unit 
cell and is considered to have an infinite number of images in space.  This replication of 
the unit cell forms an infinite lattice in three dimensions.  In three dimensions, the atoms 
of the simulated system are contained within a unit cell analogous to the unit cell of a 
crystal.  During the simulation, only the coordinates of the unit cell need are included.  If 
an atom of the unit cell leaves the unit cell by crossing the boundary, then an image atom 
enters to replace it; therefore, the number of particles is conserved.  In order to save 
computational time in evaluation of forces, the minimum image convention is 
customarily applied.  With the minimum image convention, each atom only sees one 
image of every other atom in the system.  The forces are calculated with only with closest 
periodic image.   
The choice of geometry for the periodic cell is important.  The cubic cell is the 
simplest periodic cell; however, it is appropriate to use a periodic cell that reflects the 
underlying geometry of the system.  For example, a rectangular cell is probably best 
suited for a solvated DNA system, while a more spherical cell is better for a globular or 
spherical protein.   
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The simulations in this dissertation are all performed with periodic boundary 
conditions in the crystalline environment (crystal simulations allow for better comparison 
back to experiment when the experimental structure is a crystal structure24).  The periodic 
cells and the dimensions used for the systems were those reported by the authors of the 
experimental crystal structures.   
2.2 Analysis of Trajectories 
 
2.2.1 RMSD.  For a quantitative comparison of one structure to another (such as a 
simulation-generated structure to an experimental structure), some sort of similarity 
measurement is required.  A commonly used method is to calculate the root-mean-square 
deviation (RMSD) between two structures or conformations.  This is done by first 
superimposing the structures on top of one another so as to eliminate deviations caused 
by translation or rotation and then calculating the RMSD using Eqn. 2.23.  
  
 
where N is the number of atoms in the structure, k is the index over those atoms, and the 
rk’s are the coordinates of atom k in conformations i and j.  The summation in Eqn. 2.23 
can include any set of atoms of the structure under consideration; it can include all the 
atoms in the structure or just a subset, such as the atoms of a ligand bound to a protein.  
In the analysis of biomolecular simulations, the summation usually includes only the 
heavy atoms (non-hydrogen atoms) and in the case of proteins and DNA, sometimes it 
only includes the alpha carbons of the protein backbone or the phosphate groups of the 
DNA backbone.  RMSD is usually in the units of Å. 
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2.2.2. T-tests.  The t-test25 assess whether the means of two groups are statistically 
different from each other.  The null hypothesis (H0) of the test is that the means of the 
populations are equal.  There are two forms of the t-test; one form assumes that the 
population standard deviation is the same for both sets of measurements being compared, 
and the other form assumes that the population standard deviations are different.  In 
practice, both forms give about the same results (the numerical result of the test will 
fluctuate, but the overall significance of the test usually will not).  In this dissertation, 
both forms of the t-test were used in order to compare the properties extracted from 
simulations to the experimental structure that was used as the starting point for the 
simulations.  Eqns. 2.24 and 2.25 show both forms of the t-test.   
  
  
 
Eqn. 2.24 is the form of the t-test that assumes that the population standard deviations are 
the same, and Eqn. 2.25 is the form that assumes they are different.  In both equations, s 
is the standard deviation for each population considered, n is the number of samples used, 
and x is the mean of each population.  In Eqn. 2.24, spooled is the pooled standard 
deviation (this makes use of both data sets) is calculated using Eqn. 2.26  
  
 
where s is the standard deviation of each population considered,  n is the number of 
samples, and k is the number of populations. When used in the t-test, spooled (Eqn. 2.26) 
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involves two data sets (the t-test compares the means of two groups at a time, k = 2); 
however, Eqn. 2.26 can be used to pool as many standard deviations as needed.   
 Once the tcalc value is calculated, this number is compared with the ttable number at 
the specified degrees of freedom and confidence level (the 95% confidence level is 
normally used). If tcalc is greater than ttable at the 95% confidence level, the results are 
considered to be statistically significantly different.  The number of degrees of freedom is 
determined using Eqn. 2.27.  
  
In this dissertation, the dof was ~100 for the properties being analyzed.  At the 95% 
confidence interval for 100 and greater dof, the ttable value is 1.96, and this will be used 
throughout the document, unless otherwise noted.  The specific details of what properties 
the t-test was applied to and how it was used (number of samples used, etc.) will be 
discussed with the simulation results.   
2.2.3. Principal Components Analysis.  Principal components analysis (PCA)26-29 
is a multivariate analysis technique that is used to identify patterns in data and express the 
original data in such a way as to highlight similarities and differences.  PCA transforms 
data to a new coordinate system such the greatest variance by any projection of the data 
comes to lie on the first coordinate (first principal component), the second variance lies 
on the second coordinate, and so on.  PCA can be used to reduce the dimensionality of a 
data set by retaining those characteristics of the data that contribute most to the variance 
of the data set.  The lower-order principal components are kept, while the higher-order 
ones are ignored because the lower order ones contribute most to the variance.   
1 2 2dof n n= + − Eqn. 2.27 
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 The procedure by which PCA works is typically described using an example data 
set.  Suppose that this data set consists of property with p measurements over n 
conformations for multiple MD simulations. This data set is matrix X with p columns and 
n rows.  The purpose of performing PCA in this dissertation was to see the relationship of 
a particular  property among the all conformations from different simulations and their 
relationship to an experimental structure that was used to initialize the simulations (i.e., 
which conformations among the simulations are similar or different to each other and the 
experimental structure).  PCA plots were also used to select starting structures for 
additional simulations. The data set is multidimensional, and the whole point of PCA is to 
reduce dimensionality in order to examine the relationships of the different 
conformations from the simulations.  First, for PCA to work properly, the mean of each 
dimension of the data set must be subtracted from each dimension (this produces a data 
set whose mean is zero).  Next, a covariance matrix C is constructed.  Covariance is 
measured between two dimensions, and it is used to find out how much the dimensions of 
the data vary from the mean with respect to each other (variance is the analogous 
measure in one dimension).  The covariance between two dimensions a and b, would be 
calculated by Eqn. 2.28.  
  
 
If the data set contains more than two dimensions, obviously more than one covariance 
measurement can be calculated.  For an n dimensional data set, C will be an n x n matrix, 
and each element is the result of calculating the covariance between two separate 
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dimensions (Eqn. 2.28).  The diagonal of C will contain the covariance between one of 
the dimensions and itself, which are just the variances for that dimension.  Also, since 
cov(a,b) = cov(b,a), C is symmetric about the diagonal.   
 The next step is to diagonalize C.  By doing this, a matrix of eigenvectors E and 
their corresponding eigenvalues.  For an n x n covariance matrix, n eigenvectors will be 
obtained.  All the eigenvectors of C are orthogonal to each other (as with any matrix), 
and this is important because it means that we will be able to express the original data in 
terms of these orthogonal eigenvectors rather in terms of the usual x, y, and z axes (these 
will not show how each data point relates to the rest of the data).  The eigenvalues that 
are associated with each eigenvector indicate the magnitude of the variances in the 
direction of their corresponding eigenvectors.   
 Once the eigenvectors and eigenvalues are found from C, the next step is to sort 
them in order by eigenvalue, highest to lowest.  The sorting can be visualized by using a 
Scree plot, which simply shows which components contribute most to the variance of the 
data set (the percentage that each component contributes to the variance of the data set is 
plotted versus the component number).  Usually, only the first 1 or 2 components will 
contribute most to the variance, and the lower components can be ignored.  Some 
information will be lost when components are ignored; however, if the eigenvalues are 
small, not much information is lost, and the dimensionality of the data set is reduced (if 
the data set has n dimensions, and only the first p eigenvectors are retained, the final data 
set will only contain p dimensions).  Another matrix E1 is then formed from the chosen 
eigenvectors.  
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 The final step in PCA is to project the original data set onto the new set given by 
the chosen eigenvectors.  The new components are the principal components (PCs), and 
while the original data contained n dimensions and may have been correlated, the new 
data set contains only p dimensions (if p eigenvectors were retained), and the PCs are 
uncorrelated.  The final data set (which is made up of the PCs) is computed by the 
following equation,  
  
 
where M is the final data matrix, E1T is the transposed matrix of the chosen eigenvectors, 
and XT is the transpose of the original data matrix with the means subtracted out.  To get 
the data in a plot-friendly format, it helps to transpose M.  The original data is now solely 
in terms of the chosen eigenvectors, and if not all eigenvectors were used, the dimensions 
of the data have been reduced.  The PCs can now be plotted against one another in order 
to visualize the projections of the data onto the eigenvectors with the largest variances.  
 In this dissertation, PCA was applied to DNA/polyamide complex data sets.  The 
S-plus program30 was used to perform PCA.  
2.3 Quantum Mechanical Methods 
 
2.3.1 Schrödinger Equation.  The time-independent solution to the Schrödinger 
equation for a molecular system can be expressed by the following equation 
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H EΨ = Ψ Eqn. 2.30 
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where Ψ is the wavefunction, E is the energy of the system, and H is the Hamiltonian 
operator, which is equal to 
  
 
where h is Planck’s constant, m is the mass of the particle, ∇ is the Laplacian operator, 
and V is the potential energy.  The Hamiltonian is made up of the sum of the kinetic and 
potential energy contributions of the nuclei and electrons in the system. The kinetic 
energy is a summation of 2∇  over all the particles in the molecule (first part of Eqn. 
2.31):  
  
 
The potential energy component is the Coulomb repulsion between each pair of charged 
particles:  
  
 
jkr∆  is the distance between the two particles j and k, and ej and ek are the charges on the 
particles.  For an electron, the charge is –e, and for a nucleus, the charge is Ze (Z is the 
atomic number of the atom).  
Therefore, we can write:  
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where the first term is for the nuclei-electron attraction, the second term is for electron-
electron repulsion, and the third term is for nuclear-nuclear repulsion.   
 Under the Born-Oppenheimer approximation,31 nuclear and electronic motions 
can be separated, which simplifies the Schrödinger equation.  This approximation is 
reasonable because the mass of a nucleus is thousands of times greater than that of an 
electron, and nuclei move very slowly with respect to the electrons (electrons move 
instantaneously in response to changes in nuclear position).  Therefore, the nuclei are 
fixed relative to the electrons, and the motion of the electrons can be considered to occur 
in a fixed potential produced by the nuclei.   
 
 
Where r
v
 and R
uv
designate the positions of the electrons and nuclei, respectively. The 
Born-Oppenheimer approximation says that the two parts (electronic and nuclear) can be 
solved independently, so a Hamiltonian that omits the nuclear kinetic energy term can be 
written:  
  
 
Using this electronic Hamiltonian, a Schrödinger equation is obtained for describing the 
motion and energy of the electrons in a fixed field of nuclei, where n is the number of 
electrons.  
Eqn. 2.35( ) ( ) ( , ) ( ) ( )
elec nuclear nuclear elec elec nuclearH KE r KE R V R r V r V R−= + + + +v uv uv v v uv
2 2 2
2 2 2
1
2
1
elec I
Ii i Ii i i i
I J
i Ii j i I J Ij J
ZH
x y z R r
Z Z
r r R R< <
  ∂ ∂ ∂  = − + + −   ∂ ∂ ∂ −   
      + +   − −   
∑ ∑∑
∑∑ ∑∑
uv uv
v uv uv uuv
Eqn. 2.36 
 79
  
 
The Schrödinger equation cannot be solved exactly with the exception of one-electron 
systems (such as the hydrogen atom).32, 33  The electron-electron repulsion term in Eqn. 
2.36 makes it impossible to find an analytical solution to the Schrödinger equation.  
Therefore, some sort of approximation method, such as perturbation theory, is necessary 
to obtain a solution.  
The product of the wavefunction Ψ with its complex conjugate (Ψ* Ψ) is 
interpreted the probability of finding the particle at some point in space.  The square of Ψ 
thus gives the electron density at any given point.  Therefore, Ψ must be normalized; if 
the probability of finding the particle is integrated over all space, the result must be 1 (the 
particle has to be somewhere).  
  
dτ indicates integration over all space. Aside from the normality requirement, the 
wavefunction has the requirement of being antisymmetric, which means that Ψ changes 
sign when two identical particles are interchanged (this follows from the fact that 
electrons are indistinguishable from one another, and there is a fundamental symmetry 
that the wavefunction must obey in describing the behavior of many electrons).   
 The solutions (the wavefunctions, Ψ) to the Schrödinger equation (Eqn. 2.37) 
describe some stationary state of the system (the solutions are called stationary-state 
wave functions because they are independent of time).  The wavefunction depends on 
both the position of the particle (x, y, z coordinates) and their spin states.  Solving Eqn. 
2.37 gives Ψn and En, where the Ψs are the eigenfunctions of the Hamiltonian operator 
( , ) ( ) ( , )elec n n nH r R E R r RΨ = Ψv uv uv v uv Eqn. 2.37 
* 1dτΨ Ψ =∫ Eqn. 2.38 
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and the Ens are the eigenvalues (the Ens are the allowed energy values).  E0n is the energy 
of the ground-state energy of the system, while all the Ens above that are the energies of 
the excited states.  
2.3.2 Hartree-Fock Theory.  Hartree-Fock (HF) is one of the most common 
approximations for determining the ground-state wavefunction and ground-state energies 
for a many-electron system.32-34  There is no correct solution for a many-electron system; 
there must be some way to determine if one wavefunction is better than another one.  
Hartree-Fock utilizes the variational principle, which says that for a time-independent 
Hamiltonian operator, any trial wavefunction φ  will have an energy expectation value 
that is greater than or equal to the true ground state wavefunction corresponding to the 
given Hamiltonian.   
  
 
Therefore, the Hartree-Fock energy is an upper bound to the true ground state energy of a 
given system.  
 The next approximation made by Hartree-Fock theory is that the trial 
wavefunctions to be used are approximated by a single Slater determinant.  A Slater 
determinant is the simplest form of an orbital wavefunction that satisfies the asymmetry 
requirement.  Because asymmetry must be considered, electron spin has to be taken into 
account.  Electron spin can be conveniently treated by combining spatial orbitals with the  
spin functions α and β, resulting in a spin orbital that a function of location (spatial part) 
and spin (spin part).  Eqn. 2.40 is an example of a Slater determinant 
Eqn. 2.39 
ˆ*
* gs
H d E
d
φ φ τ
φ φ τ ≥∫
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where 1
!N
 is a factor that ensures that the wavefunction is normalized, ( )i nφ  is the 
spatial orbital for the atom n, and α and β are the spin functions.   
 The Hartree-Fock equation for each spatial orbital is  
  
where iφ  is the wavefunction, εi is the energy of the orbital, and Fi is the Fock operator.  
The Fock operator has the form 
  
 
where vHF(i) is the average potential felt by the ith electron due to the other electrons; this 
average potential is approximation to the third term of Eqn. 2.36.   
 When a Hartree-Fock calculation is started, neither Fi nor iφ  are known.  An initial 
guess is made for the iφ , which in turn allows calculation of Fi.  By using the variational 
method, the iφ and Fi are optimized in order to approximate ground state energy for the 
system.  This iterative procedure is known as the self-consistent field (SCF) method.   
The largest drawback of Hartree-Fock theory is that it does not include effects of 
electron correlation.  The electrons are considered to be moving in an average potential of 
the other electrons; thus, electrons are not specifically influenced by the presence of 
individual neighboring electrons.  However, despite the lack of electron correlation, HF 
1 1
1 1
1 1
(1) (1) (1)
(2)(2) (2)1
!
( ) ( ) ( )
n
n
n
N
n n n
φ α φ β φ β
φ βφ α φ β
φ α φ β φ β
   Ψ =     
K
K
K K K
K
i i i iFφ ε φ=
2
1
1 ( )
2
M
HFA
i i
A ia
ZF v i
r=
= − ∇ − +∑
Eqn. 2.40
Eqn. 2.41 
Eqn. 2.42 
 82
does allow for quantum calculations to be applied to larger and more realistic systems, 
because it is less computationally demanding.  HF is also a useful starting point for more 
advanced quantum mechanical methods.  
2.3.3. Perturbation Theory.  Because Hartree-Fock does not include effects of 
electron correlation, it will represent many properties incorrectly, such as bond 
formation/breakage.34, 35  Methods that go beyond Hartree-Fock to include the effects of 
electron correlation are needed; these are known as post-Hartree-Fock or post-SCF 
methods.   
 One method of treating electron correlation is Møller-Plesset perturbation theory.  
This method estimates the electron correlation energy by splitting the Hamiltonian 
operator into two parts.  The perturbation Hamiltonian is the difference between the exact 
and Hartree-Fock Hamiltonians.  The true Hamiltonian H is expressed as the sum of a 
zeroeth order Hamiltonian H0 (for which a set of molecular orbitals can be obtained and 
therefore can be solved exactly) and a perturbation (λV), which is assumed to be small in 
comparison to H0.  
  
 
The eigenfunctions of the true Hamiltonian operator are Ψi with corresponding 
eigenvalues Ei.  The eigenfunctions of the zeroeth order Hamiltonian are Ψi0 with 
corresponding energies Ei0.  The ground state wavefunction and energy are therefore Ψ00 
and E00.  The parameter λ can vary from 0 to 1; when λ = 0, the H is equal to the zeroeth 
order  
0H H Vλ= + Eqn. 2.43 
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Hamiltonian, but when λ = 1, H is equal to its true value.  The eigenfunctions Ψi and 
eigenvalues Ei of H can then be expressed as powers of λ:  
  
  
 
The perturbed wavefunction and energy are then substituted into the full Schrodinger 
equation ( i i iH EΨ = Ψ ) and like powers of λ are equated to give the zeroeth (Eqn. 2.46), 
first (Eqn. 2.47), and second orders (Eqn. 2.48) of perturbation:  
  
  
  
Solving these equations yields the following for Ei and Ψi:  
  
  
 
Where 1 0 0ij i jH V dτ= Ψ Ψ∫ .  The first-order correction to the energy can be calculated by 
using the unperturbed wavefunction and the perturbed Hamiltonian: 
  
 
The higher-order terms are developed similarly; for example, the second-order correction 
is given by:  
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So far, these are the results of general perturbation theory.  In the particular case 
of Møller-Plesset theory, the Hartree-Fock wavefunction is used as the zeroeth order 
approximation, and the difference between the true electron-electron repulsions and the 
averaged ones from HF is treated as the perturbation (the perturbation Hamiltonian is the 
difference between the exact and Hartree-Fock Hamiltonians).  The zeroeth order  
Hamiltonian is a sum of Fock operators, and the zeroeth order energy is sum of orbital  
energies.  
  
  
 
The first-order energy is given by Eqn. 2.54, and adding Ei0 to Ei1 gives the full Hartree-
Fock energy.  Therefore, to get any treatment of electron correlation, the second-order 
perturbation must be incorporated.  The second-order energy and the first-order 
correction to the wavefunction are given by:  
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where the sum is over all excited states, denoted as jΨ and jE .  The 2iE  numerator is 
always positive because it is squared, while the denominator is negative because 0iΨ is 
the ground state and jΨ  is an excited state.  Therefore, the second-order energy 
correction is always negative or zero.  Higher order corrections may be either positive or 
negative.   
 The higher orders of Møller-Plesset theory perturbation are denoted as MPn, 
where n is the order of perturbation. The MP1 energy is the same as the Hartree-Fock 
energy; MP2 includes the effects of double excitation and is the most practical treatment 
for electron correlation.34, 35 Third, fourth, and higher orders of perturbation are derived 
similarly to second-order.  The terms quickly become more mathematically complicated 
and computationally expensive.  For n basis functions, HF scales as n4 and MP2 scales as 
n5; for higher orders of perturbation, the calculations become more costly.  MP2 
calculations require more computational effort; however, MP2 yields a significant 
correction to geometries and energies over the corresponding HF calculations.34, 35 
2.3.4. Density Functional Theory.  The central idea in density functional theory 
(DFT) is that a relationship exists between the total electronic energy and the overall 
electron density.  DFT methods are based on the ideas of Hohenberg and Kohn,36 who 
stated that the ground state electronic energy of a molecule can be expressed exactly as a 
functional of the electron density of the molecule.  The term functional refers to a 
function of a function, which in this case means that the total energy has a functional 
dependence on electron density, which in turn is dependent on the coordinates of the 
electrons of the system.  The approximate functionals used in DFT methods use the 
following separation of the total electronic energy.  
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ET is the kinetic energy term arising from electron motion, EV is the potential energy term 
and includes nuclear-electron attraction and nuclear-nuclear repulsion, EJ is electron-
electron repulsion term (also described as the Coulomb self-interaction of the electron 
density), and EXC is the exchange-correlation term and includes the contributions due to 
electron exchange and correlation.  All terms of Eqn. 2.57 with the exception the nuclear-
nuclear repulsion are functions of the electron density, ρ.   
Eqn. 2.57 follows the ideas of Kohn and Sham,37 who suggested that the sum of 
the kinetic energy of the electrons and the contributions from electronic interactions 
should be expressed as a sum of three terms: the kinetic energy (which is defined as the 
kinetic energy of a system with non-interacting electrons), the electron-electron repulsion 
energy, and the electron exchange-correlation energy.  In practice, Kohn-Sham DFT 
calculations are performed using an iterative approach, analogous to the SCF approach 
used in HF calculations.  An initial guess is made for ρ, which allows for derivation of a 
set of orbitals that leads to an improved value for ρ.  The improved ρ value is then used in 
the second iteration and so on until convergence is reached.33  
The exchange term in Eqn. 2.57 represents the effects of electron exchange and 
correlation on the total energy of the system, which is an advantage over HF, which does 
not treat effects of electron correlation.  However, there is no known exact expression for 
EXC (Hohenberg and Kohn showed that EXC is dependent entirely on ρ; however, the 
theorem does not provide the form of this functional).33, 36, 37  A number of approximate 
expressions for EXC have been developed, which in turn lead to a variety of methods.  In 
T V J XCE E E E E= + + + Eqn. 2.57 
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practice, EXC is usually divided into separate parts, which are the exchange and 
correlation parts.  
  
All terms are again functionals of ρ.  The functionals on the right side of the equation are 
the exchange and correlation functionals, respectively.  Both parts can be one of two 
types, a local functional (depends only on ρ) or a gradient-corrected functional (depends 
on ρ and the gradient of ρ, ρ∇ ).   
 The local exchange functional is almost always defined as  
  
where r
v
 represents the coordinates of the electrons. This is known as the local density 
approximation (LDA), and it states that in regions of the system where charge density 
varies slowly, the exchange correlation energy can be considered the same as that of a 
uniform electron gas of the same charge density.35  The LDA approximation is generally 
not of high enough accuracy to be useful for determining structural properties or 
dissociation energies of molecules.33, 35 However, the quality of the results can be 
improved by adding correction terms to Eqn. 2.59 that depend on the gradient of ρ.   
The functional developed by Becke in 198838, 39 makes a correction to the LDA 
approximation that improves upon many of its deficiencies.  The following gradient-
corrected exchange functional is Becke’s form, which is now commonly used,  
  
( ) ( ) ( )XC X CE E Eρ ρ ρ= + Eqn. 2.58 
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where 2 4/3x ρ ρ−= ∇ , and γ is a parameter chosen to fit the known exchange energies of 
inert gas atoms (Becke defines γ = 0.0042 Hartrees).38   
 As for the exchange functional, corrections (local and gradient) exist for the 
correlation functional.  A commonly used method is that of Lee, Yang, and Parr,40   
  
where a, b, c, and d are constants and 
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v .  Usually, DFT 
methods are formed by combining an exchange functional with a correlation functional. 
For example, the BLYP functional is formed by combining Becke’s gradient-corrected 
exchange functional with Lee, Yang, and Parr’s gradient-corrected correlation functional.  
 The key feature of DFT methods is the way in which electron exchange and 
correlation effects are directly incorporated; correlation effects are truly only considered 
in more complex, post-HF methods, such as MP2.  Because DFT methods include both 
exchange and correlation effects, higher accuracy is achieved compared to Hartree-Fock, 
which does not include electron correlation effects.  Despite the improvements in DFT in 
recent years, there are still difficulties in using density functional theory to describe 
properly certain intermolecular interactions, in particular, van der Waals (dispersion) 
forces.  The poor treatment of dispersion by DFT renders this method unsuitable for the 
treatment of systems that are dominated by dispersion forces, such as noble gases.33  
2.3.5. Basis Sets.  A basis set is a set of functions used to create the molecular 
orbitals of a molecule.  The functions that make up the basis set are known as basis 
1/ 32 /3 5/3 2
1/3
1 1 1{ [ 2 ]}
1 9 18
C cr
LYP F W WE a r b c t t e drd
ρ ρ ρρ
−− −
−
 = − + − + + ∇ +  ∫
v
Eqn. 2.61
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functions, and they are expanded as linear combinations to make up the basis set.33  The 
basis functions are usually centered on the atomic nuclei, so they represent atomic 
orbitals.  The accuracy of quantum mechanical calculations depends largely on the basis 
set chosen.  The basis set specifies which and how many basis functions are used to 
describe a molecule.   
 An individual molecular orbital can be defined as  
  
 
where the coefficients cµi are known as the molecular orbital expansion coefficients, 
which are determined computationally and χµ are the basis functions (these are chosen to 
be normalized).  Gaussian03,41 which was used in this dissertation for quantum 
mechanical calculations, uses Gaussian-type atomic functions as basis functions. 
Gaussian functions have the general form  
  
 
where r
v
 is made up of x, y, and z, and α is a constant that determines the size, or spread,  
of the function (a large α value gives a function that does not spread very far; a small α 
value will give a large spread). In a Gaussian function, 
2re α− is multiplied by powers of x, 
y, z, and normalization constant, so that when the square of the Gaussian function is 
integrated over all space, the result is 1.  The parameter c depends on α, l, m, and n.  
Linear combinations of primitive Gaussian functions of the form in Eqn. 2.63 are used to 
form the basis functions.  These are known as contracted Gaussians and have the form 
1
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where dµp are fixed constants within a given basis set.  The basis functions are combined 
to yield the linear expansion that forms the molecular orbital (Eqn. 2.65). 
  
 
In this dissertation, the 6-31G(d) basis set was used in all quantum mechanical 
calculations.  This is a combination of split-valence and polarized basis sets.  Valence 
electrons principally take part in chemical bonding; therefore, valence orbitals are 
represented by more than one basis function, which in turn are composed of a linear 
combination of Gaussian primitive functions.  Split-valence basis sets have two or more 
sizes of basis function for each valence orbital.  Split-valence basis sets allow orbitals to 
change size but not shape.  Polarized basis sets overcome this by adding orbitals to each 
atom with angular momentum beyond what is required for the ground state (e.g., d 
functions are added to carbon, p functions can be added to hydrogen).  In the 6-31G(d) 
basis set, one basis function comprised of six Gaussian primitives is applied to the core 
atomic orbitals, and the valence orbitals are split into two basis functions.  The first one is 
composed of three Gaussian primitives and the second by one Gaussian primitive.  In this 
specific basis set, d orbitals are added to heavy atoms.   
2.4 Description of Calculations 
 
2.4.1. General Methods.  Calculations were conducted using the computational 
resources at the Center for Computational Sciences42, 43 at Duquesne University and the 
p p
p
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Pittsburgh Supercomputing Center.  Electronic structure calculations were carried out 
with the Gaussian03 program41 with the second-order Møller-Plesset (MP2) method44 and 
the 6-31G(d) basis set.45, 46  Molecular mechanics calculations were performed using the 
CHARMM program47 and the CHARMM force field for proteins8, 48 and nucleic acids.6, 7  
The water model in all simulations was TIP3P.49 Crystal simulations employed the 
CRYSTAL50 facility in CHARMM. Molecular dynamics simulations were performed in 
the NPT51 ensemble using the Leap-Frog integrator and periodic boundary conditions 
with the SHAKE9 algorithm applied to covalent hydrogen bonds, which allowed for a 
0.002 ps timestep.  A dielectric constant of 1.0 was used in all simulations. Electrostatics 
were treated using the particle-mesh Ewald method.16 In the case of net-charged systems, 
a neutralizing background is used by default in the standard Ewald calculation.21  Ewald 
calculations were performed using the specified real space cutoffs with the Lennard-
Jones interactions truncated at the same distance.  Kappa (screening parameter) was set to 
0.36; the order parameter was set to 6.6 Nonbond pair lists were maintained to 14 Å, 
nonbond interactions were truncated at 12 Å, and the image cutoff was kept at 14.0 Å.  
Nonbond lists, hydrogen bond lists, and image lists were updated heuristically. The 
volumes of the systems were monitored to ensure that there were only minimal 
fluctuations in the volume over time.  Snapshots of the systems were saved every ten 
picoseconds.  Simulation details for each specific system are given in the following 
sections  
2.4.2. Quantum Mechanical Calculations (polyamide model compounds).  Each 
compound was energy minimized using MP2/6-31G(d).  For comparison, the structures 
were also energy minimized using HF and B3LYP with the 6-31G(d) basis set.  
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Frequency calculations were also performed at the MP2/6-31G(d) level of theory.  In 
order to obtain the potential energy surfaces (PES) for selected torsion angles,  torsion 
energies were calculated by holding the selected torsion angle fixed at different 
increments (30º increments from –180º to 180º) and geometry optimizing all other 
degrees of freedom at the three levels of theory mentioned above.   
2.4.3. Netropsin Crystal Simulation.  The starting structure for the simulation was 
an x-ray structure solved by Berman, et al.52 The crystal was of the C2/c space group 
(monoclinic crystal; unit cell dimensions are a = 21.7 Å, b = 6.37 Å, c = 42.7 Å; α = γ = 
90.0º, β = 107.0º).  The netropsin molecule was built using the CHARMM program,47 
and the HBUILD algorithm53 was used to add hydrogens to netropsin.  The structure also 
contained five crystallographic waters and one sulfate ion, which were retained for the 
simulation.  No additional water or ions were added to the system.  The system was then 
energy minimized using the steepest descent algorithm (SD) for 500 steps and for 100 
steps using the ABNR algorithm to an energy convergence of 0.001 kcal/mol.  Dynamics 
were then performed for 5 ns.  
2.4.4. DNA with Bound Polyamides. The initial structure for the simulations was 
the x-ray crystal structure PDB3 id 1CVY.54 The crystal contained a DNA decamer (5’-
CCAGATCTGG-3’) with two polyamides bound antiparallel in the minor groove 
(polyamide sequence was ImPyPyPy-β-Dp).  The polyamides recognize the six base pair 
target site 5’-AGATCT-3’.  In addition to the two DNA strands and two polyamides, the 
structure also contained 52 crystallographic waters.  The structure was solved to 2.15 Å 
resolution, and the crystal is of the P212121 space group (orthorhombic crystal; unit cell 
dimensions are a = 36.4 Å, b = 38.7 Å, c = 47.2 Å; α = β = γ = 90.0º).  The DNA-
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polyamide complex was generated in CHARMM using the revised nucleic acids 
parameters.6, 7 The HBUILD algorithm53 was used to add hydrogens to the DNA and 
polyamide molecules, and the hydrogens were then energy minimized for 50 steps using 
the steepest descent (SD) algorithm.  The 52 crystallographic waters were also added to 
the system.  The simulation was performed on the asymmetric unit of the crystal; this 
contained all the atoms of the DNA duplex and the two polyamides.  Water was added to 
fill the vacuum spaces in the crystal by generating the primary and image atoms of the 
DNA, polyamide, and crystallographic waters and overlaying them with a waterbox that 
was larger than the dimensions of the asymmetric unit (waterbox dimensions were 59.9 Å 
x 59.9 Å x 63.8 Å).  The waterbox was centered over the primary atoms, and any water 
molecules within 2.5 Å of the DNA or polyamides were deleted.  The waterbox was then 
overlayed three times with the original atoms and rotated 90º each time in order to obtain 
the correct density for the crystal (the first time the waterbox was rotated 90º degrees 
about the x-axis, the second time the waterbox was rotated 90º about the y-axis, and the 
third time the waterbox was rotated 90º about the z-axis).  Any overlapping waters with 
the original atoms were deleted.  An image update and image centering was then 
performed in order to delete the appropriate amount of waters for the size and symmetry 
of the unit cell.  The waters that moved after the image update and centering were 
deleted. No ions were identified or reported in the published x-ray crystal structure, and 
none were added. The water, DNA, and polyamide were energy minimized for 500 steps 
of steepest descent to an energy convergence of 0.001 kcal/mol.  The water was then 
equilibrated for 20 ps using the NVT ensemble with the DNA and polyamide constrained 
(RMSD of waters converged to ~5.6 Å).  Following relaxation of water, the constraints 
 94
on the DNA and polyamide were released, and all atoms were allowed to relax for 20 ps 
in the NVT ensemble (RMSD of whole complex and waters converged to ~5.8 Å; 
average RMSD of DNA/polyamide complex was 0.65 Å).  All atoms were then subjected 
to dynamics for 10 ns at 300 K.  Many studies involving DNA crystal simulations are 
performed at 300 K.7, 19, 24, 55, 56 Two more simulations were also run at 300 K; however, 
the systems were perturbed by rotating the waterbox –90º about the y-axis (rotated 90º 
about the x- and z-axes) and –90º about the z-axis (rotated 90º about the x- and y-axes) 
during the reoverlaying procedure (perturbing the systems in this way gave different 
initial coordinates for the solvent atoms and thus allowed for better sampling of 
conformational space57-61).   The systems were prepared in the same way as described 
above, and data was then collected over 10 ns in the NPT ensemble.  Because the x-ray 
crystal data was collected at –160ºC (113 K), four simulations were run at 113 K.  The 
systems were set up and run in the same way as the simulations run at 300 K (rotations of 
the waterbox, equilibration, and data collection were done in the same way as the 300 K 
crystal simulations).   
In order to improve sampling of conformational space, four more simulations 
were run at 113 K and three more simulations were run at 300 K.   Principal component 
analysis (PCA) was performed, and points (structures) that were close to the x-ray value 
on the PCA plots were used as the starting structures for the additional simulations.  In 
order to perturb the systems, each simulation was started from different initial velocities.   
A simulation was also performed with a hydroxypyrrole-containing polyamide.  
The initial structure for the simulations was the x-ray crystal structure PDB3 id 1CVX.54 
The crystal contained the DNA decamer (5’-CCAGATCTGG-3’) with two polyamides 
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bound antiparallel in the minor groove (polyamide sequence was ImPyHpPy-β-Dp).  As 
with the other simulated Dervan polyamides, the polyamides recognize the six base pair 
target site 5’-AGATCT-3’.  In addition to the two DNA strands and two polyamides, the 
structure also contained 30 crystallographic waters, which were retained for the 
simulation.  The structure was solved to 2.27 Å resolution, and the crystal is of the P31 
space group (trigonal crystal; unit cell dimensions are a = 31.2 Å, b = 31.2 Å, c = 46.1 Å; 
α = β = 90.0º, γ = 120.0°). The system was set up and generated similarly to the other 
DNA/polyamide complex simulations, and the simulation was run for 10 ns at 103 K. 
2.4.5. DNA/Netropsin Complex.  The initial structure for the simulation was the x-
ray crystal structure PDB3 id 121D.62  The crystal contained a DNA dodecamer (5’-
CGCAAATTTGCG-3’) with the drug netropsin in the minor groove.  Netropsin has a 
binding preference for AT sequences over GC sequences, and in this structure, netropsin 
covers five of the six AT base pairs of the DNA fragment.  In addition to the two DNA 
strands and netropsin, the structure also contained 47 crystallographic waters, which were 
retained for the simulation.  The structure was solved to 2.2 Å resolution, and the crystal 
is of the P212121 space group (orthorhombic crystal; unit cell dimensions are a = 25.65 Å, 
b = 42.03 Å, c = 65.33 Å; α = β = γ = 90.0º).  The system was set up and generated 
similarly to the DNA/polyamide complex simulations, and the simulation was run for 10 
ns at 300 K. 
2.4.6. DNA/Distamycin Complex.  The initial structure for the simulation was the 
x-ray crystal structure PDB3 id 121D.63  The crystal contained a DNA dodecamer (5’-
CGCAAATTTGCG-3’) with the drug netropsin in the minor groove.  Like netropsin, 
distamycin has a binding preference for AT sequences over GC sequences, and in this 
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structure, distamycin covers five of the six AT base pairs of the DNA fragment.  In 
addition to the two DNA strands and distamycin, the structure also contained 75 
crystallographic waters, which were retained for the simulation.  The structure was solved 
to 2.2 Å resolution, and the crystal is of the P212121 space group (orthorhombic crystal; 
unit cell dimensions are a = 25.20 Å, b = 41.07 Å, c = 64.65 Å; α = β = γ = 90.0º).  The 
system was set up and generated similarly to the DNA/polyamide and DNA/netropsin 
complex simulations, and the simulation was run for 10 ns at 288 K. 
2.4.7. Netropsin and DNA/Complex Simulations Using AMBER parameters.  Two 
tests were performed using previously described parameters intended for use with the 
AMBER64 force field.65, 66 The first test was a simulation of a netropsin crystal; the 
starting structure was the same used for the netropsin crystal simulation with the new 
CHARMM parameters, which is that by Berman, et al.52  The simulation was prepared 
and run for 5 ns in the same way as the netropsin simulation using the CHARMM 
parameters.  The second test was a crystal simulation of a DNA/netropsin complex.  The 
starting structure for the simulation was the same as that used for the new CHARMM 
parameters (PDB3 id 121D62).  The system was set up and run identically to the 
CHARMM DNA/netropsin simulation.  The system contained the same amount of water 
and was started from the same initial velocities as the CHARMM simulation and run for 
10 ns at 300 K. 
2.4.8. Quantum Mechanical Calculations (retinoid model compounds).  
Optimization and frequency calculations were carried out on the model compounds at the 
MP2/6-31G(d) level of theory.  In order to obtain the potential energy surfaces (PES) for 
selected torsion angles,  torsion energies were calculated by holding the selected torsion 
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angle fixed at different increments (20º increments from –180º to 180º) and geometry 
optimizing all other degrees of freedom at the three levels of theory mentioned above.   
 2.4.9. Small Retinoid Crystal Simulations.  For the retinoid crystal simulations, 
the unit cell was built using the CHARMM program.47  No water or ions were reported in 
the x-ray structures, and none were added.  The systems were energy minimized using the 
steepest descent algorithm (SD) for 500 steps and for 1000 steps using the ABNR 
algorithm to an energy convergence of 0.001 kcal/mol.  All simulations were carried out 
at the temperature in which the crystal structure was determined, unless noted otherwise.   
2.4.9.1. All-Trans Retinal Crystal. The initial structure for the simulation was the 
x-ray crystal structure CSD67 id TRETAL0168 (space group P21 (monoclinic), unit cell 
dimensions were a = 15.27 Å, b = 8.26 Å, c = 14.94 Å; α = γ = 90.0°, β = 104.7°; four 
retinal molecules were reported for the unit cell, which was what was used for the 
simulation).  Five molecular dynamics simulations started from different velocities were 
then performed for 1 ns at 273 K. 
2.4.9.2. All-Trans Retinoic Acid Crystal (Monoclinic). The initial structure for the 
simulation was the x-ray crystal structure CSD67 id VITAAC0169 (space group P21 
(monoclinic), unit cell dimensions were a = 8.078 Å, b = 34.103 Å, c = 7.387 Å; α = β = 
90.0°, γ = 118.76°).  The retinoic acid molecule parameterized for the force field is the 
deprotonated form; however, the crystal structure of the ligand contained the protonated 
form.  A patch analogous to the existing patches for neutral aspartic acid or neutral 
glutamic acid was made in order to protonate the retinoic acid.   Five molecular dynamics 
simulations started from different velocities were then performed for 1 ns at 393 K.   
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2.4.9.3. All-Trans Retinoic Acid Crystal (Triclinic). The initial structure for the 
simulation was the x-ray crystal structure CSD67 id TRETAL1070 (space group P1' 
(triclinic), unit cell dimensions were a = 8.04 Å, b = 28.49 Å, c = 5.996 Å; α = 50.58 °,β 
= 71.38°, γ = 95.7°; two molecules of retinoic acid were found in the unit cell, which was 
what was used for the simulation).  Five molecular dynamics simulations started from 
different velocities were then performed for 1 ns at 123 K. 
2.4.10. Protein/Retinoid Complex Crystal Simulations.  
 
2.4.10.1. Retinoic Acid Complexed with cellular retinoic acid binding protein II 
(CRABP II).  The initial structure for the simulation was the x-ray crystal structure PDB3 
id 1CBS71 (resolution 1.80 Å; space group P212121 (orthorhombic), unit cell dimensions 
were a = 45.65 Å, b = 47.56 Å, c = 77.61 Å; α = β = γ = 90.00).   The retinoid-protein 
complex was generated in CHARMM using the revised protein parameters,48 the 
HBUILD algorithm53 in CHARMM was used to add hydrogens to the protein and ligand 
molecules, and the hydrogens were then energy minimized for 50 steps using the steepest 
descent (SD) algorithm (energy tolerance was 0.001 kcal/mol).  The 100 crystallographic 
waters present in the x-ray structure were added, and three sodium ions were added to 
neutralize the system (no ions were reported in the crystal structure).  The sodium ions 
were placed randomly, and they were all placed at least 10 Å away from the protein to 
avoid bad contacts.  The crystal was then built using the CRYSTAL50 facility in 
CHARMM.  Water was added to fill the vacuum spaces in the crystal by generating the 
primary and image atoms of the protein, ligand, and crystallographic waters and 
overlaying them with a waterbox that was larger than the dimensions of the asymmetric 
unit (waterbox dimensions were 59.9 Å × 59.9 Å × 63.8 Å).  The waterbox was centered 
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over the primary atoms, and any water molecules within 2.5 Å of the protein or ligand 
were deleted.  The waterbox was then overlayed three times with the original atoms and 
rotated 90º each time in order to obtain the correct density for the crystal (the first time 
the waterbox was rotated 90º degrees about the x-axis, the second time the waterbox was 
rotated 90º about the y-axis, and the third time the waterbox was rotated 90º about the z-
axis).  Any overlapping waters with the original atoms were deleted (overlapping atoms 
were any atoms within 2.8 Å of the original atoms).  An image update and image 
centering was then performed in order to delete the appropriate amount of waters for the 
size and symmetry of the unit cell.  The waters that moved after the image update and 
centering were deleted.  The water, ions, protein, and ligand were energy minimized for 
500 steps of steepest descent to an energy convergence of 0.001 kcal/mol. The solvent 
was then equilibrated for 20 ps using the NVT ensemble with the protein and retinoic 
acid constrained.  Following relaxation of water, the constraints on the protein/ligand 
complex were released, and all atoms were allowed to relax for 20 ps in the NVT 
ensemble (RMSD of whole complex and solvent converged to ~14 Å; average RMSD of 
protein/retinoic acid  complex after equilibration was 0.89 Å).  All atoms were then 
subjected to dynamics for 2 ns at 277 K.  
2.4.10.2. Retinol Complexed with Cellular Retinol Binding Protein (CRBP) from 
Zebrafish.  The initial structure for the simulation was the x-ray crystal structure PDB3 id 
1KQW72 (resolution 1.38 Å; space group I4 (tetragonal), unit cell dimensions were a = 
89.02 Å, b = 89.02 Å, c = 38.27 Å; α = β = γ = 90.00).   The retinoid-protein complex 
was generated in CHARMM in the same way as the retinoic acid/CRABP II system.  The 
crystal structure was determined at pH 5.60, so the His residues were protonated for the 
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simulation.  The 194 crystallographic waters present in the x-ray structure were added, 
and three chlorine ions were added to neutralize the system (no ions were reported in the 
crystal structure).  The chloride ions were placed randomly and at least 10 Å away from 
the protein to avoid bad contacts.  The crystal was then built, and water was added to fill 
the vacuum spaces in the crystal in the same way as for the retinoic acid/CRABP II 
system.  Equilibration and dynamics were performed on the retinol/CRBP complex in the 
same way as for the retinoic acid/CRABP II complex.  All atoms were then subjected to 
dynamics for 2 ns at 100 K.  
2.4.10.3. Fenretinide Complexed with retinol binding protein (RBP).  The initial 
structure for the simulation was the x-ray crystal structure PDB3 id 1FEL73 (resolution 
1.80 Å; space group P212121 (orthorhombic), unit cell dimensions were a = 46.63 Å, b = 
49.26 Å, c = 76.64 Å; α = β = γ = 90.00).  The last 8 residues (176-183) are unresolved 
for this x-ray structure, so the missing residues were generated with homology modeling 
using the MOE homology program74, 75 based on a segment matching procedure.76  The 
residues generated with the homology modeling were then energy minimized with 
steepest descent to an energy convergence of 0.001 kcal/mol, while holding the rest of the 
protein/ligand complex fixed. The retinoid-protein complex was then generated in 
CHARMM in the same way as the retinoic acid/CRABP II and retinol/CRBP systems. 
Bovine RBP contains three disulfide bridges.   The crystal structure was determined at 
pH 5.0-5.3, so the His residues were protonated for the simulation.  The 163 
crystallographic waters present in the x-ray structure were added, and one sodium ion 
was added to neutralize the system, which was placed randomly (no ions were reported in 
the crystal structure).  The crystal was then built, and water was added to fill the vacuum 
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spaces in the crystal in the same way as for the retinoic acid/CRABP II and the 
retinol/CRBP systems.  Equilibration and dynamics were performed on the 
fenretinide/RBP complex in the same way as for the other systems.  All atoms were then 
subjected to dynamics for 3 ns at 275 K.  
 2.4.10.4. Retinal Complexed with Sensory Rhodopsin II (SRII).  The initial 
structure for the simulation was the x-ray crystal structure PDB3 id 1H6877 (resolution 
2.10 Å; space group C2221 (orthorhombic), unit cell dimensions were a = 84.83 Å, b = 
128.74 Å, c = 50.74 Å; α = β = γ = 90.00).   The asymmetric unit of the x-ray structure 
contains one chain, and this is how SRII is thought to exist biologically; however, the 
oligomeric state of SRII is unknown.  The first residue and the last 20 residues (220-239) 
are unresolved for this x-ray structure, so the missing residues were generated with 
homology modeling using the MOE homology program.74, 75  The residues generated 
with the homology modeling were then energy minimized with steepest descent to an 
energy convergence of 0.001 kcal/mol while holding the rest of the protein/ligand 
complex fixed.  The retinoid-protein complex was then generated in CHARMM in the 
same way as the other protein/ligand systems.   The crystal structure was determined at 
pH 4.6 so the His residues were protonated for the simulation.  The 27 crystallographic 
waters and one chloride ion present in the x-ray structure were added, and three sodium 
ions were added to neutralize the system.  The sodium ions were randomly placed at least 
10 Å away from the protein to avoid bad contacts.  The crystal was then built, and water 
was added to fill the vacuum spaces in the crystal in the same way as for the other 
protein/ligand systems.  Equilibration and dynamics were performed on the retinal/SRII 
complex similar to the other systems. The solvent was equilibrated for 30 ps in the NVT 
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ensemble, and the whole system was then equilibrated for 30 ps in the NVT ensemble 
(average RMSD of retinal/SRII complex after equilibration was 1.67 Å).  All atoms were 
then subjected to dynamics for 2 ns at 100 K.  
2.4.10.5. Retinal Complexed with Bacteriorhodopsin (BR).  The initial structure 
for the simulation was the x-ray crystal structure PDB3 id 1PXR78 (resolution 1.70 Å; 
space group P1211 (monoclinic), unit cell dimensions were a = 44.97 Å, b = 108.84 Å, c 
= 55.98 Å; α = γ = 90.00, β = 113.60º).  The asymmetric unit of this x-ray structure 
contains two chains; however, native BR exists in the purple membrane of 
Halobacterium salinarum as a trimeric structure.79 Also, this structure is a P50A mutant.  
The first five residues and the last 18 residues (232-249) are unresolved in both chains for 
this x-ray structure, so the missing residues were generated with homology modeling 
using the MOE homology program.74, 75 The residues generated with the homology 
modeling were then energy minimized with steepest descent to an energy convergence of 
0.001 kcal/mol, while holding the rest of the protein/ligand complex fixed.  The retinoid-
protein complex was then generated in CHARMM in the same way as the other 
protein/ligand systems.   The crystal structure was determined at pH 3.5 so the His 
residues were protonated for the simulation. Only solvent-exposed Glu and Asp residues 
were protonated.  The 124 crystallographic waters present in the x-ray structure were 
added, and ten chloride ions were added to neutralize the system.  The ions were 
randomly placed ~10 Å away from the protein to avoid any bad contacts.  The crystal 
was then built, and water was added to fill the vacuum spaces in the crystal in the same 
way as for the other protein/ligand systems.  Equilibration and dynamics were performed 
on the retinal/BR complex similarly to the other systems. The solvent was equilibrated 
 103
for 30 ps in the NVT ensemble, and the whole system was then equilibrated for 30 ps in 
the NVT ensemble.  All atoms were then subjected to dynamics for 3.5 ns at 110 K.  
2.4.11. Crambin Simulations (Convergence Analysis).  Molecular dynamics 
simulations were performed using the CHARMM program47 and the CHARMM force 
field.6 Calculations were conducted using the computational resources at the Pittsburgh 
Supercomputing Center. The water model in all simulations was TIP3P.49 Crystal 
simulations employed the CRYSTAL50 facility in CHARMM. Molecular dynamics 
simulations were performed in the NPT51 ensemble using the Leap-Frog integrator and 
periodic boundary conditions with the SHAKE9 algorithm applied to covalent hydrogen 
bonds, which allowed for a 0.002 ps timestep.  A dielectric constant of 1.0 was used in all 
simulations. Electrostatics were treated using the particle-mesh Ewald method.16 Ewald 
calculations were performed using the specified real space cutoffs with the Lennard-
Jones interactions truncated at the same distance.  Kappa (screening parameter) was set to 
0.36; the order parameter was set to 6. Nonbond pair lists were maintained to 14 Å, 
nonbond interactions were truncated at 12 Å, and the image cutoff was kept at 14.0 Å.  
Nonbond lists, hydrogen bond lists, and image lists were updated heuristically. The 
volumes of the systems were monitored to ensure that there were only minimal 
fluctuations in the volume over time.  Snapshots of the systems were saved every ten 
picoseconds.   
2.4.11.1. Long-time protein simulations. The initial protein (crambin) structure for 
all simulations was PDB3 id 1EJG.80 The crystal contained only the 46-residue protein 
crambin; no water or ions were reported in the structure. The structure was solved to 0.54 
Å resolution, and the crystal was of the P21 space group (monoclinic crystal; unit cell 
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dimensions were a = 40.82 Å, b = 18.50 Å, c = 22.37 Å; α = γ = 90.0º, β = 90.47º).  The 
protein was generated in CHARMM using the revised protein backbone parameters.48 
The HBUILD algorithm53 was used to add hydrogens to the protein molecule, and the 
hydrogens were then energy minimized for 50 steps using the steepest descent (SD) 
algorithm.  The simulation was performed on the asymmetric unit of the crystal, which 
contained only the protein. Water was added to fill the vacuum spaces in the crystal in the 
same way as was done for the DNA. No ions were added to the system, and the final 
system had a charge of 0.  The protein and water were energy minimized for 1000 steps 
of steepest descent to an energy convergence of 0.001 kcal/mol.  The water was then 
equilibrated for 20 ps using the NVT ensemble with the protein constrained.  Following 
relaxation of water, the constraints on the protein were released, and all atoms were 
allowed to relax for 20 ps in the NVT ensemble.  All atoms were then subjected to 
dynamics for 45 ns at 100 K, which was the temperature at which the x-ray crystal 
structure was determined. Nine more simulations were also run at 100 K; however, the 
systems were perturbed by assigning different initial velocities to the atoms in each 
simulation.   The systems were prepared in the same way as described above, and data 
was then collected over 45 ns in the NPT ensemble.  Snapshots were saved every 10 ps. 
The total simulation time over all ten simulations was 450 ns.   
2.4.11.2. Short-time protein simulations. The systems were set up in the same way 
as for the long-time simulations (same starting coordinates and protocol).  Each 
simulation was started from different initial velocities in order to introduce a 
perturbation.  Snapshots were collected every 10 ps.  Ten 2 ns simulation were run.  The 
first 2 ns of the long-time simulations were used along with the 10 short simulations for 
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data analysis of short-time simulations to give a total of 20 short simulations (total 
simulation time was 40 ns).  
2.4.12. DNA Simulations (Convergence Analysis).  Molecular dynamics 
simulations were performed using the CHARMM program47 and the CHARMM force 
field.6 Calculations were conducted using the computational resources at the Pittsburgh 
Supercomputing Center. The water model in all simulations was TIP3P.49 Crystal 
simulations employed the CRYSTAL50 facility in CHARMM. Molecular dynamics 
simulations were performed in the NPT51 ensemble using the Leap-Frog integrator and 
periodic boundary conditions with the SHAKE9 algorithm applied to covalent hydrogen 
bonds, which allowed for a 0.002 ps timestep.  A dielectric constant of 1.0 was used in all 
simulations. Electrostatics were treated using the particle-mesh Ewald method.16 In the 
case of charged systems, electrostatics were treated using the modified particle mesh 
Ewald method for net-charged systems.21 This modified Ewald summation is 
implemented in versions 25 and higher of the CHARMM program.  Ewald calculations 
were performed using the specified real space cutoffs with the Lennard-Jones interactions 
truncated at the same distance.  Kappa (screening parameter) was set to 0.36; the order 
parameter was set to 6. Nonbond pair lists were maintained to 14 Å, nonbond interactions 
were truncated at 12 Å, and the image cutoff was kept at 14.0 Å.  Nonbond lists, 
hydrogen bond lists, and image lists were updated heuristically. The volumes of the 
systems were monitored to ensure that there were only minimal fluctuations in the 
volume over time.  Snapshots of the systems were saved every 10 ps.  
2.4.12.1. Long-time DNA Simulations. The initial DNA structure for all 
simulations was the x-ray crystal structure PDB3 id 119D.81 The crystal contained a DNA 
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dodecamer (5’-CGTAGATCTACG-3’) along with 1 Mg+2 ion, which was retained for 
the simulations, and 137 crystallographic waters, which were also retained.    The 
structure was solved to 2.25 Å resolution, and the crystal was of the C2 space group 
(monoclinic crystal; unit cell dimensions were a = 64.83 Å, b = 35.36 Å, c = 25.35 Å; α = 
γ = 90.0º, β = 92.24º).  The DNA dodecamer was generated in CHARMM using the 
revised nucleic acids parameters.6, 7 The HBUILD algorithm53 was used to add hydrogens 
to the DNA molecule, and the hydrogens were then energy minimized for 50 steps using 
the steepest descent (SD) algorithm. The 137 crystallographic waters were then added to 
the system.  The simulation was performed on the asymmetric unit of the crystal; this 
contained all the atoms of the DNA duplex and the one Mg2+ ion.  Water was added to 
fill the vacuum spaces in the crystal by generating the primary and image atoms of the 
DNA, Mg2+ ion, and crystallographic waters and then overlaying them with a waterbox 
that was larger than the dimensions of the asymmetric unit (waterbox dimensions were 
59.9 Å x 59.9 Å x 63.8 Å).  The waterbox was centered over the primary atoms, and any 
water molecules within 2.5 Å of the DNA or magnesium ion were deleted.  The waterbox 
was then overlayed three times with the original atoms and rotated 90º each time in order 
to obtain the correct density for the crystal (the first time the waterbox was rotated 90º 
degrees about the x-axis, the second time the waterbox was rotated 90º about the y-axis, 
and the third time the waterbox was rotated 90º about the z-axis). Any overlapping waters 
with the original atoms were deleted.  An image update and image centering was then 
performed in order to delete the appropriate amount of waters for the size and symmetry 
of the unit cell.  The waters that moved after the image update and centering were 
deleted. Only the Mg2+ ion that was identified and reported in the published x-ray crystal 
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structure was used in the system; no additional ions were added. The water, DNA, and 
magnesium ion were energy minimized for 500 steps of steepest descent to an energy 
convergence of 0.001 kcal/mol. The water and Mg2+ ion were then equilibrated for 20 ps 
using the NVT ensemble with the DNA constrained (RMSD of waters converged to ~5.6 
Å).  Following relaxation of water, the constraints on the DNA were released, and all 
atoms were allowed to relax for 20 ps in the NVT ensemble (RMSD of DNA and waters 
converged to ~5.8 Å; average RMSD of DNA only was 0.65 Å).  All atoms were then 
subjected to dynamics for 150 ns at 288 K, which was the temperature at which the x-ray 
crystal structure was determined.  Many studies involving DNA crystal simulations are 
performed at 300 K.7, 19, 24, 55, 56 Three more simulations were also run at 288 K; however, 
the systems were perturbed by rotating the waterbox  –90º about the y-axis (rotated 90º 
about the x- and z-axes) and –90º about the z-axis (rotated 90º about the x- and y-axes) 
during the reoverlaying procedure (perturbing the systems in this way gave different 
initial coordinates for the solvent atoms and thus allowed for better sampling of 
conformational space57, 58, 61). The systems were prepared in the same way as described 
above, and data was then collected over 150 ns in the NPT ensemble.  The total 
simulation time over all four simulations was 600 ns.   
2.4.12.2. Short-time DNA Simulations. The short DNA simulations were set up 
similarly to the long-time simulations (same starting DNA structure, same protocol used).  
Each system was starting from different initial solvent coordinates in order to introduce a 
perturbation in each simulation.  This was achieved by rotating the waterbox in different 
degrees about the x-, y-, and z-axes.  A total of 20 simulations were run for 2 ns each 
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(total of 40 ns).  Snapshots were saved every 10 ps.  Listed below are the rotations of the 
waterbox about each axis for the 20 simulations.   
Table 2.1 Rotations about x, y, and z axes for short DNA simulations  
Simulation  x y z 
1 20 20 -20 
2 25 25 -25 
3 30 30 -30 
4 35 35 -35 
5 40 40 -40 
6 45 45 -45 
7 50 50 -50 
8 55 55 -55 
9 60 60 -60 
10 65 65 -65 
11 70 70 -70 
12 75 75 -75 
13 80 80 -80 
14 85 85 -85 
15 100 100 -100 
16 105 105 -105 
17 110 110 -110 
18 115 115 -115 
19 120 120 -120 
20 125 125 -125 
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Chapter 3  
 
 
Force Field Parameters for DNA Minor Groove-Binding 
Pyrrole-Imidazole Polyamides and Significance of Multiple 
Simulations 
 
This chapter describes the parameterization procedure for the DNA minor groove-
binding polyamides, the results of the crystal simulations performed to test the 
parameters, and conclusions made from the study.   
3.1 Parameterization of DNA minor groove-binding polyamides        
         Parameterization of the polyamides began by first dividing the polyamides into six 
model compounds and carrying out energy minimization using MP2/6-31G(d), which 
includes the effects of electron correlation and dispersive interactions.  The bond, angle, 
torsional, and improper terms were modified to match the quantum mechanical results. 
The parameters were evaluated by performing molecular dynamics crystal simulations of 
the reported x-ray crystal structures of a netropsin crystal, 2:1 Dervan polyamide/DNA 
complexes, a netropsin/DNA complex, and a distamycin/DNA complex. The new 
parameters can be used for improved simulations of polyamides and their nucleic acid 
complexes.  
Parameterization was performed by first dividing the molecule into components, 
otherwise known as model compounds.1-15  The models, shown in Figure 3.1, consist of 
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three commonly used heterocycles for DNA recognition (N-methylpyrrole, N-
methylimidazole, and N-methylhydroxypyrrole), β-alanine used for enhancing flexibility 
of the molecule, a cationic tail (dimethylaminopropylamide) used for phosphate binding, 
and γ-aminobutyric acid as a linker in hairpin polyamides.  Since heterocycles and linkers 
are joined together in the polyamide by amide bonds, compounds that contain terminal 
amide groups to represent the linkage to another heterocycle or linker in the polyamide 
sequence were chosen.  
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Figure 3.1 Model compounds for polyamides (some hydrogens not shown for clarity). 
 
 
Each model compound was energy minimized using MP2/6-31G(d).  Model 
compound 1 was also minimized using CCSD/6-31G(d) to verify the MP2 results.  
Comparison of MP2 and CCSD energy minimized structures revealed that the error for 
bonds was 0.003 ± 0.005 Å, 0.2 ± 0.1º for angles, and 0.4 ± 0.3º for dihedral angles. The 
comparison indicated that the MP2/6-31G(d) level of theory is appropriate for force field 
parameterization, a result in agreement with others for parameterization of polymers.16, 17  
For comparison, the structures were also energy minimized using HF and B3LYP with 
the 6-31G(d) basis set.  Initial topology and parameters were then created from existing 
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compounds in the CHARMM force field.18 Indole was the starting point for the pyrrole-
based rings (1 and 3), histidine was the starting point for the imidazole ring (2), and N-
methylacetamide was the starting point for the tail and linker compounds (4, 5, 6).   
The initial topology and parameters were then modified to match the quantum 
mechanical results. The minimized bond lengths and angle values obtained from the MP2 
optimized structures were used as the equilibrium bond lengths and equilibrium angle 
values for the new CHARMM parameters for the associated bond and angle types.  Each 
model compound was energy minimized with the CHARMM force field with steepest 
descent and Newton-Raphson (tolerance gradient was 10-6 kcal/mol/Å for each 
minimization).  The parameters where then adjusted to minimize the error with the 
MP2/6-31G(d) structure.  The average error between CHARMM and MP2 is 0.02 ± 0.02 
Å for bond distances and 2 ± 2º for angles.  
In addition to bonds and angles, torsion terms were also parameterized. For each 
model compound, the potential energy surfaces (PES) for selected torsion angles (see 
Figures 3.2-3.7 for selected torsion angles; the bonds with the arrows were the bonds 
which were rotated about) were calculated by holding the selected torsion angle fixed at 
different increments (30º increments from –180º to 180º) and geometry optimizing all 
other degrees of freedom.  The torsion angles selected were for rotations about the bonds 
connecting the amide groups to the heterocycle, the bond connecting the methyl group to 
the heterocycle, and the carbon-carbon single bonds of the linker and tail model 
compounds.  The torsion angles selected are necessary for the polyamide to optimize 
contacts with the bases of the minor groove of DNA.  The CHARMM dihedral angle 
parameters force constant (Kχ), multiplicity (n), and phase shift (δ) were then modified to 
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match the quantum mechanical results from the potential energy surfaces.  Each model 
compound was energy minimized in CHARMM (steepest descent and Newton-Raphson; 
tolerance gradient was 10-6 kcal/mol/Å) with the selected torsion angle held fixed, and the 
potential energy surface of the dihedral was calculated.  If the surface did not match the 
MP2 results, the multiplicity, phase shift, or force constant were adjusted as necessary.  
After the results from the CHARMM compounds matched those obtained from the QM 
calculations, the model compounds were pieced together to make the entire polyamide 
molecule for use in molecular mechanics energy minimization or molecular dynamics 
simulations.   
For N-methylpyrrole, (1) three dihedrals were selected for parameterization, 
which are the rotation of the methyl group and the rotation of the two amide groups on 
the ring.  The most flexible points on the polyamide are most likely along the backbone 
where the heterocycles are connected to the amide groups. The polyamide will have to 
rotate around those bonds to optimize interactions with the DNA, and the methyl groups 
on the ring have free rotation, which will interact with the DNA through van der Waals 
contacts, so they will also have to rotate to optimize their interactions with the DNA.  The 
heterocycles themselves are aromatic, so the rings stay planar.  The initial CHARMM 
parameters for three important dihedrals borrowed from similar functionality did not 
agree with the MP2/6-31G(d) potential energy surface (Figure 3.2).  For example, the 
methyl rotation (β) is 180° out of phase, both amide groups have energy barriers that are 
too high (~3.4 kcal/mol too high for α and ~4.1 kcal/mol too high for γ), and the second 
amide rotation (γ) does not give the lowest energy at 0°.  The energies obtained from 
HF/6-31G(d) and B3LYP/6-31G(d) do not necessarily match those obtained with MP2/6-
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31G(d).  For the methyl rotation, B3LYP gives a barrier at 0°, whereas MP2 gives a 
minimum.  HF shows the correct phase for methyl rotation with similar barriers to MP2.  
As shown for the α torsional plot, HF barriers are 34% lower than MP2.   
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Figure 3.2 Structure (top) and the three torsion energy plots for N-methylpyrrole. Blue 
diamond (♦), initial CHARMM; red square (+), MP2/6-31G(d); green triangle (▲), final 
CHARMM; pink x (X), B3LYP/6-31G(d); purple star (*), HF/6-31G(d).   
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and the methyl group on the imidazole ring.  The results for the imidazole torsions are 
shown in Figure 3.3. The initial CHARMM parameters for N-methylimidazole borrowed 
from similar functionality are also in poor agreement with the MP2/6-31G(d) results.  
The methyl rotation is out of phase by 60º, and the energy barriers are ~1.5 kcal/mol too 
high.  Both amide group rotations do not show the correct behavior. The first amide 
group rotation (α) should have a maximum at 180º and –180º; instead the maxima are at 
90º and –90º.  The second amide group rotation (γ) has energy barriers that are ~6.3 
kcal/mol too high, and there are minima at 180º and –180º, which the MP2 does not 
show.  The HF and B3LYP results agree well with MP2 for both the amide group 
rotations; however, for the methyl rotation, the B3LYP is 30º out of phase.   
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Figure 3.3  Structure (top) and the three torsion energy plots for N-methylimidazole. 
Blue diamond (♦), initial CHARMM; red square (+), MP2/6-31G(d); green triangle (▲), 
final CHARMM; pink x (X), B3LYP/6-31G(d); purple star (*), HF/6-31G(d).   
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Four torsions were chosen for hydroxypyrrole (3), the two amide group rotations, 
the methyl group rotation, and the OH group rotation.  The OH group rotation was 
chosen for this model compound because the H of the hydroxyl group hydrogen bonds 
with the O2 of thymine, so this group will have to rotate to optimize interaction with the 
DNA.  The results for hydroxypyrrole are shown in Figure 3.4.  The initial CHARMM 
parameters are in poor agreement with the MP2/6-31G(d) results; all of the selected 
torsion angles are out of phase, the energy barriers are too high for the methyl rotation 
(~1.3 kcal/mol) and the OH group rotation (~17.0 kcal/mol), and all but the methyl 
rotation show the incorrect multiplicity.  The final CHARMM parameters give correct 
methyl rotation barriers and show the right multiplicity, the rotation of the OH group on 
the pyrrole ring shows the correct maximum, the rotation of the first amide group (α) 
shows the correct minimum and multiplicity, and the rotation of the second amide group 
shows the correct barrier heights.  The height of the small maximum at 0º is ~2.5 
kcal/mol higher than that of the MP2 results; however, this is the best agreement that 
could be obtained in order to obtain simultaneous agreement for the other dihedrals of the 
hydroxypyrrole model compound.  The second amide torsion plot (γ) shows a minimum 
at 180º and a small maximum at 0º, whereas the other heterocycles show the global 
minimum at 0º for this torsion surface.  The MP2 calculations are carried out in the gas 
phase, so the amide group rotates 180º for the carbonyl oxygen to form a hydrogen bond 
with the H of the OH group, lowering the energy.   The other heterocycles do not have 
the OH group; therefore, the minimum is at 0º for the others. Both HF and B3LYP are in 
reasonable agreement with MP2 for δ; they both give the correct phase, multiplicity, and 
a maximum at 0º.  HF is 0.65 kcal/mol lower than MP2, and B3LYP is 0.52 kcal/mol 
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lower than MP2.  HF shows good agreement with MP2 for β and γ.  For β, HF shows the 
correct phase and multiplicity and is 0.28 kcal/mol higher than MP2.  For γ, HF again 
shows the correct phase and multiplicity and is 0.39 kcal/mol higher than MP2.  
However, HF shows poor agreement with MP2 for α; HF gives a maximum at 150º, and 
a minimum at 180º, while MP2 gives a maximum at 180º.  B3LYP shows reasonable 
agreement with MP2 for α and β.  For α, B3LYP gives the correct phase and multiplicity, 
and the maximum at 180º is 0.92 kcal/mol lower than MP2.  For β, B3LYP shows the 
correct phase and multiplicity, and the barriers are ~0.32 kcal/mol lower than MP2.  For 
γ, B3LYP shows the correct phase and multiplicity; however, the barriers at 90º and -90º 
are 3.41 kcal/mol higher than MP2.   
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Figure 3.4  Structure (top left) and the four torsion energy plots for hydroxypyrrole. Blue 
diamond (♦), initial CHARMM; red square (+), MP2/6-31G(d); green triangle (▲), final 
CHARMM; pink x (X), B3LYP/6-31G(d); purple star (*), HF/6-31G(d).   
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Similar analyses were carried out for the cationic tail (4), the γ-aminobutyric acid 
linker, and the β-alanine linker.  For the cationic tail, two dihedral angles were selected 
for rotation, which are for the rotation of the amide group and the rotation of the dimethyl 
amino group.   The torsion plots are shown in Figure 3.5.   
 
 
 
Figure 3.5 Structure (top) and the two torsion energy plots for the dimethylaminopropyl 
cationic tail. Blue diamond (♦), initial CHARMM; red square (+), MP2/6-31G(d); green 
triangle (▲), final CHARMM; pink x (X), B3LYP/6-31G(d); purple star (*), HF/6-
31G(d).   
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results than the initial heterocycle parameters.  The MP2 calculations were performed 
with two dihedrals constrained at 180º, which are marked by the straight red arrows.  The 
molecule was initially optimized with no constraints; however, in the gas phase, the 
molecule folded up on itself into a ball, so the constraints were necessary. The initial 
CHARMM parameters for the tail show the correct phase and number of minima and 
maxima; however, the energy barriers for both torsion angles are initially too low (1.34 
kcal/mol for α, and 1.78 kcal/mol for β).  Initially, constraints were placed on the same 
dihedrals in CHARMM when making the new parameters; however, the energy barriers 
were too high, and the constraints had to be removed.  The height of the energy barriers 
in the final CHARMM parameters is in good agreement with the calculated MP2 energy 
barriers (0.6 kcal/mol lower than MP2 for α and 0.43 kcal/mol lower for β). The HF and 
B3LYP results are in reasonable agreement with the MP2 results for α.  HF is 0.5 
kcal/mol lower than MP2 and B3LYP is 0.74 kcal/mol lower than MP2.  For β, the 
agreement is better with HF being 0.05 kcal/mol higher than MP2 and B3LYP being 0.52 
kcal/mol lower than MP2.   
Two dihedrals were selected for rotation for the γ-aminobutyric acid linker (5) and 
for the β-alanine linker (6).  For the γ-aminobutyric acid linker, the two dihedrals selected 
are for rotation of the amide groups.  The results are shown in Figure 3.6.  The initial 
CHARMM parameters for the γ-linker are in slight agreement with MP2, so they did not 
require significant modification. As with the cationic tail model compound, the MP2 
calculations were performed with two dihedrals constrained at 180º (the constrained 
dihedrals are marked by the straight red arrows) for the same reason they were place on 
the cationic tail.  Again, constraints were placed on the same dihedrals in CHARMM 
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initially, but the energy barriers were too high and could not be lowered until the 
constraints were removed.  The plots show the correct phase and multiplicity.  However, 
the one energy barrier is ~1.15 kcal/mol too high (α), and the other ~0.97 kcal/mol too 
low (β).  The final CHARMM gives energy barriers that are good agreement with MP2; 
6.24 kcal/mol for α, which is 0.19 kcal/mol higher than MP2, and 0.22 kcal/mol higher 
than MP2 for β. The energies for 120º and 150º for β do not follow the MP2 energies, but 
this is the best agreement that could be obtained in order to have both torsions agree well 
with MP2.  The HF and B3LYP results are in reasonable agreement with the MP2 results 
for both torsions.  For α, HF is 0.73 kcal/mol higher than MP2, and B3LYP is 0.34 
kcal/mol higher than MP2.  For β, the agreement is better; HF is 0.34 kcal/mol higher 
than MP2, and B3LYP is 0.09 kcal/mol higher than MP2.  
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 Figure 3.6  Structure (top) and the two torsion energy plots for the γ-aminobutyric acid 
linker. Blue diamond (♦), initial CHARMM; red square (+), MP2/6-31G(d); green 
triangle (▲), final CHARMM; pink x (X), B3LYP/6-31G(d); purple star (*), HF/6-
31G(d).   
 
As with the γ-aminobutyric acid linker, the two dihedrals selected for the β-
alanine linker are for rotation of the amide groups.  The results are shown in Figure 3.7.  
As for the tail and γ-linker model compounds, the torsion energy plots for the β-alanine 
linker show that the initial CHARMM parameters were in better agreement with MP2 
than were the initial heterocycle parameters. One dihedral was constrained at 180º 
(marked by the straight red arrow) for the MP2 calculations for the same reasons as the 
cationic tail and the γ-linker.  When the structure was energy minimized with CHARMM, 
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no constraints were used because the energy barriers were too high.  The energy barrier is 
~5.9 kcal/mol too high for α and the barrier is ~0.94 kcal/mol too low for β; however, 
they are in phase and show the correct multiplicity.  With adjustment of force constants, 
the final CHARMM parameters agree well with the MP2 results.  The energy barrier for 
β is ~0.10 kcal/mol higher than MP2, and α is 2.85 kcal/mol higher than MP2; however, 
this better than the initial CHARMM parameters and is the best agreement that could be 
obtained and still have both torsions agree well with the MP2 results. HF and B3LYP are 
in good agreement with MP2 for both dihedrals.  HF is 0.15 kcal/mol lower than MP2 
and B3LYP is 0.49 kcal/mol lower than MP2 for α.  For β, HF is 0.41 kcal/mol higher 
than MP2 and B3LYP is 0.39 kcal/mol lower than MP2.  
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Figure 3.7 Structure (top) and the two torsion energy plots for the -alanine linker. Blue 
diamond (♦), initial CHARMM; red square (+), MP2/6-31G(d); green triangle (▲), final 
CHARMM; pink x (X), B3LYP/6-31G(d); purple star (*), HF/6-31G(d).   
 
The same trend of systematic errors in multiplicity, phase shift, and force constant 
is observed for all six model compounds.  Because HF and B3LYP do not necessarily 
show the same behavior as MP2, electron correlation and dispersion effects are probably 
important for this class of compounds and are necessary in polyamide parameter 
development.  HF and B3LYP are therefore not appropriate methods to use for 
parameterization of these compounds.  
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Final CHARMM parameters for the model compounds produce structures and 
energies in good agreement with MP2/6-31G(d) results.  Overall, the error between 
CHARMM and MP2 geometry optimized structures is 0.02 ± 0.02 Å for bonds, 2 ± 2° for 
angles, and 5 ± 9° for dihedrals.  The error in barrier heights between CHARMM and 
MP2 is 0.38 ± 0.40 kcal/mol.  
3.2 DNA/polyamide Simulations in the Crystal Environment 
 
Simulations were performed in the crystal environment in order to validate the 
new force field parameters for polyamides.  There are several high-resolution crystal 
structures of DNA with bound polyamides available,1-3, 19 and performing the simulations 
in the crystal environment allows for a direct comparison back to experiment.  
Simulations were analyzed by comparing the calculated DNA helical parameters and 
DNA/polyamide distances back to the starting x-ray structure using the t-test.   
3.2.1 Netropsin Crystal Simulation. As an initial test of the parameters, a 5 ns 
crystal simulation of netropsin  (CCSD20 id NETRSN21; R-factor 6.7%) was performed.   
The system contained one netropsin molecule, five water molecules, and one sulfate ion. 
The average RMSD of the simulation was 0.42 ± 0.09 Å, as shown in Figure 3.8 (top 
right).  The low RMSD indicates that the parameters are in good agreement with the 
experimental crystal structure.   
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Figure 3.8 Structure of netropsin (top left) and RMSD vs. time plot (top right) for the 
netropsin simulation (hydrogens not included in RMSD).  The bottom plot is the RMSD 
vs. time for different parts of the netropsin molecule (rings in blue, amide backbone in 
red, and tails in green).  
 
Exploration of the differences between the simulated and experimentally derived 
structures was done by examining the RMSDs of the pyrrole rings, amide backbone, and 
the cationic tail. It was found that the tail region moves more than any other region 
during the simulation (RMSD of 0.4 ± 0.1 Å).  The backbone has the next largest 
contribution with an average RMSD of 0.27 ± 0.07 Å, and the rings contribute the least 
with an average RMSD of 0.22 ± 0.08 Å (Figure 3.8, bottom).   This is reasonable 
because the rings are aromatic and planar so there will not be as much movement within 
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the rings, the backbone has a little more freedom to move, but not as much as the tail.  
Rotation is allowed where the amide groups are attached to the rings, and the tails consist 
primarily of C-C single bonds so free rotation is allowed.  The high RMSD of the tail 
with the amidino group at the end involves a rotation around the carbon-carbon bonds 
from ~ 40° to 80° (Figure 3.9).   
 
  
 
Figure 3.9  Time series (bottom) for one dihedral of the amidino group tail (indicated by 
arrow on netropsin structure on the top).  This end of the molecule appears to contribute 
most to the RMSD due to rotation about carbon-carbon bonds.  The overlay of the x-ray 
(red) and average structures (green) shows that the simulated structure retains the same 
orientation of the amidino group.   
 
The x-ray value for the dihedral shown is 65°; the simulation yields 54.7 ± 9.7°.  The 
overlay of the x-ray and average structures shows that even though the dihedrals of the 
tail show deviation, on average, the tail retains the same orientation as the x-ray structure.  
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3.2.2. Nucleic Acid Helical Parameters.  The next tests of the developed 
parameters were crystal simulations of DNA/polyamide complexes.  An important part of 
nucleic acid simulation analysis is the examination of helical parameters.  Helical 
parameters describe how the bases and base pairs are oriented with respect to each other 
and/or the global helical axis of the DNA.22-25 Because they describe the relative 
orientation of the bases and base pairs, and a ligand that binds to a nucleic acid will affect 
these orientations, a successful force field for ligands that bind to nucleic acids should be 
able to reproduce these parameters accurately.26 As part of the validation of the new 
parameters, the helical parameters of the simulated DNA were compared the values of the 
starting x-ray crystal structure using a t-test at the 95% confidence level.   
A complete set of helical parameters (definitions, names, and spatial arrangements 
of bases and base pairs) was established at a 1988 conference,25 a standard reference 
frame has also been adopted,23 which is used by the Nucleic Acids Database (NDB)27 for 
calculating helical parameters. Various computer programs22, 28-35 have been developed to 
calculate nucleic acid helical parameters, and although the algorithms used are different, 
this has been found to have a limited effect on the computed parameters.24, 36  However, 
the choice of reference frame was found to have a profound effect on the computed 
parameters.24 Figure 3.10 shows the standard reference frame and helical parameters that 
are calculated by most helical parameter analysis programs. 
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Figure 3.10  Standard reference frame (top left) and helical parameters.  In the 
reference frame, the x-axis points away from the minor groove.  Translations 
are shown in the upper half of the figure (x-displacment through rise) and 
rotations are shown in the bottom half of the figure (buckle through tip).  Each 
small tile represents a DNA base; two of them together represent a base pair.  
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The helical parameters can be divided into translational motions and rotational motions; 
they can also be divided further into three families: base pair-axis parameters, intrabase 
pair parameters, and interbase pair parameters.   
There are two different ways of describing nucleic acid helical parameters, which 
are termed global and local.37, 38  In the global approach, the helical parameters calculated 
describe the overall arrangement of the bases and base pairs with respect to a global 
helical axis, which is an axis that runs vertically down a double-stranded helix and is 
usually taken to be linear.  The difficulty with a global approach is that a linear helical 
axis is not an appropriate assumption for many irregular nucleic acid conformations (e.g., 
a structure with a bend).  In the local approach, the helical parameters calculated describe 
the orientations of the bases/base pairs within the local framework of two successive base 
pairs along the nucleic acid fragment; a local helical axis is calculated for each base pair 
step rather than a global helical axis for the entire fragment.  There has been no final 
decision on calculating global versus local helical parameters; both have their advantages 
and disadvantages.37  Local parameter algorithms have the advantage that they avoid the 
difficulty of defining a global helical axis, and they also yield parameters that depend 
only the conformation of the given base pair step.  Global parameters depend on the 
conformation of the whole fragment and involve the determination of the global helical 
axis.  However, global parameters have the advantage of distinguishing between the 
different helical conformations (e.g., A-DNA vs. B-DNA).  If there is curvature in the 
fragment, the location and extent can be identified more easily with global parameters.37  
The various available computer algorithms utilize one of the two approaches, but as 
mentioned, neither method has been found to be truly superior to another.37  In this 
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dissertation, the 3DNA program,28 which uses the local approach, was used for 
calculation of helical parameters.  
3.2.3. DNA/Dervan polyamide complex simulations.  Adequate sampling of 
conformational space is a difficult task, especially for large biomolecules such as DNA in 
which the potential energy surface contains many local minima.39-41  In this study, we 
employ multiple trajectories because other studies have reported that this method 
improves sampling of conformational space.42-45  For this system, four initial trajectories 
were performed at the temperature at which the starting x-ray structure was determined 
(113 K), and three initial trajectories were performed at 300 K.  The theoretical melting 
temperature for this DNA fragment is 305 K (2°C for AT pairs and 4°C for GC pairs), 
which will be increased a few degrees by the polyamides in the minor groove, so the 
melting temperature should be above the simulation temperature.  
RMSD. Shown in Figure 3.11 is the RMSD, relative to the starting x-ray crystal 
structure (PDB46 id 1CVY3); left side of Figure 3.11), of the DNA/polyamide complexes 
from the seven initial simulations done at the low temperature (113 K) and high 
temperature (300 K).     
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Figure 3.11  Starting structure for DNA/Dervan polyamide simulations (PDB46 id 
1CVY3; left).  The DNA is in red, and the polyamides are in green.  The structure of the 
polyamides bound in the minor groove is shown on the bottom right (there are two of 
them bound antiparallel in the minor groove).The plot on the top right is the RMSD vs. 
time for the 113 K simulations (bottom) and for the 300 K simulations (top) compared to 
the starting x-ray crystal structure. 
 
The RMS deviation converges quickly to 0.8-1 Å for all of the low temperature 
simulations, with the exception of one low temperature simulation (LT2), which 
converges with the rest of the low temperature simulations at ~ 5 ns.  As expected for the 
300 K simulations, the RMSD shows more fluctuation than for the lower temperature 
simulations.  The RMSD stays below 3 Å, but there is great amount of fluctuation up to 
~6 ns of simulation time.  After 6 ns, the RMS deviations start to converge to around 1.7 
Å, with the exception of one simulation (HT3), which shows deviations greater than 2.5 
Å.  Table 3.1 lists the average RMSDs of the complex, DNA, and polyamides separately.    
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                                Table 3.1  RMSDs of complexes, DNA, and polyamides 
 
    RMSD (Å)  
simulation Temp (K) complex DNA only polyamides only 
HT1 300.0 ± 0.83 1.64 ± 0.13 1.15 ± 0.15 2.52 ± 0.33 
HT2 300.0 ± 0.84 1.95 ± 0.27 1.87 ± 0.28 1.68 ± 0.24 
HT3 300.0 ± 0.83 1.71 ± 0.24 1.65 ± 0.24 1.42 ± 0.25 
     
LT1 113.0 ± 0.29 0.96 ± 0.04 0.89 ± 0.04 1.13 ± 0.06 
LT2 113.0 ± 0.29 0.86 ± 0.04 0.73 ± 0.04 1.01 ± 0.05 
LT3 113.0 ± 0.30 0.79 ± 0.05 0.58 ± 0.04 0.95 ± 0.15 
LT4 113.0 ± 0.31 0.90 ± 0.05 0.83 ± 0.05 1.00 ± 0.05 
 
For all of the low temperature simulations and one high temperature simulation, the 
RMSD for the complex is influenced specifically from the tails of the polyamide, which 
contain C-C single bonds with free rotation.  In the remaining two high temperature 
simulations, the end base pairs of the DNA exhibit some fraying, which is the most likely 
cause of higher RMSD contribution of the DNA.  
Statistical Analysis of Helical Parameters.  Helical parameters were computed 
using the 3DNA program.28  The helical parameters were computed and then averaged 
from snapshots from the simulations. A t-test was then performed between the computed 
and x-ray helical parameters at the 95% confidence level (see Chapter 2, Section 2.2.2 for 
a description and formulas for the t-test).  The output from 3DNA gives a value for each 
base or base pair in the DNA fragment (depending on what parameter is being measured); 
therefore, there is an average and standard deviation associated with each parameter for 
each snapshot. Figure 3.12 shows a sample output from 3DNA.   
 
 143
    bp    Shear    Stretch   Stagger   Buckle  Propeller  Opening 
  1 C-G   0.71     -0.26     -0.27      9.75    -18.27     -3.72 
  2 C-G   0.67     -0.12     -0.01      6.20    -14.32      1.72 
  3 A-T  -0.13      0.08     -0.50    -15.35    -25.94     26.90 
  4 G-C  -0.21     -0.08     -0.19    -21.65     -8.44      2.00 
  5 A-T   0.03     -0.23      0.30     -5.25     -4.01     -3.27 
  6 T-A   0.11     -0.18     -0.08     -5.73    -10.23      0.31 
  7 C-G   0.10     -0.12      0.05    -15.78     -3.56     -0.07 
  8 T-A   0.17      0.53     -0.27     14.11    -18.42     24.29 
  9 G-C  -0.41     -0.32     -0.35     -6.05     -5.31     -2.27 
 10 G-C  -0.64      0.16     -0.67    -10.19     -7.20      5.08 
        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
    ave.  0.04     -0.05     -0.20     -4.99    -11.57      5.10 
    s.d.  0.42      0.25      0.28     11.73      7.43     11.14 
Figure 3.12  Sample output from 3DNA for a DNA 10-mer for six helical parameters.   
 
 
An average of each helical parameter was taken over all snapshots used for a simulation.  
In order to take the standard deviation from each snapshot in account, a pooled standard 
deviation was performed for each helical parameter.  For each 10 ns simulation, 100 
snapshots, or samples, (one every 100 ps) were evaluated using 3DNA, and an overall 
average and a pooled standard deviation (Eqn.3.1) was calculated for each helical 
parameter.   
  
 
n =10 for each snapshot (n =9 in the case of base pair step parameters), s is the standard 
deviation for each snapshot taken from a simulation, and k =100 (100 snapshots used).  
After the pooled standard deviation was calculated, the t-test comparing the 
simulation averages to the x-ray values was performed for each helical parameter.   
  
 
Eqn. 3.1 
1 2
2 2
1 1 2 2( / ) ( / )
calc
x xt
s n s n
−=
+ Eqn. 3.2 
2 2 2
1 1 2 2
1 2
( 1) ( 1) ... ( 1)
...
k k
pooled
k
s n s n s ns
n n n k
− + − + + −= + + + −
 144
x1 is the simulation average, x2 is the x-ray average, s1 is the simulation standard 
deviation (this number is the number obtained from the pooled standard deviation), s2 is 
the x-ray standard deviation (obtained from the 3DNA output for the x-ray structure), n1 
is the number of samples for the simulation, and n2 is the number of samples for the x-ray 
structure.  For the simulations, n1 = 1000 (100 snapshots * 10 values) for individual base 
pair parameters, or n1 = 900 (100 snapshots * 9 values) for base pair step parameters (the 
DNA/Dervan polyamide systems contained 10 base pairs).  For the DNA/netropsin 
complex, the DNA/distamycin complex, and DNA with no bound polyamides, n1 = 1200 
for individual base pairs, and n1 = 1100 for base pair steps (these systems contained 12 
base pairs). The number of samples (n2) for the x-ray structure was set to 10 (1 structure * 
10 values); 9 was used for the helical parameters that involve base pair steps rather than 
individual base pairs (in the case of the DNA/netropsin complex, DNA/distamycin 
complex, and DNA with no bound polyamides, 12 and 11 were used).    
T-test results for Helical Parameters.  According to the t-test, there is good 
agreement between the helical parameters calculated from both the low and high 
temperature simulations and the x-ray structure, where 17 out of the 18 helical parameters 
measured are not statistically significant according to the t-test.  The only helical 
parameter that was significantly different in all seven individual simulations is stagger at 
the 95% confidence level.  Tables of the t-test results for the individual simulations can 
be found in Appendix A.   
Because stagger was the only helical parameter that was found to be statistically 
significant in all seven individual simulations, t-tests were performed on the combined 
sets of simulations (one t-test performed on the low temperature simulations and one t-
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test performed on the high temperature simulations) to see if the combined t-test result 
would be non-significant.  The t-tests were performed using Eqn. 3.3,  
  
where x1 is the simulation average, x2 is the x-ray value, spooled is the pooled standard 
deviation of the simulations and x-ray standard deviation, n1 is the number of samples 
used from the simulations, and n2 is the number of samples used for the x-ray structure. 
In order to see if the combined t-test results and how the t-values fluctuated over time, the 
t-test was performed in the following way.  Rather than taking the average value of 
stagger over the ten bases of the DNA fragment for each snapshot, all ten values from the 
100 snapshots were used for the t-test for each simulation. Because this t-test was 
performed over multiple simulations, the t-test for the high temperature simulations used 
300 snapshots, and the t-test for the low temperature simulations used 400 snapshots.  For 
comparison to the x-ray structure, the x-ray values of stagger for each base were 
compared to the corresponding bases from the simulations rather using the average over 
the ten bases.  The snapshots from the simulations were ordered chronologically, the 
stagger value for each base at each snapshot was averaged over all simulations 
considered, and a t-test was then performed between each snapshot and the x-ray value.  
Because the stagger values were averaged over all simulations considered, there were 100 
snapshots and thus a total of 100 t-tests performed.  The resulting time series plots 
showed how the t-values for stagger evolve with time.   
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Figure 3.13  Time series plots of t-values over time for the stagger helical parameter.  
The time series for the low temperature simulations is on the top; the time series for the 
high temperature simulations is on the bottom.  The red lines denote the t-table value 
(1.96) at the 95% confidence level.   
 
Stagger is also observed to be statistically significant when all low temperature 
simulations are examined together and when all high temperature simulations are 
examined together.   In the time series plot for the low temperature simulations, all 100 t-
tests performed yield a t-value greater than the t-table value (1.96) at the 95% confidence 
level. The average of the t-values is 3.16; stagger is statistically significant when all low 
temperature simulations are considered together.  For the high temperature simulations, 
the average of the t-values is 2.51, so stagger is still statistically significant when all high 
temperature simulations are considered together.  For comparison, the t-test results of a 
helical parameter (buckle) that did not exhibit any statistical significance in the individual 
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simulations is shown in Figure 3.14.  Over the four low temperature simulations, all t-
values are less than 1.96, and the average t-value is 0.93.  For the high temperature 
simulations, all t-values are again less then 1.96, and the average t-value is 0.64.   
 
 
Figure 3.14  Time series plots of t-values over time for the buckle helical parameter.  The 
time series for the low temperature simulations is on the top; the time series for the high 
temperature simulations is on the bottom.  None of the individual or combined 
simulations exhibited significance with respect to buckle.   
 
 Principal Components Analysis (PCA).  Neither the high nor the low temperature 
simulations appear to be sampling the x-ray value for the stagger parameter properly.  In 
order to examine where the simulations are sampling with respect to the x-ray value of 
stagger and which simulations sample the x-ray value best (or not at all), PCA was 
performed on the stagger parameter for both the high and low temperature simulations 
(Figure 3.15).  
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Figure 3.15  Principal component analysis plots of stagger (low temperature 
simulations, top; high temperature simulations, middle). The different colors represent 
the different simulations. The red diamond on each PCA plot represents the x-ray 
value.  The Scree plots associated with the PCA plots are shown at the bottom (low T, 
left; high T, right).  
 
Upon examination of the PCA plots, the x-ray point falls outside of the regions where the 
simulations are sampling. Three of the low temperature simulations (green, light blue, 
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and most of the pink) are not even in the region of where the x-ray value falls; the dark 
blue simulation is sampling right on the edge of where the x-ray value falls.  The high 
temperature simulations seem to better sample the region of conformational space where 
the x-ray value falls for stagger; however, the x-ray value lies on the edge of the sampling 
area.  The PCA plots confirm that the simulations simply are not sampling enough 
conformational space to sample the x-ray value.   
 For comparison, PCA was also carried out for the buckle parameter, which did 
not show statistical significant using the t-test.  For the low temperature simulations 
(Figure 3.16, top) the x-ray point falls in the middle of the region around where each of 
the simulations sample; the simulations average out to sample the x-ray value.  For the 
high temperature simulations (Figure 3.16, middle), the x-ray point falls in the middle of 
the region where the simulations sample.  The PCA plots show that x-ray value of buckle 
is sampled efficiently by both sets of simulations, unlike stagger.  
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Figure 3.16  Principal component analysis plots of buckle (low temperature simulations, 
top; high temperature simulations, middle). The different colors represent the different 
simulations. The red diamond on the PCA plots represents the x-ray value.  The Scree 
plots associated with the PCA plots are shown at the bottom.  
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 Additional Simulations. To help improve sampling of conformational space of the 
stagger parameter, additional simulations were performed (four new simulations at the 
lower temperature (113 K) and three new simulations at the higher temperature (300 K)).  
The simulations were started from structures that were in regions not well sampled by the 
simulations on the PCA plots for stagger (each started from different initial velocities).  
Shown in Figure 3.17 is the RMSD vs. time for the DNA/polyamide complexes for the 
additional simulations.  
 
Figure 3.17  RMSD vs. time plots for the 113 K simulations (bottom) and for the 300 K 
simulations (top) compared to the starting structures for the simulations.  
 
The RMS deviation converges quickly to ~0.5 Å for all of the low temperature 
simulations at ~ 4 ns.  As expected for the 300 K simulations, the RMSD shows more 
fluctuation than for the lower temperature simulations.  There is a great amount of 
fluctuation during the simulations, with HT3 having the most fluctuation.  However, the 
RMSD does not rise above ~2.5 Å for any of the simulations, and HT3 has the lowest 
RMSD at ~1-1.5 Å.   Table 3.2 lists the average RMSDs of the complex, DNA, and 
polyamides separately.    
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                               Table 3.2  RMSDs of complexes, DNA, and polyamides 
 
    RMSD (Å)  
simulation Temp (K) complex DNA only polyamides only 
HT1 300.0 ± 0.82 1.80 ± 0.24 1.76 ± 0.22 1.56 ± 0.57 
HT2 300.0 ± 0.85 1.88 ± 0.18 1.81 ± 0.18 1.80 ± 0.25 
HT3 300.0 ± 0.83 1.26 ± 0.23 1.29 ± 0.25 0.86 ± 0.16 
     
LT1 113.0 ± 0.30 0.36 ± 0.04 0.42 ± 0.05 0.28 ± 0.04 
LT2 113.0 ± 0.28 0.38 ± 0.04 0.38 ± 0.04 0.30 ± 0.03 
LT3 113.0 ± 0.32 0.40 ± 0.06 0.42 ± 0.07 0.27 ± 0.05 
LT4 113.0 ± 0.31 0.31 ± 0.03 0.31 ± 0.03 0.25 ± 0.03 
 
For two of the high temperature simulations and three of the low temperature simulations, 
the DNA contributes most to the RMSD of the complex.  Some fraying of the end base 
pairs was observed, which is most likely the cause of the higher contribution of the DNA.  
In the remaining simulations, the polyamides contribute more to the RMSD which is due 
to the tails of the polyamides (free rotation is allowed about the C-C single bonds of the 
tails).   
 Low-Temperature Simulations. A total of eight simulations were performed at 113 
K (four original and four new).  All individual simulations with the exception of one 
showed that stagger is statistically significantly different from the x-ray structure (all 
other helical parameters are non-significant; see Appendix A for tables of helical 
parameter and t-values).  When all eight simulations were combined together, the stagger 
parameter is still statistically significant according to the t-test (Figure 3.18, top).  All t-
values are greater than 1.96; the average t-value is 3.11 (this is a slight improvement over 
the four initial simulations, which had an average t-value of 3.16).  A PCA plot of the 
stagger parameter shows that the four new simulations do improve sampling; more 
simulation points are in the region where the x-ray value (red diamond) lies.  However, 
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some simulations are still not sampling even near where the x-ray value lies (e.g., the 
green, light blue, and pink simulations).  Even when these three simulations were not 
considered in the analysis, the t-test still yielded statistical significance (average t-value 
was 3.04; plot not shown).  In the case of the low temperature simulations, even the 
additional sampling is not sufficient because according to the t-test, stagger is still 
statistically significant from the x-ray structure at the 95% confidence level.   
High-Temperature Simulations. A total of six simulations were performed at 300 
K (three original and three new).  In the original three individual simulations, stagger is 
the only statistically significant helical parameter; in the three new simulations, none of 
the helical parameters are statistically significant. When the six simulations were 
considered together, the t-test yields statistical significance at the 95% confidence level, 
but not at the 97% confidence level (t-table97% =2.24) (Figure 3.19; top).  The average t-
value is 2.03, which is just above 1.96; however, this value is less than 2.24.  The 
additional high temperature simulations did improve the average t-value (the three 
original simulations yielded an average t-value of 2.51), and the improvement observed is 
greater than that for the low temperature simulations.  A PCA plot of stagger for the six 
simulations shows that the additional simulations improve the sampling of stagger 
(Figure 3.19, middle).  
Because the six simulations together produced an average t-value that was close 
to the t-table value at the 95% confidence interval, only the three new high temperature 
simulations were then considered together for the t-test.  With only the three new 
simulations, the t-test result for stagger is overall non-significance (Figure 3.20, top) at 
the 95% confidence level (average t-value is 1.64).  Upon examination of a PCA plot of 
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stagger for only the three new simulations (Figure 3.20, middle), the simulations do 
sample the x-ray value more efficiently than the first three simulations and even when all 
six simulations are averaged together.  For the three new simulations, all of the 
simulations appear to sample values that fall in the region of the x-ray value.   
 
 
 
Figure 3.18  T-test for all eight low temperature simulations (top); PCA plot of all eight 
simulations (x-ray value is shown as a red diamond, middle); Scree plot corresponding to 
PCA plot (bottom).  
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Figure 3.19  T-test for all six high temperature simulations (top).  The t-table value at the 
95% CL (1.96) is marked by the red line, and the t-table value at the 97% CL (2.24) is 
marked by the blue line.  PCA plot of all six simulations (x-ray value is shown as a red 
diamond, middle); Scree plot corresponding to PCA plot (bottom).  
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Figure 3.20  T-test for three new high temperature simulations (top).  The t-table value at 
the 95% CL (1.96) is marked by the red line, and the t-table value at the 97% CL (2.24) is 
marked by the blue line.  PCA plot of three new simulations (x-ray value is shown as a 
red diamond, middle); Scree plot corresponding to PCA plot (bottom).  
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marginally (3.16 vs. 3.11), whereas in the high temperature simulations, a larger 
improvement is observed (2.51 vs. 2.03).  From the average t-value and the PCA plot, the 
additional sampling with the low temperature simulations is not sufficient to obtain non-
statistical significance for the stagger parameter.  The high temperature simulations do 
achieve non-significance.  All six simulations together show statistical significance at the 
95% confidence level but not at the 97% confidence level, which is already an 
improvement over the initial three simulations.  When only the three new simulations are 
considered, stagger is not statistically significant at the 97% or 95% confidence level.  As 
expected, the temperature at which the simulations are run influence the sampling of 
stagger for this particular system, and the higher temperature is the obvious choice for 
better sampling.   
 Although the high and low temperature simulations yielded a statistically 
significant t-value when considered by temperature, all 14 (8 low temperature and 6 high 
temperature) simulations gave a non-significant t-value for all helical parameters when 
considered together.  The figure below shows the value of the t-test over time for all 14 
simulations.  The average t-value was 1.04.  None of the other helical parameters were 
statistically significant over all 14 high or low temperature simulations (see Appendix A 
for a table of t-values).   
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Figure 3.21  T-test for combined high and low temperature simulations.  The t-table 
value at the 95% CL (1.96) is marked by the red line.   
 
 
 Although the t-test for stagger displays non-significant results when the 14 
simulations are combined, the high temperature simulations are obviously contributing 
more to the non-significance.  The additional high temperature simulations showed more 
improvement in the t-test results than the low temperature simulations.  The low 
temperature simulations did not sample enough to get the x-ray value; however, the 
additional high temperature simulations do improve sampling.  However, what is 
different about the high-temperature structures that lie close to the x-ray value and those 
that are far away from it on the PCA plot for stagger? Are there conformations/structural 
features of the DNA that cause stagger to deviate in the structures that are far away from 
the x-ray value?  To answer these questions, structures that lay farthest from the x-ray 
value on the PCA stagger plot were examined by RMSD analysis, and the largest 
contribution to RMSD in structures was the DNA bases (not including backbone or 
sugars).  An example of one of the simulated structures is shown below in Figure 3.22.    
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Figure 3.22   Comparison of x-ray structure and high temperature simulated structure. The 
x-ray structure is in red; polyamides are bound in the minor groove (also in red).  One of 
the simulated structures that was far away from the x-ray point on the stagger PCA plot is 
shown with the DNA in green with the polyamides bound in the minor groove in colors.  
Gaps appear in the structures because only the bases of the DNA are shown (backbone of 
the DNA is not shown for clarity).  The simulated structure has a wider minor groove and 
a more bent helix than the x-ray structure does.   
 
The simulated structure is obviously distorted and has a wider minor groove (Figure 3.22, 
top left) and a more bent helix (Figure 3.22, bottom) than the x-ray structure does.  The 
polyamides appear to have been “pushed” out the groove; the polyamides in the x-ray 
structure are deeper inside the groove than those in the simulated structures.  The top 
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right picture shows the view from the major groove instead of the minor groove.  This 
view is just to show that the polyamides really are not coming out of the groove (they 
look like like they are in the top left picture).  The hydrogen bonding contacts are still 
where they should be; the polyamide tail parts that are flipped out of the groove appear to 
make hydrogen bonds with nearby waters.  The distortion of the helix that is observed is 
why structures that look like this are farthest from the x-ray point on the stagger PCA 
plot.   
The tilted/bent structures that are observed exhibit characteristics of A-DNA.47-49  
In A-DNA, the bases are more tilted with respect to the helical axis, which is seen in the 
structures.  Also, the average inclination and x-displacement of the bases in those 
structures are closer to those of A-DNA, which are around 20° and -4 Å, respectively.   
A-DNA has a more shallow and a wider minor groove than B-DNA.  The structures 
where the polyamide is getting "pushed out" of the minor groove are in line with A-form; 
the DNA adopts features of A-form, and the polyamide gets pushed out, because the 
groove has become narrower, and it also appears wider from the snapshots.  However, the 
structures have not completely converged to the A-form; the rise (~2.6 Å in A-DNA and 
3.4 Å in B-DNA) and twist helical parameters (31° in A-DNA and 36° in B-DNA), the 
distance between the phosphates in each strand (~5.0 Å for A-DNA and ~7.0 Å for B-
DNA, and the width of the helix (26 Å in A-DNA and 20 Å in B-DNA) in these 
structures have B-form (or closer to B-form) values.  An overstabilization of A-DNA was 
previously observed the CHARMM22 force field for nucleic acids;50 this has since been 
corrected with revised parameters,16, 26 which were used in this study, so the force field 
parameters should not be an issue.  
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Structures from the low temperature simulations were also examined to see if they 
exhibited the same distortion of the DNA helix.  The low temperature structures do not 
exhibit the widened minor groove or the distorted helix, and the polyamides stay where 
they are; they are not pushed out of the groove as in the high temperature structures.   
  
Figure 3.23   Comparison of x-ray structure and low temperature simulated structure. 
The x-ray structure is in red; polyamides are bound in the minor groove (green).  A 
representative example of a simulated low temperature structure is shown with the 
DNA in purple with the polyamides bound in the minor groove in colors.  Gaps appear 
in the structures because only the bases of the DNA are shown (backbone of the DNA 
is not shown for clarity).  
 
 To further examine the high and low temperature structures, histograms were 
made based on the minor groove width of the structures.  The histogram from the eight 
low temperature simulations (Figure 3.24) show that a few structures have a wider 
groove, but most have a narrower minor groove (~13.0-13.6 Å), which is consistent with 
the representative structure shown in Figure 3.23 and the other structures examined from 
the low temperature simulations.  The histogram from the six high temperature 
simulations (Figure 3.25) shows approximately a normal distribution of minor groove 
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widths, with most of them being wider (~14.0-15.0 Å) than the low temperature 
simulations.   
 
 
Figure 3.24 Probability density curve (top) and histogram bar plot (bottom) for 
minor groove width of low temperature simualtions.   
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Figure 3.25   Probability density curve (top) and histogram bar plot (bottom) for minor 
groove width of high temperature simualtions.   
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high temperature simulations, almost all structures have the wider minor groove that is 
characteristic of A-form DNA.  Why are the distortion and the A-like features observed 
only in the high temperature structures?  Also, because more distortion is observed in the 
high temperature simulations, why is more statistical significance not observed with the 
helical parameters (the high temperature simulations actually show better results for 
stagger than the low temperature)?   
 Force fields often do not get melting temperatures correct.51-56  This particular 
fragment of DNA has a theoretical melting temperature of 305 K; the melting 
temperature of the DNA/polyamide complex is probably a few degrees higher.  
Polyamides have been found to increase the melting temperature57, 58 of the DNA alone; 
the magnitude of the increase depends on the sequence of the polyamide, the DNA 
fragment, and how tightly the polyamide binds to the fragment.59  The simulation 
temperature for the high temperature simulations is 300 K.  The simulation temperature is 
too close to that of the melting temperature, and because the force field does not account 
perfectly for the melting temperature, the DNA/polyamide complex is starting to melt in 
the high temperature simulations.  The melting causes the distortion and thus the A-like 
features, which makes the minor groove wider and narrower, which in turn pushes the 
polyamides out.  As far as the sampling is concerned, the higher temperature simulations 
do sample better and thus less statistical significance is observed for the stagger 
parameter.  The low temperature simulations yield solid and undistorted structures, but 
they just do not sample well.   
Polyamide/DNA interaction.  Polyamides bind to the minor groove of DNA by 
hydrogen bonding, so these contacts were examined to ensure that they stayed in place 
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over time during the simulations and that the polyamide was not sliding around in the 
minor groove.  For direct comparison back to the crystal structure, only heavy atom 
distances were measured.  The distances that were measured are shown in the Figure 3.26 
and denoted by the “x” with a number above the distance lines.  As with the helical 
parameters, a statistical comparison back to the starting x-ray crystal structure was also 
performed with the DNA/polyamide distances (95% confidence level) as a test of the 
parameters.    
 
Figure 3.26  Polyamide distances measured (dashed lines) in the x-ray structure and from 
the low and high temperature crystal simulations. The “ladder” in the middle represents 
the DNA binding site of the polyamides.  The circles in the middle represent the 
hydrogen bond donors or acceptors in the minor groove of the DNA.  
 
 
The distances measured from the simulations are in good agreement with the x-ray 
structure (tables of measured distances and t-values can be found in Appendix A).  Over 
the seven initial individual simulations, two distances were statistically different from the 
x-ray structure.  The distance (x1a) is much larger than that in the crystal structure (x1a = 
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4.99 Å for the calculated average, and x1a = 3.3 Å for the x-ray structure) in one low 
temperature simulation.  Upon closer examination of the atoms of the polyamide and 
DNA that show this large distance, a water molecule was discovered above the minor 
groove. The x1a distance is from an NH group in the polyamide backbone to the O2 of 
thymine.  However, the NH group appears to be forming a strong hydrogen bond (~ 1.8 
Å) with the oxygen of the water molecule above the groove rather than forming a strong 
hydrogen bond with the O2 of thymine.  The other simulations do not have a water 
molecule in this position or anywhere near this position in order to form a hydrogen 
bond.  
The distance from the H of the NH group to the water oxygen over the whole 10 
ns of simulation 2 was plotted (shown in Figure 3.27, top).  At the start of the simulation, 
the distance was ~3.5 Å; also, waters were deleted within 2.5 Å of the DNA/polyamide 
complex, but the water molecule moves right in to the polyamide, and the distance then 
stays small (~1.9 Å).  Upon closer examination of the starting structure, the water 
forming the hydrogen bond to the polyamide was actually in the minor groove between 
the two polyamides, but it was still at least 3 Å from either of them and the DNA.  It was 
trapped and moved closer to the NH of the polyamide backbone.  The water and the DNA 
are therefore competing for hydrogen bonding to the polyamide.     
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Figure 3.27  Plot of distance from water to thymine O2 over the 10 ns time span of the 
simulation for low temperature simulation (top). The bottom plot shows the distance from 
polyamide to nearby water molecules.  The water molecules exchange, but they still 
hydrogen bond to the polyamide. The straight red line on the bottom plot is at 3 Å, which 
is the average length of the hydrogen bond formed from the polyamide to the exchanging 
waters.  There are water molecules hydrogen bonding to the polyamide at most times 
during the simulation.  
 
 
One of the distances (x4) in one high temperature simulation is much larger (~1 
Å) than that of the crystal structure (calculated x4 = 3.95 Å; x-ray x4 = 2.95 Å).  Upon 
closer examination of the simulation snapshots, a water molecule hydrogen was found to 
be hydrogen bonding to a carbonyl oxygen in the polyamide backbone.  However, it was 
not the same water molecule hydrogen bonding to the polyamide for the duration of the 
simulation; the water molecules appear to be exchanging with each other, but nonetheless 
forming a strong hydrogen bond to a carbonyl oxygen in the polyamide backbone (Figure 
3.27, bottom plot).    The waters exchanging to form the hydrogen bond is probably a 
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consequence of the 300K simulations having more kinetic energy than the 113K 
simulations; the atoms move more and can thus exchange to form the hydrogen bond to 
the polyamide. Because good agreement between the calculated and x-ray distances was 
achieved with the initial seven simulations, distances were not measured for additional 
simulations (those were considered only for improvement of sampling).   
Even though individual simulations exhibited statistical significance for 
DNA/polyamide distances due to intruding water molecules, when the distances were 
averaged over all simulations (low temperature and high temperature distances averaged 
separately), none of the distances showed statistical significance.  The t-tests for the 
combined simulation distances were performed similarly to the combined t-tests for the 
helical parameters.  For example, for distance x1 for the low temperature simulations, 
1000 values were taken from each of the four simulations, the values at each time were 
averaged, and a t-test was performed between the simulation values and x-ray value at 
each time (1000 t-tests total for each distance).  A table of the average t-values obtained 
for each distance can be found in Appendix A.   
3.2.4. DNA/Dervan hydroxypyrrole polyamide complex.  A 10 ns crystal 
simulation of a different DNA/Dervan polyamide complex was also performed. In this 
simulation, one pyrrole heterocycle in each of the polyamides is replaced by the 
hydroxypyrrole heterocycle.  The polyamides in the simulations discussed in Section 
3.2.3 and in this section recognize the same bases in the minor groove of DNA (5’-
AGATCT-3’) and the DNA sequence is the same; however, the hydroxypyrrole moiety 
reduces the binding affinity due to elongation of the Watson-Crick hydrogen bonds of the 
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target T-A base pairs.3  The starting structure for the simulation was PDB46 id 1CVX.3  
The RMSD plot of the DNA/hydroxypyrrole polyamide is shown in Figure 3.28. 
  
 
Figure 3.28  Starting structure for DNA/hydroxypyrrole polyamide simulation (PDB46 id 
1CVX3; left).  The DNA is in purple, and the polyamides are in silver in the minor 
groove.  The structure of the polyamides bound in the minor grove is shown on the 
bottom right (two are bound antiparallel in the minor groove).  The plot of RMSD vs. 
time of DNA/polyamide complex is on the top right. 
 
 
The average RMSDs of the complex, DNA, and polyamides are 1.44 ± 0.05 Å, 1.44 ± 
0.05 Å, and 1.08 ± 0.05 Å, respectively.  The RMSD of the complex and the DNA 
stabilizes at ~6 ns to 1.44 Å, while the RMSD of the polyamides is steady until about 7 
ns.  At 7 ns, the RMSD of the polyamides decreases to just above 1 Å.  The DNA 
contributes more the RMSD than the polyamides, which is probably due to some fraying 
of the end bases.  The contribution to the polyamide RMSD is most likely due to the 
polyamide tails, which contain C-C single bonds about which free rotation is allowed.  
This conformational freedom is reflected by the disorder in the starting x-ray structure, 
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because there were two possible conformations identified for the positions of the 
polyamide tails.3 
 The same analysis for the DNA helical parameters and DNA/polyamide distances 
was carried out for the hydroxypyrrole simulation.  None of the 18 helical parameters 
examined were statistically significantly different from the x-ray structure values (a table 
of helical parameter and calculated t-values can be found in Appendix A).  Figure 3.29 
shows the DNA/polyamide distances measured (a table of measured distances is in 
Appendix A). Seven distances were measured for each polyamide to its respective DNA 
strand; only two distances out of the 14 measured were statistically significant according 
to the t-test.  The distances showing statistical significance were the x5 and x1a distances.   
The x-ray values for these distances are 3.16 Å and 2.54 Å, respectively; whereas the 
average simulation distances are 4.93 Å and 5.93 Å (both are over an angstrom longer 
than the x-ray values).  
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Figure 3.29  Polyamide distances measured (dashed lines) in the x-ray structure and from 
the hydroxypyrrole polyamide crystal simulations. The “ladder” in the middle represents 
the DNA binding site of the polyamides.  The circles in the middle represent the 
hydrogen bond donors or acceptors in the minor groove of the DNA.  
 
 
These distances are at the ends of the polyamide and the DNA strand, where water 
molecules were identified in the minor groove in two of the other DNA/polyamide 
simulations.  In this simulation, water molecules were also found to be hydrogen bonding 
to the DNA or polyamide in this region, causing the distances to be large.  Not only does 
water get into the groove at the ends, but the identification of two possible orientations of 
the polyamide tails in the x-ray structure indicates that there is a lot of conformational 
freedom in the tails.  In one orientation, the tail is inside the minor groove where it can 
hydrogen bond with the DNA, and in the other orientation, the tail is projected outside of 
the minor groove.  The simulation does sample the latter conformation, which contributes 
to the large distances observed.   
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3.2.5. DNA/Netropsin and DNA/Distamycin complexes.  The fourth test of the 
new parameters was a 10 ns crystal simulation of a DNA/netropsin complex and a 10 ns 
crystal simulation of a DNA/distamycin complex.  Netropsin and distamycin are both 
antibiotics that bind in the minor groove of DNA, preferentially to A-T rich sequences.  
Netropsin covers ~4 base pairs; distamycin covers ~5 base pairs.  Like the Dervan 
polyamides, they contain pyrrole heterocycles linked by an amide backbone, and they 
recognize the minor groove by the hydrogen bonding pattern.  Figure 3.30 shows the 
molecular structures of netropsin and distamycin and how each one binds in the minor 
groove of DNA.  
  
  
Figure 3.30  Starting structure for DNA/netropsin simulation (PDB46 id 121D60; top left) 
and the molecular structure of netropsin (top right).  The bottom panel shows the starting 
structure for the DNA/distamycin simulation (PDB46 id 2DND61; bottom left) and the 
molecular structure of distamycin (bottom right).  
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DNA/netropsin complex. The RMSD plot of the DNA and netropsin complex is 
shown below (Figure 3.31). The average RMSD of the complex was 1.85 ± 0.29 Å.  The 
DNA contributes the most to the RMSD (average RMSD was 1.83 ± 0.31 Å), while the 
netropsin has a lower RMSD (average RMSD was 0.91 ± 0.12 Å).  The DNA/netropsin 
simulation was performed at 300K, and the RMSD for the DNA/netropsin complex is in 
the same range as the DNA/polyamide high temperature simulations. The geometric 
parameters of the netropsin molecule were examined and compared back to the x-ray 
structure, and the simulated structure is in good agreement with experiment.  The average 
bond error was 0.03 ± 0.02 Å, the average angle error was 4 ± 3°, and the average 
dihedral error was 8 ± 12°.  The large dihedral error stems from the rotation about the 
carbon-carbon bonds at the ends of the netropsin molecule.  An overlay of the x-ray 
structure and the simulation average structure is shown in Figure 3.31.  The tails of the 
molecule, especially the amidino group tail which contains two carbon-carbon single 
bonds, do not align with each other as the pyrrole rings in the middle.  Free rotation is 
allowed about these carbon-carbon bonds, and this is responsible for the large dihedral 
angle error.  The B-factors reported for the x-ray structure are slightly higher for the 
atoms of the tails of netropsin,60 indicating that there is some disorder in the crystal for 
the tails.  This is most likely observed because the tails contain C-C single bonds, and 
free rotation is allowed about these bonds; thus, the tail could adopt different orientations, 
leading to uncertainty in the positions of the atoms.     
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Figure 3.31 RMSD vs. time of DNA/netropsin complex (left).  Overlay of x-ray 
structure (red) of netropsin and simulation average structure (green) (right). 
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Figure 3.32  Hydrogen bond distances (numbered) from netropsin to DNA.  The figure 
shows the middle eight base pairs of the DNA fragment and the hydrogen bonds formed 
from the netropsin N atoms to the atoms of the DNA bases (h-bonds represented by 
dashed lines).  The netropsin molecule is represented by the numbered Ns in the middle 
of the figure. Red dashed lines show significant differences between experiment and 
simulation.  
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DNA/distamycin complex. The RMSD plot of the complex, DNA, and distamycin 
is shown below (Figure 3.33). The average RMSD of the complex was 2.33 ± 0.27 Å.   
The DNA contributes the most to the RMSD (average RMSD was 2.41 ± 0.27 Å), while 
the distamycin has a lower RMSD (average RMSD was 0.75 ± 0.10 Å).  The cause of the 
high RMSD does not appear to be the distamycin; one base from the helix that does not 
interact with the distamycin flipped out slightly from the helix (THY7).  The movement 
of this base did not appear to affect the DNA/distamycin distances or helical parameters 
greatly. The geometric parameters of the distamycin molecule were examined and 
compared back to the x-ray structure, and the simulated structure is in good agreement 
with the x-ray structure.  The average bond error was 0.04 ± 0.04 Å, the average angle 
error was 4 ± 3°, and the average dihedral error was 12 ± 24°.  The dihedral error stems 
from the rotation about the carbon-carbon bonds at the ends of the distamycin molecule.  
An overlay of the x-ray structure and the simulation average structure is shown in Figure 
3.33.  The tails of the molecule, especially the formamide group tail where the carbonyl 
oxygens are turned in opposite directions, do not align with each other as the pyrrole 
rings in the middle.    
  
Figure 3.33  RMSD vs. time of DNA/distamycin complex (left).  Overlay of x-ray 
structure (red) of distamycin and simulation average structure (green) (right).  
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 The helical parameters of the DNA were examined from the DNA/distamycin 
simulation.  The analysis was performed in the same way as for the other simulations.  
One helical parameter was found to be significantly different than the x-ray value, which 
was the opening parameter.  This statistical significance can be attributed to the flipping 
out of Thy7.  The hydrogen bond distances from distamycin to the DNA were also 
examined (Figure 3.34).   For the DNA/distamycin complex, one of the 7 distances were 
found to be significantly different from the values determined from the x-ray structure.   
 
Figure 3.34  Hydrogen bond distances from distamycin to DNA (numbered).  The figure 
shows the middle eight base pairs of the DNA fragment and the hydrogen bonds formed 
from the distamycin N atoms to the atoms of the DNA bases (h-bonds represented by 
dashed lines).  The distamycin molecule is represented by the numbered Ns in the middle 
of the figure.  The W indicates a water molecule found in the minor groove. Figure 
adapted from Coll, et al.61 
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of 2.7-3.5 Å).   The water molecule identified in the minor groove that forms a hydrogen 
bond to Thy9 and Ade17 also exchanges with other waters during the simulation.  
Initially, the water molecule is ~2.6 Å from Thy9 (O2) and 3.1 Å from Ade17 (N3).  
During the simulation, the water molecule exchanges with other waters but the water 
molecule always forms a hydrogen bond to the DNA bases.  The distance between the 
water and the DNA bases changes slightly (distances range from 2.8 to 4.1 Å) and in 
some snapshots there are two water molecules (one forming a hydrogen bond to Thy9 
and one forming the hydrogen bond to Ade17); however, the same trend is usually 
followed:  the distance from Thy9 to the water is usually shorter than the distance from 
Ade17 to the water.  
 3.2.6. DNA/Netropsin Crystal Simulation with AMBER Parameters.  A 10 ns 
crystal simulation of the DNA/netropsin complex was also performed using the 
previously reported parameters for netropsin62 for use with the AMBER63 force field.  
The netropsin molecule was not explicitly parameterized for the force field; instead, 
analogous parameters in the force field were adopted for netropsin.  The same starting 
conditions (same structure, same number of water molecules, same system preparation) 
were used as with the CHARMM simulation. The RMSD plot for the DNA/netropsin 
complex is in Figure 3.35.  The RMSD of the complex was 2.17 ± 0.21 Å, and the DNA 
contributes more to the RMSD (2.16 ± 0.20 Å) than the netropsin (1.16 ± 0.40 Å).  The 
RMSDs of all parts of the system are higher than those obtained from the CHARMM 
parameters.  There is also a large jump in RMSD for the netropsin at ~ 8ns.  This is due 
to the large structural distortion of the netropsin relative to the starting x-ray structure 
(Figure 3.31).  
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Figure 3.35  RMSD vs. time of DNA/netropsin complex using AMBER parameters 
(left).  Comparison (right) of x-ray structure (red) of netropsin and simulation average 
structure (green). 
 
The average simulation structure shows the failure of agreement of the AMBER 
parameters with the x-ray structure.  The pyrrole ring on the left of the molecule is 
distorted, and the force constants for the connection between the pyrrole rings is 
obviously not large enough to keep the bond length correct (the VMD64 viewer did not 
even draw a bond).  The bond length between the amide nitrogen and the carbon of the 
pyrrole ring should be 1.44 Å (x-ray), but the average simulation structure yields 2.15 Å.  
The force constants are also flawed for the connection of the methyl groups to the 
nitrogen of the pyrrole rings.  In the picture on the right, the green dots are the methyl 
groups that are supposed to be attached to the pyrrole rings (again, the viewer did not 
even draw a bond).  The length in the x-ray structure for those bonds is ~1.50 Å, but the 
average simulation structure yields an average value of 3.76 Å.   
 The helical parameters and DNA-netropsin distances were also examined using 
the t-test.  Of the 18 helical parameters measured, nine of them are statistically significant 
from the x-ray value.  The significant parameters are x-displacement, inclination, stretch, 
stagger, opening, slide, twist, helical rise, and helical twist. Despite the fact that the 
RMSD vs. time (DNA/netropsin complex--AMBER)
0
0.5
1
1.5
2
2.5
3
3.5
4
0 2000 4000 6000 8000 10000
time (ps)
RM
S
D 
(a
ng
st
ro
m
s)
complex
DNA
netropsin
 180
netropsin molecule does not stay bonded together, it does stay in the minor groove of the 
DNA.  For the DNA/netropsin distances, 3 out of the 11 distances measured were 
statistically significant. These three distances are also found to be statistically significant 
using the CHARMM parameters (tables of calculated helical parameters and distances 
can be found in Appendix A).  Overall, the AMBER parameters do not allow for a good 
comparison back to experiment; therefore, an explicit parameterization of the compounds 
of interest must be performed rather than simply taking analogous parameters from 
existing molecules in the force field.  
3.3 Conclusions 
 
 New force field parameters for the CHARMM force field for DNA minor groove 
binding pyrrole-imidazole polyamides have been developed. To test the parameters, 
crystal simulations of DNA with different polyamides bound in the minor groove have 
been performed.    
The computed helical parameters were in excellent agreement with experiment 
(17 out of the 18 examined were not statistically significant).  The stagger helical 
parameter was the only parameter that was statistically different from the x-ray structure 
in both sets of DNA/polyamide simulations (113K and 300K).  However, upon running 
additional trajectories, the sampling of stagger was improved.  Overall, the low 
temperature simulations still yield statistical significance with respect to stagger, and 
stagger is still significant for the high temperature simulations at the 95% confidence 
level but not at the 97% confidence level.  When only the three additional high 
temperature simulations are considered, stagger is not statistically significant. 
Temperature obviously influences the sampling of stagger; the higher temperature allows 
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for better sampling and thus non-statistically significant results according to the t-test.  
The fact that the high and low simulations do not show non-significance overall for all 
helical parameters underscores the importance of running multiple trajectories.   
The high temperature simulations yield structures that are distorted and exhibit A-
DNA features, and as a result, the polyamides are pushed out of the minor groove in these 
structures.  The temperature of the simulations is too close to that of the melting 
temperature of the DNA fragment, causing the DNA to start melting, which gives rise to 
the distorted structures.  However, the high temperature structures are still in good 
agreement with experiment; most helical parameters are non-significant, and we do not 
observe the rigid structure of the crystal.  The authors of the x-ray structure most likely 
could not obtain crystals at 300 K either.  The low temperature simulations yield solid 
and undistorted structures, much like the starting x-ray structure. Again, we get good 
agreement with experiment because we see the crystal at 113 K.  Although the distortion 
is observed, the high temperature simulations sample better than the low temperature 
simulations, thus, stagger is sampled better at the high temperature and yields better t-test 
results.   
The DNA/netropsin, DNA/distamycin, and DNA/hydroxypyrrole polyamide 
simulations show excellent agreement with the x-ray structure.  The DNA/netropsin 
simulation and the DNA/hydroxypyrrole did not exhibit any statistically significant 
helical parameters. Opening was the only significantly different parameter in the 
DNA/distamycin simulation.  This can be attributed to one base (Thy7) that flips out 
slightly out from the rest of the helix during the simulation.  This slight flipping out did 
not affect the DNA/distamycin distances measured or the other helical parameters.   
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 The distances measured from the atoms in the polyamides to their hydrogen 
bonding partners in the DNA show good agreement with the x-ray structure with the 
exception of two distances over all simulations.   In one low temperature simulation, a 
water molecule was discovered to be hydrogen bonding to the H of an NH group in the 
polyamide backbone; as a result, the NH group was not hydrogen bonding to the DNA.  
In one high temperature simulation, a water molecule was again found to be hydrogen 
bonding to the polyamide; however, the water molecules appear to be exchanging with 
each other, nonetheless forming a hydrogen bond with the polyamide.  The water 
molecules are therefore competing with the DNA for hydrogen bonding with the 
polyamide (which could happen with any molecule that relies on hydrogen bonding for 
recognition and binding to its target site), which is a possible factor for why some 
polyamides show reduced binding affinity for their target sequences.  Even though 
individual simulations exhibited statistical significance for two of the DNA/polyamide 
distances, when the distances are averaged together over all low temperature and all high 
temperature simulations, none of the distances are significantly different.  The distance 
measurements, like the helical parameters, show the utility of multiple trajectories; the 
behavior of the intruding water molecules may have gone unnoticed with only one 
simulation.  
 The DNA/distamycin, DNA/netropsin, and DNA/hydroxypyrrole polyamide 
simulations exhibited similar behavior with respect to water molecule hydrogen bonding 
to the ligand.  The DNA/hydroxypyrrole simulation had two distances that were 
significantly different from the x-ray distances.  These distances were at the ends of the 
DNA groove, which is accessible to water molecules.  As in the other DNA/polyamide 
 183
simulations, water molecules were observed to be forming hydrogen bonds to the DNA 
or polyamide.  The DNA/netropsin simulation had three distances that were significantly 
different from the x-ray structure and the DNA/distamycin simulation had one.  These 
distances were from nitrogens on the ends of the ligands to DNA bases.  Water molecules 
were observed to form hydrogen bonds to these nitrogens and although the water 
molecules appear to exchange during the simulation, they still form hydrogen bonds with 
the ligand.  This does not seem unusual because the minor groove of DNA normally 
contains a spine of hydration, so water is present in the minor groove.  The netropsin and 
distamycin ligands replace this spine of hydration in the middle of the groove, but water 
molecules were identified in the x-ray structures near the ends of the grooves closer to the 
ends of the ligands.60, 61  
The simulation performed using the AMBER63 parameters emphasizes that 
explicit parameterization of the force field for new molecules is necessary.  The netropsin 
molecule was not explicity parameterized for the AMBER force field63; instead, the 
parameters were guessed at by simply using analogous parameters for existing molecules 
in the force field.  The simulation exhibited large fluctuations in the RMSD of the 
DNA/netropsin complex, and this was due to large structural distortions of the pyrrole 
rings of netropsin.  The guessed bond force constants were incorrect because the bond 
lengths of the methyl groups to the pyrrole rings are much too long for a nitrogen-carbon 
bond.  The AMBER parameters did not yield a satisfactory comparison back to 
experiment; thus, unique and explicit parameterization must be performed.   
The simulations performed have validated the new force field parameters for the 
polyamides, and new simulation studies can now be performed to further understand the 
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interactions and dynamics between polyamides and DNA.  From this knowledge, new 
ligands can be designed that have a higher affinity for or bind better to their target site 
(new molecules or different heterocycles or linkages may improve the current design of 
polyamides).  Also, new ligands can be designed that use polyamides as a sequence-
specific recognition element that incorporate another type of molecule that will distort the 
DNA in a way that transcriptional proteins cannot bind to their target site.
 185
References 
 
(1)  Kielkopf, C. L.; White, S.; Szewczyk, J. W.; Turner, J. M.; Baird, E. E.; Dervan, P. 
B.; Rees, D. C., A Structural Basis for Recognition of AT and TA Base Pairs in the 
Minor Groove of B-DNA, Science, 1998, 282, 111-115. 
(2)  Kielkopf, C. L.; Baird, E. E.; Dervan, P. B.; Rees, D. C., Structural Basis for GC 
Recognition in the DNA Minor Groove, Nat. Struct. Biol., 1998, 5, 104. 
(3)  Kielkopf, C. L.; Bremer, R. E.; White, S.; Szewczyk, J. W.; Turner, J. M.; Baird, E. 
E.; Dervan, P. B.; Rees, D. C., Structural Effects of DNA Sequence on TA Recognition 
by Hydroxypyrrole/Pyrrole Pairs in the Minor Groove, J. Mol. Biol., 2000, 295, 557-567. 
(4)  White, S.; Baird, E. E.; Dervan, P. B., Effects of the AT/TA Degeneracy of Pyrrole-
Imidazole polyamide recognition in the Minor Groove of DNA, Biochemistry, 1996, 35, 
12532-12537. 
(5)  White, S.; Baird, E. E.; Dervan, P. B., Orientation Preferences of Pyrrole-Imidazole 
Polyamides in the Minor Groove of DNA, J. Am. Chem. Soc., 1997, 119, 8756-8765. 
(6)  White, S.; Turner, J. M.; Szewczyk, J. W.; Baird, E. E.; Dervan, P. B., Affinity and 
Specificity of Multiple Hydroxypyrrole/Pyrrole Ring Pairings for Coded Recognition of 
DNA, J. Am. Chem. Soc., 1999, 121. 
(7)  Swalley, S. E.; Baird, E. E.; Dervan, P. B., Discrimination of 5'-GGGG-3', 5'-GCGC-
3', and 5'-GGCC-3' Sequences in the Minor Groove of DNA by Eight-Ring Hairpin 
Polyamides, J. Am. Chem. Soc., 1997, 119, 6953-6961. 
(8)  Swalley, S. E.; Baird, E. E.; Dervan, P. B., Effects of γ-Turn and β-Tail Amino Acids 
on Sequence-Specific Recognition of DNA by Hairpin Polyamides, J. Am. Chem. Soc., 
1999, 121, 1113-1120. 
(9)  Wurtz, N. R.; Pomerantz, J. L.; Baltimore, D.; Dervan, P. B., Inhibition of DNA 
Binding by NF-κB with Pyrrole-Imidazole Polyamides, Biochemistry, 2002, 41, 7604-
7609. 
(10)  Trauger, J. W.; Baird, E. E.; Dervan, P. B., Recognition of DNA by Designed 
Ligands at Subnanomolar Concentrations, Nature, 1996, 382, 559-561. 
 186
(11)  Trauger, J. W.; Baird, E. E.; Dervan, P. B., Recognition of 16 Base Pairs in the 
Minor Groove of DNA by a Pyrrole-Imidazole Polyamide Dimer, J. Am. Chem. Soc., 
1998, 120, 3534-3535. 
(12)  Turner, J. M.; Baird, E. E.; Dervan, P. B., Recognition of Seven Base Pair 
Sequences in the Minor Groove of DNA by Ten-Ring Pyrrole-Imidazole Polyamide 
Hairpins, J. Am. Chem. Soc., 1997, 119, 7636-7644. 
(13)  Rucker, V. C.; Melander, C.; Dervan, P. B., Influence of β-alanine on Hairpin 
Polyamide Orientation in the DNA Minor Groove, Helv. Chim. Acta, 2003, 86, 1839-
1851. 
(14)  Chiang, S.-Y.; Burli, R. W.; Benz, C. C.; Gawron, L.; Scott, G. K.; Dervan, P. B.; 
Beerman, T. A., Targeting the Ets Binding Site of the HER2/neu Promoter with Pyrrole-
Imidazole Polyamides, J.Biol. Chem., 2000, 275, 24246-24254. 
(15)  Dickinson, L. A.; Trauger, J. W.; Baird, E. E.; Ghazal, P.; Dervan, P. B.; Gottesfeld, 
J. M., Anti-Repression of RNA Polymerase II Transcription by Pyrrole-Imidazole 
Polyamides, Biochemistry, 1999, 38, 10801-10807. 
(16)  Foloppe, N.; MacKerell, A. D., Jr., All-Atom Empirical Force Field for Nucleic 
Acids: I. Parameterization Optimization Based on Small Molecule and Condensed Phase 
Macromolecular Target Data, J. Comp. Chem., 2000, 21, 86-104. 
(17)  Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A., Development 
and Testing of a General AMBER Force Field, J. Comp. Chem., 2004, 25, 1157-1174. 
(18)  MacKerell, A. D., Jr.; Bashford, D.; Bellott, M.; Dunbrack, R. L.; Evanseck, J. D.; 
Field, M.; Fischer, S.; Gao, J.; Guo, H.; Ha, S.; Joseph-McCarthy, D.; Kuchnir, L.; 
Kuczera, K.; Lau, F. T. K.; Mattos, C.; Michnick, S.; Ngo, T.; Nguyen, D. T.; Prodhom, 
B.; Reiher, W. E.; Roux, B.; Schlenkrich, M.; Smith, J. C.; Stote, R.; Straub, J.; 
Watanabe, M.; Wiorkiewicz-Kuczera, J.; Yin, D.; Karplus, M., All-Atom Empirical 
Potential for Molecular Modeling and Dynamics Studies of Proteins, J. Phys. Chem. B, 
1998, 102, (18), 3586-3616. 
(19)  Kielkopf, C. L.; Ding, S.; Kuhn, P.; Rees, D. C., Conformational Flexibility of B-
DNA at 0.74 Angstrom Resolution, J. Mol. Biol., 2000, 296, 787-801. 
 187
(20)  Allen, F. H., The Cambridge Structural Database: A Quarter of a Million Crystal 
Structures and Rising, Acta Crystallographica Section B: Structural Science, 2002, 58, 
380. 
(21)  Berman, H. M.; Neidle, S.; Zimmer, C.; Thrum, H., Netropsin, A DNA-Binding 
Oligopeptide: Structural and Binding Studies, Biochimica et Biophysica Acta--Nucleic 
Acids and Protein Synthesis, 1979, 561, 124-131. 
(22)  Lavery, R.; Sklenar, H., The Definition of Generalized Helicoidal Parameters and of 
Axis Curvature for Irregular Nucleic Acids, J. Biomolecular Structure and Dynamics, 
1998, 6, 63-91. 
(23)  Olson, W. K.; Bansal, M.; Burley, S. K.; Dickerson, R. E.; Gerstein, M.; Harvey, S. 
C.; Heinemann, U.; Lu, X. J.; Neidle, S.; Shakked, Z.; Sklenar, H.; Suzuki, M.; Tung, C. 
S.; Westhof, E.; Wolberger, C.; Berman, H. M., A Standard Reference Frame for the 
Description of Nucleic Acid-Base Pair Geometry, J. Mol. Biol., 2001, 313, 229-237. 
(24)  Lu, X. J.; Olson, W. K., Resolving the Discrepancies Among Nucleic Acid 
Conformational Analyses, J. Mol. Biol., 1999, 285, 1563-1575. 
(25)  Dickerson, R. E., Definitions and Nomenclature of Nucleic Acid Structure 
Components, Nucleic Acids Research, 1989, 17, 1797. 
(26)  MacKerell, A. D., Jr.; Banavali, N., All-Atom Empirical Force Field for Nucleic 
Acids: II. Application to Molecular Dynamics Simulations of DNA and RNA in Solution, 
J. Comp. Chem., 2000, 21, 105-120. 
(27)  Berman, H. M.; Olson, W. K.; Beveridge, D. L.; Westbrook, J.; Gelbin, A.; 
Demeny, T.; Hsieh, S.-H.; Srinivasan, A. R.; Schneider, B., The Nucleic Acid Database: 
A Comprehensive Relational Database of Three-Dimensional Structures of Nucleic 
Acids, Biophys. J., 1992, 63, 751-759. 
(28)  Lu, X. J.; Olson, W. K., 3DNA: A Software Package for the Analysis, Rebuilding, 
and Visualization of Three-Dimensional Nucleic Acid Structures, Nucleic Acids 
Research, 2003, 31, 5108. 
(29)  Dickerson, R. E., DNA Bending: the prevalence of kinkiness and the virtues of 
normality, Nucleic Acids Research, 1998, 26, 1906-1926. 
 188
(30)  El Hassan, M. A.; Calladine, C. R., The assessment of the geometry of dinucleotide 
steps in double-helical DNA: a new local calculation scheme, J. Mol. Biol., 1995, 251, 
648-664. 
(31)  Lu, X. J.; El Hassan, M. A.; Hunter, C. A., Structure and conformation of helical 
nucleic acids analysis program (SCHNAap), J. Mol. Biol., 1997, 273, 668-680. 
(32)  Gorin, A. A.; Zhurkin, V. B.; Olson, W. K., B-DNA twisting correlates with base-
pair morphology, J. Mol. Biol., 1995, 247, 34-48. 
(33)  Kosikov, K. M.; Gorin, A. A.; Zhurkin, V. B.; Olson, W. K., DNA Stretching and 
Compression: Large-Scale Simulations of Double Helical Structures, J. Mol. Biol., 1999, 
289, 1301-1326. 
(34)  Bansal, M.; Bhattacharyya, D.; Ravi, B., NUPARM and NUCGEN: Software for 
analysis and generation of sequence dependent nucleic acid structures, CABIOS, 1995, 
11, 281-287. 
(35)  Tung, C. S.; Soumpasis, D. M.; Hummer, G., An Extension of the Rigorous Base-
Unit Oriented Description of Nucleic Acid Structures, J. Biol. Struct. Dynam., 1994, 11, 
1327-1344. 
(36)  Babcock, M. S.; Olson, W. K., The effect of mathematics and coordinate systems on 
comparability and "dependencies" of nucleic acid structure parameters, J. Mol. Biol., 
1994, 237, 98-124. 
(37)  Lavery, R.; Zakrzewska, K., Base and Base Pair Morphologies, Helical Parameters, 
and Definitions. In Oxford Handbook of Nucleic Acid Structure, Oxford University Press: 
Oxford, 1999. 
(38)  Schlick, T., Molecular Modeling and Simulation: An Interdisciplinary Guide. 
Springer-Verlag: New York, 2000; 21. 
(39)  Clarage, J. B.; Romo, T.; Andrews, B. K.; Pettit, B. M.; Phillips, G. N., Jr., A 
Sampling Problem in Molecular Dynamics Simulations of Macromolecules, Proc. Natl. 
Acad. Sci. USA, 1995, 92, 3288-3292. 
(40)  Frauenfelder, H.; Sligar, S. G.; Wolynes, P., The Energy Landscapes and Motions 
of Proteins, Science, 1991, 254, 1598. 
 189
(41)  Karplus, M.; McCammon, A., Molecular Dynamics Simulations of Biomolecules, 
Nature Structural Biology, 2002, 9, (9), 646. 
(42)  Auffinger, P.; Louise-May, S.; Westhof, E., Multiple molecular dynamics 
simulations of the anticodon loop of tRNAAsp in aqueous solution with counterions, J. 
Am. Chem. Soc., 1995, 117, 6720-6726. 
(43)  Caves, L. S. D.; Evanseck, J. D.; Karplus, M., Locally Accessible Conformations of 
Proteins: Multiple Molecular Dynamics Simulations of Crambin, Protein Science, 1998, 
7, 649-666. 
(44)  Schulze, B. G.; Evanseck, J. D., Cooperative Role of Arg45 and His64 in the 
Spectroscopic A3 State of Carbonmonoxy Myoglobin: Molecular Dynamics Simulations, 
Multivariate Analysis, and Quantum Mechanical Computations, J. Am. Chem. Soc., 1999, 
121, 6444-6454. 
(45)  Grossfield, A.; Feller, S. E.; Pitman, M. C., Convergence of Molecular Dynamics 
Simulations of Membrane Proteins, Proteins: Structure, Functions, and BioInformatics, 
2007, 67, 31-40. 
(46)  Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; 
Shindyalov, I. N.; Bourne, P. E., The Protein Data Bank, Nucleic Acids Research, 2000, 
28, 235-242. 
(47)  Sinden, R. R., DNA Structure and Function. Academic Press: San Diego, CA, 1994. 
(48)  Bloomfield, V. A.; Crothers, D. M.; Tinoco, I., Nucleic Acids: Structures, 
Properties, and Functions. University Science Books: Sausalito, CA, 2000. 
(49)  Neidle, S., Nucleic Acid Structure and Recognition. Oxford University Press: New 
York, NY, 2002. 
(50)  Feig, M.; Pettitt, M., Structural Equilibrium of DNA Represented with Different 
Force Fields, Biophysical Journal, 1998, 75, 134-149. 
(51)  Zheng, L.; Thompson, D. L., On the Accuracy of Force Fields for Predicting the 
Physical Properties of Dimethylnitramine, J. Phys. Chem. B., 2006, 110, 16082-16088. 
 190
(52)  Jas, G. S.; Kuczera, K., Equilibrium Structure and Folding of a Helix-Forming 
Peptide: Circular Dichroism Measurements and Replica-Exchange Molecular Dynamics 
Simulations, Biophys. J., 2004, 87, 3786-3798. 
(53)  Pitera, J. W.; Swope, W., Understanding Folding and Design: Replica-Exchange 
Simulations of "Trp-Cage" Miniproteins, Proc. Natl. Acad. Sci. USA, 2003, 100, 7587-
7592. 
(54)  Damm, W.; van Gunsteren, W. F., Reversible Peptide Folding: Dependence on 
Molecular Force Field Used, J. Comp. Chem., 2000, 21, 774-787. 
(55)  Garcia, A. E.; Sanbonmatsu, K. Y., a-Helical Stabilization by Side Chain Shielding 
of Backbone Hydrogen Bonds, Proc. Natl. Acad. Sci. USA, 2002, 99, 2782-2787. 
(56)  Zhou, R., Trp-Cage: Folding Free Energy Landscape in Explicit Water, Proc. Natl. 
Acad. Sci. USA, 2003, 100, 13280-13285. 
(57)  Pilch, D. S.; Poklar, N.; Baird, E. E.; Dervan, P. B.; Breslauer, K. J., The 
Thermodynamics of Polyamide-DNA Recognition: Hairpin Polyamide Binding in the 
Minor Groove of Duplex DNA, Biochemistry, 1999, 38, 2143-2151. 
(58)  Pilch, D. S.; Poklar, N.; Gelfand, C. A.; Law, S. M.; Breslauer, K. J.; Baird, E. E.; 
Dervan, P. B., Binding of a Hairpin Polyamide in the Minor Groove of DNA: Sequence 
Specific Enthalpic Discrimination, Proc. Natl. Acad. Sci. USA, 1996, 93, 8306-8311. 
(59)  James, P. L.; Le Strat, L.; Ellervik, U.; Bratwall, C.; Norden, B.; Brown, T.; Fox, K. 
R., Effects of a Hairpin Polyamide on DNA Melting: Comparison with Distamycin and 
Hoechst 33258, Biophysical Chem., 2004, 111, (3), 205-212. 
(60)  Tabernero, L.; Verdaguer, N.; Coll, M.; Fita, I.; van der Marel, G. A.; van Boom, J. 
H.; Rich, A.; Aymami, J., Molecular Structure of the A-tract DNA Dodecamer  
d(CGCAAATTTGCG) Complexed with the Minor Groove Binding Drug Netropsin, 
Biochemistry, 1993, 32, 8403-8410. 
(61)  Coll, M.; Frederick, C. A.; Wang, A. H.-J.; Rich, A., A Bifurcated Hydrogen-
Bonded Conformation in the Base Pairs of the DNA Dodecamer  
d(GCGAAATTTGCG) and Its Complex with Distamycin, Proc. Natl. Acad. Sci. USA, 
1987, 84, 8385-8389. 
 191
(62)  Wellenzohn, B.; Winger, R. H.; Hallbrucker, A.; Mayer, E.; Liedl, K. R., 
Simulation of EcoRI Dodecamer Netropsin Complex Confirms Class I Complexation 
Mode, J. Am. Chem. Soc., 2000, 122, 3927-3931. 
(63)  Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M., Jr.; Ferguson, 
D. M.; Spellmeye, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A., A Second Generation 
Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules, J. Am. 
Chem. Soc., 1995, 117, 5179-5197. 
(64)  Humphrey, W.; Dalke, A.; Schulten, K., VMD: Visual Molecular Dynamics, J. Mol. 
Graphics, 1996, 14, 33-38. 
 
 192
 
 
Chapter 4  
 
 
Force Field Parameters for the Simulation of Conjugated 
Dienes with a Focus on Retinoids 
 
This chapter describes the parameterization procedure for the retinoid molecules, 
the results of the crystal simulations performed to test the parameters, and conclusions 
derived from the simulations.   
4.1 Parameterization of Retinoids 
CHARMM force field topology and parameters for π-conjugated systems were 
developed and tested against four retinoid compounds (retinoic acid, retinol, fenretinide, 
and retinal). The parameterization strategy involved the subdivision of key retinoid 
functionality into 17 small organic (model) compounds.  In force field development, one 
possible approach is to divide a larger molecular system into smaller representative, or 
model compounds that contain the important functionalities.1   MacKerell and coworkers 
have used quantum mechanical data to parameterize various classes of molecules for the 
CHARMM force field.2-12  Quantum mechanical data has also been used to parameterize 
the Merck Molecular Force Field,13 the AMBER force field,14 the OPLS-AA force 
field,15, 16 the GROMOS force field,17 and the CVFF force field.18 Typically, 
experimental data is critical for force field development.  However, geometries derived 
from quantum mechanical data are particularly useful for force field parameterization, 
since the time or length scale of experimental studies could introduce significant error or 
prohibit the measurement process.13, 19 
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Model compounds must be selected so that they capture the important bond and 
nonbond attributions of the molecular system, and be small enough to be computationally 
tractable.  The model compounds are shown in Figure 4.1.  Models 1-5 were selected 
because all retinoids contain a chain of alternating single and double bonds with methyl 
groups attached to various carbons on the chain.  Structures 6 and 7 are for use in the 
fenretinide molecule, which contains amide and phenol groups at the tail end. The 
cyclohexene ring portion that is in all retinoid compounds was modeled by 8 and 9. The 
tail ends were parameterized using 10-12.  Model 10 is for retinoic acid, 11 is for retinol, 
and 12 is for retinal. Models 13 and 14 were parameterized to examine rotation/energetics 
about the double bonds in retinoids.  Models 15-17 were parameterized for the Schiff 
base linkage for retinal (when retinal binds to rhodopsin or bacteriorhodopsin, it binds 
covalently to a lysine residue through a Schiff base linkage).  Models 18 and 19 are used 
to create patches for making the covalent linkage from retinal to the lysine of the protein; 
the patches simply delete the hydrogens on the nitrogen of the side chain of lysine and the 
oxygen of the carbonyl group on the tail of retinal and make a double bond between the 
lysine nitrogen and the carbonyl carbon of retinal. 
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Figure 4.1 Model compounds and patch residues for retinoids (some hydrogens not 
shown for clarity).  Models 1-17 are the model compounds, and 18 and 19 are used to 
create patches for forming Schiff bases. 
 
New atom types were created to allow for proper treatment of alternating single 
and double bonds.  The previous CHARMM parameters used only two atom types for 
conjugated systems, CE1 for internal carbons and CE2 for terminal carbons. Previously, 
alternation between single and double bonds was not possible with only one atom type 
for the internal carbons (Figure 4.2). The previous parameters (when the structure was 
energy minimized) showed only a 0.002 Å difference between the carbon-carbon single 
and double bonds, whereas microwave20 and infrared data21 resulted in a difference of 
0.13 Å, Raman data gave a difference 0.14 Å,22 and electron diffraction data showed a 
difference between 0.12 to 0.15 Å.23-26    
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New atom types for π-conjugated systems have been created, which are CC2 for 
terminal carbons and CC1A and CC1B for internal carbons (Figure 4.2).  Each model 
compound was energy minimized at the MP2/6-31G(d) level of theory.13, 27, 28  The 
average MP2/6-31G(d) carbon-carbon bond lengths over all model compounds was 1.50 
± 0.03 Å for single bonds, and 1.35 ± 0.02 Å for double bonds.  The average bond 
lengths calculated from MP2 were used as the equilibrium bond lengths for the new 
CHARMM parameters for the associated bond type. The force constants were based on 
MP2/6-31G(d) frequency computations for 1, 13, 15, and 16 in Figure 4.1 as an initial 
guess.   Each model compound was energy minimized with the CHARMM force field 
with steepest descent and Newton-Raphson (tolerance gradient was 10-6 kcal/mol/Å for 
each minimization).  The parameters where then adjusted to minimize error with the 
MP2/6-31G(d) structure. The average value for the CHARMM single bonds is 1.51 ± 
0.02 Å, and the average value for double bonds is 1.36 ± 0.02 Å.  The average error 
between MP2 and CHARMM for single bonds is 0.01 ± 0.01 Å, and 0.005 ± 0.006 Å for 
double bonds.  The average error between MP2 and CHARMM over all bonds (not just 
carbon-carbon bonds) in the model compounds is 0.012 ± 0.009 Å.   
New angle terms and angle modifications were also made.  The minimized angle 
values obtained from the MP2 optimized structures were used as the equilibrium angle 
 
Figure 4.2  Previous 1,3,5-hexatriene carbon atom types (top).  New 1,3,5-
hexatriene atom types (bottom). 
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values for the new CHARMM parameters. The force constants were based on MP2/6-
31G(d) frequency computations for 1, 13, 15, and 16 in Figure 4.1 as an initial guess. 
Each model compound was energy minimized with the CHARMM force field with 
steepest descent and Newton-Raphson (tolerance gradient was 10-6 kcal/mol/Å).  The 
parameters were adjusted to minimize the error across all model compounds. The average 
error between MP2 and CHARMM was calculated for angles as 2 ± 2º.   
Torsion angle terms were also reparameterized. The torsion angles chosen were 
selected because they involve low energy barriers that are important in describing the 
dynamics allowing the retinoids to interact with various proteins; the single bonds and 
any bonds linking the conjugated hydrocarbon chain of the retinoids to a functional group 
must be able to rotate in order for the retinoid molecule to maximize favorable 
interactions with amino acids in the binding site of the protein.  For each model 
compound, the potential energy surfaces (PES) for selected torsion angles (see Figures 
4.3-4.9 for selected torsion angles; the bond with the arrows were the bonds which were 
rotated about) were calculated by holding the selected torsion angle fixed at different 
increments (20º increments from –180º to 180º) and geometry optimizing all other 
degrees of freedom.  The torsion angles selected were for rotations about the single bond  
between two double bonds, rotation of a particular functional group that is necessary for 
optimizing ligand-protein contacts, or rotations necessary for ring puckering.   The 
CHARMM dihedral angle parameters force constant (Kχ), multiplicity (n), and phase 
shift (δ) were then modified to match the quantum mechanical results from the potential 
energy surfaces.  Each model compound was energy minimized in CHARMM (steepest 
descent and Newton-Raphson; tolerance gradient was 10-6 kcal/mol/Å) with the selected 
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torsion angle held fixed, and the potential energy surface of the dihedral was calculated.  
If the surface did not match the MP2 results, then the multiplicity, phase shift, or force 
constant were adjusted as necessary.   
For models 1-5 in Figure 4.1, the single bond between the two double bonds of 
the molecules was rotated from –180º to 180º in 20º increments.   Figure 4.3 shows the 
torsion angle results for 1,3-butadiene and 1,3-pentadiene.   
 
 
Figure 4.3 Torsion energy plots for 1,3-butadiene (top) and 1,3-pentadiene (bottom).  
Diamonds, final CHARMM; square, MP2/6-31G(d). 
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to lower the barriers and the multiplicity (n) to get the correct number of barriers.  The 
final CHARMM results show the correct phase and multiplicity as the MP2 results.  The 
CHARMM energy barrier at 0º, which corresponds to cis-1,3-butadiene, is 1.03 kcal/mol 
higher than the MP2 results, but overall, the results agree well.   
1,3-Butadiene has been examined by several experiments, including electron 
diffraction,23-26 UV,29 IR,21, 30, 31 microwave,32 Raman,22, 33 and computational studies.34-38 
The trans form is the dominant conformation, and the cis (0º) or gauche (~40º) 
conformation is the minor component. However, there is still debate on whether the cis or 
gauche conformer is the more stable minor conformer.39-44 Computational studies show 
that the cis form is a “transition structure” between the two gauche conformers, but 
generally, experimental studies say that the cis form is the minor conformer.31, 45  This 
difference has been attributed to conditions under which the torsional potential was 
calculated or measured.  Theoretical and vapor phase spectroscopy results favor the 
gauche form as the second stable conformer, while spectroscopic measurements 
performed in an argon matrix favor the cis form as the second stable conformer of 1,3-
butadiene (the interaction with the surrounding Ar matrix stabilizes the cis form and thus 
changes the torsional potential).46 Also, it is difficult to distinguish the cis and gauche 
forms from one another by an experimental direct measurement because only ~1% of the 
minor conformer is present at room temperature, and 1,3-butadiene is reactive at higher 
temperatures.42, 44  
For 1,3-pentadiene (bottom of Figure 4.3), the initial CHARMM had energy 
barriers that are too high (~92 kcal/mol; see Appendix B), and the multiplicity was 
incorrect. The energy barriers were lowered by decreasing the value of the force constant 
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(Kχ) to 0.5600 kcal/mol/Å2, and the correct number of barriers was obtained by changing 
the multiplicity (n) to 2.  The final CHARMM surface shows the correct phase and 
multiplicity, and the energy barriers are in good agreement with the MP2 results. The 
CHARMM energy barriers at 100º and –100º are ~0.58 kcal/mol lower than the MP2, and 
the CHARMM energy barrier at 0º is ~0.34 kcal/mol lower than the MP2.  
Figure 4.4 shows the torsion angle results for the conjugated methylated butanes 
and pentenes. As for 1,3-butadiene, all of the methylated dienes have two minima 
(gauche conformers) in addition to the global minimum (trans conformer) on their 
potential energy surfaces.  Also, the initial CHARMM for the methylated dienes shows 
very high energy barriers and incorrect multiplicities (Appendix B).  2-Methyl-1,3-
butadiene shows a maximum at 116 kcal/mol for the initial CHARMM, 2-methyl-1,3-
pentadiene shows a maximum at 125 kcal/mol, and 4-methyl-1,3-pentadiene has a 
maximum at 93 kcal/mol.  The final CHARMM parameters are in good agreement with 
the MP2 results.  For 2-methyl-1,3-pentadiene, the CHARMM barrier height is 0.62 
kcal/mol lower than MP2 at 0º and 0.57 kcal/mol lower than MP2 at –100º and 100º.  4-
Methyl-1,3-pentadiene has a CHARMM surface that is 0.90 kcal/mol higher than MP2 at 
0º and 0.76 kcal/mol higher at 100º.  2-Methyl-1,3-butadiene has good agreement 
between CHARMM and MP2 with CHARMM having barriers only 0.28 kcal/mol higher 
than MP2 at the barrier at 0º.   
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Figure 4.4 Torsion energy plots for 2-methyl-1,3-butadiene (top left), 4-methyl-1,3-
pentadiene (top right), and 2-methyl-1,3-pentadiene (bottom). Diamonds—final 
CHARMM surfaces; square—MP2/6-31G(d) surface. 
 
 
Model compounds 6 and 7 are for use in the fenretinide molecule, which contains 
and amide and phenol group at the tail end.  
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Figure 4.5 Torsion energy plot for N-3-dimethyl-2-butenamide (top) and p-acetamide 
phenol (bottom). Diamonds; MP2/6-31G(d); squares; final CHARMM.  
 
 
N-3-dimethyl-2-buteneamide shows high energy barriers for the initial CHARMM 
(Appendix B) and also shows the wrong phase and multiplicity.  The final CHARMM 
shows much better agreement with MP2, with the CHARMM being 0.86 kcal/mol lower 
than MP2 at the maxima (180° and -180°).   
 The initial CHARMM energy barriers for p-acetamide phenol, 7, are too high 
(~13 kcal/mol; Appendix B), but the phase and multiplicity are correct.  The final 
CHARMM maxima at 80º are in better agreement with MP2, and the minimum at 0º is 
~0.80 kcal/mol higher than MP2. 
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Models 8 and 9 were parameterized for the cyclohexene ring portion that is in all 
retinoid compounds.   
  
 
 
Figure 4.6 Torsion energy surfaces for 1,6,6-trimethyl-2-ethene-cyclohexene (top) and 
1,2,6,6-tetramethylcyclohexene (bottom).  Diamonds, MP2/6-31G(d); squares, final 
CHARMM. 
 
 
The initial CHARMM parameters for the 1,6,6-trimethyl-2-ethene cyclohexene 
behave like the others; the energy barriers are too high (~120 kcal/mol; Appendix B).  
The final CHARMM parameters are in better agreement, but they show an increase in 
energy at 150º and -150º, whereas MP2 does not.  Also, CHARMM is ~1.1 kcal/mol 
higher than MP2 at the maximum at 0º.    The dihedral surface for 1,2,6,6-
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tetramethylcyclcohexene was examined for the purpose of deciding which ring pucker 
was more favorable, C2-endo (C2 carbon above the plane of the ring) or C3-endo (C3 
carbon above the plane of the ring).  The side of the ring containing the double bond stays 
planar, but the other side of the ring can move and pucker with either the C2 or C3 above 
the ring plane. The dihedral examined was rotated from –50º to 50º in 10º increments (the 
dihedral is constrained being in the cyclohexene ring).  When the dihedral is at –10º, the 
ring is in the C3-endo conformation, and when the dihedral is at 10º, the ring is in the C2-
endo conformation.  Since both conformations are at a minimum on the surface, each 
structure was geometry optimized to find which conformation was lowest in energy.  The 
MP2 calculations showed that the both conformations were nearly the same in energy; 
the C2-endo structure was only 3.00 x 10-4 kcal/mol lower in energy than the C3-endo 
structure. The initial and final CHARMM parameters are almost the same for this model 
compound (Appendix B), and after revision, the final CHARMM parameters are only 0.5 
kcal/mol higher than the initial parameters at 50º.  MP2 is ~1.3 kcal/mol higher than 
CHARMM at 10º and -10º.  
Models 10, 11, and 12 were parameterized for the tail ends of the retinoids. Model 
10 is for retinoic acid, Model 11 is for retinol, and Model 12 is for retinal.  For Models 10, 
11, and 12, rotation to obtain the surfaces was about the C-C single bond in the middle of 
the structure.   
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Figure 4.7 Torsion energy surfaces for 2-propenoic acid (top left), 2-propenol (top right), 
and 2-propenal (bottom). Diamonds, final CHARMM; squares, MP2/6-31G(d). 
 
 
The initial CHARMM parameters for 2-propenoic acid, 2-propenol, and 2-propenal do 
not show the same magnitude of high energy barriers as the conjugated dienes.  
Nevertheless, the initial parameters do not agree with the MP2 results (see Appendix B).  
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The final CHARMM parameters for 2-propenoic acid are in good agreement; CHARMM 
shows the correct minima (at 0º, 180º, and -180º) and maxima; CHARMM is only 0.08 
kcal/mol higher than MP2 at the maxima. For 2-propenol, the final CHARMM 
parameters are 1.1 kcal/mol higher than MP2 at 180º and –180º, and they give the correct 
phase and multiplicity. The final CHARMM parameters for 2-propenal are in also in 
good agreement with MP2, showing the correct barrier heights; CHARMM is only 0.5 
kcal/mol higher than MP2 at the maxima.  
In general, the initial CHARMM parameters delivered unrealistic torsional 
energetic barriers, which were parameterized by changing the force constants and 
multiplicities to match the MP2 data.  For each case, the changes are given in Appendix 
B.  The final CHARMM torsional surfaces agree well with those calculated from MP2.  
The largest difference observed between MP2 and CHARMM was 1.1 kcal/mol.  
Models 13 and 14 were parameterized to examine rotation/energetics about the 
double bonds in the retinoids.  CHARMM follows MP2 at the higher values for the 
dihedral (120º-180º), but as the compound approaches the lower values and gets closer to 
a cis conformation (105º down to 45º), CHARMM deviates from MP2, and at 45º, there 
is a 49 kcal/mol difference. As for 2-butene, the CHARMM parameters for 1,3,5-
hexatriene follow MP2 when the molecule has a trans geometry (-180º to -120º), but as 
the structure approaches a more cis conformation about the middle double bond, 
CHARMM starts to deviate from MP2.  At 60º, CHARMM even starts to show a 
decrease in energy.  This deviation is due to a conformational change of the end groups 
that are on either side of the double bond being rotated.  The CHARMM structures do not 
show as much movement of the end groups.   
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Figure 4.8 Torsion energy surfaces for 2-butene (left) and 1,3,5-hexatriene (right). 
Diamonds, final CHARMM; squares, MP2/6-31G(d). 
 
 
Models 15, 16, and 17 in Figure 4.1 were parameterized for the Schiff base 
linkage for retinal.  When retinal binds to rhodopsin or bacteriorhodopsin, it binds 
covalently to a lysine residue through a Schiff base linkage.  Model 15 is for a 
deprotonated Schiff base linkage, and 16 and 17 are for protonated Schiff base linkages. 
The CHARMM for the first two Schiff base compounds (Figure 4.9) follows the MP2 up 
to the last two points tested, and then it starts to deviate by about 9 kcal/mol.  The double 
bond was used to examine the rotation/energetics for the Schiff base linkage in retinal.  
The CHARMM parameters for the third Schiff base compound (Figure 4.9) are in 
excellent agreement with MP2; the multiplicity and phase are correct, and the barrier 
heights coincide almost exactly.  
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Figure 4.9 Torsion energy plot for deprotonated Schiff base (top left) and protonated 
Schiff base (top right and bottom). Diamonds, final CHARMM; squares, MP2/6-31G(d). 
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The last two models in Figure 4.1 (18 and 19) are for patches making the covalent 
linkage from retinal to the lysine of the protein.  The Schiff base linkages they contain 
were parameterized (15, 16, and 17); the patches simply delete the hydrogens on the 
nitrogen of the side chain of lysine and the oxygen of the carbonyl group on the tail of 
retinal and make a double bond between the lysine nitrogen and the carbonyl carbon of 
retinal.   
The final CHARMM parameters for the model compounds are in good agreement 
with the MP2/6-31G(d) results.  The initial CHARMM parameters not only treated the 
alternating single and double bonds incorrectly, but for many of the model compounds, 
the energy barriers for the torsion angles were too high (over 60 kcal/mol), and some 
were out of phase.  The final CHARMM parameters exhibit the correct barrier heights 
and phases, and largest difference between CHARMM and MP2 was 1.15 kcal/mol 
(CHARMM is higher than MP2 for 1,6,6-trimethyl-2-ethene-cyclohexene at the maxima 
at –180º and 180º). The average error between CHARMM and MP2 in bond distances is 
0.012 ± 0.009 Å, the average error for angles is 1 ± 1º, and the average error for dihedrals 
is 2 ± 4º.   
4.2 Comparison to Available Experimental Data 
 Some of model compounds and the retinoids built from them were compared to 
available experimental data.  Experimental data for all model compounds is not available, 
nor is experimental data for all four retinoids.   The most experimental data was for 1,3-
butadiene, and this included mainly electron diffraction data;23-26 however, there was 
infrared,21 microwave,32 and Raman22 data as well. Electron diffraction data was also 
found for 2-methyl-1,3-butadiene47 and 1,3,5-hexatriene,25 and x-ray diffraction data was 
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found for p-acetamide phenol48 and 2-propenoic acid.49  For the final retinoids, x-ray 
structures of all-trans retinoic acid50, 51 and all-trans retinal52 were compared to the final 
retinoids in CHARMM.  The experimental comparisons with the new CHARMM 
parameters and MP2 results (in the case of the smaller model compounds) for 1,3-
butadiene are shown in Table 4.1 (CHARMM atom numbering referred to in Table 4.1 is 
shown above the table).  
 
 
 
 
 
 Table 0.1 Experimental, QM, and MM comparison for 1,3-butadiene. 
Method C1-C2   C2-C3   C3-C4   C-H (all)     C1-C2-C3     C2-C3-C4       C=C-C        C=C-H    C1-C2-C3-C4
EDa 1.35 1.46 1.35 1.06 124 ± 2 124 ± 2   180
EDb 1.337 1.483 1.337 1.082   122.4 119.8 180
EDc 1.344 1.467 1.344 1.094   122.8 ± 0.5 119.5 ± 1 180
EDd 1.341 1.463 1.341 1.086   123.3 ± 0.5 121.8 ± 1.2 180
IRe 1.338 1.464 1.338 1.086   123.2 ± 0.2 119.6 ± 0.2 180
Microwavef 1.337 1.467  1.087 123.5   120.9 ± 1.13 180
Ramang 1.337 1.476 1.337 1.085   122.9 ± 0.5 120 180
MP2/6-31G(d) 1.344 1.458 1.344 1.087 123.7 123.7 123.7 ± 0.2 120.9 ± 1.05 180
CHARMM 1.346 1.471 1.346 1.1 123.7 123.7 123.7 ± 0.3 120.1 ± 1.34 180
 
Bonds in Å; angles and dihedrals in degrees. 
a see ref. 23 
b see ref. 24; C=C bond error 0.005 Å, C-C bond error 0.01 Å, C-H bond error 0.01 Å.  
c see ref. 25   
d see ref. 26; C=C bond error 0.002 Å, C-C bond error 0.003 Å, C-H bond error 0.04 Å.  
e see ref. 21; C-C bond error 0.003 Å.  
f  see ref. 32 
g see ref. 22 C-C bond error 0.01 Å.  
 
From Table 4.1, the MP2/6-31G(d) results and the final CHARMM results 
compare well to the experimental bonds, angles, and dihedral angle.  MP2 and 
CHARMM both give the trans structure (180º) of 1,3-butadiene after energy 
C1
C2
C3
C4
H21
H31
H41
H42
H12
H11
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minimization; all of the experimental techniques find this as well. Also, the average error 
between MP2 and CHARMM compared with experimental bonds is 0.007 ± 0.005 Å and 
0.009 ± 0.008 Å, respectively, and the average error between MP2 and CHARMM 
compared with experimental angles is 0.7 ± 0.5º and 0.6 ± 0.4º, respectively.   When 
comparing the computed values to electron diffraction results, it should be kept in mind 
that the average carbon-carbon bond length can be determined with high accuracy when 
equivalent bonds are present, but if non-equivalent bonds are present, the individual 
values can be much less accurate.53  
Table 4.2 shows the comparison of experimental data with the structures obtained 
from the final CHARMM parameters for isoprene (2-methyl-1,3-butadiene).  
 
 
Table 0.2 Experimental, QM, and MM comparison for 2-methyl-1,3-butadiene. 
 
   C=C  C2-C3  C2-C5 Csp2-H Csp3-H C1-C2-C3 C2-C3-C4 C1-C2-C5 H12-C1-C2  C2-C5-H1 
EDa 1.34 1.46 1.51 1.08     1.11    121.4    127.3 121 124.3 109.1 
MP2/6-31G(d) 1.35 1.47 1.51 1.09     1.09    122.6    122.6       119.8      121.7        111 
CHARMM 1.35 1.49 1.51 1.1      1.1    121.8    128.4       119.4 121.3 114.3 
MP2/ED error 0.01 0.01 0 0.01 0.02        1.2       4.7 1.2 2.6 1.9 
CH/ED error 0.01 0.03 0 0.02 0.01        0.4       1.1 1.6 3 5.2 
MP2/CH error 0 0.02 0 0.01 0.01        0.8       5.8 0.4 0.4 3.3 
Bonds in Å; angles in degrees.  
a see ref. 47; no error reported 
 
For isoprene, the MP2 and CHARMM results compare well to the ED data.  The average 
error for bonds between MP2 and the ED data and CHARMM and the ED data is 0.01 ± 
0.01 Å and 0.01 ± 0.02 Å, respectively.  The average error for angles compared to the ED 
C1
C2
C3
C4
C5
H31
H41
H42
H12
H11
H1
H2
H3
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C1
C2
CG
OD1
OD2-
H21
H11
H12
data is 2.5 ± 1.4º for MP2 and 3.1 ± 2.7º for CHARMM. The MP2 and CHARMM results 
are also in good agreement; the average error for bonds between MP2 and CHARMM is 
0.008 ± 0.009 Å, and the average error for angles is 2.4 ± 2.2º.  
  
 
Table 0.3  Experimental, QM, and CHARMM comparison of 2-propenoic acid. 
   C2-CG C1-C2 CG-OD2 CG-OD1 OD1-OD2  OD1-CG-C2       OD1-CG-OD2         C1-C2-CG-OD2        C1-C2-CG-OD1
x-raya      1.47 1.3 1.28 1.26 2.66 116 122 0 180 
MP2/6-31G(d) 1.48 1.34 1.27 1.26 2.29 113.9 130               0 180 
CHARMM 1.5 1.34 1.26 1.26 2.22 116.2 123.6 0 180 
MP2/x-ray error 0.01 0.04 0.01 0 0.37 2.1 8 0 0 
CH/x-ray error 0.03 0.04 0.02 0 0.44 0.2 1.6 0 0 
MP2/CH error 0.02 0 0.01 0 0.07 2.3 6.4 0 0 
 
Bonds in Å; angles and dihedrals in degrees. 
h see ref. 49  
 
An x-ray structure has been reported for 2-propenoic acid.49 The average error for 
bonds between CHARMM and the x-ray data is 0.1 ± 0.2 Å (Table 4.3).  This error is 
larger than the other comparisons when CHARMM is compared to experimental data; 
and this is probably due to the fact that CHARMM gives bond lengths that are slightly 
longer than the x-ray data for the carbon-carbon bonds, and one of the carbon-oxygen 
bonds is shorter than what was found in the x-ray structure.  The error between MP2 and 
the x-ray data is smaller than that of CHARMM, with the error being 0.09 ± 0.1 Å.  The 
error between MP2 and CHARMM is smallest at 0.02 ± 0.02 Å. Two of the MP2 angles 
are slightly less than the x-ray structure, and the angle between the two oxygens is larger 
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than the x-ray structure, giving an average error of 5.4 ± 3.0º.  The error between 
CHARMM and the x-ray structure is smaller for the angles at 1.2 ± 0.8º.  The average 
angle error between CHARMM and MP2 is 4.3 ± 2.1º.  An overlay of the x-ray structure 
(red) and the CHARMM minimized structure (blue) is shown above Table 4.3; the 
RMSD between the two structures is 0.0001 Å.   
An electron diffraction structure has been reported for 1,3,5-hexatriene.25 All 
three structures give the trans conformation about the double bonds, and most of the 
bonds and angle from CHARMM and MP2 agree with those of the experimental structure 
(average bond errors are 0.01 ± 0.03 Å for MP2 and ED and 0.02 ± 0.02 Å for 
CHARMM and ED).  However, CHARMM gives slightly longer carbon-carbon single 
bonds (~0.02 Å) than the x-ray and MP2 structures (Table 4.4).   
 
 
Table 0.4 Experimental, QM, and MM comparison of 1,3,5-hexatriene 
 C1-C2 C2-C3 C3-C4 C4-C5 C5-C6 C-H (all)     C=C-C      C=C-H        C-C-C-C
EDa 1.345  1.45 1.345 1.45 1.345 1.103 124.3 ± 1.5 117.8 180
MP2/6-31G(d) 1.346 1.451 1.345 1.451 1.346 1.088 123.8 ± 0.04 120.4 180
CHARMM 1.346 1.475 1.346 1.476 1.345 1.1 123.8 ± 0.26 119.8 180
MP2/ED error 0.001 0.001 0 0.001 0.001    0
CH/ED error 0.001 0.025 0.001 0.026 0    0
CH/MP2 error 0 0.024 0.001 0.025 0.001    0
Bonds in Å; angles and dihedrals in degrees. 
a see ref. 25 
 
An x-ray structure was reported for p-acetamide phenol, and the bonds, angles, 
and dihedrals from MP2 and CHARMM agree with those of the x-ray structure (Table 
C1
C2
C3
C4
H21
H31
H41
C5
H12
H11 C6
H61
H62
H51
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4.5).  The average errors between MP2 and the x-ray structure are 0.01 ± 0.01 Å for 
bonds, 1.1 ± 1.3º for angles, and 4.1 ± 5.8º for dihedrals.  The average errors between 
CHARMM and the x-ray structure are 0.02 ± 0.01 Å for bonds, 1.0 ± 0.7º for angles, and 
1.7 ± 1.1º for dihedrals. CHARMM is in good agreement with the x-ray structure for 
dihedrals; the largest deviations for MP2 and the x-ray structure are the dihedrals C23-
C22-N21-C15 and C27-C22-N21-C15, which are the two dihedrals connecting the amide 
group to the phenol ring.  An overlay of the x-ray structure (red) and the CHARMM 
minimized structure (blue) is shown above Table 4.5; the RMSD between the two 
structures is 0.0010 Å.  For clarity, the ring hydrogens and methyl group hydrogens on 
C14 are not shown.  
 
 
Table 0.5  Experimental, QM, and MM comparison of p-acetamide phenolb 
 C22-C27 C22-N21 C15-O29 C27-C26 C22-C27-C26-C25 C25-C24-C23-C22 O28-C25-C26-C27 
x-raya 1.39 1.42 1.22 1.39 0.45 0.4 -178.2 
MP2/6-31G(d) 1.4 1.41 1.22 1.39 0.09 0.07 -180 
CHARMM 1.41 1.41 1.23 1.39 0.26 0.18 -179.9 
MP2/x-ray error 0.01 0.01 0.01 0 0.36 0.33 1.8 
CH/x-ray error 0.02 0.01 0 0.01 0.19 0.22 1.7 
CH/MP2 error 0.01 0.01 0.01 0.01 0.17 0.11 0.1 
Bonds in Å; dihedrals in degrees. 
a see ref. 48  
b Only some bonds and dihedrals are shown in the table.  For a complete table, see Appendix B. 
C23
C24
C25
C26
C27
C22
O28
H281
N21
H291 C15
C14
O29
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Two retinoids (retinal and retinoic acid) had available experimental data.   The 
crystal structure of all-trans retinal was taken from the reference of Hamanaka, et al., 
52(Cambridge Structural Database54 id TRETAL01), and the average bond error between 
x-ray and CHARMM was 0.02 ± 0.02 Å, the average angle error was 1.93 ± 1.73º, and 
the average dihedral error was 15.6 ± 30.5º.  The RMSD between CHARMM and x-ray is 
1.92 Å.  The cyclohexene ring of both structures has the same conformation (C2-endo), 
but several dihedrals in the chain show large differences between the structures; this is 
what causes the different orientations of the methyl groups (Figure 4.10).  There are three 
dihedrals of the chain that show large differences between the CHARMM minimized and 
x-ray structures and two dihedrals of the ring that show large differences.  These 
dihedrals are all rotations about single bonds of the chain, and because they are different 
in the two structures, the orientations of the methyl groups are different (see Appendix B 
for a table of bonds, angles, and dihedrals for CHARMM and the x-ray structure).  
  
Figure 4.10 The left structure is that of retinal, and the right picture shows an overlay of 
the x-ray structure (red) and the CHARMM energy minimized structure (blue).  The 
heavy atom RMSD between CHARMM and x-ray is 1.92 Å.   
 
 
The triclinic crystal structure of all-trans retinoic acid was taken from the 
reference of Stam and MacGillavry51 (Cambridge Structural Database54 id VITAAC10).  
The average bond error between crystal and CHARMM is 0.04 ± 0.09 Å, the average 
angle error is 2.4 ± 1.7º, and the average dihedral error is 11.8 ± 20.2º.  The RMSD 
H
O
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between x-ray and CHARMM is 2.18 Å.  The methyl groups of the chain point in the 
same direction in both structures; however, some dihedrals along the chain show large 
differences between the two structures, and the cyclohexene rings are in different 
conformations (Figure 4.11).  The x-ray structure shows a C2-endo conformation for the 
ring, while CHARMM gives a C3-endo conformation (see Appendix B for a comparison 
of CHARMM to the x-ray structure bonds, angles, and dihedrals).  
  
Figure 4.11 The structure on the right is that of retinoic acid, and the right picture is a 
comparison of the x-ray structure (red) and the CHARMM energy minimized structure 
(blue) for the triclinic form of retinoic acid. 
 
 
The monoclinic crystal structure of all-trans retinoic acid was taken from the 
reference of Stam50 (Cambridge Structural Database54 id VITAAC01; search date 
2/17/07).  The average bond error between crystal and CHARMM is 0.04 ± 0.09 Å, the 
average angle error is 1.9 ± 1.6º, and the average dihedral error is 13.6 ± 26.0º.  RMSD 
between x-ray and CHARMM is 2.72 Å.   The cyclohexene rings have the same 
conformation; both are C3-endo. This is different than the triclinic crystal, where the 
chain sticks out from the ring, but the cyclohexene ring is in a different conformation 
(C2-endo in the triclinic form and C3-endo in the monoclinic form).  However, the chain 
off the ring is oriented differently and so are the methyl groups. This is the result of the 
chain dihedrals being different (Figure 4.12; for a table of bonds, angle, and dihedrals, 
see Appendix B).  
O
O
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Figure 4.12 Comparison of monoclinic crystal and CHARMM forms (red, x-ray; blue, 
CHARMM). RMSD between x-ray and CHARMM is 2.72 Å. 
 
 
Overall, the CHARMM minimized structures of retinal and retinoic acid agree 
well with the x-ray structures in terms of bonds and angles (largest average bond error is 
0.04 ± 0.09 Å, and the largest angle error is 2.4 ± 1.7 º).  However, there are some large 
differences in the dihedral angles, especially in the chain parts of the retinoids.  In retinal, 
both the x-ray structure and CHARMM show the same C2-endo ring conformation for 
the cyclohexene ring, but three dihedrals of the chain cause the different orientations of 
the methyl groups.  The largest dihedral difference in retinal arises because the last 
methyl group at the end of the chain (C20) is oriented differently in the CHARMM and 
x-ray structures.  In retinoic acid, CHARMM shows differences with both the triclinic 
and monoclinic x-ray crystal forms.  For the triclinic crystal, the cyclohexene rings are in 
different orientations (CHARMM gives C3-endo while the x-ray structure gives C2-
endo).  As for retinal, there are several dihedrals of the chain that cause different 
orientations of the methyl groups and the end carboxyl group.  Unlike retinal, however, 
the differences in the methyl group orientations are not as pronounced for the CHARMM 
and triclinic forms of retinoic acid.  For the monoclinic crystal, the cyclohexene ring of 
the x-ray structure and the CHARMM structure are in the same C3-endo conformation; 
however, the chain attached to the ring is oriented differently (the chain from the x-ray 
structure seems to point up, and the chain from the CHARMM structure points out), 
 217
which gives rise to large differences for the dihedrals that connect the ring to the chain.  
The triclinic and monoclinic crystals show differences with each other and CHARMM.  
The triclinic crystal and CHARMM have different ring conformations, but the chain off 
the ring seems to stick out from the ring more, and it doesn’t stick up. The monoclinic 
crystal and CHARMM show the same ring conformations, but the chain off the ring 
sticks up more in the monoclinic crystal, whereas the CHARMM chain sticks out and not 
up.  The differences between the ring conformations and how the chain is oriented off the 
cyclohexene ring in the triclinic and monoclinic structures are probably due to different 
crystal packing arrangements.  In all structures, none of the chains off the cyclohexene 
ring are completely planar, both in the x-ray and CHARMM structures. The reason for 
the large differences in the dihedrals is that a solid (x-ray) structure with neighboring 
molecules is being compared to a gas-phase minimized structure (CHARMM).   
4.3 Retinoid Crystal Simulations 
Crystal simulations were performed for retinal and both crystalline forms of 
retinoic acid.  Five 1 ns simulations were performed for each ligand in the crystal 
environment, and geometric parameters (bonds, angles, and dihedrals) of the ligands were 
examined.  For simulation details, see Chapter 2. 
4.3.1 Retinoic acid (Triclinic Form). Two molecules of retinoic acid were 
reported for the unit cell of the triclinic form of retinoic acid, CSD id54 VITAAC10.51  
The bonds, angles, and dihedrals for each retinoic acid molecule were measured from the 
simulations and compared back to the x-ray structure.  The RMSDs over time (compared 
to starting x-ray structure) for both retinoic acid molecules in the crystal for the five 
simulations are in Table 4.6.  The RMSD is under 0.5 Å for all simulations, so the 
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simulated structure does not deviate much from the x-ray structure. The bond, angle, and 
dihedral error between the simulated and x-ray structure was also low (see Table 4.6 for 
average errors over all five 1 ns simulations).  Unlike in the protein/retinoid simulations, 
which will be discussed later, the retinoic acid in the crystal simulation does not show 
large dihedral angle deviations about bonds of the chain.  This may be because the 
simulation was done at a slightly lower temperature (123 K) than the protein/retinoic acid 
complex simulation (277 K), so the system here does not have as much energy to rotate 
as much around the single bonds of the chain.  In the crystal, the chain remains relatively 
planar throughout the simulations, and the chain does not move much relative to the 
cyclohexene ring.  The cyclohexene rings in both ligands retain the C2’-endo 
conformation found in the x-ray structure.  Figure 4.13 shows overlays of the simulation 
average structures (blue) and the x-ray structure (red).  
Table 0.6 RMSD of ligands compared to x-ray structure for triclinic form of retinoic acid 
  RTAC1  RTAC2 
 
Simulation 1 (1 ns)  0.33 ± 0.08 Å 0.34 ± 0.09 Å 
Simulation 2 (1 ns)  0.35 ± 0.08 Å 0.44 ± 0.09 Å 
Simulation 3 (1 ns)  0.38 ± 0.12 Å 0.32 ± 0.09 Å 
Simulation 4 (1 ns)  0.32 ± 0.09 Å 0.40 ± 0.13 Å 
Simulation 5 (1 ns)  0.33 ± 0.09 Å 0.30 ± 0.08 Å 
Average RMSD (5 ns)  0.34 ± 0.09 Å 0.36 ± 0.11 Å 
Average bond error  0.03 ± 0.02 Å 0.03 ± 0.03 Å 
Average angle error  3.0 ± 3.1°  3.0 ± 3.0°  
Average dihedral error  6.6 ± 8.1°  6.3 ± 6.6°  
 
  
Figure 4.13 Examples of overlayed x-ray (red) and simulation average structures (blue) 
from Simulation 1. 
 219
  
4.3.2 Retinal (Monoclinic).  Four molecules of retinal were reported for the unit 
cell of the monoclinic form of retinal, CSD id54 TRETAL01.52  The bonds, angles, and 
dihedrals for each retinal molecule were measured from the simulations and compared 
back to the x-ray structure.  The RMSDs over time (compared to starting x-ray structure) 
for the four retinal molecules in the crystal for the five simulations are in Table 4.7.  The 
RMSD is under 0.5 Å for all simulations, so the simulated structure does not deviate 
much from the x-ray structure. The bond, angle, and dihedral error between the simulated 
and x-ray structure was also low (See Table 4.7 for average errors over the five 1 ns 
simulations).  As for the retinoic acid, the retinal in the crystal simulation does not show 
large dihedral angle deviations about bonds of the chain.  In the crystal, the chain remains 
relatively planar throughout the simulations, and the chain does not move much relative 
to the cyclohexene ring (the chain is slightly twisted relative to the ring in the x-ray 
structure, and the retinal molecules retain this twisted configuration during the 
simulation).  The cyclohexene rings in all four molecules in the crystal retain the C2’-
endo conformation found in the x-ray structure. Figure 4.14 shows the overlays of 
simulated structures (blue) with the x-ray structure (red). 
Table 0.7 RMSD of ligands compared to x-ray structure for retinal 
 RTAL1 RTAL2 RTAL3 RTAL4  
 
Simulation 1 (1 ns) 0.30 ± 0.06 Å 0.34 ± 0.06 Å 0.38 ± 0.09 Å 0.35 ± 0.06 Å 
Simulation 2 (1 ns) 0.33 ± 0.09 Å 0.37 ± 0.07 Å 0.42 ± 0.10 Å 0.39 ± 0.09 Å 
Simulation 3 (1 ns) 0.31 ± 0.08 Å 0.37 ± 0.08 Å 0.39 ± 0.09 Å 0.41 ± 0.09 Å 
Simulation 4 (1ns) 0.37 ± 0.11 Å 0.39 ± 0.08 Å 0.41 ± 0.09 Å 0.42 ± 0.10 Å 
Simulation 5 (1ns) 0.43± 0.11 Å 0.41 ± 0.08 Å 0.46 ± 0.10 Å 0.46 ± 0.09 Å 
Average RMSD (5 ns) 0.35± 0.09 Å 0.38± 0.07 Å 0.41± 0.09 Å 0.41± 0.09 Å 
Average bond error 0.02 ± 0.01 Å 0.02 ± 0.01 Å 0.02 ± 0.02 Å 0.02 ± 0.02 Å 
Average angle error 3.0 ± 4.5°  3.4 ± 5.0°  4.3 ± 5.9°  4.0 ± 5.3°  
Average dihedral error 6.6 ± 9.6°  5.9 ± 5.6°  7.4 ± 6.4°  5.7 ± 5.6°  
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Figure 4.14 Examples of overlayed x-ray (red) and simulation average structures (blue) 
(Simulation 2). Only ligands 1 (left) and 3 (right) of the x-ray structure are shown. 
 
 
4.3.3 Retinoic acid (Monoclinic Form).  Four molecules of retinoic acid were 
reported for the unit cell of the monoclinic form of retinoic acid, CSD id54 VITAAC01.50  
The bonds, angles, and dihedrals for each retinoic acid molecule were measured from the 
simulations and compared back to the x-ray structure.  The RMSDs over time (compared 
to starting x-ray structure) for the four retinoic acid molecules in the crystal for the five 
simulations are in Table 4.8.  
Table 0.8 RMSD of ligands compared to x-ray structure for monoclinic form of retinoic 
acid 
 RTAC RTAC2 RTAC3 RTAC4  
 
Simulation 1 (1 ns) 0.52 ± 0.10 Å 0.51 ± 0.11 Å 0.52 ± 0.10 Å 0.52 ± 0.11 Å 
Simulation 2 (1 ns) 0.56 ± 0.10 Å 0.50 ± 0.10 Å 0.55 ± 0.10 Å 0.55 ± 0.09 Å 
Simulation 3 (1 ns) 0.46 ± 0.11 Å 0.49 ± 0.11 Å 0.50 ± 0.11 Å 0.45 ± 0.11 Å 
Simulation 4 (1 ns) 0.38 ± 0.11 Å 0.40 ± 0.09 Å 0.51 ± 0.09 Å 0.50 ± 0.10 Å 
Simulation 5 (1 ns) 0.48± 0.11 Å 0.49 ± 0.09 Å 0.52 ± 0.10 Å 0.51 ± 0.08 Å 
Average RMSD (5 ns) 0.48± 0.11 Å 0.48± 0.10 Å 0.52± 0.10 Å 0.51± 0.10 Å 
Average bond error 0.02 ± 0.02 Å 0.02 ± 0.02 Å 0.03 ± 0.04 Å 0.03 ± 0.04 Å 
Average angle error 3.6 ± 3.3°  3.6 ± 3.3°  3.4 ± 3.3°  3.8 ± 3.3°  
Average dihedral error 21 ± 33°  21 ± 32°  19 ± 32°  16 ± 24°  
 
Unlike the triclinic form of retinoic acid and retinal, the RMSD does go above 0.5 Å, but 
the RMSD does not go above 1 Å.  The bond and angle error between the simulated and 
x-ray structure was also low (See Table 4.8 for average errors over the five 1 ns 
simulations).  Unlike the triclinic form of retinoic acid and retinal, the monoclinic form of 
retinoic acid in the crystal simulation shows some large dihedral angle deviations about 
bonds of the chain, and the chain moves relative to the x-ray structure.  The chain of 
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retinoic acid in the x-ray structure points upward from the ring, but during the simulation, 
the chain starts to point downward, and there is rotation about the single bonds of the 
chain.  However, the cyclohexene rings in all four molecules in the crystal retain the C3’-
endo conformation found in the x-ray structure.  The reason for the higher RMSDs and 
more movement about the single bonds of the chain could be that this set of simulations 
was performed at a high temperature (393 K).  Retinoic acid crystallizes in two forms 
(monoclinic and triclinic); however, the monoclinic form is metastable, and at ~ 80° C 
and above, the monoclinic form converts irreversibly to the triclinic form.50, 51 This is 
what appears to be happening in the high temperature simulations.   The chain starts to 
point more outward than upward, which is observed in the triclinic form, and rotation 
occurs about the single bonds, probably because of the higher temperature.   Figure 4.15 
shows examples of simulation average structures (blue) overlayed with the starting x-ray 
structure (red).  
  
Figure 4.15 Example of overlayed x-ray (red) and simulation average structures (blue) 
(Simulation 1).  The chain on the cyclohexene ring appears to point more outward than 
upward.   
 
 
4.4 Retinoid/Protein Complex Simulations 
Five simulations of retinoid protein complexes in the crystal environment were 
performed in order to validate the new force field parameters for the retinoids.  In each 
simulation, amino acid-ligand contacts, ligand-water contacts, amino-acid water contacts, 
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and any other distances or parameters of interest were examined and compared back to 
the starting x-ray crystal structure.  Each simulation was run at the temperature at which 
the crystal structure was determined, and distances, angles, and torsions measured from 
the simulations are for heavy atoms only in order to allow for direct comparison back to 
the x-ray structure. The structures of the four retinoids, all-trans retinoic acid, all-trans 
retinol, all-trans retinal, and fenretinide, which were built from the model compounds, 
are shown in Figure 4.16.  All retinoids considered differ only in the functional group on 
the end of the chain.  For simulation details, see Chapter 2. 
  
  
Figure 4.16  The four retinoids built from the model compounds for use in simulations. 
Retinoic acid, top left; retinol, top right; retinal, bottom left; fenretinide, bottom right. 
 
 
4.4.1 Retinoic Acid Complexed with Celluar Retinoic Acid Binding Protein II. 
Retinoic acid binds non-covalently to cellular retinoic acid binding protein II (CRABP 
II).  The simulation was started from the crystal structure of Kleywegt, et al.,55 which is 
shown in Figure 4.17. 
O
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H
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OH
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Figure 4.17  Retinoic acid complexed with CRABPII (PDB56 id 1CBS55).  Protein show 
in red; ligand shown in cyan with carboxyl group oxygens in red.  Figure rendered using 
the VMD program.57 
   
CRABPs (types I and II) are thought to modulate the amount of retinoic acid that is 
available to nuclear retinoic acid receptors.55  From the x-ray structure, it was observed 
that CRABPII has a one domain with two orthogonal β-sheets that form a barrel, which 
in turn are made up of 10 β-strands.55 The middle of the first β-strand contains a bulge at 
residue 10, which results in a directional change that allows this strand to form part of 
both β-sheets of the protein.  This forms a cavity, which contains the retinoic acid ligand.  
The carboxyl group of the ligand points into the cavity, while the cyclohexene ring points 
out and is accessible to solvent.  Shown below are the RMSD plots (compared to the 
starting x-ray crystal structure) for different parts of the complex.   
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Figure 4.18  RMSD plots of the retinoid acid/CRABPII complex (top left) and different 
parts of the system individually (bottom).   
 
 
The RMSD of the whole complex shows initial fluctuation, but appears to stabilize at 
~700-800 ps.  Upon examination of the individual RMSDs of the protein and ligand, the 
ligand appears to contribute the most to the RMSD of the complex (average of rmsd of 
ligand is ~0.29 Å higher than the average RMSD of the protein alone).  The ligand 
RMSD is higher than that of the protein, but it follows a similar pattern of initial 
fluctuation and then stabilizes around 800 ps.   
 The geometric parameters (bonds, angles, and dihedrals) of the ligand from the 
simulation were examined, and the error with respect to the x-ray structure was 
calculated.  The error for bonds of the ligand was 0.02 ± 0.02 Å, the error for angles of 
Average RMSDs 
Protein/ligand complex   1.18 ± 0.12 Å 
Protein only                     1.15 ± 0.12 Å 
Ligand only                     1.44 ± 0.25 Å 
Alpha C only                   0.74 ± 0.01 Å 
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the ligand was 5.5 ± 3.0°, and the error for dihedrals of the ligand was 13 ± 22º.  The 
source of this large error is that the chain of the ligand turns with respect to the ring in the 
binding site of the protein. Also, there are three dihedrals of the chain that deviate from 
the orientation found in the x-ray structure that contribute to this large error.   The chain 
rotates with respect to the cyclohexene ring during the simulation, which causes large 
deviations in the torsion angles that are involved around the connection of the ring to the 
chain. The other sources of large RMSD differences involve parts of the chain. These 
differences are seen during the simulation because these are single bonds, and the ligand 
will probably try to orient itself to optimize contacts with the protein side chains, and this 
does not appear to cause any major distortion of the surrounding protein residues (see 
Appendix B (Figure C.5) for figures of retinoic acid and large dihedral differences).  The 
cyclohexene ring retains the C2’-endo conformation during the simulation.  Because of 
the large deviations of these ligand dihedrals, different parts of the ligand were examined 
more closely. Figure 4.19 shows the RMSD for different parts of the retinoic acid 
(denoted as RTAC) ligand.  
 
Figure 4.19 RMSD over time of different parts of the retinoic acid ligand. 
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The ring (including methyl groups) by itself does not give a high RMSD, and the chain 
(excluding the carboxyl group on the end) gives an RMSD intermediate between the ring 
by itself and ring and chain together.  However, the ring and the chain together (including 
methyl groups but not including the carboxyl group on the end) do give higher RMSDs.  
This appears to account for most of the RMSD of the ligand.  Upon closer examination of 
the average structure from the simulation and several snapshots, it appears that the 
cyclohexene ring rotates around, while the ligand is in the binding site and that the chain 
rotates around two of the single bonds in the chain.  Figure 4.20 shows some snapshots 
from the simulation.   
From the top pictures in Figure 4.20, cyclohexene ring of the ligand appears to 
rotate in the binding site because the methyl groups are not aligned when the structures 
are superimposed.  The bottom pictures show the starting structure from the simulation 
(bottom left) and the ending structure (bottom right).  The ring starts out with the two 
methyl groups of the ring pointed to the right; however, during the simulation, the ring 
turns so that the two methyl groups are pointed in the opposite direction.   Also, it can be 
seen from the overlays of the ligand structures that the chain appears to reorient itself in 
several places, probably to optimize contacts with protein sidechains.   The rotation of the 
cyclohexene ring in the binding site and the reorientation of some of the chain dihedrals 
is the cause for the large RMSD of the ligand and for the large average error in the 
torsion angles between the simulated structure and the x-ray structure.   
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Figure 4.20 Overlay of the average structure of the ligand from the simulation (green) 
and the x-ray structure (red); top pictures.  Starting structure (bottom left) and ending 
structure (bottom right) from the simulation. 
 
 
Several ligand-protein and protein-protein contacts were mentioned by the authors 
of the x-ray structure. These distances were measured in the simulation, and they are 
shown in the table below and some of the plots are shown (for CHARMM atom names 
and remaining time series plots of these distances, see Appendix B).  
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Table 0.9 Protein-ligand and protein-protein distances (CRABPII/retinoic acid complex) 
Protein-ligand    
contact x-ray (Å) Computed (Å) 
Arg132(NH)—RTAC(O29) 2.73 2.69 ± 0.12  
Tyr134(OH)--RTAC(O29) 2.57 2.91 ± 0.51 
Ala32(CB)--RTAC(C8) 3.97 3.78 ± 0.30 
Ala36(CB)--RTAC(C12) 4.49 4.04 ± 0.37 
Leu28(CD1)--RTAC(C4) 5.14 4.87 ± 0.59 
Ala35(CB)--RTAC(C19) 4.45 3.90 ± 0.39 
Leu19(CD2)--RTAC(C16) 8.63 4.69 ± 1.32 
Ile9(CD)--RTAC(C20) 7.01 7.67 ± 0.63 
Phe15(CZ)--RTAC(C10) 3.91 4.22 ± 0.40 
Pro39(CB)--RTAC(C20) 3.80 3.90 ± 0.38 
   
Protein-protein   
Arg59(NH)--Gln74(OE1) 2.97 3.00 ± 0.50  
Glu73(OE2)--Gln97(NE2) 2.97 3.09 ± 0.29 
Glu73(OE2)--Trp109(NE1) 2.95 2.86 ± 0.14 
Ser4(O)--Arg136(NE) 2.97 2.83 ± 0.12 
Asn2(O)--Arg136(NH2) 2.97 3.18 ± 0.36 
Glu73(OE2)--Ser83(OG) 2.81 2.71 ± 0.13 
Arg111(NH1)—Trp109(CZ) 3.19 3.41 ± 0.20 
 
The carboxyl oxygens make contact with three residues of the protein, which are Arg132, 
Tyr134, and Arg111, which are monitored in Figure 4.21.  The retinoic acid (RTAC) 
ligand starts out and stays close to Arg132, and the x-ray value falls within the average 
and standard deviation computed from the simulation.  The RTAC ligand starts out near 
Tyr134, moves away during the 100-550 ps time period, and then moves close to the Tyr 
residue again and stays there for the remainder of the simulation.  The x-ray value falls 
into the overall average and standard deviation computed from the simulation. 
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Figure 4.21 Distance vs. time plots of Arg132 and Tyr134 to retinoic acid. 
 
 
The contact between Arg111 and one of the carboxylic oxygens of RTAC is 
mediated by a water molecule that was found in the crystal structure (Figure 4.22).  From 
the top plot in Figure 4.22, the water molecules exchange but they still hydrogen-bond to 
Arg111.  The closest water in the x-ray structure was 3.02 Å away (labeled as H2O15).  
However, there are several waters that exchange positions, because at different time 
periods of the simulation, different water molecules are closest to Arg111.  In the second 
plot in Figure 4.22, it can be seen again that H2O15 and H2O10 exchange positions.  At 
the beginning of the simulation, H2O15 is closest to the RTAC ligand, but as the 
simulation progresses, this water is replaced by H2O10.  The third plot shows the distance 
over time from Arg111 to the RTAC ligand.  The distance is greater than that observed in 
the x-ray structure (average computed distance is 1.76 Å greater than x-ray distance); this 
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is probably because more water molecules are present in the simulation than in the x-ray 
structure, and thus more waters can get between the Arg111 and ligand, pushing them 
farther apart.  The bottom plot in Figure 4.22 shows all the different water molecules that 
are close to the carboxyl oxygens of the ligand.  The Arg111 distance is also shown for 
comparison, and water molecules appear to be closer to the ligand over most of the 
simulation time rather than Arg111.   
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Figure 4.22 Distance from Arg111 to different water oxygens (top); distance from 
retinoic acid to different water oxygens (second from top), distance from Arg111 to 
RTAC (second from bottom), and ligand water distances (bottom). 
Arg111(NH2) to water oxygens
0
2
4
6
8
10
12
0 500 1000 1500 2000
time (ps)
di
st
an
ce
 (a
ng
st
ro
m
s)
h2o15
h2o10
h2o9
h2o641
h2o94
RTAC (O29B) to water oxygens
0
2
4
6
8
10
0 500 1000 1500 2000
time (ps)
di
st
an
ce
 (a
ng
st
ro
m
s)
computed (h2o15)
x-ray
computed (h2o10)
Arg111(NH2) to RTAC (O29B)
0
1
2
3
4
5
6
7
8
0 500 1000 1500 2000
time (ps)
di
st
an
ce
 (a
ng
st
ro
m
s)
computed
x-ray
RTAC--water/RTAC--Arg111
0
5
10
15
20
25
0 500 1000 1500 2000
time (ps)
di
st
an
ce
 (a
ng
st
ro
m
s)
h2o3
h2o582
arg111
h2o9
h2o15
 232
 
Several other protein-ligand contacts from the simulation were also tracked.  Most 
of these interactions were nonpolar residues with nonpolar parts of the ligand (most of the 
ligand is nonpolar, except the tail with the carboxyl group).  Two of the contacts are 
shown in Figure 4.23.  
 
 
Figure 4.23 Two of the nonpolar ligand-protein contacts (retinoic acid/CRABPII).  
 
 
Pro39 and Phe15 are two of the nonpolar residues that were in contact with the ligand.  
For both residues, there is some initial fluctuation at the beginning of the simulation, then 
the movement of them stabilizes and fluctuates around the x-ray value for the remainder 
of the simulation.  The other nonpolar ligand-protein contacts showed similar behavior.  
 Several protein-protein contacts were examined to make sure that the new 
parameters for the ligand were not distorting the protein.  Two of these plots are shown in 
Figure 4.24.  
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Figure 4.24 Two of the protein-protein distances (retinoic acid/CRABPII).  
 
 
The Arg111-Trp109 contact is mediated through an “amido/aromatic ring hydrogen 
bond”.55 Burley and Petsko explain that side-chain amino groups interact with aromatic 
side chains, and that the amino groups of amino acids such as Lys, Arg, etc. are 
preferentially located within 6 Å of the ring centers of Phe, Tyr, and Trp.58 The distance 
from the amino group of Arg111 to one of the carbons of the aromatic ring of Trp109 
was measured (top plot in Figure 4.24).  The computed average is 0.02 Å higher than the 
distance measured from the x-ray structure, which is in good agreement.  The other 
protein-protein contact shown is for Glu73 and Ser83 (bottom plot in Figure 4.24), and 
this distance fluctuates around the x-ray value for the entire simulation.   
 Overall, the simulated retinoic acid/CRABPII complex agrees with the x-ray 
structure.  The ligand gave a large RMSD over time and a large torsion angle error, which 
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can be attributed to the cyclohexene ring rotating in the binding site and the two chain 
dihedrals rotating.  The ring is probably able to rotate freely because not many protein-
ligand contacts were identified for the ring portion of the ligand; most are for the chain 
and carboxyl end group. Not many protein residues are contacting that ring strongly and 
forcing it to stay in any one position.  One carbon of the ring was identified as a close 
contact with the protein (Leu28), but even that residue is 5.14 Å away from the ligand.  
The authors of the x-ray structure reported higher B-factors for the cyclohexene ring part 
of the ligand than for the chain part,55 which means that there is more uncertainty for the 
positions of the ring atoms.  It is possible the ring is free to rotate; however, a single x-ray 
structure will capture only one orientation, and through the simulations, the rotation is 
observed.  The chain dihedrals probably rotate in order to optimize contacts with protein 
sidechains. The turning motion of the cyclohexene ring in the binding site could be 
important in ligand binding and dynamics or interaction of the complex with other 
proteins.  
4.4.2 Retinol Complexed with Cellular Retinol Binding Protein. Retinol binds 
non-covalently to cellular retinol binding proteins (CRBPs).  The simulation was started 
from the crystal structure determined by Calderone, et al.59 The retinol ligand complexed 
with zebrafish CRBP is shown in Figure 4.25.  
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Figure 4.25 Retinol complexed with zebrafish CRBP (PDB56 id 1KQW59).  The ligand is 
in cyan with the OH oxygen in red, and the protein in yellow. Figure was rendered with 
VMD.57 
 
 
CRBPs are found in a variety of tissues, are retinol-specific, and are suspected to aid in 
retinol storage, uptake, and metabolism.60, 61  Four types of mammalian CRBPs have been 
identified and characterized, and zebrafish CRBP appears to have a similar amino acid 
sequence and structure to the mammalian types (sequence identity is highest with 
mammalian CRBPII—73%).59 The CRBPs, intracellular lipid binding proteins (which 
include the CRABPs), and fatty acid binding proteins have been show to have low 
sequence identity, but they have a conserved structural fold,62 so the CRBPs look similar 
to the CRABPs.  They have the same β-barrel structure formed from 10 antiparallel β-
strands, which forms the cavity where the ligand binds, and the open end of the β-barrel 
is capped by an α-helical region.  In the x-ray structure of zebrafish CRBP complexed 
with retinol (as with rat CRBPI and CRBPII), the retinol is almost completely enclosed 
within the cavity of the protein.  The hydroxyl group on the end is toward the inside of 
the cavity, while the cyclohexene ring is the near the α-helical region near the top of the 
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cavity.63, 64  Shown below in Figure 4.26 are the RMSD plots for different parts of the 
CRBP/retinol complex.   
 The RMSD of the protein/ligand complex stabilizes quickly to 0.6 Å at the 
beginning of the simulation, and fluctuates around 0.6 Å for the remainder of the 
simulation. The alpha carbons follow the same trend as the protein alone but at a lower 
RMSD (alpha carbons alone fluctuate at around 0.4 Å.  As for the retinoic acid/CRABP 
complex, the retinol of the retinol/CRBP complex contributes the most to the RMSD of 
the complex (protein alone is 0.6 Å, and the ligand alone is 0.74 Å).  The ligand and 
protein RMSDs follow different patterns; the protein RMSD stabilizes quickly at the 
beginning of the simulation, but the ligand RMSD is initially at ~0.8 Å and then falls to 
~0.7 Å at 1 ns and stays around 0.7 Å for the rest of the simulation.   
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Figure 4.26 RMSD plots of the retinol/CRBP complex (top) and different parts of the 
system individually (bottom).   
  
 The geometric parameters (bonds, angles, and dihedrals) of the ligand from the 
simulation were examined, and the error with respect to the x-ray structure was 
calculated.  The error for bonds was 0.02 ± 0.01 Å, the error for angles was 2.9 ± 3.0°, 
and the error for dihedrals was 21 ± 25º.  The origin of this large dihedral error is rotation 
about the C12-C13 bond of the chain of retinol.  
Average RMSDs 
Protein/ligand complex   0.61 ± 0.05 Å 
Ligand only                     0.74 ± 0.09 Å 
Protein only                     0.60 ± 0.05 Å 
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Figure 4.27  Overlay of x-ray (red) and simulation average structure (blue) (top) and 
CHARMM atom names in retinol (bottom).  The arrow indicates the dihedrals where the 
large deviations from the starting x-ray crystal structure occur. 
 
 
The two dihedrals that show the largest deviations from the x-ray structure are rotations 
about the C12-C13 bonds.  The deviation can be seen in the overlayed structures; the 
C11-C12 bond points in opposite directions in the x-ray structure and in the simulation 
average structure.  As with the retinoic acid ligand in the CRAPBII simulation, the ligand 
probably tries to optimize contacts with protein side chains; thus, there is rotation about 
single bonds.  The retinol ligand has only two dihedrals showing a major deviation from 
the x-ray structure along the chain, while the retinoic acid has several dihedrals with 
major deviations from the x-ray structure. However, unlike the retinoic acid/CRAPBII 
complex, the retinol does not show any rotation of the cyclohexene ring with respect to 
the chain of the ligand.  This large deviation from the x-ray dihedral does not appear to 
cause any major distortion of the surrounding protein residues. C11 and C13 move closer 
to surrounding protein residues, while C12, C14, and C20 remain relatively unaffected 
(see Appendix B for time series plots from these atoms to surrounding protein residues). 
The cyclohexene ring retains the C2’-endo conformation during the simulation.  
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 The reference for the x-ray structure listed the protein residues with at least one 
atom within 4.5 Å of the ligand (some contacts were up to 6 Å away), which was used for 
the protein-ligand contacts to measure from the simulation.  Table 4.10 lists the 
calculated and x-ray distances.  Some plots are shown; the rest can be found in Appendix 
B.  
Table 0.10 Protein-ligand distances (CRBP/retinol complex) 
 
Protein-ligand    
contact x-ray (Å)  Computed (Å) 
Ile25(CD)--RTOL(C18) 4.00 3.83 ± 0.17 
Thr29(CG2)--RTOL(C4) 5.10 4.72 ± 0.20 
Gln38(CD)--RTOL(C17) 3.88 4.32 ± 0.33 
Ile42(CD)--RTOL(C17) 6.31 6.54 ± 0.23 
Thr53(OG1)--RTOL(C12) 4.16 4.30 ± 0.14 
Phe57(CD2)--RTOL(C3) 3.79 4.17 ± 0.20 
Val62(CG2)--RTOL(C14) 7.36 7.78 ± 0.31 
Trp106(CZ2)--RTOL(C14) 4.59 4.28 ± 0.27 
Leu117(CD2)--RTOL(C20) 3.86 4.05 ± 0.09 
Ile119(CD)--RTOL(C19) 3.95 4.35 ± 0.26 
Arg58(CB)--RTOL(C16) 4.24 3.97 ± 0.16 
Thr53(CB)--RTOL(C11) 5.10 4.04 ± 0.16 
Trp106(CZ2)--RTOL(C13) 4.96 4.56 ± 0.27 
Met20(SD)--RTOL(C18) 3.90 3.81 ± 0.15 
Ser55(OG)--RTOL(C17) 4.04 3.90 ± 0.17 
Ala33(CB)--RTOL(C4) 4.01 3.92 ± 0.14 
Leu36(CD1)--RTOL(CZ) 4.25 4.00 ± 0.26 
Tyr60(CD2)--RTOL(C11) 5.00 4.46 ± 0.29 
Thr51(OG1)—RTOL(OR) 5.15 5.86 ± 0.22 
Gln108(NE2)—RTOL(OR) 4.51 4.13 ± 0.24 
Gln108(NE2)—RTOL(OR) 3.00 2.67 ± 0.07 
Val19(CG1)—RTOL(C19) 6.41 7.30 ± 0.41 
 
There were only two polar contacts mentioned, which are shown below (these would be 
hydrogen bonds, but since no hydrogens were identified in the x-ray structure, they are 
measured as heavy atom distances).  The retinol ligand is designated as RTOL.  
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Figure 4.28 Polar protein/ligand contacts (retinol/CRBP). 
 
 
The Thr51—RTOL distance from the simulation is larger than that measured from the x-
ray structure (~0.71 Å larger).  However, there is a residue in closer contact with the 
hydroxyl group than Thr51, which is Gln108.  The nitrogen of the sidechain of Gln108 is 
not only closer to the ligand in the x-ray structure (4.51 Å vs. 5.15 Å), but the ligand 
stays near Gln108 during the simulation.  The distance between the ligand and oxygen of 
the sidechain of Gln108 fluctuates around ~2.7 Å during the whole simulation, which is 
about 0.3 Å closer than that reported in the x-ray structure.  The authors of the crystal 
structure refined two positions for the hydroxyl group of retinol so that in one position a 
hydrogen bond forms between the hydroxyl group and the oxygen of the sidechain of 
Gln108, and in the other position, the hydrogen bond from the ligand is formed to 
Thr51.59  For the simulation, we chose the hydroxyl position in which the hydrogen bond 
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is formed with Gln108; this mode of retinol binding was also observed in structures of rat 
CRBP I and rat CRBP II complexed with retinol.63, 64 Therefore, even though the retinol 
ligand is not forming a hydrogen bond with Thr51, it is forming (keeping during the 
simulation) a hydrogen bond with sidechain oxygen of Gln108, and the amino group of 
Gln108 presents another possible hydrogen bond donor/acceptor for the hydroxyl group.  
 All of the other ligand-protein contacts listed by the paper were contacts of 
protein residues with the chain or ring of the ligand (not the hydroxyl group).  Four of 
them are shown below.  
 
 
Figure 4.29  Two of the contacts from the retinol ligand chain to the protein 
(retinol/CRBP). 
 
 
The amino acid residue contacts with the ligand chain measured from the simulation are 
in good agreement with the x-ray structure distances.  For both distances shown, the 
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ligand chain and amino acid residues do not appear to move away from each other during 
the simulation.  Met20 and the retinol ligand move ~0.5 Å closer to each other; Ser55 and 
retinol stay about the same distance apart during the whole simulation.   
 
 
Figure 4.30 Two of the contacts of the retinol ligand ring to the protein (retinol/CRBP). 
 
 
As with the amino acid residue contacts with the ligand chain, the amino acid contacts 
with the ligand ring measured from the simulation are in good agreement with the x-ray 
structure.  The ring of the retinol ligand does appear to move away from either Ala33 or 
Leu36 during the simulation, and the distances fluctuate around the x-ray value.  The 
other distances measured from the simulation are shown in Appendix B.  Three of the 
average distances measured from the simulation became shorter over time than the 
distance measured from the x-ray structure; the Thr29 distance to the retinol ligand 
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decreased the most, becoming 0.38 Å shorter than that of the x-ray structure.  Several 
distances measured from the simulation increased over time (ligand and amino acid 
residues drifted apart), and the most increased distance was for Val19 to the ligand (plot 
is in Appendix B).  This distance increased on average 0.89 Å (initially increased to ~8.0 
Å and then decreased to ~7 Å); however, initially, this distance was 6.41 Å, which was 
not extremely close to the ligand in the x-ray structure.  The distance increase of 0.89 Å 
does not seem unusual, considering the starting distance and that water is present in the 
binding cavity, which could have pushed the residues farther apart.  
 The authors of the x-ray structure identified seven water molecules in the ligand 
binding cavity of zebrafish CRBP.  The structure on the left of Figure 4.31 shows the 
seven water molecules in the binding cavity in the x-ray structure.  The structure on the 
top right shows the average structure of the complex from the simulation.  Six of the 
original crystallographic waters are still in the cavity; however, one of them appears to 
have moved out (that is the water molecule farthest to the right in the average structure of 
the simulation).  Upon closer examination of the average structure, this water molecule 
appears to have moved outside of the binding cavity because it forms a strong hydrogen 
bond with Asn13.  
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Figure 4.31 Water in binding cavity of zebrafish CRBP. The protein is shown in blue, the 
ligand is shown in green, and the water oxygens are shown in red. The starting structure 
is shown on the top left, and the average structure from the simulation is on the top right. 
The plot on the bottom is the distance from the water molecule to Asn13. 
  
 
When the water molecule moves toward the edge of the cavity, it forms a strong 
hydrogen bond with Asn13 (2.00 ± 0.18 Å), and thus stays in that position for the 
remainder of the simulation.   
Overall, the distances measured from the simulation agree well with the x-ray 
structure.  Two of the distances from protein residues to the ligand decrease over time (by 
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0.38 Å at the most), and several of the distances increase.  The largest increase was 0.89 
Å, and the distance between the amino acid and ligand was over 6 Å in the starting 
structure, so movement of the protein and water in the binding site could have pushed the 
ligand and the residue apart.  Six of the seven crystallographic waters stayed in the 
binding site during the simulation, and the one that did move to the edge was stabilized 
by a hydrogen bonding interaction with Asn13.  Unlike the retinoic acid ligand 
complexed with CRABPII, the cyclohexene ring of the retinol ligand did not appear to 
rotate in the binding site of CRBP.   
 
Figure 4.32 Starting structures for retinoic acid/CRABPII complex (left) and for 
retinol/CRBP complex (right). 
 
 
Upon closer examination of the starting structures for both complexes, the retinol appears 
to be positioned deeper into the binding cavity of CRBP than retinoic acid is positioned 
into CRABPII (Figure 4.31).  As a result, retinoic acid probably is not constrained as 
much by the protein residues around it (especially the ring at the top), so the ring has 
more space to rotate and move around.  Because retinol is positioned farther down into 
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the binding site, it probably does not have as much room to move around due to the 
protein residues around it.  
4.4.3 Fenretinide Complexed with Retinol Binding Protein (RBP). The starting x-
ray crystal structure for the simulation was determined by Zanotti and coworkers.65 The 
structure of the fenretinide/RBP complex is shown in Figure 4.33.  
 
Figure 4.33  Fenretinide/RBP complex (PDB56 id 1FEL65).  The ligand is shown in cyan 
with the nitrogen atom in blue and oxygens in red.  The protein is in purple. Figure 
rendered with VMD.57 
 
 
Retinol binding protein carries retinol through the blood and delivers retinol from storage 
sites to target cells.  RBP contains one binding site for retinol, and in the blood, RBP is 
found bound to transthyretin (TTR); the formation of the complex is believed to prevent 
filtration of the small RBP through the kidneys.65 Like CRBPs and CRABPs, RBP binds 
the ligand noncovalently and contains a β-barrel which forms the binding cavity for the 
ligand.  However, in the case of RBP, the cyclohexene ring binds inside the β-barrel, and 
the chain is extended out with the hydroxyl group reaching the surface (the ligand binds 
the opposite way in CRBPs and CRABPs).65  Studies have shown that modifications to 
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ligands in the vicinity of the cyclohexene ring render them unable to bind to RBP, 
however, retinoids modified in the area of the hydroxyl group will bind well to RBP.66-68 
 With the increasing interest in synthetic retinoids that show pharmacological and 
antitumor activity, some questions about how they interact with retinoid-binding proteins, 
other proteins, and nuclear retinoid receptors have been raised. Synthetic retinoids may 
interact with retinoid-binding proteins involved in retinoid metabolism, and it has been 
shown that some synthetic retinoids may affect plasma transport of retinol, which could 
be a result of their interaction with RBP.67  Fenretinide is a retinol analog in which the 
hydroxyl end group is replaced by a hydroxyphenyl amide group.  This particular 
synthetic retinoid has been examined for use as an antitumor chemopreventative agent in 
humans.65  Studies have shown the fenretinide binds well to apo RBP, but the 
fenretinide/RBP complex does not show any affinity for TTR.69 
 In the x-ray structure of the fenretinide/RBP complex, the fenretinide ligand fits 
into the β-barrel cavity where the retinol ligand would fit.  The cyclohexene ring and 
chain take the place of the corresponding parts of retinol (cyclohexene ring is inside the 
cavity with the chain protruding up), while the hydroxyphenyl amide group comes out 
toward the solvent, replacing the position of the hydroxyl group of retinol.  Shown below 
are the RMSD plots for the whole complex and different parts of the complex.  
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Figure 4.34 RMSD plots of the fenretinide/RBP complex (top) and different parts of the 
system individually (bottom).   
 
 
The RMSD of the protein-ligand complex continues to increase until ~1.5 ns, after which 
the RMSD levels off and stays just under 2 Å.  The RMSD for the alpha carbons of the 
protein follows the RMSD pattern of the whole protein, only the magnitude is ~0.5 Å 
lower for the alpha carbons.  The ligand RMSD decreases from the beginning of the 
simulation to ~1.5 ns into the simulation, then it jumps up to over 1.5 Å and starts to 
decrease again.  To examine what caused the large increase, the RMSDs for different 
parts of the ligand were plotted, which is shown at the top of Figure 4.35.  
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Figure 4.35  RMSDs for different parts of the ligand (top) and time series plot for 
rotation of the phenol ring of fenretinide (bottom). 
 
 
The chain is the isoprene chain including the methyl groups on it, the cyclohexene ring 
includes the three methyl groups attached to it, the phenol/amide part is the phenol ring 
and the amide group, and the phenol/chain is the isoprene chain including methyl groups, 
the amide group, and the phenol ring.  The cyclohexene ring contributes the least to the 
RMSD, while the phenol/amide and phenol/chain parts seem to contribute the most, so 
the phenol ring and amide are the parts that are moving around the most in the binding 
site.  The time series of the dihedral for rotation of the phenol ring is shown in Figure 
4.35 (bottom).  
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The time series shows a large increase in the dihedral value at ~1.5 ns, which is 
where the large increase is seen the RMSD plot for the ligand.  From the plot, it appears 
that the phenol ring is turning in binding site during the simulation, and this will be 
supported further by distances measured from the ligand to nearby residues and from 
snapshots taken from the simulation.   
The geometric parameters (bonds, angles, and dihedrals) of the ligand from the 
simulation were examined, and the error with respect to the x-ray structure was 
calculated.  The error for bonds was 0.03 ± 0.03 Å, the error for angles was 4.9 ± 4.9°, 
and the error for dihedrals was 15 ± 12º.  The origin of this large dihedral error is the 
rotation of the phenol ring, which was mentioned above. This dihedral shows an 
approximate 30° difference on average from the x-ray structure.   
The authors of the x-ray structure mentioned few details about the ligand 
conformation and position; they explain that the resolution is not high enough and allows 
only a limited discussion of the bound ligand conformation.65 In the x-ray structure, the 
cyclohexene ring is in a half-chair conformation (C3-endo), and from the picture below, 
the average structure from the simulation also shows the C3-endo conformation.   
 
Figure 4.36 Overlay of x-ray structure of ligand and simulation average structure of 
ligand. The x-ray structure is shown in red, and the simulation average structure is shown 
in green.   
 
 
C3 of cyclohexene ring 
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From the overlay of the two structures, the rotation/shift of the phenol ring can also be 
seen.  The authors also mention that two water molecules were found near the hydroxyl 
group of the phenol ring (each water was ~2.8 Å away).  The fenretinide ligand is 
abbreviated as FRET.  
 
Figure 4.37 Distance from hydroxy group of the phenol ring of the ligand to various 
water molecules. 
 
 
Over time, the water molecules near the hydroxy group of the phenol ring appear to be 
exchanging, but are still close to the phenol ring.   
Due to limited resolution, the paper did not make mention of any ligand-protein 
contacts. Amino acid-ligand distances that were within ~6 Å in the x-ray structure were 
measured from the simulation.  The table below shows the x-ray and simulation averages 
of these distances (for CHARMM atom names and remaining distance plots, see 
Appendix B).   
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Table 0.11 Protein-ligand distances (RBP/fenretinide complex) 
 
Protein-ligand    
contact x-ray (Å) Computed (Å) 
Ile41(CG2)--FRET(C17) 5.37 5.57 ± 0.58 
Ala55(CB)--FRET(C4) 3.78 3.74 ± 0.21 
Val61(CG1)--FRET(O29) 5.11 4.75 ± 0.48 
Phe137(CZ)--FRET(C17) 4.61 4.07 ± 0.33 
Gln117(CD)--FRET(C16) 4.64 4.28 ± 0.28 
Ala43(CB)--FRET(C2) 4.55 3.81 ± 0.24 
His104(CE1)--FRET(C16) 3.65 4.06 ± 0.56 
Phe36(O)--FRET(N21) 3.00 3.58 ± 1.15 
Tyr90(CE1)--FRET(C19) 5.46 4.57 ± 0.70 
Trp91(O)--FRET(C18) 5.69 6.40 ± 0.64 
Gly75(N)--FRET(C18) 4.27 3.90 ± 0.32 
Ala57(CB)--FRET(C5) 3.69 3.93 ± 0.30 
Ala71(CB)--FRET(C12) 5.64 6.13 ± 1.59  
Leu97(CD1)--FRET(C14) 6.05 6.39 ± 0.54 
Leu97(CD2)--FRET(C14) 4.23 4.88 ± 0.54 
Gln98(N)--FRET(O29) 3.40 2.99 ± 0.25 
Leu97(CA)--FRET(O29) 4.56 3.77 ± 0.40 
Leu64(CG)--FRET(O28) 5.91 4.26 ± 0.77 
Leu64(CB)--FRET(O28) 4.40 3.53 ± 0.51 
Leu37(CD2)--FRET(C12) 4.27 4.05 ± 0.38  
Leu64(CD1)—FRET(O28) 6.66 4.59 ± 1.01 
Leu64(CD2)—FRET(O28) 6.70 4.88 ± 0.62 
 
The distances listed in Table 4.11 show good agreement between the x-ray structure and 
the simulation; the x-ray value is within the averages and standard deviations from the 
simulation.  However, some distances increase (ligand and protein residue drift apart) and 
some distances decrease (ligand and protein residue drift closer together); the largest 
deviation from the x-ray structure is 2.07 Å. This large change in distance occurs for 
Leu64 (sidechain carbons) to fenretinide.   
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Figure 4.38 Distance over time for sidechain carbons of Leu64 to ligand. 
 
 
The sidechain carbons of Leu64 and the oxygen of the phenol ring of the ligand move 
closer together during the simulation and then move farther apart near the end of the 
simulation.  However, the backbone part of Leu64 moves away from the ligand during 
the 1.5-2.0 ns period of the simulation, which follows the pattern of the RMSD increase 
and the phenol ring rotation dihedral change.  The backbone nitrogen of Leu64, the 
carbonyl oxygen of Arg62, and the carbonyl oxygen of Phe96 all show the same pattern 
of moving away from the ligand during 1.5-2.0 ns.   
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Figure 4.39 Distances over time for resides that move away from the ligand during the 
1.5-2.0 ns time period.  
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The four distances shown in Figure 4.39 all exhibit the same pattern as the ligand RMSD 
and the dihedral for the phenol ring rotation (all show an increase during the 1.5-2.0 ns 
time period).  Also, the ligand atoms in the plots of Figure 4.39 are all atoms of the 
phenol ring.  An overlay of the ligand from different snapshots of the simulation shows 
that the fenretinide ligand does indeed move in the binding site.   
 
Figure 4.40 Overlay of snapshots of the fenretinide ligand.  
 
 
Figure 4.40 shows an overlay of snapshots of the fenretinide ligand at different times 
during the simulation.  The green (500 ps) and pink (1170 ps) structures are from the first 
part of the simulation before the RMSD and distances increased.  The red (1600 ps) and 
yellow (1800 ps) structures are from the time period where the RMSD and distances 
increased.  The blue (3000 ps) structure is from the last part of the simulation where the 
RMSD started to decrease again.  The RMSD of the different parts of the ligand, the time 
series of dihedral for rotation of the phenol ring, and the increase in the protein-ligand 
distances for ligand atoms in or near the phenol ring are all evidence that the phenol ring 
at the end of the fenretinide ligand turns and shifts in the binding cavity, and that is what 
causes any large deviations in protein-ligand distances measured from the simulation.   
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 A closer examination of some simulation snapshots reveals a possible explanation 
for the movement of the ligand.  There are water molecules forming a “bridge” between 
the Leu35 oxygen to the hydroxyl group oxygen of the phenol ring of the ligand.  The 
distance between Leu35 and the ligand decreases during the 1.5-2.0 ns; however, the 
distance is too large for a hydrogen bond--~4-6 Å (top plot in Figure 4.41).  The water 
molecules start out in bulk solvent, but they move into the cavity with the ligand and 
form the “bridge” between Leu35 and the ligand.  
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Figure 4.41 Distance from Leu35 to ligand (top), distance from Leu35 to water 
molecule 414 (second plot), and distance from ligand to various water molecules 
(third plot), and distance from water 414 to different nearby water molecules 
(bottom). 
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Figure 4.41 shows the distance over time from the water molecule to Leu35 and the 
distance from the ligand to various water molecules.  The water molecule (numbered 414 
in the simulation) is initially far away from the ligand and Leu35, but it moves in during 
the 1.5-2.0 ns time period and forms a hydrogen bond with the oxygen of Leu35 during 
most of that time period (second plot from the top in Figure 4.41).  Different water 
molecules move near the ligand during this period to form a hydrogen bond with the 
hydroxyl group of the ligand and with water molecule number 414 (second from the 
bottom and bottom plots in Figure 4.41).  The hydroxyl group of the ligand forms a 
hydrogen bond to different waters, which in turn form a hydrogen bond to water 414, 
which then forms a hydrogen bond to the carbonyl oxygen of Leu35 (some distances 
appear large because the O-O distance is shown in the plots.  The O-H distances 
measured were all under 3.2 Å).  
 This water “bridge” may not be what is actually causing the ligand to shift and 
turn in the binding site, but this is probably what is stabilizing the conformation(s) seen 
during the 1.5-2.0 ns time period.  The ligand appears to go back to its initial position in 
the binding site (see Figure 4.40) because the position of the phenol ring at 3 ns looks 
similar to that at 500 and 1170 ps (at 3 ns, the ligand conformation looks more similar to 
the structure at 500 ps than the conformation at 1600 ps does).  The protein does not 
appear to undergo any major conformation changes (Figure 4.42) from the overlay of the 
structure at 500 ps (yellow ligand/blue protein) and the structure at 1600 ps (green 
ligand/red protein).  
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Figure 4.42 Overlays of the ligand/protein complex at 500 ps (yellow ligand/blue 
protein; before large RMSD change) and at 1600 ps (green ligand/red protein; 
during large RMSD change). 
 
 
The end of the ligand with the phenol group looks like it shifts/turns in the binding 
cavity, but this does not appear to cause major structural changes to the protein (at least 
not on the timescale of the simulation).  As with retinoic acid and CRABP, there is 
probably enough space in the binding site so the ligand can move around with little 
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consequence for the protein.  Shown below are the residues around the ligand at 500 ps 
and at 1600 ps (Figures 4.43 and 4.44).   
 
Figure 4.43 Snapshot from 500 ps (before distance increase). The labeled residues 
are the ones that showed a large increase in distance from the ligand during the 1.5-
2.0 ns time period.   
 
 
 
Figure 4.44 Snapshot from 1600 ps (after distance increase).  The labeled residues 
are the ones that showed a large increase in distance from the ligand during the 1.5-
2.0 ns time period.   
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Figures 4.43 and 4.44 show the orientation of the ligand with respect to the surrounding 
residues (those that showed a large distance change).  The turn and shift of the ligand is 
visible from the snapshots.  Overall, the simulated fenretinide/RBP complex agrees well 
with the x-ray structure.  Most of the distances measured were in good agreement, the 
bonds and angle errors are small, and the fenretinide is not floating out of the binding 
cavity or distorting the protein much even with turning and shifting of the phenol ring.  
From the pictures in Figure 4.42, it appears that the fenretinide just has some space to 
move around in the binding cavity without disrupting too much of the protein, especially 
near the top of the β-barrel near the phenol ring.  Because the turning/shifting of the 
phenol ring is not affecting the protein much (except for the amino acids right in the 
vicinity of the ligand), this does not appear to be a problem (this is the cause of the large 
dihedral error with respect to the x-ray structure).  These motions of the ligand could be 
important in binding and dynamics of the fenretinide or other synthetic retinoid ligands.  
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4.4.4 Retinal Complexed with Sensory Rhodopsin II (SRII).  The starting x-ray 
crystal structure for the simulation was determined by Royant and coworkers.70  The 
structure of the SRII/retinal complex is shown in Figure 4.45.  
 
Figure 4.45 Sensory rhodopsin II complexed with retinal.  The retinal ligand along with 
Lys205 are shown in cyan, and the protein is in orange. 
 
 
Sensory rhodopsins I and II belong to the family of archaeal rhodopsins, which contain 
seven transmembrane helices (A through G) and a retinal chromophore covalently bound 
to a Lys residue.70-72  SRI and SRII are coupled to the membrane-bound tranducer 
proteins, HtrI and HtrII.  Excitation of SRI or SRII by light causes activation of these 
tranducer proteins, which in turn initiate phosphorylation cascades that result in attractant 
or repellent phototaxis, respectively (meaning the whole organism moves in response to 
the stimulus light).72, 73  Analogous to bacteriorhodopsin (BR), SRI and SRII can work as 
light-driven proton pumps when they are not coupled to HtrI and HtrII, which indicates 
that the pump mechanism of BR is conserved in SRs.73  Stimulation by light induces 
tilting of the helices on the cytoplasmic side of the SRs, and the how this structural 
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change in SRII translates into signal tranduction is unclear.70, 72  The x-ray structure was 
determined in order to understand more about the mechanism of action of SRII.   
The RMSD of the protein/ligand complex stabilizes quickly and stays at ~1.75 Å 
for the remainder of the simulation.  The RMSD of the alpha carbons follows the pattern 
of the protein RMSD; the alpha carbon RMSD is ~0.5 Å lower that that of the protein 
RMSD.  The retinal ligand appears to contribute most to the RMSD at ~1.77 Å; however, 
the ligand RMSD is stable and does not show any large increases or decreases.   
  
 
Figure 4.46  RMSD plots of the protein-ligand complex (top) and RMSDs of protein, 
ligand and alpha carbons (bottom). 
 
 
The geometric parameters (bonds, angles, and dihedrals) of the ligand from the 
simulation were examined, and the error with respect to the x-ray structure was 
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calculated.  The error for bonds was 0.03 ± 0.02 Å, the error for angles was 3.0 ± 2.3°, 
and the error for dihedrals was 25 ± 33º.  The origin of this large dihedral error is the 
movement of the chain relative to the cyclohexene ring, and several rotations about bonds 
of the chain.  
 
 
Figure 4.47 Overlay of the x-ray ligand (red) with the simulation average structure (blue) 
(top).  The bottom picture shows the numbering of the carbon atoms of retinal and the 
dihedrals that contribute most to the dihedral error. 
 
 
The chain of the ligand in the x-ray structure points upward, while the chain appears to 
move downwards during the simulation.  The rotation about the C6-C7 bond contributes 
to the large dihedral error (C1-C6-C7-C8 and C5-C6-C7-C8).  Three of the chain 
dihedrals also show large deviations from the x-ray dihedrals, and this can be seen in the 
overlayed structures in Figure 4.45 (C7-C8-C9-C19 and C11-C12-C13-C20).  The 
rotation about the C10-C11 bond also shows deviation from the x-ray structure.  This is 
similar to the retinoic acid ligand; rotations about the same single bonds of the chain 
show deviations from the x-ray structure.  This movement probably occurs so that the 
ligand can optimize contacts with protein sidechains.  The cyclohexene ring retains the 
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RTAL(C15) to Lys205(NZ) (Schiff base linkage)
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C2’-endo conformation. There does not appear to be much distortion of the surrounding 
protein residues, and most of the protein residue contacts stay in place over the time of 
the simulation.  The largest deviation from the x-ray distances is ~0.5 Å (time series plots 
can be found in Appendix B).  
Because the Schiff base linkage to the retinal ligand was parameterized, this 
distance was examined for the simulation to make sure it stayed in place.  Figure 4.48 
shows the Schiff base linkage over time, and the simulation shows excellent agreement 
with experiment (computed distance was 1.28 ± 0.015 Å; x-ray was 1.28 Å) 
 
Figure 4.48 Schiff base linkage over time. 
 
 
The authors described the binding site of SRII and some protein-protein 
interactions in detail, and these distances and features were all examined in the 
simulation. Some of these distances are shown in Table 4.12, some of the time series 
plots are shown, and the remaining time series plots can be found in Appendix B.  
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Table 0.12 Protein-ligand and protein-protein distances (SRII/retinal complex) 
protein-ligand   
contact x-ray (Å) Computed (Å) 
Trp76(CE3)--RTAL(C10) 4.18 4.10 ± 0.19 
Trp171(CZ2)--RTAL(C20) 3.83 3.98 ± 0.12 
Tyr174(CZ)--RTAL(C12) 3.60 3.85 ± 0.15 
Ile83(CD)--RTAL(C20) 3.96 3.81 ± 0.17 
Ala111(CB)--RTAL(C3) 5.69 5.62 ± 0.32 
Leu126(O)--RTAL(C3) 5.38 4.98 ± 0.16 
Gly130(O)--RTAL(C4) 4.24 4.01 ± 0.15 
Val108(CG1)--RTAL(C7) 3.72 4.31 ± 0.15 
Pro175(CB)--RTAL(C4) 3.87 4.17 ± 0.17 
Ile43(CG2)--RTAL(C15) 5.75 6.10 ± 0.21 
Ala47(CB)--RTAL(C15) 5.91 5.94 ± 0.15 
Asp75(OD2)--RTAL(C15) 5.30 4.60 ± 0.32 
Thr79(OG1)--RTAL(C15) 4.00 3.83 ± 0.19 
Met109(CE)--RTAL(C10) 3.87 4.07 ± 0.22 
Trp171(CB)--RTAL(C19) 3.72 4.15 ± 0.22 
Asp201(OD2)--RTAL(C14) 3.44 3.36 ± 0.11 
Thr204(OG1)--RTAL(C15) 3.74 3.99 ± 0.27 
Arg72(NH1)--Cl- ion 3.56 4.28 ± 0.18 
Tyr73(OH)--Cl- ion 3.51 3.47 ± 0.28 
Phe69(O)--Cl- ion 3.35 3.51 ± 0.12 
Water406(OH2)--Cl- ion 4.04, 2.83 3.28 ± 0.12 
Water407(OH2)--Cl- ion 3.68 3.13 ± 0.08 
Lys205(NZ)--Asp75(OD1) 4.07 3.58 ± 0.16 
Lys205(NZ)--Thr79(OG1) 3.67 4.15 ± 0.34 
Thr79(OG1)--Asp75(OD1) 2.81 2.81 ± 0.14 
 
The authors identified one Cl- ion in the structure, and they explain that this ion is 
coordinated to Arg72, Tyr73, Phe69, and two water molecules. Figure 4.49 shows these 
distances over time during the simulation.   
 
 
 
 
 
 267
 
 
 
 
Figure 4.49 Cl- ion distances to nearby residues (retinal/SRII).  
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The Cl- ion moves away from Arg72 by ~0.72 Å, but the ion stays close to Tyr73 and 
Phe69.  Two positions were identified for water 406, and the Cl- ion stays in between the 
two positions.  The ion and water 407 move ~0.5 Å closer together.   
 The protonated Schiff base is hydrogen bonded to a water molecule (numbered 
402), which is also hydrogen bonded to two aspartic acid residues (Asp75 and Asp201).   
From the top plot of Figure 4.50, water 402 moves away from the Schiff base nitrogen 
(NZ) of Lys205, and an oxygen (OD1) of Asp201 appears to moves closer to the Schiff 
base nitrogen of Lys205, replacing the hydrogen bond that was formed between water 
402 and Lys205.  The second plot in Figure 4.50 shows the distance from Asp75 to water 
402 and Lys205 over time.  Water 402 moves away from the oxygen (OD2) of Asp75, 
but the Schiff base nitrogen of Lys75 stays close throughout the simulation.  The contact 
between the Schiff base nitrogen and Asp75 (OD1) is part of the salt bridge that is 
hypothesized to keep SRII in its inactive conformation (the other part of the salt bridge is 
the Schiff base nitrogen to Asp75 (OD2).73 Even though water 402 moves away from 
Asp75, water 401 stays close during the entire simulation (third plot in Figure 4.50) and 
forms a hydrogen bond.  The bottom plot of Figure 4.50 shows the distance over time 
from Asp201 to water 402, which stays about the same throughout the simulation.   
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Figure 4.50 Distances for Lys205, Asp75, Asp201, water 401, and water 402. 
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 The chain of the retinal ligand is constrained at the Schiff base end by aromatic 
residues (Trp76, Trp171, and Tyr174).  
 
 
 
Figure 4.51 Distances from retinal ligand to aromatic residues. 
 
 
Figure 4.51 shows the distances from the Schiff base end of the ligand to nearby aromatic 
residues.  All of the measured simulation distances are in good agreement with the x-ray 
values; the retinal ligand appears to stay in place at the Schiff base end.   
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 The authors made note of several protein-protein and protein-water contacts in 
and near the binding site of the ligand.  
 
 
 
Figure 4.52 Protein-protein contacts near the ligand (retinal/SRII).  
 
 
 Lys205 stays near Asp75 throughout the simulation (top plot in Figure 4.52).  This 
distance is the other part of the salt bridge that keeps the receptor in its inactive 
conformation.  During the simulation, these two residues move about 0.5 Å closer 
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together.  Lys205 moves away from Thr79 (~0.5 Å) about half way through the 
simulation (second plot in Figure 4.50); however, Asp75 stays close enough to Thr79 to 
form a hydrogen bond from one its sidechain oxygens to the hydroxyl group of Thr79.  
Thr79 and Lys205 move away from each other at about the same time that water 402 
moves away from Lys205 (see Figure 4.50, top plot); however, Asp201 moves in and 
forms a hydrogen bond to the Schiff base nitrogen of Lys205 (Figure 4.50).  Figure 4.53 
shows the protein-water distances mentioned by the authors of the x-ray structure.  The 
waters that are present in the x-ray structure in the active site stay there during the course 
of the simulation and form hydrogen bonds to Asp201 and Arg72.   
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Figure 4.53 Protein water distances near the ligand (retinal/SRII).  
 
 
The authors of the x-ray structure did not mention any other protein-ligand 
contacts, but several were measured from the simulation for comparison back to the x-ray 
structure.  Three of them are shown here, and the rest can be found in Appendix B.  
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Figure 4.54 Three of the protein-ligand contacts measured from the simulation 
(retinal/SRII).  
 
 
The protein-ligand contacts shown in Figure 4.54 show that there is good agreement 
between the crystal structure and the simulation.  The top plot is from Ile83 to the 
isoprene chain of retinal, and the bottom two plots are from protein residues to the 
cyclohexene ring of retinal.  In Figure 4.54, the protein residues and the ligand fluctuate 
around the value from the x-ray structure with the exception of Leu126, in which case the 
 275
residue and ligand move ~0.4 Å closer together.  Figure 4.51 also contains time series 
plots for distances from the isoprene chain of retinal to nearby protein residues.  
The rest of the protein-ligand contacts measured from the simulation can be found 
in Appendix B.  Some of the distances for the protein-ligand contacts deviate from the 
starting x-ray value over time; the largest deviation (increase in distance) from the x-ray 
structure for protein-ligand distances observed from the simulation was ~0.5 Å (Val108 
to retinal (C7); Appendix B).  Solvating the protein in water instead of using a lipid 
bilayer could be the cause of some of these deviations.  Most other distances fluctuated 
around the x-ray value or did not deviate by more than 0.5 Å.  The simulated retinal/SRII 
complex agrees well with the x-ray structure. The Schiff base linkage from Lys205 to 
retinal stays intact, and the retinal ligand stays inside the protein.  Most of the protein-
ligand distances measured are in good agreement with the x-ray structure; in fact, this 
simulation had the most simulation distances that simply fluctuated around the x-ray 
structure values for the whole simulation time (did not show much deviation from x-ray).  
This is probably due to the fact that the retinal is covalently bound to SRII, rather than 
noncovalently, as in the other complexes.   The average bond and angle error for the 
retinal is low; however, the average dihedral error is high.  This is due to the chain of the 
ligand moving with respect to the cyclohexene ring and rotation around several of the 
single bonds of the chain.  There does not seem to be any major distortion in the protein 
residue surrounding the ligand, so the ligand is probably moving simply to optimize 
contacts with the nearby sidechains.  
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4.4.5. Retinal Complexed with Bacteriorhodopsin from Halobacterium salinarum 
(BR). The starting x-ray crystal structure for the simulation was determined by Faham 
and coworkers.74  
 
Figure 4.55  Retinal complexed with bacteriorhodopsin. The retinal ligand for each chain 
is shown in cyan, and the two protein chains of BR are shown in dark blue.   
 
 
Bacteriorhodopsin (BR) is a light-driven proton pump (converts light energy into a proton 
gradient) present in the cell membrane of Halobacterium salinarum, an organism found 
in highly saline environments.  BR contains seven transmembrane helices (A through G), 
which are linked by short loops on either side of the membrane.  Each BR chain contains 
one molecule of retinal, which is covalently bound by a Schiff base linkage to Lys216 in 
helix G.  Absorption of a photon by BR causes isomerization of all-trans retinal 
(protonated Schiff base linkage) to 13-cis retinal.  The Schiff base is then depronated 
(which causes the retinal chromophore to straighten and push against helix F, causing it 
to tilt), and the proton is transferred to Asp85.  Asp96 reprotonates the Schiff base, and a 
proton is taken in from the inner, cytoplasmic side to reprotonate Asp96 (helices F and G 
open a narrow channel in which a proton can come through).  The proton on Asp85 is 
transferred through a network of hydrogen bonds and water molecules to the outside.  
The retinal then relaxes back to the all-trans configuration (ground state), and another 
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photocycle can then start.  The proton pumping mechanism of BR has been studied 
extensively by a variety of experimental75-84 and computational methods,85-94 and the 
proton route through the membrane can now be followed in detail. The great interest in 
BR has continued for several reasons: BR is the most well-understood ion pump, it serves 
as a model for G-protein coupled receptors and other proteins which contain 
transmembrane helices, and it has become the paradigm of a membrane transporter.95  
 The simulation was performed on the asymmetric unit of the crystal structure, 
which was of a dimer of BR, rather than the native form, which is a trimer, or a 
monomer, which is commonly the result when the trimer form is solubilized by nonionic 
detergent.75, 78  The RMSD and distance plots for protein-ligand or protein-protein 
distances were calculated for both chains, and only one x-ray distance is plotted because 
the x-ray distances were same for both chains of BR.  Shown below are the RMSD plots 
for the whole complex, the protein only, the alpha carbons, and the ligands only.   
The RMSD of the ligand/protein complex and the protein chains without the 
ligands both stabilize quickly to ~3 Å (both chains together and individually).  The 
RMSD of the alpha carbons also stabilizes at the beginning of the simulation to just under 
3 Å.  The ligands together show an RMSD of ~1.2 Å until 2 ns into the simulation, where 
the RMSD then decreases to just above 1 Å.  Ligand A follows the same pattern; a 
decrease in RMSD is observed at 2 ns.  Ligand B shows an initial increase in RMSD, 
stabilizes at ~1 ns, and then converges to where Ligand A converges to (~0.7 Å).   
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Figure 4.56  RMSD plots for retinal/BR complex. Ligand/protein complex (top), protein 
chains and alpha carbons only (middle), and retinal ligands only (bottom). 
 
 
Average RMSDs                all                         chain A              chain B 
Protein/ligand complex       3.04 ± 0.16 Å          2.85 ± 0.15 Å        2.92 ± 0.16 Å 
Protein only                         3.05 ± 0.16 Å          2.86 ± 0.15 Å        2.93 ± 0.16 Å 
Alpha carbons only             2.92 ± 0.16 Å          2.62 ± 0.14 Å        2.79 ± 0.15 Å 
Ligands only                       1.16 ± 0.10 Å          0.71 ± 0.06 Å        0.62 ± 0.07 Å 
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The geometric parameters (bonds, angles, and dihedrals) of the ligands from the 
simulation were examined, and the error with respect to the x-ray structure was 
calculated.  The error for bonds was 0.02 ± 0.02 Å for both ligands, the error for angles 
was 5 ± 4° for the first ligand and 5 ± 5° for the second ligand, and the error for dihedrals 
was ~33 ± 20º for both ligands.  The origin of these large dihedral errors is the rotation 
about single bonds of the chain, and movement of the chain relative to the cyclohexene 
ring.   
  
 
Figure 4.57 Overlays of x-ray structure (red) and simulation average structure (blue).  
The bottom picture shows the rotations about the single bonds that deviate from the x-ray 
structure. 
 
 
The largest differences in the dihedrals are seen for the attachment of the ring to the chain 
(rotation about the C6-C7 bond), and for rotation about several bonds of the chain (C8-
C9, C10-C11, and C12-C13).  This is similar to the behavior seen the SRII/retinal and 
CRABPII/retinoic acid simulations; the deviations from the x-ray structure are rotations 
about the same bonds.  The bonds that show rotation are single bonds, so the ligand 
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probably rotates about these to optimize contacts with protein sidechains.  Both ligands 
retain the C3’-endo conformation for the cyclohexene ring found in the x-ray structure.   
As for the retinal complexed with SRII, the Schiff base linkage was examined to 
make sure it stayed in place for both ligands.  Figure 4.58 shows that the Schiff base 
linkage stays in place for both BR chains.  
  
Figure 4.58 Schiff base linkages for retinal/BR complex. 
 
 
Table 4.13 contains many of the protein-ligand distances measured from the 
simulation. Several time series plots are shown; additional properties measured can be 
found in Appendix B.  The x-ray distances were measured for both chains, and the 
distance was found to be the same for both; thus, only one value is given for the x-ray 
distance in the table and on the time series plots.  
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Table 0.13 Protein-ligand and protein-protein distances (BR/retinal complex) 
protein-ligand    
contact x-ray (Å) computed chain A (Å) computed chain B (Å) 
Ser141(OG)—RTAL(C2) 3.61 3.54 ± 0.12 3.65 ± 0.16 
Tyr185(CD)—RTAL(C10) 3.95 3.42 ± 0.12 3.78 ± 0.19 
Trp86(CD1)—RTAL(C14) 3.41 3.42 ± 0.10 3.49 ± 0.09 
Met145(SD)—RTAL(C18) 3.89 3.62 ± 0.12 3.68 ± 0.15 
Pro186(CB)—RTAL(C3) 4.97 4.00 ± 0.13 3.80 ± 0.14 
Tyr185(CE1)—RTAL(C11) 3.86 3.73 ± 0.13 4.19 ± 0.22 
Thr90(CG2)—RTAL(C12) 3.77 3.81 ± 0.16 4.36 ± 0.19 
Asp85(CG)—RTAL(C15) 5.36 4.33 ± 0.20 4.42 ± 0.13 
Met20(CE)—RTAL(C15) 5.79 6.64 ± 0.15 6.87 ± 0.42 
Thr89(CB)—RTAL(C15) 4.32 4.31 ± 0.13 4.72 ± 0.16 
Leu93(CD1)—RTAL(C20) 3.55 4.20 ± 0.37 3.63 ± 0.14  
Lys41(NZ)—Asp38(OD1) 4.14 4.58 ± 0.10 3.87 ± 0.12 
Lys41(NZ)—Asp38(OD2) 3.78 2.59 ± 0.07 2.67 ± 0.08  
Thr46(OG1)—Asp96(OD2) 2.88 2.62 ± 0.05 2.80 ± 0.13 
 
Several protein-protein distances were mentioned by the authors of x-ray structure, and 
three of those are shown below. Lys41 (NZ) forms an intrahelical salt bridge with Asp38 
(top plot in Figure 4.59), and Thr46 forms a hydrogen bond to Asp96 (second plot in 
Figure 4.59).  The hydrogen bond from Thr46 to Asp96 appears to stay intact over the 
entire simulation for both chains.  The intrahelical salt bridge distance (Lys41 to Asp38) 
shortens for chain B but gets larger for chain A by ~0.44 Å.  However, the distance 
decreases for both chains when measured from Lys41 to the other oxygen of Asp38 
(distances decreases from 3.78 Å to ~2.60 Å), so the intrahelical salt bridge contact stays 
in place, just to the other oxygen of Asp38.  Tyr30 makes another intrahelical salt bridge 
with Lys30 (bottom of Figure 4.59).  The original hydrogen bond is broken in both 
chains; however, new ones are formed.  In chain A, Tyr43 forms a hydrogen bond to 
Leu224, and Lys30 forms a hydrogen bond to Tyr26.  In chain B, Tyr43 forms hydrogen 
bond to Met32, and Lys30 forms a hydrogen bond to Arg225.   
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Figure 4.59 Protein-protein contacts measured from BR/retinal simulation. 
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Many contacts were measured from the retinal ligand to surrounding protein residues; 
however, only four of them will be shown here and the remaining ones are in Appendix 
B.  The protein-ligand distances shown in Figure 4.60 show good agreement between the 
simulation and the x-ray structure.  The distances measured from chain A and chain B 
appear to fluctuate around the x-ray value for the whole simulation time; however, the 
Tyr185 and Met145 distances to the ligand decrease ~0.5 Å from the x-ray value.  The 
distances shown in Appendix B also show good agreement between the computed values 
and the x-ray structure.  If any contacts appeared to be broken (i.e. ligand or protein 
distances increased), usually another protein residue near the ligand was found that 
replaced the original contact.  This did not seem unusual; the ligand probably has some 
room to move around in the binding site even though it is covalently bound to the protein.   
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Figure 4.60 Four of the ligand-protein distances measured from the BR/retinal 
simulation.   
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Studies on bacteriorhodopsin have found that water molecules near the retinal 
ligand are extensively involved in both the structure and function of the protein.79, 82, 83, 96  
Water molecules were identified in the active site of the x-ray structure, and some of the 
distances of the water molecules to the ligand are shown in Figure 4.61.  The top two 
plots in Figure 4.61 are for the ligand of chain A, and the bottom two plots are for the 
ligand of chain B.  In chain A, a crystallographic water (denoted WATX14) stays close to 
the ligand for the entire simulation.  WATX6 and WATX114 drift away from the ligand 
but are replaced by other crystallographic waters or waters added for the simulation.   In 
chain B, WATX 23 and the ligand move closer together as the simulation progresses, and 
a bulk water replaces the replaces the WATX32-retinal contact.   Even though other 
crystallographic or bulk waters replace the original water-retinal contacts, the interactions 
appear to stay intact over the simulation time period.   
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Figure 4.61 Water-ligand distances measured from the BR/retinal simulation. 
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Overall, the BR/retinal simulation compares well to the x-ray structure.  The 
Schiff base linkage stays in place and if any ligand-protein or ligand-water contacts were 
broken, usually another protein residue or water was found near the ligand to make a new 
contact.  The RMSD is highest for the BR/retinal complex, and this could be due to the 
fact that the protein is membrane-bound but the simulation was performed in water in 
order to save computational time.  The average bond and angle errors are low; however, 
the average dihedral error is high.  This is due to the chain moving relative to the 
cyclohexene ring and to the rotation about several single bonds of the chain. The 
surrounding protein residues do not appear to be disturbed much by the movement of the 
ligands.  
4.6 Conclusions 
Presented are parameters for the CHARMM force field that allow for molecular 
modeling and simulation studies of systems with alternating single and double bonds, 
specifically, retinoids.   The bonds, angles, and dihedral angles have been parameterized 
against MP2/6-31G(d) target data, and the error between CHARMM and the quantum 
mechanical data is in excellent agreement.  The CHARMM model compounds and full 
retinoids obtained from the new parameters were compared against available 
experimental data (spectroscopic and x-ray crystal data), and the comparison yields good 
agreement with respect to geometric parameters.  The retinoids made from new 
parameters were also compared against five reported x-ray structures of protein/retinoid 
complexes.  The structural and geometric analysis of these simulations also compares 
well to the experimental structures.    
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 The CHARMM torsion energy surfaces show excellent agreement with those 
obtained from MP2/6-31G(d).  The largest difference over all model compounds between 
barrier heights is ~1.15 kcal/mol (CHARMM is higher than MP2 for model 8).  The 
bond, angle, and dihedral error for between CHARMM and MP2 is low, with bond error 
being 0.012 ± 0.009 Å, angle error is 1 ± 1°, and dihedral error is 2 ± 4°.   
 Comparison of the new CHARMM parameters with available experimental data 
shows that CHARMM is in good agreement with experiment.  The model compounds 
were compared to available experimental structures; the average bond error is 0.03 ± 0.06 
Å, the average angle error is 2 ± 2°, and the average dihedral error is 3 ± 3°.  Crystal 
simulations of the new retinoids show that the new parameters yield the proper bond 
lengths for compounds with alternating single and double bonds.  The simulated 
structures of retinal and retinoic acid do not deviate much from the starting x-ray crystal 
structures; the cyclohexene ring retains the proper conformation, the chain does move 
much relative to the cyclohexene ring, and the single bonds of the chain show minimal 
rotation (chain stays relatively planar).  Another important observation from the crystal 
simulations is that the new CHARMM parameters show the proper crystal 
transformations at high temperature.  Retinoic acid crystallizes in the monoclinic and 
triclinic forms; however, at high temperature, the monoclinic form transforms irreversibly 
to the triclinic form.  The crystal simulations at high temperature of retinoic acid in the 
monoclinic form show the beginnings of this transformation.  The chain starts to move 
outward from the cyclohexene ring during the simulation, which is what is seen in the 
triclinic form (the monoclinic structure has the chain pointing upward from the ring).   
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In the crystal simulations of the protein/retinoid complexes, some retinoids show 
rotation about the single bonds of the chain and rotation of the chain relative to the 
cyclohexene ring.  This behavior is observed because the retinoid ligand will try to 
optimize contacts with nearby protein side chains.  These movements of the retinoids do 
not appear to cause any major conformational changes or disruptions of the protein, and 
the retinoid ligands stay inside the binding cavities of the proteins during the simulations 
and retain contacts found in the x-ray structures.  Some ligand motions were also 
discovered that could be important in ligand binding and dynamics or interaction of the 
protein/ligand complex with other molecules.  In the case of the retinoic acid/CRABPII 
complex, the cyclohexene ring turns in the binding site of the protein.  In the 
fenretinide/RBP complex, the phenol ring turns and shifts in the binding site of RBP.   
The new parameters yield good agreement with experiment and now exhibit the 
proper bond lengths, angles, and torsion angles for compounds with alternating single and 
double bonds.  The new parameters can now be used in simulations of proteins that bind 
retinoids to better understand the structure and dynamics of those systems and in drug 
design to make new retinoids that have therapeutic and anticancer potential.   
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Chapter 5 
 
 
Convergence Testing in Biomolecular Simulations 
  
This chapter discusses the statistical tests performed to test for convergence in 
long and short simulations of DNA and proteins.  The purpose of this study was to try to 
assess convergence in biomolecular systems, and this was done by performing a few very 
long simulations and many very short simulations.  A simple statistical test (potential 
scale reduction test) was then applied to observe which simulation procedure exhibited 
better convergence among simulations.   
5.1 Potential Scale Reduction Test  
 
 The potential scale reduction test, also termed the variance ratio method, was 
developed by Gelman and Rubin in 1992 1 and is a popular convergence diagnostic used 
by statisticians in order to monitor convergence in multiple Markov chain Monto Carlo 
simulations.2-4  The most obvious way to compare the parameters measured from each 
simulation (and see if they converge) is to look at time series plots of a particular 
parameter for each simulation.  The potential scale reduction test (PSRT) is a quantitative 
way (does not rely on visual inspection of the simulations) to compare a particular 
parameter and is based on analysis of variance.  Approximate convergence is assumed 
when the variance between the different simulations for a particular parameter is no 
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larger than the variance seen in that particular parameter from an individual simulation.5  
This approach to monitoring convergence is based on whether or not the simulations have 
“forgotten” their starting points by comparing multiple simulations to see if they are 
indistinguishable.  With these particular sets of simulations, different properties (18 
helical parameters for DNA and 16 geometric parameters for crambin) were monitored 
for convergence.  It is assumed that when the parameters measured have converged by 
the criteria of the PSRT, that they are sampling the same regions of conformational space 
at that point and the value of that parameter overlap.  In other words, they have 
“forgotten” their starting points and have become indistinguishable because their values 
overlap.  
 For each parameter measured ψ, we have ψij, where j =1,…,n and i =1,…,m.  The 
parameter m is the number of simulations and n is the number of samples used from each 
simulation. Two variances are calculated, the between-sequence variance (variance 
between different simulations), B, and the within-sequence variance (variance within an 
individual simulation), W:  
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where  
  
  
  
 
B contains a factor of n because it is based on the variance of the within-sequence means,  
iψ (each of these is an average of n values ijψ ).   
 From B and W, two estimates of variance of ψ are calculated.  The first, ˆ( )v ψ , is 
an overestimate of the variance under the assumption that the starting points (in our case 
the seed for the random number generator for the starting velocities) of the simulations 
are drawn from a wide range of values (this is termed overdispersion).  
  
 
For any finite n, W should underestimate the variance of ψ because the individual 
simulations have not had time to range over all of the possible values and will thus have 
less variability.  As n approaches infinity, both ˆ( )v ψ and W will approach the actual 
variance, var(ψ), but they do so from opposite directions.   
The convergence of the simulations is monitored by estimating the factor by 
which the overestimate of the variance, ˆ( )v ψ , can be reduced.  In other words, it is the 
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ratio between the upper ( ˆ( )v ψ ) and lower bounds (W) for the standard deviation of ψ, 
which is termed the estimated potential scale reduction.  
  
The potential scale reduction is designated as Rˆ  instead R because both the numerator 
and denominator are estimates of the upper and lower bounds of the variance.  
 As the simulations converge (and as n goes to infinity), the within-sequence 
variance exceeds the between-sequence variance (there is more variability within an 
individual simulation than between the different simulations), and the potential scale 
reduction will approach 1. The different simulations will now have overlapping values 
for the parameter being tested.  If the potential scale reduction is high, then the value of 
the parameter being measured is not converging for all simulations, and the values 
sampled for a particular parameter are not overlapping.  In practice, if Rˆ values are less 
than or equal 1.2, then the particular property being measured is said to have converged.5      
5.2 Protein Convergence 
 
5.2.1. Long-Time Simulations.  The PSRT was applied to 10 long (45 ns each) 
simulations of crambin in the crystal environment (see Chapter 2 for simulation 
methods).  A total of 16 geometric parameters were examined, which were the radius of 
gyration, helix-helix distance (measured from the backbone nitrogen of Asn14 to the 
backbone nitrogen of Ala27), three beta turn distances (listed in Table 5.1; CA denotes 
the alpha carbon), and a total of 11 hydrogen bonds in the two α-helices (helix 1 has 
seven hydrogen bonds and helix 2 has 4 hydrogen bonds; these distances are listed in 
Table 5.1).  The hydrogen bonds were measured from the amide hydrogen (denoted HN) 
Eqn. 5.7 
ˆ( )ˆ vR
W
ψ=
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to the backbone carbonyl oxygen (denote O). Table 5.1 lists the Rˆ  values for each 
parameter. All snapshots saved were used for the analysis (total of 4500 snapshots for 
each simulation).  
Table 5.1 PSRT results (long-time crambin simulations) 
parameter  Rˆ long  
radius of gyration     3.3  
helix-helix distance     1.4  
beta turn 1 (Arg17 CA to Gly20 CA)     1.6  
beta turn 2 (Pro41 CA to Tyr44 CA)     1.7  
beta turn 3 (Gly42 CA to Ala45 CA)     2.6  
   
helix 1   
hbond 1 (Ser11 HN to Ile7 O)    1.3  
hbond 2 (Asn12 HN to Val8 O)    2.1  
hbond 3 (Phe13 HN to Ala9 O)    1.2  
hbond 4 (Asn14 HN to Arg10 O)    1.4  
hbond 5 (Val15 HN to Ser11 O)    1.5  
hbond 6 (Cys16 HN to Asn12 O)    1.2  
hbond 7 (Arg17 HN to Phe13 O)    1.2  
   
helix 2   
hbond 1 (Ala27 HN to Glu23 O)    1.2  
hbond 2 (Thr 28 HN to Ala24 O)    1.1  
hbond 3 (Tyr29 HN to Ile25 O)    1.2  
hbond 4 (Thr30 HN to Cys26 O)    3.7  
   
 
Only six of the measured parameters converge for all ten simulations, and all of these 
parameters are hydrogen bond distances.  Two of the time series plots for the hydrogen 
bond distances that did converge are shown in Figure 5.1.  All of the simulations overlap 
and thus sample approximately the same range of values.  
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Figure 5.1 Examples of time series plots for hydrogen bonds.  Both of these parameters 
converged according to the PSRT.  The different colors represent the different 
simulations. 
 
 
The parameters that did not converge were also examined with time series plots to see 
which simulations were not sampling the same values as the others.  Figure 5.2 shows the 
time series plots for two of the parameters that did not converge.  The top plot shows the 
time series for the radius of gyration, and it is very obvious that the simulations do not 
sample the same values.  For example, the red and dark blue simulations sample lower 
values than the light blue and green simulations.  The bottom plot is for the helix-helix 
distance, which shows more overlap between the different simulations than the radius of 
gyration; however, the helix-helix distance still does not converge according to the PSRT.  
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Even though the simulations exhibit overlap for the helix-helix distance, the PSRT yields 
non-convergence, which shows the importance of using a quantitative and non-visual 
test.  The other time series plots looked similar.  
 
 
Figure 5.2 Time series plots for radius of gyration (top) and helix-helix distance 
(bottom).  Neither of these parameters converged according to the PSRT.  The different 
colors represent the different simulations. 
 
 
The time series plots and Table 5.1 illustrate the importance of running multiple 
simulations.  Some simulations sample different ranges of values than other simulations 
and thus sample different regions of conformational space. If only one simulation had 
been performed, none of these differences in behavior would have been discovered. The 
conclusions made from only one simulation would not apply to the rest of the simulations 
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and thus would not have been representative of the system.  One simulation is not going 
to sample all possible values that a particular parameter can take on, and this would have 
gone unnoticed if only a single simulation had been run.   
 Because convergence could not be achieved for the radius of gyration by 
removing simulations (and because PCA has been used in other studies to assess 
convergence), a PCA plot was made to observe which simulations did not sample the 
same regions of conformational space as the others (Figure 5.3, top).   None of the 
simulations appear to be outliers; they all appear to sample in the same regions.  The 
Scree plot (Figure 5.3, bottom) does not show any large contributions to variance.  The 
highest principal component only contributes ~18% of the variance.  The PCA plot 
clearly shows that the simulations sample in the same areas, but according the PSRT, the 
simulations do not converge.  The ten simulations have averages for the radius of 
gyration in the range of 9.82 to 9.92, which is only a tenth of an angstrom difference.  
PCA does not reflect this small difference, but the convergence test is sensitive enough 
that even a small difference is magnified.  
 308
 
 
Figure 5.3 PCA plot for radius of gyration for the long-time simulations (top) and Scree 
plot corresponding to PCA plot (bottom). 
 
 
5.2.2. Short-time Simulations.  A total of 20 short-time (2 ns each) simulations 
were performed of crambin in the crystal environment (see Chapter 2 for simulation 
methods).  The same geometric parameters were tested in the short simulations, and all 
saved snapshots were used for analysis (200 snapshots for each simulation).  Table 5.2 
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lists the Rˆ  values for each parameter for the short simulations.  As for the long-time 
simulations, only six parameters converge according to the PSRT, and they are all 
hydrogen bond distances.  The converging hydrogen bond distances are not the same in 
the long and short simulations, but they have four in common, which are the third and 
seventh distances in helix 1 and the first and second distances in helix 2.  Two of the time 
series plots for the short-time simulations are in Figure 5.4.  The top plot is for the second 
hydrogen in helix 2, and as for the long-time simulations, the short-time simulations 
overlap and sample the same range of values.  The bottom plot is for the radius of 
gyration; some simulations sample higher values (the green and yellow simulations) 
while others (blue simulations) sample lower values.  
Table 5.2 PSRT results (short-time crambin simulations) 
 
parameter Rˆ  short 
radius of gyration 2.6 
helix-helix distance 2.1 
beta turn 1 (Arg17 CA to Gly20 CA) 1.8 
beta turn 2 (Pro41 CA to Tyr44 CA) 1.7 
beta turn 3 (Gly42 CA to Ala45 CA) 2.1 
  
helix 1  
hbond 1 (Ser11 HN to Ile7 O) 1.1 
hbond 2 (Asn12 HN to Val8 O) 1.4 
hbond 3 (Phe13 HN to Ala9 O) 1.2 
hbond 4 (Asn14 HN to Arg10 O) 1.2 
hbond 5 (Val15 HN to Ser11 O) 1.3 
hbond 6 (Cys16 HN to Asn12 O) 1.3 
hbond 7 (Arg17 HN to Phe13 O) 1.2 
  
helix 2  
hbond 1 (Ala27 HN to Glu23 O) 1.1 
hbond 2 (Thr 28 HN to Ala24 O) 1.1 
hbond 3 (Tyr29 HN to Ile25 O) 1.3 
hbond 4 (Thr30 HN to Cys26 O) 3.2 
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As for the long-time simulations, time series plots were examined for the short-time 
simulations to see which simulations were the outliers.  Figure 5.4 shows the time series 
plots for hydrogen bond 2 of helix 2 (top) and the radius of gyration (bottom).  For the 
hydrogen bond, the values of all simulations overlap and thus the parameter converges.  
However, for the radius of gyration, the opposite is observed; the simulations do not have 
overlapping values, and the variance within individual simulations is greater than that 
among the different simulations.   
 
 
Figure 5.4  Examples of time series plots for short-time simulations. The top plot is for 
the second hydrogen bond of helix 2, which converged.  The bottom plot is for the radius 
of gyration, which did not converge. The different colors represent the different 
simulations. 
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Table 5.3 shows the averages and standard deviations for the parameters for both 
the long and short sets of simulations.   
Table 5.3 Parameter averages for long and short crambin simulations 
 
 
 
 
 
 
 
 
 
 
 
 
Most of the average values calculated from the short and long simulations agree with one 
another or they are at least within the standard deviations of each other. Both sets of 
simulations appear to reach the same range of values, whether this happens in a long time 
or a short time.  The long and short simulations appear to converge to the same values, 
even though the individual simulations within the sets do not converge according to the 
potential scale reduction test.  Because they reach the approximately the same average 
values and show similar convergence behavior, the short simulations are probably the 
better choice for convergence when time and effort are considered. 5.3 DNA 
Convergence 
parameter long average (Å)  short average (Å) 
radius of gyration 9.88 ± 0.14 9.89 ± 0.19 
helix-helix distance 9.40 ± 0.51 8.37 ± 0.84 
beta turn 1 5.31 ± 0.67 5.30 ± 1.35 
beta turn 2 5.52 ± 0.45 5.51 ± 0.65 
beta turn 3 5.08 ± 0.83 5.08 ± 1.06 
   
helix 1   
hydrogen bond 1 1.87 ± 0.27 1.88 ± 0.37 
hydrogen bond 2 1.98 ± 0.37 1.96 ± 0.43 
hydrogen bond 3 2.25 ± 0.51 2.26 ± 0.71 
hydrogen bond 4 1.98 ± 0.33 1.94 ± 0.40 
hydrogen bond 5 2.25 ± 0.51 2.24 ± 0.68 
hydrogen bond 6 1.93 ± 0.30 1.94 ± 0.44 
hydrogen bond 7 2.05 ± 0.33 2.05 ± 0.48 
   
helix 2   
hydrogen bond 1 1.86 ± 0.26 1.87 ± 0.36 
hydrogen bond 2 1.96 ± 0.30 1.95 ± 0.44 
hydrogen bond 3 2.01 ± 0.35 1.97 ± 0.48 
hydrogen bond 4 2.21 ± 0.86 2.31 ± 1.39 
 312
 
5.3.1. Long-Time Simulations. The PSRT was applied to 4 long (150 ns each) 
simulations of DNA in the crystal environment (see Chapter 2 for simulation methods).  
The DNA fragment was a 12 base pair fragment of DNA (5’-CGTAGACTCAGC-3’; no 
ligands bound) and the same 18 helical parameters that were examined in 
DNA/polyamide study were analyzed with the PSRT.  All 15,000 snapshots saved from 
each simulation were used for analysis.  Table 5.4 lists the Rˆ  values for each helical 
parameter for the four long simulations.  
Table 5.4 PSRT results (long-time DNA simulations; 12 bases) 
 
parameter Rˆ  
shear 1.2 
stretch 2.9 
stagger 2.6 
buckle 1.2 
propeller 3.1 
opening 2.5 
shift 2.0 
slide 1.4 
rise 2.2 
tilt 2.4 
roll 4.6 
twist 2.6 
x-displacement 3 
y-displacement 1.8 
helical rise 2.6 
inclination 5.1 
tip 2.8 
helical twist 1.1 
 
Almost all of the helical parameters with the exception of three (shear, buckle, and helical 
twist) do not converge according to the PSRT.  Upon examination of time series plots of 
the parameters, it was obvious that the simulations had a wide range of values for some 
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parameters and that the simulations appear to sample very different ranges of values.  
Shown below are the time series plots for propeller and stretch.  
 
 
Figure 5.5 Time series plots for propeller and stretch for long DNA simulations.  The 
values plotted are averages over all 12 base pairs of the DNA fragment.   
 
 
For propeller, the values sampled range from ~5º to -25º, and Simulation 1 has higher 
values of propeller than the other simulations.  Simulation 2 samples the widest range of 
values with a range of ~20º.  Simulation 2 also exhibits the widest range of values for 
stretch (0.5 to –1.5 Å).  Simulation 1 has a large range of value for stretch (0.5 to –0.5 Å), 
but not as large as Simulation 2. Simulations 3 and 4 appear to sample the same values 
for stretch and opening, and they do not appear to have as much variation.   
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 Because fraying of the end base pairs is a commonly observed phenomenon in 
both experimental6-15 and computational16-23 studies of DNA, this is most likely occurring 
here. The terminal base pairs are not as constrained as internal bases, which are held in 
place by the stacking of the bases.24 The conformational flexibility possessed by the end 
base pairs contributes to non-hydrogen bonded base pairs in the Watson-Crick double 
helix.  Fraying of the end bases causes the helical parameter values to sample different 
values than the bases in the middle of the helix, and when the averages are taken over the 
12 base pairs, the large variation between the ends and the middle bases is reflected in the 
average.  In order to see which bases in the four simulations contributed most to fraying, 
the RMSD of the DNA with different bases was plotted.  The RMSD was plotted for all 
12 bases, 10 bases (one base on each end removed), 8 bases (two bases on each end 
removed), 6 bases (three bases on each end removed), and 4 bases (central four bases).   
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Figure 5.6 RMSD plots for 12, 10, 8, 6, and 4 DNA bases. 
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From the RMSD plots, it can be seen that there are a lot of fluctuations and bumps (the 
system is most likely moving between various substates) in the RMSD, in particular for 
Simulations 1 and 2.  Upon removal of one, two, and three base pairs, the RMSD over 
time is still bumpy. When four base pairs are removed from each end of the helix, most 
of the fluctuation is eliminated, which means that fraying effects penetrate four base pairs 
in from the ends of the helix (at least for this DNA fragment).   From the RMSD plots, 
only the middle bases are left for analysis.  Because most simulation studies on DNA use 
only small fragments (10-20 base pairs), many authors eliminate one base from each end 
for analysis or add an extra base pair “cap” to each end, which is then left out of the 
analysis.  However, the RMSD plots obtained from the four 150 ns simulations described 
here show that fraying affects not only the end bases, but four bases in from the ends.  
This RMSD analysis was helpful in deciding which bases should be included in the 
convergence analysis.   When the helical parameters were averaged over the 12 base 
pairs, the effects of fraying obviously affect the convergence analysis.  The abnormal 
helical parameter values obtained from the end bases are reflected in the averages and 
thus skew the convergence test.  Even though the whole fragment shows large changes in 
RMSD, the middle 4 pairs do not, and this shows that not only are the middle four bases 
not affected as much by fraying, but because they are not affected as much by the fraying, 
their dynamics appear to converge more quickly.   
 To see if the helical parameters of the middle really did exhibit better 
convergence than the whole fragment, the PSRT was performed on only the middle four 
base pairs of the DNA fragment (5’-GATC-3’).  The helical parameter values were 
averaged over the middle four bases.  Table 5.5 gives the Rˆ  values.  
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Table 5.5 PSRT results (long-time DNA simulations; 4 bases) 
 
parameter Rˆ  
shear 1.1 
stretch 1.0 
stagger 1.0 
buckle 1.1 
propeller 1.0 
opening 1.0 
shift 1.2 
slide 1.1 
rise 1.1 
tilt 1.1 
roll 1.0 
twist 1.0 
x-displacement 1.2 
y-displacement 1.3 
helical rise 1.5 
inclination 1.0 
tip 1.0 
helical twist 1.0 
 
When only the middle four bases are used, only two helical parameters do not converge 
according the PSRT, which are y-displacement and helical rise.  The fraying of the end 
bases do influence the convergence of the simulations, and even in 150 ns, the dynamics 
of the end bases do allow the helical parameters to converge.  A total of 16 out of 18 the 
helical parameters for the middle four bases converge; the dynamics of the middle four 
bases obviously converge more quickly than those of the ends.  Thus, the middle bases 
appear to be the better choice for analysis rather than the whole DNA fragment because 
they are not influenced by the fraying of the ends.   The time series plots below are for 
the middle four base pairs for twist (which converged) and y-displacement (did not 
converge).  
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Figure 5.7 Time series plots for twist and y-displacement for the middle four bases of the 
DNA fragment. 
 
 
Unlike the time series plots shown in Figure 5.5 for propeller and stretch for all 12 bases, 
twist does not show the large variation in values for the four simulations (other helical 
parameter plots were similar).  All simulations appear to sample in the same small range 
of ~34º to 42º and thus exhibit convergence.  However, even for twist, which did 
converge, the blue simulation shows an increase up until 35 ns into the simulation.  This 
simulation showed similar behavior for other parameters, so even up to 35 ns, the system 
structural properties have not relaxed.  Simulations 1,3,and 4 have about the same values 
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for y-displacement; however, Simulation 2 has more variation in values, and this is most 
likely why y-displacement does not converge even for the middle four bases.   
5.3.2. Short-Time Simulations. From the long-time DNA simulations, the middle 
four base pairs of this DNA fragment obviously converged more quickly and are the 
better choice for helical parameter analysis.  However, due to the amount of 
computational time needed to run 150 ns of DNA dynamics, many short simulations were 
run to see if they yielded similar results with the PSRT.  A total of 20 short (2 ns each) 
simulations were run with same DNA fragment, and the PSRT was applied to all 12 bases 
and the four middle bases.  Table 5.6 gives the results of the PSRT for the short 
simulations using all 12 bases.   
Table 5.6 PSRT results (short-time DNA simulations; 12 bases) 
 
parameter Rˆ  
shear 3.3 
stretch 3.1 
stagger 1.8 
buckle 1.7 
propellor 1.7 
opening 1.6 
shift 2.9 
slide 1.9 
rise 2.0 
tilt 1.4 
roll 2.1 
twist 1.5 
x-displacement 1.5 
y-displacement 1.4 
helical rise 2.3 
inclination 2.0 
tip 1.6 
helical twist 1.4 
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The convergence results for the short simulations show that none of the helical 
parameters converge when an average over all 12 base pairs is used.  The time series 
plots below are for opening and shift for the 12 base pairs (other time series plots looked 
similar).  
 
 
Figure 5.8 Time series plots for opening and shift for all 12 base pairs of the the 20 short 
DNA simulations. 
 
 
As for the long simulations, the helical parameter values exhibit large variation (opening) 
and some simulations simply sample a different range of values than others (shift).  
Again, this is due to fraying, and since the majority of the helical parameters did not 
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converge for the 150 ns simulations for all 12 base pairs, it is not surprising that none of 
the helical parameters converge in two 2 ns when all bases are considered.  Even though 
more simulations were run for 2 ns than 150 ns, each of the 20 simulations will diverge, 
and the dynamics of the end bases in each of those will need time plenty of time to relax 
(from the long simulations, they obviously need > 150 ns).  From the plot of shift versus 
time in Figure 5.8, the system needs ~500 ps for the trajectories to exhibit divergence (for 
shift, the trajectories coincide up to 500 ps, and then start to diverge); therefore, in 2 ns, 
the systems will not have enough time for the helical parameters to converge for all 
bases.  
 As for the long simulations, the convergence of the helical parameters for the 
middle four bases was examined using the PSRT.  Table 5.7 shows the results of the 
PSRT for the middle four bases of the short DNA simulations.  
Table 5.7 PSRT results (short-time DNA simulations; 4 bases) 
 
 
 
 
 
 
 
 
 
parameter Rˆ  
shear 1.2 
stretch 1.2 
stagger 1.1 
buckle 1.2 
propellor 1.3 
opening 1.4 
shift 1.2 
slide 1.7 
rise 1.2 
tilt 1.2 
roll 1.5 
twist 1.6 
x-displacement 1.3 
y-displacement 1.4 
helical rise 1.2 
inclination 1.7 
tip 1.3 
helical twist 1.4 
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When only the middle four bases are used, more of the helical parameters converge than 
when all 12 bases are used, so there is some improvement. The plots below are for shift 
and opening (compare to Figure 5.8 for all 12 bases).  Shift converged when only 4 bases 
are used; opening did not.  
 
 
Figure 5.9 Time series plots for shift and opening for the middle four base pairs of the 
the 20 short DNA simulations. 
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Shift improved when the middle four bases were used; most of the simulations sample the 
same range of values for the middle four bases, while some trajectories clearly diverged 
when all 12 bases were used.  For opening, some trajectories (most notably, the pink and 
blue simulations in Figure 5.9) sample a higher range of values than others even for the 
middle four bases and thus do not converge. 
Even though half of the helical parameters converged when the middle four bases 
were used, nine parameters still did not converge.  The long-time simulations exhibited 
convergence for all parameters with the exception of two for the middle four bases.  The 
short-time simulations obviously do not show similar convergence behavior to the long-
time simulations.   A simulation of 2 ns is not enough for most of the helical parameters 
even for the middle four bases to converge.  As with the 12 bases for 2 ns, some of the 
simulations diverge from the others, and it takes ~500 ps or longer for this to occur (for 
example, in Figure 5.9, it took 800 ps for opening to diverge).  It takes > 500 ps for 
divergence to be observed, and in 2 ns, the simulations do not have enough time to both 
diverge and then start to sample the same values again, and therefore, converge.  The 
long simulations, in the case of the DNA, are the better choice.  However, since half of 
the helical parameters did converge for the short simulations, the simulations probably do 
not need to be run for 150 ns nor do 20 of them need to be run.  A smaller number of 
simulations and a short time period (for example, 10 simulations run for 10 ns each) may 
yield similar convergence results to the long-time simulations for the middle four bases.    
Table 5.8 shows the averages and standard deviations for the parameters for both 
the long and short sets of DNA simulations.   
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Table 5.8 Parameter averages for long and short DNA simulations (12 and 4 bases) 
 
 
As for the protein simulations, most of the average values calculated from the short and 
long DNA simulations (12 and 4 bases) agree with one another or they are at least within 
the standard deviations of each other. Both sets of simulations appear to reach a similar 
range of values, whether this happens in a long time or a short time.  The long and short 
simulations appear to sample and thus converge to similar values, even though the 
individual simulations within the sets do not converge according to the potential scale 
reduction test.  The long and short simulations sample the same range of values for both 
12 and 4 base pairs; however, they show different convergence behavior with the 
potential scale reduction test, especially when the middle four bases are used.   
parameter 
long simulations 
(12bp) 
short simulations 
(12bp) 
long simulations 
(4bp) 
short simulations 
(4bp) 
shear -0.04 ± 0.36 0.05 ± 1.35 -0.012 ± 0.73 0.05 ± 0.88 
stretch 0.03 ± 0.45 -0.10 ± 0.88 -0.11 ± 0.16 -0.11 ± 0.43 
stagger 0.04 ± 1.13 0.06 ± 1.04 0.03 ± 0.40 0.05 ± 0.93 
buckle 2.33 ± 8.83 -0.04 ± 23.5 5.49 ± 15.1 4.40 ± 25.4 
propellor -8.75 ± 11.32 -8.75 ± 16.6 -20.5 ± 13.7 -18.7 ± 18.8 
opening 2.48 ± 6.27 -0.31 ± 18.4 1.89 ± 5.90 2.43 ± 18.6 
shift -0.01 ± 0.38 0.28 ± 1.14 -0.03 ± 0.88 0.01 ± 1.07 
slide 0.04 ± 0.34 0.37 ± 1.10 -0.07 ± 0.48 -0.11 ± 1.27 
rise 3.31 ± 0.31 3.39 ± 0.60 3.51 ± 0.32 3.44 ± 0.51 
tilt -0.53 ± 5.38 -0.21 ± 8.85 0.37 ± 4.59 0.39 ± 8.80 
roll 0.04 ± 8.19 0.88 ± 10.6 0.28 ± 5.04 1.34 ± 10.1 
twist 33.6 ± 1.91 34.0 ± 8.79 38.5 ± 7.56 38.1 ± 6.91 
x-displacement -0.25 ± 1.39 0.28 ± 2.68 -0.26 ± 1.01 -0.59 ± 2.12 
y-displacement -0.16 ± 1.01 -0.52 ± 2.67 0.10 ± 1.28 0.07 ± 2.17 
helical rise 3.08 ± 0.45 3.18 ± 1.23 3.47 ± 0.30 3.38 ± 0.61 
inclination 0.46 ± 15.0 1.54 ± 20.2 0.75 ± 7.62 2.86 ± 19.0 
tip 0.46 ± 8.02 -0.15 ± 14.4 -0.67 ± 7.17 -0.69 ± 15.1 
helical twist 36.1 ± 4.33 36.4 ± 12.2 39.2 ± 7.51 38.8 ± 6.41 
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5.4 Conclusions 
 
 The potential scale reduction test (PSRT) was applied to multiple simulations of 
two biomolecular systems in order to assess convergence of several geometric properties.  
The systems examined were a small protein (crambin) and a 12-base pair fragment of 
DNA, both in the crystal environment.  For both systems, a set of a few long simulations 
and a set of many short simulations were run in order to assess which set would exhibit 
better convergence with respect to the properties measured.   
 For the crambin system, 16 geometric parameters were measured for both sets of 
simulations (see Table 5.1).  Ten long (45 ns each) and 20 short (2 ns each) simulations 
were run for crambin, and the PSRT was applied to the parameters measured for both sets 
of trajectories.  For the long simulations, only six parameters measured converged for the 
ten simulations, all of which were hydrogen bond distances.  The same was observed for 
the 20 short simulations; six parameters converged, and all were hydrogen bond 
distances.  The distances that converged in the long and short simulations were not all the 
same distances, but they were all hydrogen bond distances.  The other parameters 
measured (beta turn distances, radius of gyration, and helix-helix distance) are “looser” 
distances, and the hydrogen bond distances are “tighter”—the former are distances that 
can vary from simulation to simulation more easily than the hydrogen bond distances.  
The hydrogen bond distances measured were all in the α-helices of the protein, and the 
hydrogen bonds in the helices do not deviate greatly unless the α-helices break apart. The 
α-helices stayed intact during the simulations, so most of the hydrogen bonds stayed 
around the same values for most simulations.  A distance such as the helix-helix distance, 
however, can fluctuate more among simulations because the helices can drift apart during 
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the simulations (more or less in different simulations) without the protein unfolding, 
secondary structure elements breaking down, or any major conformational changes 
occurring.  Because the hydrogen bond distances are “tighter”, this is most likely why all 
the parameters that do converge are hydrogen bond distances; it is more likely that most 
simulations will sample the same values for hydrogen bonds rather than for a distance 
like the helix-helix distance.  Even for the hydrogen bond distances that do not converge, 
the distances measured for all simulations are a normal value for a hydrogen bond (~1.8-
3.0 Å).  Both the long and short simulations exhibit similar convergence behavior when 
examined with the PSRT.  Six parameters converge for both sets, all of which are 
hydrogen bond distances.  
 When the averages over all long simulations and all short simulations are 
examined (Table 5.3), most of the average values calculated from the short and long 
simulations agree with one another or they are at least within the standard deviations of 
each other. Both the long and short sets of simulations appear to reach the same range of 
values, even though the individual simulations within the sets do not converge according 
to the potential scale reduction test (even in 45 ns).  Because they reach the 
approximately the same average values and show similar convergence behavior, the short 
simulations are probably the better choice for convergence when time and effort are 
considered.  
For the DNA system, 18 helical parameters were examined.  Four long (150 ns 
each) and 20 short (2 ns each) simulations were run for the DNA, and the PSRT was 
applied to the parameters measured for both sets of trajectories. The PSRT was applied to 
the helical parameter averages for all 12 bases of the DNA fragment and also to the 
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averages over the middle four bases of the fragment.  When the PSRT was applied to the 
averages over all 12 bases of the long simulations, only three helical parameters 
converged.  The lack of convergence is due to fraying of the end base pairs.  Fraying 
causes the end bases to sample a different (and wider) range of values than the bases in 
the middle of the helix, and when the averages are taken over the 12 base pairs, the large 
variation between the ends and the middle bases is reflected in the average.  The lack of 
convergence observed for the helical parameters over 12 bases shows agreement with 
experimentally observed results for DNA relaxation.  Local structural relaxation of three 
different B-DNA 16-mers was measured, and complete relaxation and convergence was 
not observed even at 40 ns (the experiment did not go past 40 ns because reliability is lost 
beyond that).25  However, some relaxation times were only tens of picoseconds; the 
authors suggest that this broad timescale indicates a complex convergence over a large 
number of conformational substates.25  The simple convergence test used here shows that 
even at 150 ns, convergence of the helical parameters is not achieved for all 12 bases.   
When the RMSD was plotted for different parts of the DNA fragment 
(eliminating 1, 2, 3, and 4 base pairs from the ends), the fluctuations in the RMSD were 
removed only when four bases on each end were chopped off.  The effects of fraying 
penetrate four base pairs in from the ends, and this left only the middle four bases for 
analysis.  To see whether the helical parameter averages over the middle four bases 
exhibited better convergence than the helical parameter averages over all 12 bases, the 
PSRT was applied to the helical parameters obtained from the middle four bases.  When 
only the middle four bases are used, the convergence was improved (only two helical 
parameters do not converge according the PSRT).   The fraying of the end bases did 
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influence the convergence of the simulations, and even in 150 ns, the dynamics of the end 
bases do allow the helical parameters to converge.  For a total of 16 out of 18 the helical 
parameters for the middle four bases converge; the dynamics of the middle four bases 
obviously converge more quickly than those of the ends.  Thus, the middle bases are the 
better choice for analysis rather than the whole DNA fragment (at least for this particular 
piece of DNA).  The RMSD analysis (chopping off successive bases from each end) 
should be performed on simulated DNA fragments to decide which bases should be used 
in further analysis of the simulations.  The middle four bases are not affected as much by 
fraying, the values sampled for the helical parameters of these bases do not show as much 
variation, and thus, their dynamics converge more quickly for the simulations.   
The same analysis was carried out on the short-time DNA simulations.  When all 
12 bases were used for analysis with the PSRT, none of the helical parameters converged.   
This is again due to fraying, and for some parameters, the system needs ~500 ps for the 
trajectories to even diverge.  In the long simulations, the helical parameters did not even 
converge over 150 ns; therefore, 2 ns is obviously not enough time for the trajectories to 
diverge and then start to sample the same values in order to converge.   When only the 
middle four bases were used in the analysis of the short simulations, improvement was 
observed.  Nine of the helical parameters converged, but nine still did not converge.  The 
convergence behavior for the short simulations is obviously different than that of the long 
simulations, in which only two helical parameters did not converge.   
Simulations of 2 ns is not enough for most of the helical parameters even for the 
middle four bases to converge.  As with the 12 bases for 2 ns, some of the simulations 
diverge from the others, and it takes over 500 ps for divergence to be observed, and in 2 
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ns, the simulations do not have enough time to both diverge and then converge.  Because 
the long and short simulations do not exhibit similar convergence behavior, the long 
simulations are the better choice in the case of the DNA.   
Other computational studies have reported different results for convergence times 
for DNA helical parameters.  From the results of 10 ns DNA (10 base pairs) simulations, 
Feig and Pettitt report that structural parameters of the DNA appear to relax around 4 ns 
into the simulation (for the middle eight bases) and suggest that a timescale of several 
nanoseconds is probably necessary to obtain convergence of structural parameters, 
although they did not specify the actual amount of time necessary.16  From the results of a 
60 ns DNA simulation (12 base pairs), Ponomarev, et al. report that helical parameters 
relax at ~500 ps into the simulation; however, this was for only one base pair step in the 
middle of the helix and only one simulation was performed.26  From our multiple short 
simulations, 500 ps is not enough time for the helical parameters to relax for even the 
middle four base pairs.  In some of the simulations for some parameters, 500 ps appears 
to be long enough for relaxation, but this does not occur in all simulations.  Our results 
appear to be in better agreement with those of Feig and Pettitt; the structural parameters 
need a nanosecond timescale for relaxation (> 150 ns for all 12 bases and at least 35 ns 
for relaxation for the middle four bases).  Overall, for each system of interest, there is a 
balance between the number of simulations and the length of time that they need to be 
run.  Detailed studies for each unique system are required in order to determine what that 
balance is.   
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Appendix A  
 
This appendix contains tables of simulated helical parameter values and 
calculated t-values for the DNA/polyamide simulations.  Tables A.1-A.4 contain the 
helical parameter values and t-values for the DNA/Dervan polyamide simulations (low 
and high temperature), Tables A.5-A.7 contain the DNA/Dervan polyamide distances, 
Tables A.9 and A.10 contain the DNA/hydroxpyrrole helical parameters and distances, 
Tables A.11 and A.12 contain the DNA/netropsin helical parameters and distances, 
Tables A.13 and A.14 contain the DNA/distamycin helical parameters and distances, 
Tables A.15 and A.16 contain the helical parameters and distances from the AMBER 
simulation of the DNA/netropsin complex, and Table A.17 contains the helical parameter 
t-values for the low and high temperature simulations combined.  The polyamide 
topology and parameters are at the end of this appendix.   
Table A.1.  Computed and x-ray averages and standard deviations of helical parameters 
for initial four low temperature (113 K) simulations 
 
Simulation 1     
helical parameter (Å)  computed avg./sd x-ray value/sd t-test value significant? 
x-displacement  0.29 ± 1.69                0.21 ± 2.21               0.10 no 
y-displacment  0.017 ± 1.14               0.05 ± 0.96               0.10 no 
shear -0.038 ± 0.67               0.04 ± 0.40               0.58 no 
stretch -0.15 ± 0.11               -0.15 ± 0.18             0 no  
stagger -0.0095 ± 0.25              0.23 ± 0.13               5.47 yes 
shift  0.12 ± 0.87                0.01 ± 0.95               0.36 no 
slide  0.98 ± 0.66                0.82 ±  0.73              0.67 no 
rise  3.33 ± 0.22                3.31 ± 0.17               0.42 no 
helical rise  3.42 ± 0.34                3.29 ± 0.18               2.28 yes 
helical parameter (º)     
inclination 12.27 ± 9.71               9.19 ± 16.06             0.57 no 
tip -0.09 ± 7.12               -0.57 ± 6.57             0.21 no 
buckle 4.46 ± 6.38               -1.14 ± 5.39             3.11 no 
propellor -11.25 ± 7.51             -13.41 ± 9.86           0.66 no 
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Table A.1 (cont’d.)     
opening  0.13 ± 5.78               -0.86 ± 6.05             0.49 no 
tilt 0.10 ± 4.24                0.35 ± 4.17               0.18 no 
roll 6.89 ± 4.99                4.63 ± 8.70               0.78 no 
twist 34.4 ± 7.02              34.99 ± 6.41             0.26 no 
helical twist 35.72 ± 7.53              36.62 ± 4.96             0.54 no 
Simulation 2     
helical parameter (Å)  computed avg./sd x-ray value/sd t-test value significant? 
x-displacement 0.076 ± 2.04 0.21 ± 2.21               0.18 no 
y-displacment -0.053 ± 1.12              0.05 ± 0.96               0.32 no 
shear -0.029 ± 0.46              0.04 ± 0.40               0.51 no 
stretch -0.16 ± 0.12              -0.15 ± 0.18            0.13 no  
stagger -0.21 ± 0.29               0.23 ± 0.13               9.91 yes 
shift -0.51 ± 0.75               0.01 ± 0.95               0.19 no 
slide 1.02 ± 0.69               0.82 ±  0.73              0.81 no 
rise 3.29 ± 0.35               3.31 ± 0.17               0.37 no 
helical rise 3.32 ± 0.48               3.29 ± 0.18               0.48 no 
helical parameter (°)     
inclination 14.18 ± 12.87             9.19 ± 16.06             0.93 no 
tip 0.91 ± 9.74              -0.57 ± 6.57             0.67 no 
buckle 0.31 ± 9.23              -1.14 ± 5.39             0.80 no 
propellor -14.52 ± 4.96            -13.41 ± 9.86           0.34 no 
opening  -1.76 ± 4.54             -0.86 ± 6.05             0.45 no 
tilt -0.46 ± 5.24              0.35 ± 4.17               0.58 no 
roll 7.45 ± 6.29              4.63 ± 8.70               0.97 no 
twist 33.65 ± 8.41            34.99 ± 6.41             0.62 no 
helical twist 35.55 ± 7.09            36.62 ± 4.96             0.64 no 
Simulation 3     
helical parameter (Å)  computed avg./sd x-ray value/sd t-test value significant? 
x-displacement 0.36 ± 2.31              0.21 ± 2.21               0.21 no 
y-displacment 0.26 ± 1.13              0.05 ± 0.96               0.65 no 
shear -0.010 ± 0.45              0.04 ± 0.40               0.38 no 
stretch -0.16 ± 0.10             -0.15 ± 0.18             0.23 no  
stagger -0.02 ± 0.37              0.23 ± 0.13               5.55 yes 
shift -0.11 ± 0.92               0.01 ± 0.95               0.38 no 
slide 1.22 ± 0.95               0.82 ±  0.73              1.63 no 
rise 3.33 ± 0.36               3.31 ± 0.17               0.27 no 
helical rise 3.39 ± 0.65               3.29 ± 0.18               1.60 no 
helical parameter (°)     
inclination 13.17 ± 16.59             9.19 ± 16.06             0.74 no 
tip -0.17 ± 8.83              -0.57 ± 6.57             0.18 no 
buckle 0.62 ± 11.95            -1.14 ± 5.39            0.96 no 
propellor -12.86 ± 5.67            -13.41 ± 9.86           0.17 no 
opening  -1.27 ± 3.52             -0.86 ± 6.05             0.20 no 
tilt 0.25 ± 5.02              0.35 ± 4.17               0.07 no 
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Table A.1 (cont’d.)     
roll 6.98 ± 9.09              4.63 ± 8.70               0.81 no 
twist 33.95 ± 7.80             34.99 ± 6.41             0.49 no 
helical twist 36.23 ± 6.33             36.62 ± 4.96             0.24 no 
Simulation 4     
helical parameter (Å)  computed avg./sd x-ray value/sd t-test value significant? 
x-displacement 0.017 ± 1.96              0.21 ± 2.21               0.26 no 
y-displacment 0.066 ± 1.38              0.05 ± 0.96               0.05 no 
shear 0.081 ± 0.51              0.04 ± 0.40               0.32 no 
stretch -0.15 ± 0.13             -0.15 ± 0.18             0.09 no  
stagger -0.08 ± 0.27               0.23 ± 0.13               7.36 yes 
shift -0.042 ± 0.93              0.01 ± 0.95               0.16 no 
slide 0.708 ± 0.82              0.82 ±  0.73              0.46 no 
rise 3.35 ± 0.30               3.31 ± 0.17               0.68 no 
helical rise 3.35 ± 0.41               3.29 ± 0.18               0.92 no 
helical parameter (º)     
inclination 10.12 ± 9.38               9.19 ± 16.06             0.17 no 
tip 0.74 ± 8.30              -0.57 ± 6.57             0.59 no 
buckle 1.39 ± 7.90              -1.14 ± 5.39             1.47 no 
propellor -11.99 ± 8.18           -13.41 ± 9.86          0.45 no 
opening  -2.58 ± 4.86              -0.86 ± 6.05             0.90 no 
tilt -0.41 ± 4.52              0.35 ± 4.17               0.54 no 
roll 5.36 ± 4.83              4.63 ± 8.70               0.25 no 
twist 34.03 ± 7.33            34.99 ± 6.41             0.45 no 
helical twist 35.12 ± 6.67            36.62 ± 4.96             0.90 no 
 
*helical rise and helical twist are parameters which describe the regularity of the DNA helix, while rise and twist describe the 
geometry of a base pair step from a local perspective. For more details, see Lu, X.J. and Olson, W.K, Nuc. Acids Res. 2003, 31, 5108.  
 
Table A.2. Computed and x-ray averages and standard deviations of helical parameters for 
initial three high temperature (300 K) simulations 
 
Simulation 1 
    
helical parameter (Å) computed avg./sd  x-ray value/sd  t-test value significant? 
x-displacement 0.0081 ± 1.92             0.21 ± 2.21                 0.27 no 
y-displacment 0.0041 ± 1.46             0.05 ± 0.96                 0.14 no 
shear -0.033 ± 0.60             0.04 ± 0.40                  0.54 no 
stretch -0.081 ± 0.19            -0.15 ± 0.18                 1.15 no  
stagger -0.198 ± 0.56             0.23 ± 0.13                  9.15 yes 
shift -0.0072 ± 0.98            0.01 ± 0.95                  0.05 no 
slide 0.84 ± 0.79             0.82 ±  0.73                 0.08 no 
rise 3.28 ± 0.41             3.31 ± 0.17                  0.46 no 
helical rise 3.29 ± 0.46             3.29 ± 0.18                  0.02 yes 
Helical parameter (°)         
inclination 13.28 ± 13.4            9.19 ± 16.06                0.76 no 
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Table A.2 (cont’d).      
tip 0.08 ± 12.2           -0.57 ± 6.57                  0.22 no 
buckle 0.77 ± 17.8           -1.14 ± 5.39                  1.02 no 
propellor -12.17 ± 9.36         -13.41 ± 9.86                 0.37 no 
opening  -1.34 ± 8.39            -0.86 ± 6.05                  0.24 no 
tilt 0.29 ± 6.72             0.35 ± 4.17                  0.04 no 
roll 7.45 ± 7.68              4.63 ± 8.70                  0.97 no 
twist 33.8 ± 8.07            34.99 ± 6.41                 0.54 no 
helical twist 36.1± 7.28              36.62 ± 4.96                 0.32 no 
Simulation 2     
helical parameter (Å) computed avg./sd x-ray value/sd t-test value significant? 
x-displacement -0.571 ± 2.45              0.21 ± 2.21                 1.05 no 
y-displacment 0.034 ± 1.69             0.05 ± 0.96                 0.05 no 
shear -0.0029 ± 0.64             0.04 ± 0.40                  0.34 no 
stretch -0.099 ± 0.24             -0.15 ± 0.18                 0.89 no  
stagger -0.123 ± 0.49               0.23 ± 0.13                  8.04 yes 
shift -0.063 ± 1.18              0.01 ± 0.95                  0.23 no 
slide 0.69 ± 0.89              0.82 ±  0.73                 0.55 no 
rise 3.33 ± 0.37              3.31 ± 0.17                  0.26 no 
helical rise 3.27 ± 0.53               3.29 ± 0.18                  0.31 no 
Helical parameter (°)         
inclination 16.81 ± 15.9               9.19 ± 16.06                1.42 no 
tip 0.71 ± 13.1              -0.57 ± 6.57                  0.58 no 
buckle 1.37 ± 12.3              -1.14 ± 5.39                  1.44 no 
propellor -7.85 ± 10.5            -13.41 ± 9.86                 1.77 no 
opening  1.83 ± 9.76              -0.86 ± 6.05                  1.39 no 
tilt -0.29 ± 7.33               0.35 ± 4.17                  0.46 no 
roll 9.33 ± 8.46               4.63 ± 8.70                 1.61 no 
twist 31.9 ± 7.46             34.99 ± 6.41                 1.41 no 
helical twist 35.4 ± 6.28              36.62 ± 4.96                 0.75 no 
Simulation 3     
helical parameter (Å) computed avg./sd x-ray value/sd t-test value significant? 
x-displacement -0.507 ± 2.04              0.21 ± 2.21                 0.97 no 
y-displacment 0.158 ± 1.43              0.05 ± 0.96                 0.33 no 
shear 0.0064 ± 0.59              0.04 ± 0.40                  0.26 no 
stretch -0.107 ± 0.19             -0.15 ± 0.18                 0.76 no  
stagger -0.164 ± 0.46              0.23 ± 0.13                  9.04 yes 
shift -0.073 ± 1.14              0.01 ± 0.95                  0.26 no 
slide 0.68 ± 0.82               0.82 ±  0.73                 0.58 no 
rise 3.34 ± 0.35               3.31 ± 0.17                  0.27 no 
helical rise 3.34 ± 0.49               3.29 ± 0.18                  0.77 no 
Helical parameter (°)         
inclination 15.88 ± 13.3             9.19 ± 16.06                1.24 no 
tip -0.33 ± 11.9            -0.57 ± 6.57                  0.11 no 
buckle 2.79 ± 12.0            -1.14 ± 5.39                  2.25 no 
 337
Table A.2 (cont’d).      
propellor -9.87 ± 9.11          -13.41 ± 9.86                 1.13 no 
opening  0.148 ± 6.79            -0.86 ± 6.05                  0.52 no 
tilt 0.259 ± 7.14             0.35 ± 4.17                  0.06 no 
roll 9.16 ± 7.42             4.63 ± 8.70                  1.56 no 
twist 33.5 ± 6.59            34.99 ± 6.41                 0.67 no 
helical twist 36.2 ± 5.58             36.62 ± 4.96                 0.23 no 
 
Table A.3. Computed and x-ray averages and standard deviations of helical parameters for 
additional three high temperature (300 K) simulations 
 
Simulation 1 
    
helical parameter (Å) computed avg./sd  x-ray value/sd  t-test value significant? 
x-displacement -0.78 ± 2.54             0.21 ± 2.21                 1.22 no 
y-displacment  0.14 ± 1.66             0.05 ± 0.96                 0.17 no 
shear  0.02 ± 0.70             0.04 ± 0.40                  0.08 no 
stretch -0.08 ± 0.25            -0.15 ± 0.18                 0.91 no  
stagger -0.05 ± 0.52             0.23 ± 0.13                  1.71 no 
shift -0.05 ± 1.19            0.01 ± 0.95                  0.14 no 
slide  0.63 ± 0.84             0.82 ±  0.73                 0.70 no 
rise  3.33 ± 0.39             3.31 ± 0.17                  0.15 no 
helical rise  3.24 ± 0.53             3.29 ± 0.18                  0.27 no 
Helical parameter (°)         
inclination  17.3 ± 17.2            9.19 ± 16.06                1.49 no 
tip -0.64 ± 12.3           -0.57 ± 6.57                  0.02 no 
buckle  3.61 ± 15.8           -1.14 ± 5.39                  0.95 no 
propellor -8.43 ± 10.2         -13.41 ± 9.86                 1.54 no 
opening   2.64 ± 9.85            -0.86 ± 6.05                  1.12 no 
tilt 0.03 ± 6.97             0.35 ± 4.17                  0.15 no 
roll 9.21 ± 8.91              4.63 ± 8.70                  1.62 no 
twist 32.3 ± 8.59            34.99 ± 6.41                 1.00 no 
helical twist 35.5 ± 7.08              36.62 ± 4.96                 0.51 no 
Simulation 2     
helical parameter (Å) computed avg./sd  x-ray value/sd  t-test value significant? 
x-displacement -0.23 ± 2.29             0.21 ± 2.21                 0.61 no 
y-displacment -0.11 ± 1.57             0.05 ± 0.96                 0.33 no 
shear -0.003 ± 0.64             0.04 ± 0.40                  0.21 no 
stretch -0.11 ± 0.15            -0.15 ± 0.18                 0.80 no  
stagger -0.006 ± 0.54             0.23 ± 0.13                  1.37 no 
shift  0.08 ± 1.13            0.01 ± 0.95                  0.21 no 
slide  0.69 ± 0.72             0.82 ±  0.73                 0.58 no 
rise  3.32 ± 0.32             3.31 ± 0.17                  0.12 no 
helical rise  3.31 ± 0.44             3.29 ± 0.18                  0.12 no 
Helical parameter (°)         
inclination  11.7 ± 14.4            9.19 ± 16.06                0.54 no 
tip  0.006 ± 12.4           -0.57 ± 6.57                  0.15 no 
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Table A.3 (cont’d.)     
buckle  1.34 ± 14.2           -1.14 ± 5.39                  0.55 no 
propellor -10.4 ± 9.22        -13.41 ± 9.86                 1.02 no 
opening   0.03 ± 6.17            -0.86 ± 6.05                  0.45 no 
tilt  0.17 ± 7.02             0.35 ± 4.17                  0.08 no 
roll  5.98 ± 7.07             4.63 ± 8.70                  0.60 no 
twist  33.4 ± 8.60            34.99 ± 6.41                 0.60 no 
helical twist  35.4 ± 7.39              36.62 ± 4.96                 0.52 no 
Simulation 3     
helical parameter (Å) computed avg./sd  x-ray value/sd  t-test value significant? 
x-displacement -0.009 ± 2.52             0.21 ± 2.21                 0.28 no 
y-displacment -0.07 ± 2.08             0.05 ± 0.96                 0.18 no 
shear -0.007 ± 0.66            0.04 ± 0.40                  0.23 no 
stretch -0.04 ± 0.52            -0.15 ± 0.18                 0.70 no  
stagger -0.01 ± 0.53            0.23 ± 0.13                  1.46 no 
shift -0.009 ± 1.39            0.01 ± 0.95                  0.04 no 
slide  1.11 ± 1.01             0.82 ±  0.73                 0.91 no 
rise  3.36 ± 0.38            3.31 ± 0.17                  0.45 no 
helical rise  3.44 ± 0.59           3.29 ± 0.18                  0.82 no 
Helical parameter (°)         
inclination  17.6 ± 17.9            9.19 ± 16.06                1.48 no 
tip  1.25 ± 14.1          -0.57 ± 6.57                  0.41 no 
buckle -0.62 ± 12.8           -1.14 ± 5.39                  0.13 no 
propellor -6.42 ± 12.0        -13.41 ± 9.86                 1.83 no 
opening   4.09 ± 14.1            -0.86 ± 6.05                  1.10 no 
tilt -0.27 ± 7.64             0.35 ± 4.17                  0.26 no 
roll  9.46 ± 9.52             4.63 ± 8.70                  1.59 no 
twist  31.5 ± 8.14            34.99 ± 6.41                 1.36 no 
helical twist  35.1 ± 6.43              36.62 ± 4.96                 0.73 no 
 
Table A.4. Computed and x-ray averages and standard deviations of helical parameters for 
additional four low temperature (113 K) simulations 
 
Simulation 1 
    
helical parameter (Å) computed avg./sd  x-ray value/sd  t-test value significant? 
x-displacement  0.09 ± 1.68             0.21 ± 2.21                 0.21 no 
y-displacment  0.03 ± 1.18             0.05 ± 0.96                 0.05 no 
shear -0.02 ± 0.56             0.04 ± 0.40                  0.35 no 
stretch -0.18 ± 0.11            -0.15 ± 0.18                 0.84 no  
stagger -0.02 ± 0.26             0.23 ± 0.13                  3.07 yes 
shift 0.005 ± 0.90            0.01 ± 0.95                  0.02 no 
slide  0.87 ± 0.63             0.82 ±  0.73                 0.23 no 
rise  3.36 ± 0.23             3.31 ± 0.17                  0.63 no 
helical rise  3.42 ± 0.33            3.29 ± 0.18                  1.27 no 
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Table A.4 (cont’d.) 
Helical parameter (°)         
inclination  12.4 ± 9.9            9.19 ± 16.06                1.00 no 
tip -0.33 ± 6.72           -0.57 ± 6.57                  0.11 no 
buckle  3.21 ± 6.37           -1.14 ± 5.39                  2.15 yes 
propellor -10.9 ± 9.01         -13.41 ± 9.86                 0.88 no 
opening  -0.95 ± 4.11            -0.86 ± 6.05                  0.07 no 
tilt 0.24 ± 3.99             0.35 ± 4.17                  0.09 no 
roll 7.08 ± 5.41              4.63 ± 8.70                  1.42 no 
twist 34.6 ± 6.74            34.99 ± 6.41                 0.18 no 
helical twist 35.9 ± 6.16              36.62 ± 4.96                 0.34 no 
Simulation 2     
helical parameter (Å) computed avg./sd  x-ray value/sd  t-test value significant? 
x-displacement  0.23 ± 1.88             0.21 ± 2.21                 0.04 no 
y-displacment -0.04 ± 1.12             0.05 ± 0.96                 0.26 no 
shear -0.07 ± 0.71             0.04 ± 0.40                  0.50 no 
stretch -0.15 ± 0.45            -0.15 ± 0.18                 0.01 no  
stagger -0.002 ± 0.44             0.23 ± 0.13                  1.68 no 
shift 0.06 ± 0.90            0.01 ± 0.95                  0.18 no 
slide  0.94 ± 0.72             0.82 ±  0.73                 0.51 no 
rise  3.33 ± 0.26             3.31 ± 0.17                  0.24 no 
helical rise  3.39 ± 0.34            3.29 ± 0.18                  0.96 no 
Helical parameter (°)         
inclination  11.9 ± 10.3            9.19 ± 16.06                0.83 no 
tip -0.52 ± 7.94           -0.57 ± 6.57                  0.02 no 
buckle  6.53 ± 6.84           -1.14 ± 5.39                  3.54 yes 
propellor -11.1 ± 7.98         -13.41 ± 9.86                 0.93 no 
opening  -1.31 ± 9.72            -0.86 ± 6.05                  0.15 no 
tilt 0.47 ± 4.49             0.35 ± 4.17                  0.08 no 
roll 6.56 ± 6.82              4.63 ± 8.70                  0.89 no 
twist 34.4 ± 9.92            34.99 ± 6.41                 0.17 no 
helical twist 35.7 ± 9.58              36.62 ± 4.96                 0.30 no 
Simulation 3     
helical parameter (Å) computed avg./sd  x-ray value/sd  t-test value significant? 
x-displacement  0.33 ± 1.95             0.21 ± 2.21                 0.19 no 
y-displacment  0.13 ± 1.09             0.05 ± 0.96                 0.23 no 
shear  0.05 ± 0.78             0.04 ± 0.40                  0.06 no 
stretch -0.14 ± 0.09            -0.15 ± 0.18                 0.18 no  
stagger -0.03 ± 0.25             0.23 ± 0.13                  3.35 yes 
shift -0.10 ± 0.88            0.01 ± 0.95                  0.39 no 
slide  1.03 ± 0.71             0.82 ±  0.73                 0.93 no 
rise  3.36 ± 0.23             3.31 ± 0.17                  0.66 no 
helical rise  3.44 ± 0.34            3.29 ± 0.18                  1.36 no 
Helical parameter (°)         
inclination  12.4 ± 11.3            9.19 ± 16.06                0.88 no 
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Table A.4 (cont’d.)     
tip  0.46 ± 7.69           -0.57 ± 6.57                  0.42 no 
buckle  6.67 ± 6.97           -1.14 ± 5.39                  3.53 yes 
propellor -11.4 ± 9.16         -13.41 ± 9.86                 0.70 no 
opening  -0.004 ± 7.21            -0.86 ± 6.05                  0.37 no 
tilt -0.16 ± 4.86             0.35 ± 4.17                  0.33 no 
roll 6.96 ± 5.65              4.63 ± 8.70                  1.29 no 
twist 34.8 ± 7.35            34.99 ± 6.41                 0.08 no 
helical twist 36.3 ± 6.55              36.62 ± 4.96                 0.16 no 
Simulation 4     
helical parameter (Å) computed avg./sd  x-ray value/sd  t-test value significant? 
x-displacement  0.21 ± 1.73             0.21 ± 2.21                 0.002 no 
y-displacment -0.03 ± 1.06             0.05 ± 0.96                 0.25 no 
shear -0.08 ± 0.56             0.04 ± 0.40                  0.69 no 
stretch -0.17 ± 0.11            -0.15 ± 0.18                 0.46 no  
stagger -0.03 ± 0.26             0.23 ± 0.13                  3.06 yes 
shift  0.03 ± 0.82            0.01 ± 0.95                  0.09 no 
slide  0.89 ± 0.71             0.82 ±  0.73                 0.35 no 
rise  3.36 ± 0.22             3.31 ± 0.17                  0.76 no 
helical rise  3.43 ± 0.35            3.29 ± 0.18                  1.27 no 
Helical parameter (°)         
inclination  11.7 ± 9.7            9.19 ± 16.06                0.80 no 
tip  0.005 ± 6.91           -0.57 ± 6.57                  0.26 no 
buckle  4.64 ± 6.85           -1.14 ± 5.39                  2.66 yes 
propellor -11.1 ± 7.54         -13.41 ± 9.86                 0.98 no 
opening  -1.23 ± 4.35            -0.86 ± 6.05                  0.27 no 
tilt  0.03 ± 3.90             0.35 ± 4.17                  0.25 no 
roll  6.55 ± 5.08             4.63 ± 8.70                  1.18 no 
twist  34.3 ± 6.82            34.99 ± 6.41                 0.29 no 
helical twist  35.6 ± 6.22              36.62 ± 4.96                 0.53 no 
 
Table A.5.  Polyamide distances (distances in Å; standard deviation for the x-ray structure 
is the resolution, 2.15 Å) for three initial high temperature simulations (300K) 
Simulation 1       
distance computed average x-ray t-value significant?   
x1 3.58 ± 0.24                  3.08 0.74 no   
x2 3.55 ± 0.27                  3.13 0.62 no   
x3 3.58 ± 0.34                  2.93 0.96 no   
x4 3.95 ± 0.36                  2.95 4.64 yes   
x5 2.94 ± 0.22                  3.13 0.28 no   
x1a 2.96 ± 0.19                  3.3 0.50 no   
x2a 3.83 ± 0.36                  3.39 0.65 no   
x3a 3.44 ± 0.30 3.12 0.47 no   
x4a 3.46 ± 0.24 2.77 1.01 no   
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Table A.5 
(cont’d.)        
x5a 3.59 ± 0.24                  3.16 0.63 no   
Simulation 2       
distance computed average x-ray t-value significant?   
x1 3.30 ± 0.20                  3.08 0.32 no   
x2 3.27 ± 0.21                  3.13 0.20 no   
x3 3.13 ± 0.21                  2.93 0.29 no   
x4 3.12 ± 0.22                  2.95 0.25 no   
x5 2.81 ± 0.12                  3.13 0.47 no   
x1a 2.93 ± 0.20                  3.3 0.54 no   
x2a 3.14 ± 0.24                  3.39 0.36 no   
x3a 3.12 ± 0.22 3.12 0 no   
x4a 3.30 ± 0.22 2.77 0.77 no   
x5a 3.29 ± 0.20                  3.16 0.19 no   
Simulation 3     
distance computed average x-ray t-value significant? 
x1 3.22 ± 0.18               3.08 0.20 no 
x2 3.29 ± 0.21               3.13 0.23 no 
x3 3.12 ± 0.21               2.93 0.28 no 
x4 3.12 ± 0.22               2.95 0.25 no 
x5 2.82 ± 0.12               3.13 0.45 no 
x1a 2.91 ± 0.23               3.3 0.57 no 
x2a 3.22 ± 0.27               3.39 0.25 no 
x3a 3.17 ± 0.22 3.12 0.07 no 
x4a 3.32 ± 0.22               2.77 0.80 no 
x5a 3.30 ± 0.20               3.16 0.20 no 
 
Table A.6. Polyamide distances (distances in Å; standard deviation for x-ray structure is 
2.15 Å) for low temperature simulations (113K) 
Simulation 1        
distance computed average x-ray t-value significant?    
x1 3.15 ± 0.091              3.08 0.10 no    
x2 3.20 ± 0.115              3.13 0.10 no    
x3 3.34 ± 0.15                2.93 0.60 no    
x4 2.99 ± 0.11                2.95 0.47 no    
x5 3.27 ± 0.19               3.13 0.21 no    
x1a 3.19 ± 0.11         3.3 0.66 no    
x2a 3.12 ± 0.13                 3.39 0.40 no    
x3a 3.13 ± 0.12 3.12 0.01 no    
x4a 2.85 ± 0.085 2.77 0.62 no    
x5a 3.34 ± 0.12                 3.16 0.26 no    
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Table A.6 
(cont’d.)        
Simulation 2        
distance computed average x-ray t-value significant?    
x1 3.47 ± 0.12                  3.08 0.57 no    
x2 3.21 ± 0.10                  3.13 0.12 no    
x3 3.07 ± 0.11                  2.93 0.21 no    
x4 2.74 ± 0.06                 2.95 0.21 no    
x5 3.09 ± 0.12             3.13 0.57 no    
x1a 4.99 ± 0.19                  3.3 2.49 yes    
x2a 4.09 ± 0.18                  3.39 1.03 no    
x3a 3.22 ± 0.14                  3.12 0.15 no    
x4a 3.19 ± 0.11 2.77 0.62 no    
x5a 3.19 ± 0.10                  3.16 0.04 no    
Simulation 3 computed average x-ray t-value significant? 
x1 3.20 ± 0.10                  3.08 0.17 no 
x2 3.14 ± 0.10                  3.13 0.01 no 
x3 3.33 ± 0.14                  2.93 0.58 no 
x4 2.78 ± 0.07                2.95 0.13 no 
x5 3.04 ± 0.11                 3.13 0.51 no 
x1a 3.19 ± 0.11                3.3 0.54 no 
x2a 3.63 ± 0.21                  3.39 0.35 no 
x3a 3.13 ± 0.13 3.12 0.01 no 
x4a 2.93 ± 0.11 2.77 0.61 no 
x5a 3.27 ± 0.12                  3.16 0.16 no 
Simulation 4 computed average x-ray t-value significant? 
x1 3.23 ± 0.12                  3.08 0.22 no 
x2 3.19 ± 0.11                  3.13 0.09 no 
x3 3.24 ± 0.16                  2.93 0.46 no 
x4 2.90 ± 0.09                 2.95 0.59 no 
x5 3.35 ± 0.19           3.13 0.34 no 
x1a 3.16 ± 0.10                  3.3 0.47 no 
x2a 3.49 ± 0.15                  3.39 0.15 no 
x3a 3.01 ± 0.10 3.12 0.16 no 
x4a 2.98 ± 0.13 2.77 0.57 no 
x5a 3.40 ± 0.12                  3.16 0.35 no 
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Table A.7. T-test results for combined polyamide distances  
Low temperature (113 K) simulations 
distance # significant tests      % avg. t-value significant? 
x1              16 1.6 0.99         no 
x2 7 0.7 0.72         no 
x3 425 42.5 1.92         no  
x4 5 0.5 0.42         no 
x5 3 0.3 0.37         no 
x1a 2 0.2 0.19         no 
x2a 0 0 0.11         no 
x3a 0 0 0.28         no 
x4a 102 10.2 1.47         no 
x5a 35 3.5 1.12         no 
 
Table A.8. T-test results for combined polyamide distances  
Low temperature (300 K) simulations 
distance # significant tests     % avg. t-value significant? 
x1              49 4.9 1.10         no 
x2              26 2.6 0.87         no 
x3              22 2.2 0.94         no  
x4              59 5.9 0.81         no 
x5 0 0 0.38         no 
x1a              81 8.1 0.92         no 
x2a                5      0.5 0.33         no 
x3a 1      0.1 0.34         no 
x4a            318     31.8 1.82         no 
x5a 22 2.2 0.78         no 
Table A.9. Computed and x-ray averages and standard deviations of helical parameters for 
hydroxypyrrole polyamide simulation 
helical parameter (Å) computed avg./sd  x-ray value/sd  t-test value significant? 
x-displacement  0.59 ± 1.76              0.37 ± 1.32                 0.41 no 
y-displacment -0.31 ± 3.00             -0.23 ± 1.25                 0.08 no 
shear  0.15 ± 1.72             -0.12 ± 0.56                 0.49 no 
stretch -0.09 ± 0.31            -0.21 ± 0.12                 1.22 no  
stagger  0.01 ± 0.56               0.15 ± 0.30                 0.79 no 
shift  0.04 ± 1.51              0.01 ± 0.84                 0.07 no 
slide  0.76 ± 1.13              0.76 ±  0.72                0.006 no 
rise  3.15 ± 0.43               3.29 ± 0.26                 1.01 no 
helical rise  3.20 ± 0.81             3.33 ± 0.33                  0.50 no 
Helical parameter (°)         
inclination  7.44 ± 14.1              7.36 ± 9.54                0.02 no 
tip  1.66 ± 11.1            0.49 ± 8.79                  0.33 no 
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Table A.9 (cont’d.)      
buckle  2.72 ± 10.9            -0.55 ± 7.17                 0.94 no 
propellor -9.12 ± 12.6         -15.13 ± 5.79                 1.51 no 
opening  -3.39 ± 6.04             -0.53 ± 5.60                  1.49 no 
tilt -0.36 ± 5.70              0.11 ± 4.94                 0.26 no 
roll  3.88 ± 7.14               4.24 ± 4.75                 0.16 no 
twist  32.6 ± 9.00             35.04 ± 9.32                0.84 no 
helical twist  34.1 ± 8.32              35.95 ± 8.88                0.69 no 
 
Table A.10. Polyamide distances (distances in Å; standard deviation for x-ray structure is 
2.27 Å) for hydroxypyrrole polyamide simulation 
Simulation 1        
distance computed average x-ray t-value significant?    
x1 3.43 ± 0.13              3.34 0.12 no    
x2 3.31 ± 0.12              2.92 0.55 no    
x3 3.13 ± 0.14                2.73 0.55 no    
x4 4.17 ± 0.15                3.23 1.31 no    
x5 4.93 ± 0.17               3.16 2.47 yes    
x6 3.28 ± 0.15               2.51 1.07 no    
x7 3.14 ± 0.07               2.99 0.21 no    
x1a 5.53 ± 0.28         2.60 4.17 yes    
x2a 4.36 ± 0.14                 3.30 1.73 no    
x3a 3.13 ± 0.12 2.67 0.64 no    
x4a 3.06 ± 0.7 2.91 0.29 no    
x5a 3.58 ± 0.14                 3.25 0.47 no    
x6a 2.98 ± 0.09              2.75 0.31 no    
x7a 3.28 ± 0.08                 3.00 0.94 no    
 
Table A.11. Computed and x-ray averages and standard deviations of helical parameters 
for DNA/netropsin simulation 
helical parameter (Å) computed avg./sd  x-ray value/sd  t-test value significant? 
x-displacement -0.55 ± 1.84              0.24 ± 1.31                 1.49 no 
y-displacment -0.05 ± 0.20              0.04 ± 1.12                 1.41 no 
shear  0.004 ± 0.56              0.09 ± 0.55                 0.53 no 
stretch -0.13 ± 0.17            -0.22 ± 0.24                 1.86 no  
stagger -0.09 ± 0.47              0.13 ± 0.49                 1.65 no 
shift  0.06 ± 0.76            -0.14 ± 0.64                 0.91 no 
slide  0.05 ± 0.62             0.27 ±  0.61                1.24 no 
rise  3.29 ± 0.33              3.31 ± 0.38                 0.18 no 
helical rise  3.18 ± 0.40             3.27 ± 0.40                  0.80 no 
Helical parameter (°)         
inclination  6.08 ± 13.1               0.82 ± 8.32                1.39 no 
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Table A.11 (cont’d.)     
tip -0.43 ± 9.34             0.87 ± 8.87                 0.48 no 
buckle -1.62 ± 12.1            -3.23 ± 10.6                 0.46 no 
propellor -10.7 ± 10.7         -11.81 ± 10.5                 0.35 no 
opening   1.30 ± 6.18              -0.09 ± 7.21                0.77 no 
tilt  0.18 ± 5.48              -0.41 ± 5.24                 0.37 no 
roll  3.36 ± 7.46               0.07 ± 5.14                 1.52 no 
twist  34.8 ± 6.12              35.7 ± 5.44                 0.54 no 
helical twist  36.1 ± 5.52                36.4 ± 5.28                0.16 no 
 
Table A.12. Polyamide distances (distances in Å; standard deviation for x-ray structure is 
2.20 Å (resolution)) for DNA/netropsin simulation 
Simulation 1        
distance computed average x-ray t-value significant?    
1 3.59 ± 0.66              2.52 1.54 no    
2 6.55 ± 0.60              3.24 4.76 yes    
3 3.11 ± 0.20                3.40 0.42 no    
4 3.25 ± 0.18                3.50 0.36 no    
5 3.69 ± 0.35               2.70 1.42 no    
6 3.38 ± 0.26               3.70 0.46 no    
7 3.33 ± 0.29               2.70 0.91 no    
8 3.35 ± 0.18         2.90 0.65 no    
9 3.66 ± 0.31                 3.30 0.52 no    
10 5.43 ± 0.63 3.20 3.20 yes    
11 5.87 ± 0.74 3.50 3.40 yes    
 
        
Table A.13. Computed and x-ray averages and standard deviations of helical parameters 
for DNA/distamycin simulation 
helical parameter (Å) computed avg./sd  x-ray value/sd  t-test value significant? 
x-displacement  0.06 ± 2.08              0.25 ± 1.41                 0.44 no 
y-displacment -0.28 ± 1.42              0.16 ± 0.79                 1.81 no 
shear  0.04 ± 0.85             -0.07 ± 0.28                 1.26 no 
stretch -0.15 ± 0.38            -0.11 ± 0.08                 1.38 no  
stagger  0.36 ± 1.73              0.14 ± 0.36                 1.83 no 
shift  0.20 ± 1.01            -0.08 ± 0.47                 1.92 no 
slide  0.35 ± 1.05             0.14 ±  0.79                0.88 no 
rise  3.36 ± 0.51              3.37 ± 0.38                 0.07 no 
helical rise  3.46 ± 1.05             3.33 ± 0.47                  0.89 no 
Helical parameter (°)         
inclination  3.01 ± 14.8              -0.49 ± 9.87                1.17 no 
tip  1.29 ± 10.6             -0.02 ± 7.50                 0.57 no 
buckle  0.60 ± 19.9            1.38 ± 9.29                 0.28 no 
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Table A.13 (cont’d).      
propellor -11.6 ± 20.5           -15.1 ± 5.50                 1.91 no 
opening   1.51 ± 9.58              -2.73 ± 4.17                 3.29 yes 
tilt -0.89 ± 7.06              0.08 ± 4.84                 0.66 no 
roll  1.36 ± 11.1               -0.23 ± 5.95                 0.87 no 
twist  36.7 ± 11.3              36.5 ± 4.64                 0.10 no 
helical twist  38.5 ± 12.1                37.2 ± 4.47                0.88 no 
 
Table A.14. Polyamide distances (distances in Å; standard deviation for x-ray structure is 
2.20 Å) for DNA/distamycin simulation 
Simulation 1        
distance computed average x-ray t-value significant?    
1 4.65 ± 0.86              3.03 2.33 yes    
2 3.26 ± 0.21              3.17 0.13 no    
3 3.47 ± 0.42                2.93 0.77 no    
4 3.54 ± 0.29                3.14 0.58 no    
5 3.76 ± 0.41               3.25 0.74 no    
6 4.18 ± 0.97               3.13 1.50 no    
7 3.91 ± 0.69               3.24 0.96 no    
 
Table A.15. Computed and x-ray averages and standard deviations of helical parameters 
for DNA/netropsin simulation with AMBER parameters 
helical parameter (Å) computed avg./sd  x-ray value/sd  t-test value significant? 
x-displacement -0.78 ± 2.98              0.24 ± 1.31                 2.53 yes 
y-displacment -0.25 ± 3.27              0.04 ± 1.12                 0.82 no 
shear -0.22 ± 0.97              0.09 ± 0.55                 1.86 no 
stretch  0.12 ± 0.61            -0.22 ± 0.24                 4.52 yes  
stagger -0.17 ± 0.62              0.13 ± 0.49                 2.04 yes 
shift -0.38 ± 1.43            -0.14 ± 0.64                 1.22 no 
slide -0.32 ± 0.61             0.27 ±  0.61                3.19 yes 
rise  3.26 ± 0.39              3.31 ± 0.38                 0.39 no 
helical rise  2.95 ± 0.88             3.27 ± 0.40                  2.57 yes 
Helical parameter (°)         
inclination  10.5 ± 21.8               0.82 ± 8.32                3.76 yes 
tip -0.61 ± 11.2             0.87 ± 8.87                 0.55 no 
buckle -1.30 ± 13.1            -3.23 ± 10.6                 0.61 no 
propellor -16.5 ± 16.3         -11.81 ± 10.5                 1.47 no 
opening  -9.22 ± 42.8              -0.09 ± 7.21                3.65 yes 
tilt  0.57 ± 6.83              -0.41 ± 5.24                 0.62 no 
roll  0.65 ± 11.7               0.07 ± 5.14                 0.36 no 
twist  30.1 ± 15.1              35.7 ± 5.44                 3.30 yes 
helical twist  29.5 ± 20.9               36.4 ± 5.28                4.03 yes 
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Table A.16. Polyamide distances (distances in Å; standard deviation for x-ray structure is 
2.20 Å (resolution)) for DNA/netropsin simulation with AMBER parameters 
Simulation 1        
distance computed average x-ray t-value significant?    
1 3.17 ± 0.29              2.52 0.94 no    
2 5.78 ± 0.41              3.24 3.65 yes    
3 2.85 ± 0.12                3.40 0.79 no    
4 3.33 ± 0.21                3.50 0.25 no    
5 3.06 ± 0.22               2.70 0.52 no    
6 3.17 ± 0.25               3.70 0.77 no    
7 3.06 ± 0.20               2.70 0.52 no    
8 3.53 ± 0.25         2.90 0.91 no    
9 3.40 ± 0.27                 3.30 0.15 no    
10 5.29 ± 0.55 3.20 3.01 yes    
11 6.62 ± 0.50 3.50 4.49 yes    
 
 
Table A.17.  T-values for combined high and low temperature DNA/polyamide 
simulations 
 
Parameter (Å) 
300 K (6 
simulations) 
113 K (8 
simulations)  all (14 simulations)  
shear 0.391 0.228 0.271 
stretch 0.752 0.278 0.35 
stagger 2.24 3.11 1.4 
shift 0.214 0.089 0.127 
slide 0.508 0.121 0.25 
rise 0.231 0.267 0.171 
x-displacement 0.727 0.078 0.366 
y-displacement 0.214 0.102 0.119 
helical rise 0.391 0.505 0.331 
Parameter (º)    
buckle 0.642 1.92 1.276 
propellor 0.963 0.306 0.663 
opening 0.443 0.303 0.198 
tilt 0.222 0.178 0.113 
roll 1.33 0.533 0.98 
twist 0.668 0.291 0.478 
inclination 1.11 0.676 0.949 
tip 0.253 0.307 0.244 
helical twist 0.349 0.425 0.397 
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CHARMM Topology and Parameters for Polyamides 
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Figure A.1 Model compounds for polyamides (some hydrogens not shown for clarity).  
 
 
Topology for 1 (topology was added to the topology for small molecules, 
top_all22_model.inp and topology for DNA/proteins, top_all27_prot_na.inp) 
 
RESI PYRR      0.00    !N-methyl-pyrrole (with amide groups) 
GROUP                  !               HM 
ATOM HG   HP     0.115 !               | 
ATOM CG   CY    -0.145 !         HZ    N2      HG  
ATOM CD2  CPT   -0.020 !           \  /  \     / 
ATOM CD1  CA     0.035 !            CB   CG—-CD2      HA 
ATOM HD1  HP     0.115 !            ||   ||   ||      / 
ATOM NE1  NY    -0.230 !            O2   CD1  CE2   N1 
ATOM CE2  CPT    0.130 !                / \   /  \  / \ 
GROUP                  !              HD1  NE1    CA  HB 
ATOM C1   CT3   -0.27  !                    |     || 
ATOM H1   HA     0.09  !                    C1    O1 
ATOM H2   HA     0.09  !                   / | \ 
ATOM H3   HA     0.09  !                  H1 H2 H3 
GROUP                  ! 
ATOM CA    C      0.51 
ATOM O1    O     -0.51 
ATOM N1    NH1   -0.62 
ATOM HA     H     0.31 
ATOM HB     H     0.31  
GROUP  
ATOM N2    NH1    -0.47 
ATOM HM     H      0.235 
ATOM CB     C      0.51  
ATOM O2     O     -0.51 
ATOM HZ     H      0.235    
 
BOND CD2 HG  CD2 CG  NE1 CD1    
BOND NE1 CE2  
BOND CD1 HD1 
DOUBLE CD1 CG  CE2 CD2  
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BOND C1 NE1 
BOND C1 H1  C1 H2  C1 H3 
BOND CA CE2  N1 CA  N1 HA  N1 HB 
DOUBLE CA O1  CB O2 
BOND N2 CG  N2 HM  N2 CB  CB HZ 
!ic's for pyrrole ring 
IC CG   CD1  NE1  CE2   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD2  CB   *CG  CD1   0.0000  0.0000 180.0000  0.0000  0.0000 
IC CD1  CG   CD2  CE2   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD2  CG   CD1  NE1   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD1  CE2  *NE1 C1   0.0000  0.0000 -180.0000  127.0  1.46 
IC CG   NE1  *CD1 HD1   0.0000  0.0000 180.0000  0.0000  0.0000 
IC CE2  CG   CD2  HG    0.0000  0.0000 -180.0000  126.9  1.08 
!ic's for methyl group  
IC  CD1 NE1 C1 H1          1.37    123.2   0.00    109.5   1.08 
IC  CD1 NE1 C1 H2          1.37    123.2  -120.0   109.5   1.08 
IC  CD1 ND1 C1 H3          1.37    123.2   120.    109.5   1.08 
ic  CE2 NE1 C1 H3          1.37    123.2   -60.0   109.5   1.08 
!ic's for amide group on CE2 
ic  O1  CA  N1  HA     1.2233 122.84  180.  119.23  0.9933  
ic  O1  CA  N1  HB     1.2233 122.84  0.00  119.23  0.9933 
ic  HA  N1  CA  CE2    0.9933 119.23    0.  116.25  1.47 
ic  HB  N1  CA  CE2    0.9933 119.23 -180.0 116.25  1.47 
ic  N1  CA  CE2 NE1    1.3418 116.25  180.  122.1  1.38  
ic  N1  CA  CE2 CD2    1.3418 116.25    0.  130.3  1.40 
ic  NE1 CE2 CA  O1     1.38   122.0   0.00  123.5  1.2233 
ic  CD2 CE2 CA  O1     1.40   130.3   180.0 123.5  1.2233 
IC  CG  CD2 CE2 CA     1.40   107.1  -180.0 130.3  1.46  
ic  CD1 NE1 CE2 CA     1.37   109.8   180.0 122.1  1.46 
ic  C1  NE1 CE2 CA     1.46   127.0   0.00  122.1  1.46 
!ic's for amide group on CG 
ic  O2  CB  N2  HM      1.2233 122.84  -180.  119.23  0.9933  
ic  HM  N2  CB  HZ      0.9933 119.23    0.   112.25  1.10  
ic  O2  CB  N2  CG      1.2233 122.84    0.   125.57  1.40  
ic  CB  N2  CG  CD2     1.3418 122.57  180.   124.9  1.41  
ic  CB  N2  CG  CD1     1.3418 122.57    0.   127.2  1.40 
IC  N2  CG  CD2 CE2     1.40   124.9   180.   107.1  1.40 
ic  N2  CG  CD1 NE1     1.40   127.2  -180.0  107.6  1.37 
 
Parameters for 1 (parameters were added to the parameters for DNA/proteins, 
par_all27_prot_na.inp) 
BONDS 
!N-methyl-pyrrole 
CPT  HP    500.00     1.08    
CT3  NY    500.000    1.46 
C    CPT   500.00     1.47 
NH1  CY    500.00     1.40 
C    H     500.00     1.10 
ANGLES 
!N-methyl-pyrrole 
CPT  CY   NH1    40.000    124.9     CA   CA   NH1    40.000    127.2  
HP   CPT  CY     40.000    126.9 
HP   CPT  CPT    40.000    125.9 
CA   NY   CT3    40.000    123.3 
CPT  NY   CT3    40.000    127. 
CPT  CPT  C      40.000    130.2 
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NY   CPT  C      40.000    122.1 
NY   CT3  HA     40.000    109.5 
CPT  C    O      40.000    123.5 
CPT  C    NH1    40.000    114.4 
H   NH1   H      40.000    115.7 
CY  NH1   H      40.000    117.2 
CY  NH1   C      40.00     125.2 
NH1  C    H      40.00     112.0  
CA   CY   NH1    40.000    127.2 
CA   CY   C      40.00     100.3 
CPT  CY   C      40.000    151.9 
CPT  CY   CPT    40.000    36.3 
DIHEDRALS 
!N-methyl-pyrrole 
 
!------------------------------------------------ 
CA  NY   CT3  HA     1.60     1       0.00   !methyl group 
CA  NY   CT3  HA     0.000    3     -120.0 
CA  NY   CT3  HA     0.000    2     -60.0 
!------------------------------------------------ 
!------------------------------------------ 
CPT NY   CT3  HA     0.065   3        0.0    !methyl group 
CPT NY   CT3  HA     0.00    1      -120. 
CPT NY   CT3  HA     0.00    2       -60.0 
!------------------------------------------ 
HP  CPT  CY   CA     2.0     1        180.0 
HP  CPT  CY   NH1    2.8     2        180.0 
CY  CA   NY   CT3    0.8     2        180.0 
CY  NH1  C     O     1.5     2        180.0 
CY  NH1  C     H     1.20    1        180.0 
CPT CY   NH1   H     0.000   1         0.00 
CPT CY   NH1   C     0.200   1        180.0 
CPT  CPT  NY   CT3   0.8     2        180.0 
CPT  CPT  C    O     2.5     2        180.0 
CPT  CPT  C    NH1   1.5     2        180.0 
CA   NY   CPT  C     2.00    1        180.0 
HP   CA   CY   NH1   1.00    2        180.0 
CA   CY   NH1  H     0.0     1         0.00 
CA   CY   NH1  C     2.0     2        180.0   
CA   CY   NH1  C     2.0     1        180.0    
 
HP   CA   NY   CT3   0.4000  2      180.0 
NY   CA   CY   NH1   2.0     2      180.0 
NY   CPT  C    O     1.0     2      180.0   
NY   CPT  C    O     3.0     1      180.0  
NY   CPT  C    NH1   1.0     1        0.0 
CPT  CPT  CY   NH1   3.0     2      180.0 
CT3  NY   CPT  C     0.8     2      180.0 
H    NH1  C    H     1.4     2      180.0 
CPT  C    NH1   H    2.5     2      180.0 
 
 
 
Topology for 2 (topology was added to topology for small molecules, 
top_all22_model.inp and to DNA/proteins, top_all27_prot_na.inp) 
RESI IMID      0.00    !N-methyl-imidazole  
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GROUP                 ! 
ATOM CG   CPH1  -0.05 !             
ATOM HG   HR3    0.09 !                  HN 
ATOM CD2  CPH1   0.32 !                  | 
ATOM ND1  NR1   -0.36 !             HY   N4 
ATOM CE1  CPH2   0.38 !               \ / \   
ATOM NE2  NR2   -0.38 !               CD  CD2--NE2      HC 
                      !               ||  ||    ||      / 
GROUP                 !               O4  CG    CE1    N3 
ATOM C2   CT3    -0.27!                  /  \   /  \  / \ 
ATOM HC1   HA     0.09!                HG    ND1    CC   HD 
ATOM HC2   HA     0.09!                       |     || 
ATOM HC3   HA     0.09!                       C2    O3 
                      !                      / | \         
GROUP                 !                   HC3 HC2 HC1 
ATOM CC    C      0.51! 
ATOM O3    O     -0.51! 
ATOM N3    NH1   -0.62 
ATOM HC     H     0.31 
ATOM HD     H     0.31  
 
GROUP 
ATOM N4    NH1    -0.47 
ATOM HN     H      0.235 
ATOM CD     C      0.51  
ATOM O4     O     -0.51 
ATOM HY     H      0.235 
 BOND NE2 CD2  ND1 CG  CE1 ND1        
BOND CG HG 
DOUBLE NE2 CE1  CD2 CG 
BOND ND1 C2  C2 HC1  C2 HC2  C2 HC3 
BOND CE1 CC  CC N3  N3 HC  N3 HD 
DOUBLE CC O3  CD O4 
BOND CD2 N4  N4 HN  N4 CD  CD HY 
! KEEPS HYDROGENS IN RING PLANE 
IMPH ND1  CG   CE1  C2       ND1  CE1  CG   C2 
IMPH CD2  CG   NE2  N4       CD2  NE2  CG   N4 
IMPH CE1  ND1  NE2  CC       CE1  NE2  ND1  CC 
IMPH CG   CD2  ND1  HG        CG   ND1  CD2  HG 
IC   HG    CG    ND1   CE1    1.5421  122.67 -173.67  109.79   1.2987 
IC   CG    ND1   CE1   NE2    1.2854  109.79    0.21  110.31   1.3071 
IC   ND1   CE1   NE2   CD2    1.2987  110.31    0.03  105.82   1.3165 
IC   CE1   NE2   CD2   CG     1.3071  105.82   -0.23  108.68   1.3758 
IC   NE2   CD2   CG    ND1    1.3165  108.68    0.35  105.39   1.2854 
IC   NE2   CD2   CG    HG     1.3165  108.68  172.86  131.52   1.5421 
IC   CD2   CG    ND1   CE1    1.3758  105.39   -0.34  109.79   1.2987 
IC   CD2   NE2   CE1   CC     1.3165  105.82  -180.0  124.7    1.46 
IC   NE2   CE1   ND1   C2      1.34  110.31    180.0  127.8    0.9770 
IC   HG    CG    CD2   N4      1.07  131.52     0.00  129.3   1.40 
!ic's for methyl group  
IC  CG ND1 C2 HC1          1.37    124.7   0.00    109.5   1.08 
IC  CG ND1 C2 HC2          1.37    124.7  -120.0   109.5   1.08 
IC  CG ND1 C2 HC3          1.37    124.7   120.    109.5   1.08 
ic  CE1 ND1 C2 HC3         1.37    124.7   -60.0   109.5   1.08 
impr C2 CG ND1 CE1  !for now 
!ic's for amide group on CE1 
IMPR  CC CE1 N3 O3   !for now 
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ic  O3  CC  N3  HC     1.2233 122.84  -180.  119.23  0.9933  
ic  O3  CC  N3  HD     1.2233 122.84  0.00  119.23  0.9933 
ic  HC  N3  CC  CE1    0.9933 119.23    0.  116.25  1.47 
ic  HD  N3  CC  CE1    0.9933 119.23  180.0 116.25  1.47 
ic  N3  CC  CE1 ND1    1.3418 116.25  180.  122.1   1.38  
ic  N3  CC  CE1 NE2    1.3418 116.25    0.  130.3   1.40 
ic  ND1 CE1 CC  O3     1.38   122.0   0.00  123.5   1.2233 
ic  NE2 CE1 CC  O3     1.40   130.3   180.0 123.5   1.2233 
IC  CD2 NE2 CE1 CC     1.40   107.1  -180.0 130.3   1.46  
ic  CG  ND1 CE1 CC     1.37   109.8   -180.0 122.1   1.46 
ic  C2  ND1 CE1 CC     1.46   127.0   0.00  122.1   1.46 
!ic's for amide group on CD2 
IMPR  CD HY N4 O4    
ic  O4  CD  N4  HN      1.2233 122.84   180.  119.23  0.9933  
ic  HN  N4  CD  HY      0.9933 119.23    0.   112.25  1.10  
ic  O4  CD  N4  CD2      1.2233 122.84    0.   125.57  1.40  
ic  CD  N4  CD2  NE2     1.3418 122.57  -180.   124.9  1.41  
ic  CD  N4  CD2  CG     1.3418 122.57    0.   127.2  1.40 
IC  N4  CD2 NE2 CE1     1.40   124.9   -180.   107.1  1.40 
ic  N4  CD2 CG  ND1     1.40   127.2  -180.0  107.6  1.37 
impr HN CG CD2 N4   
   
Parameters for 2 (parameters were added to parameters for DNA/proteins, 
par_all27_prot_na.inp) 
BONDS 
!N-methyl-imidazole 
NR1 CT3   500.00      1.46    
CPH2 C    500.000     1.47 
CPH1 NH1  500.00      1.40 
C    H    500.00      1.10 
ANGLES 
!N-methyl-imidazole 
CPH1 CPH1 NH1    40.000   129.3   
NR2  CPH1 NH1    40.000   120.0 
CPH1 NR1  CT3    40.000   124.7 
CPH2 NR1  CT3    40.000   127.8 
NR1  CPH2 C      40.000   123.8 
NR2  CPH2 C      40.000   124.8 
NR1  CT3  HA     40.000   107.4 
CPH2 C    O      40.000   122.6 
CPH2 C    NH1    40.000   112.9 
H   NH1   H      40.000   121.1 
CPH1 NH1  H      40.000   115.7 
CPH1 NH1  C      40.000   124.5 
NH1  C    H      40.000   112.4  
DIHEDRALS 
!N-methyl-imidazole 
!--------------------------------------------------- 
CPH1 NR1  CT3  HA      1.60  1     0.00 
CPH1 NR1  CT3  HA      0.000  3     -120.0     !methyl group 
CPH1 NR1  CT3  HA      0.000  2    -60.0 
!---------------------------------------------------- 
!-------------------------------------------------- 
CPH2 NR1 CT3 HA        0.0100   3    0. 
CPH2 NR1 CT3 HA        0.0000   1   -120.0     !methyl group 
CPH2 NR1 CT3 HA        0.0000   2   -60.0 
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!-------------------------------------------------- 
 
CPH1 CPH1 NH1 H        0.1      2   -180.0   
CPH1 CPH1 NH1 H        0.00     1    0.00 
CPH1 CPH1 NH1 C        1.5      1    180.0 
CPH1 CPH1 NH1 C        1.0      2    00.0 
HR3  CPH1 CPH1 NH1     0.5000   2    0.00 
CPH1 NH1  C    O       0.2000   2    0.00 
CPH1 NH1  C    O       3.000    1    180.0 
CPH1 NH1  C   H        0.80000  2   -180.0 
CPH1 NH1  C   H        0.5000   1     0.00 
NR1  CPH1 CPH1 NH1     1.0000   1   -180.0 
CPH2 NR2 CPH1 NH1      0.2000   1   -180.0 
NR2 CPH1 NH1  H        1.3      2     0.0 
NR2 CPH1 NH1  C        1.3      2   -180.0 
H   NH1  C   H         0.2000   2    0.00 
CPH1 CPH1 NR1  CT3     0.2000   1   -180.0 
O  C  NH1  H           2.5000   2    180.0 
!---------------------------------------------------- 
CPH1 NR1  CPH2 C       0.2000  1    -180.0   
HR3  CPH1 NR1  CT3     0.2000  1      0.00     
CPH1 NR2  CPH2 C       0.2000  1    -180.0 
NR1  CPH2 C   O        5.500   2     180.0 
NR1  CPH2 C   O        3.000   1     180.0 
NR1  CPH2 C  NH1       1.00    2      0.0   
NR2 CPH2 C   O         1.0000  1      0.0     
NR2 CPH2 C  NH1        0.0     1      0.00     
CPH2 C   NH1  H        0.2000  1      0.00 
CPH2 C   NH1  H        0.2000  2     180.0 
NR2 CPH2 NR1 CT3       0.2000  1     180.0 
CT3 NR1  CPH2 C        0.2000  1      0.00 
IMPROPER 
!N-methyl-imidazole 
CT3 CPH1 NR1 CPH2    90.000    0      180.0   
C   NR1  CPH2 NR2    90.000    0     -180.0 
NR1 CPH1 CPH2 CT3    90.000    0       0.00 
NR1 CPH2 CPH1 CT3    90.000    0       0.00 
CPH1 CPH1 NR2 NH1    90.0000   0       0.00 
CPH1 NR2 CPH1 NH1    90.000    0       0.00 
CPH2 NR1 NR2  C      90.000    0       0.00 
CPH2 NR2 NR1  C      90.000    0       0.00 
 
 
Topology for 3 (added to topology for DNA/proteins, top_all27_prot_na.inp)   
RESI OHPY       0.00   !Hydroxy pyrrole  
GROUP                  !              HM 
ATOM CG   CY    -0.030 !              |      
ATOM CD2  CPT   -0.020 !        HZ    N2      OH--HH 
ATOM CD1  CA     0.035 !          \  /  \     / 
ATOM HD1  HP     0.115 !           CB   CG—-CD2     HA 
ATOM NE1  NY    -0.230 !           ||   ||  ||     / 
ATOM CE2  CPT    0.130 !           O2  CD1  CE2   N1 
                                      /  \   / \  / \ 
GROUP                  !             HD1  NE1   CA   HB 
ATOM OH   OH1   -0.43  !                   |    || 
ATOM HH   H      0.43  !                  C1    O1 
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                                         / | \ 
GROUP                  !                H1 H2 H3 
ATOM C1   CT3   -0.27  ! 
ATOM H1   HA     0.09  ! 
ATOM H2   HA     0.09  ! 
ATOM H3   HA     0.09  ! 
 
GROUP  
ATOM CA    C     0.51 
ATOM O1    O     -0.51 
ATOM N1    NH1   -0.62 
ATOM HA     H     0.31 
ATOM HB     H     0.31  
 
GROUP  
ATOM N2    NH1    -0.47 
ATOM HM     H      0.235 
ATOM CB     C      0.51  
ATOM O2     O     -0.51 
ATOM HZ     H      0.235    
BOND CD2 CG  NE1 CD1   !CD2 HG  CD2 CG  NE1 CD1 
BOND CD2 OH  OH  HH    
BOND NE1 CE2  
BOND CD1 HD1 
DOUBLE CD1 CG  CE2 CD2  
BOND C1 NE1 
BOND C1 H1  C1 H2  C1 H3 
BOND CA CE2  N1 CA  N1 HA  N1 HB 
DOUBLE CA O1  CB O2 
BOND N2 CG  N2 HM  N2 CB  CB HZ 
!ic's for pyrrole ring 
IC CG   CD1  NE1  CE2   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD2  CB   *CG  CD1   0.0000  0.0000 180.0000  0.0000  0.0000 
IC CD1  CG   CD2  CE2   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD2  CG   CD1  NE1   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD1  CE2  *NE1 C1    0.0000  0.0000 -180.0000  127.0  1.46 
IC CG   NE1  *CD1 HD1   0.0000  0.0000 180.0000  0.0000  0.0000 
IC CE2  CG    CD2 OH    0.0000  0.0000 -180.0000  126.9  1.37 
IC CG   CD2  OH   HH    1.39    128.9   180.0     106.4  0.98 
 
 
!ic's for methyl group  
IC  CD1 NE1 C1 H1          1.37    123.2   0.00    109.5   1.08 
IC  CD1 NE1 C1 H2          1.37    123.2  -120.0   109.5   1.08 
IC  CD1 ND1 C1 H3          1.37    123.2   120.    109.5   1.08 
ic  CE2 NE1 C1 H3          1.37    123.2   -60.0   109.5   1.08 
!ic's for amide group on CE2 
ic  O1  CA  N1  HA     1.2233 122.84  180.  119.23  0.9933  
ic  O1  CA  N1  HB     1.2233 122.84  0.00  119.23  0.9933 
ic  HA  N1  CA  CE2    0.9933 119.23    0.  116.25  1.47 
ic  HB  N1  CA  CE2    0.9933 119.23 -180.0 116.25  1.47 
ic  N1  CA  CE2 NE1    1.3418 116.25  180.  122.1  1.38  
ic  N1  CA  CE2 CD2    1.3418 116.25    0.  130.3  1.40 
ic  NE1 CE2 CA  O1     1.38   122.0   0.00  123.5  1.2233 
ic  CD2 CE2 CA  O1     1.40   130.3   180.0 123.5  1.2233 
IC  CG  CD2 CE2 CA     1.40   107.1  -180.0 130.3  1.46  
ic  CD1 NE1 CE2 CA     1.37   109.8   180.0 122.1  1.46 
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ic  C1  NE1 CE2 CA     1.46   127.0   0.00  122.1  1.46 
!ic's for amide group on CG 
ic  O2  CB  N2  HM      1.2233 122.84  -180.  119.23  0.9933  
ic  HM  N2  CB  HZ      0.9933 119.23    0.   112.25  1.10  
ic  O2  CB  N2  CG      1.2233 122.84    0.   125.57  1.40  
ic  CB  N2  CG  CD2     1.3418 122.57  180.   124.9  1.41  
ic  CB  N2  CG  CD1     1.3418 122.57    0.   127.2  1.40 
IC  N2  CG  CD2 CE2     1.40   124.9   180.   107.1  1.40 
ic  N2  CG  CD1 NE1     1.40   127.2  -180.0  107.6  1.37 
 
Parameters for 3 (added to parameters for DNA/proteins, par_all27_prot_na.inp) 
BONDS 
!hydroxy pyrrole 
CPT  OH1  500.000      1.37    
CT3  NY   500.000      1.46  
C   CPT   500.00       1.45 
NH1 CY    500.000      1.40 
C    H    500.000      1.10 
ANGLES 
!Hydroxy pyrrole 
CPT  CY  NH1    40.00    123.1     
CA   CY  NH1    40.000   129.7 
CY  CPT  OH1    40.00    123.1 
CPT CPT  OH1    40.00    129.0 
CA  NY   CT3    40.000   124.3 
CPT NY   CT3    40.000   125.9 
CPT CPT  C      40.000   128.3 
NY  CPT  C      40.000   124.3 
CPT OH1  H      40.000   106.4 
NY  CT3  HA     40.00    107.4 
CPT  C   O      40.000   125.5 
CPT  C   NH1    40.00    112.5 
H   NH1  H      40.000   111.8 
CY  NH1  H      40.00    116.2 
CY  NH1  C      40.000   124.6 
NH1  C   H      40.000   112.3 
CPT CPT CC      40.00    128.25394 
NY CPT CC       40.00    124.31412 
CPT CC O        40.00    125.47897 
CPT CC NH2      40.00    112.47125 
DIHEDRALS 
!Hydroxy pyrrole 
 
!from pyrrole 
!------------------------------------------------ 
CA  NY   CT3  HA     1.60     1       0.00   !methyl group 
CA  NY   CT3  HA     0.000    3     -120.0 
CA  NY   CT3  HA     0.000    2     -60.0 
!------------------------------------------------ 
!------------------------------------------ 
CPT NY   CT3  HA     0.065   3        0.0    !methyl group 
CPT NY   CT3  HA     0.00    1      -120. 
CPT NY   CT3  HA     0.00    2       -60.0 
!------------------------------------------ 
 
HP  CPT  CY   CA     2.0     1        180.0 
 356
HP  CPT  CY   NH1    2.8     2        180.0   
CY  CA   NY   CT3    0.8     2        180.0 
CY  NH1  C     O     2.0     2        180.0 
CY  NH1  C     H     0.3     1        180.0    
CPT CY   NH1   H     0.000   1         0.00   
CPT CY   NH1   C     0.5     1        180.0   
CPT  CPT  NY   CT3   0.8     2        180.0 
CPT  CPT  C    O     2.5     2        180.0 
 
CPT  CPT  C    NH1   2.5     2        180.0   
CPT  CPT  C    NH1   2.0     1        0.00 
 
CA   NY   CPT  C     2.30    2        180.0   
 
HP   CA   CY   NH1   1.0     2        180.0 
 
CA   CY   NH1  H     1.5     1         0.00 
 
CA   CY   NH1  C     1.5     2        180.0  
CA   CY   NH1  C     0.0     1        180.0 
 
HP   CA   NY   CT3   0.4000  2        180.0 
NY   CA   CY   NH1   1.0     2        180.0 
 
NY   CPT  C    O     1.0     2        180.0   
NY   CPT  C    O     5.5     1        180.0 
 
NY   CPT  C    NH1   1.0     1        180.0 
 
CPT  CPT  CY   NH1   4.0     2        180.0   
CT3  NY   CPT  C     0.8     2        180.0 
 
H    NH1  C    H     1.4     2        180.0   
CPT  C    NH1   H    4.0     2        180.0 
!-------------------------------------------------- 
 
CY  CPT  OH1 H       0.0000  2        90.0 
CY  CPT  OH1 H       4.0     1         0.0 
 
 
CPT CPT OH1 H         0.5      2    180.00  
CPT CPT OH1 H         0.30     1    0.0 
 
 
OH1 CPT CY NH1        0.200     2   180.0 
 
CA  CY  CPT OH1       3.1       2   180.0   
 
IMPROPER 
!hydroxy-pyrrole 
C   CPT  NH1  O     90.0         0    0.00 
C   NH1  CPT  O     90.0         0    0.00 
O    NY   CPT  C    90.00        0    0.00 
CPT  CA   NY   CT3   90.000      0   -180.0 
C  NH1   O   CPT    90.000       0    0.00 
NH1  NY   CPT C     90.000       0    0.00 
O1   CPT  CPT C     90.000       0    0.00 
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H   CY  CPT  OH1    45.000       0   -26.0 
OH1  CY  CPT CPT    90.000       0   -180.0 
H  CPT CPT OH1      90.000       0    14.0 
NH1 CA  CY  CPT     90.00        0   -180.0 
 
 
 
Topology for 4 (added to topology for DNA/proteins, top_all27_prot_na.inp) 
RESI TAIL      1.00   !cationic tail group for polyamides 
GROUP                ! 
ATOM CL   CT3   -0.27! 
ATOM HL1  HA     0.09!                                HX2 HX3 
ATOM HL2  HA     0.09!                                 \ / 
ATOM HL3  HA     0.09!   HL1       H    HR1  HS1  HT1  CX—HX1 
ATOM C    C      0.51!    \        |    |    |    |  + / 
ATOM O    O     -0.51!HL2-CL---C---N---CR---CS---CT---N1--HC 
ATOM N    NH1   -0.47!    /    ||       |    |    |    \ 
ATOM H    H      0.47! HL3     O       HR2  HS2  HT2   CY—HY1 
ATOM CR   CT2   -0.11!                                /  | 
ATOM HR1  HA     0.09!                               HY2 HY3 
ATOM HR3  HA     0.09! 
                     ! 
GROUP                 ! 
ATOM CS  CT2     -0.11! 
ATOM HS1  HA      0.09! 
AtOM HS2  HA      0.09! 
ATOM CT   CT2    -0.11! 
ATOM HT1  HA      0.09! 
ATOM HT2  HA      0.09! 
 
GROUP 
ATOM N1   NH3     -0.30     
ATOM H1   HC       0.33  
ATOM CX   CT3      0.23 
ATOM HX1  HA       0.05 
ATOM HX2  HA       0.05 
ATOM HX3  HA       0.05 
ATOM CY   CT3      0.23 
ATOM HY1  HA       0.05 
ATOM HY2  HA       0.05 
ATOM HY3  HA       0.05 
 
BOND CL C  C N  N CR  N H 
BOND CL HL1  CL HL2  CL HL3 
BOND CR HR1   CR HR3  CR CS 
DOUBLE C O 
BOND CS HS1  CS HS2  CS CT 
BOND CT HT1  CT HT2  CT N1 
BOND N1 H1  N1 CX  N1 CY 
BOND CX HX1  CX HX2  CX HX3 
BOND CY HY1  CY HY2  CY HY3 
!------------------------------------------------------- 
!ic table 
IMPR  N  C  CR H 
IMPR  C  CL N  O    
IC  O   C   N   H      1.2233 122.84  180. 119.23 0.9933  
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IC  H   N   C   CL     0.9933 119.23    0. 116.25 1.5118  
IC  O   C   N   CR     1.2233 122.84    0. 122.57 1.4488  
IC  N   C   CL  HL1    1.3418 116.25  154. 109.3  1.109   
IC  N   C   CL  HL2    1.3418 116.25   33. 109.3  1.109   
IC  N   C   CL  HL3    1.3418 116.25  -87. 109.3  1.109   
IC  C   N   CR  HR1    1.3418 122.57   -180. 110.7  1.113   
IC  C   N   CR  CS     1.3418 122.57   60. 110.7  1.50   
IC  C   N   CR  HR3    1.3418 122.57  -60.  110.7  1.113   
 
IC  N  CR  CS CT       1.47   109.5   180.0  109.5  1.50 
IC  N  CR  CS HS1      1.47   109.5   60.0  109.5  1.10 
IC  N  CR  CS HS2      1.47   109.5    -60.0  109.5  1.10 
IC  CR CS  CT HT1      1.50   109.5    -60.0  109.5  1.10 
IC  CR CS  CT HT2      1.50   109.5    60.0 109.5  1.10 
IC  CR CS  CT N1       1.50   109.5    180.0 109.5  1.10 
   
IC  CS CT N1 H1         1.50   109.5   60.00   109.5  1.10 
IC  CS CT N1 CX        1.50   109.5  -60.0  109.5  1.47 
IC  CS CT N1 CY        1.50   109.5   180.0  109.5  1.47 
 
IC  CT N1 CX HX1       1.47   109.5   -60.0  109.5  1.10 
IC  CT N1 CX HX2       1.47   109.5    60.0  109.5  1.10 
IC  CT N1 CX HX3       1.47   109.5   -180.  109.5  1.10 
IC  CT N1 CY HY1       1.47   109.5    60.0  109.5  1.10 
IC  CY N1 CY HY2       1.47   109.5    180.0 109.5  1.10 
IC  CY N1 CY HY3       1.47   109.5   -60.0  109.5  1.10 
 
IC  HY2 CY N1 H1        1.10   109.5    -60.0    109.5  1.10 
IC  HY3 CY N1 H1        1.10   109.5     60.0    109.5  1.10 
Parameters for 4 (added to parameters for DNA/proteins, top_all27_prot_na.inp) 
ANGLES 
!cationic tail 
CT2  NH3  CT3   40.00      111.4   
CT3  NH3  CT3   40.0       110.8 
 
DIHEDRALS 
CT3  C   NH1  H          2.5      2     180.0     
CT3  C   NH1  CT2        1.6      1     0.00      
CT3  C   NH1  CT2        2.5      2     180.0     
 
HA  CT3  C    O          0.0      3     180.0   
HA  CT3  C   NH1         0.0      3     0.00    
 
C   NH1  CT2  HA         0.00     3     0.00     
C   NH1  CT2  CT2        1.0      2     0.00    
C   NH1  CT2  CT2        0.5      1     0.00 
 
O    C   NH1   H         2.5      2     180.0   
O    C   NH1  CT2        2.5      2     180.0   
 
NH1  CT2  CT2  HA        0.1950   3     0.00    
NH1  CT2  CT2  CT2       0.1950   3     0.00   
 
H  NH1  CT2  HA          0.000    3     0.00   
 
H  NH1  CT2 CT2          0.000    1     0.00    
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CT2 CT2  CT2   HA        0.1950   3     0.00   
CT2 CT2  CT2  NH3        0.1950   3     0.00   
 
H  CT2   CT2  HA         0.1950   3     0.00    
CT2  CT2  NH3  HC       0.100      3     0.00    
 
CT2  CT2  NH3  CT3      0.4000     3     0.000   
 
HA   CT2  CT2  NH3      0.1950     3     0.00    
CT2  NH3  CT3  HA       0.09000    3     0.00    
 
HA   CT2  CT2  HA       0.1950     3     0.00   
 
HA   CT2  NH3  HC       0.1000     3     0.00    
HA   CT2  NH3  CT3      0.100      3     0.00     
 
HC   NH3  CT3  HA       0.09000    3     0.00    
CT3  NH3  CT3  HA       0.0900     3     0.00    
 
 
IMPROPER 
NH1  C  CT2 H     20.00     0       0.00 
C   CT3 NH1 O     120.0     0       0.00 
 
 
 
Topology for 5 (added to topology for DNA/proteins, top_all27_prot_na.inp) 
RESI GAMM      0.00   !gamma aminobutyric acid linker for polyamides 
GROUP                ! 
ATOM CL   CT3   -0.27! 
ATOM HL1  HA     0.09!     HL1       H   HR1  HS1  HT1  OM    H2 
ATOM HL2  HA     0.09!      \        |    |    |    |   ||    / 
ATOM HL3  HA     0.09! HL2—-CL---C---N---CR---CS---CT---CM---N2 
ATOM C    C      0.51!      /    ||       |    |    |         \ 
ATOM O    O     -0.51!     HL3   O       HR2  HS2  HT2         H3 
ATOM N    NH1   -0.47! 
ATOM H    H      0.47! 
ATOM CR   CT2   -0.18! 
ATOM HR1  HA     0.09! 
ATOM HR3  HA     0.09! 
                     ! 
GROUP                !     
ATOM CS   CT2    -.18! 
ATOM HS1  HA    0.09 
ATOM HS2  HA    0.09 
ATOM CT   CT2   -.18 
ATOM HT1  HA    0.09 
ATOM HT2  HA    0.09 
GROUP 
ATOM CM   CC     0.51 
ATOM OM   O    -0.51   
ATOM N2   NH2   -0.47 
ATOM H2   H      0.235 
ATOM H3   H      0.235 
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BOND CL HL1  CL HL2  CL HL3 
BOND CL C  C N  N H  N CR 
DOUBLE C O 
BOND CR HR1  CR HR3  CR CS 
BOND CS HS1  CS HS2  CS CT 
BOND CT HT1  CT HT2  CT CM 
DOUBLE CM OM 
BOND CM N2  N2 H2  N2 H3 
!ic table  
IMPR  N  C  CR H 
IMPR  C  CL N  O    
IC  O   C   N   H      1.2233 122.84  180. 119.23 0.9933  
IC  H   N   C   CL     0.9933 119.23    0. 116.25 1.5118  
IC  O   C   N   CR     1.2233 122.84    0. 122.57 1.4488  
IC  N   C   CL  HL1    1.3418 116.25  180. 109.3  1.109   
IC  N   C   CL  HL2    1.3418 116.25   60. 109.3  1.109   
IC  N   C   CL  HL3    1.3418 116.25  -60. 109.3  1.109   
IC  C   N   CR  HR1    1.3418 122.57  -30. 110.7  1.113   
IC  C   N   CR  CS    1.3418 122.57    90. 110.7   1.50  
IC  C   N   CR  HR3    1.3418 122.57  -150. 110.7  1.113  
 
IC  N CR CS CT         1.47   109.5  -180.0  109.5  1.50 
IC  N CR CS HS1        1.47   109.5  -60.0  109.5  1.10 
IC  N CR CS HS2        1.47   109.5   60.0  109.5  1.10 
IC  CR CS CT HT1       1.50   109.5   60.0  109.5  1.10 
IC  CR CS CT HT2       1.50   109.5  -60.0  109.5  1.10 
IC  CR CS CT CM        1.50   109.5   180.0 109.5  1.50 
IC  CS CT CM OM        1.50   109.5  -30.00  123.1  1.22233   
IC  CS CT CM N2        1.50   109.5   150.0 115.0  1.37 
IC  CT CM N2 H2        1.50   115.0  -180.0 120.6  1.10 
IC  CT CM N2 H3        1.50   115.0   0.00  120.6  1.10 
 
IMPR  CM CT N2 OM  
 
 
Parameters for 5 (added to parameters for DNA/proteins, par_all27_prot_na.inp) 
ANGLES 
!gamma linker 
H  NH1 H        25.00    117.0  
 
DIHEDRALS 
 
CT3  C   NH1  H     2.5     2    180.0   
 
CT3  C   NH1  CT2   1.6     1     0.00    
CT3  C   NH1  CT3   2.5     2    180.0   
 
HA  CT3 C   O       0.000   3    180.0 
HA  CT3 C   NH1     0.000   3    0.00     
 
C   NH1  CT2  HA    0.00    3    0.00      
 
C   NH1  CT2  CT2   0.5     2    0.00       
O   C    NH1  H     2.5     2    180.0      
O   C    NH1  CT2   2.5     2    180.0      
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NH1  CT2  CT2  HA   0.1950  3    0.00      
 
NH1  CT2  CT2  CT2  0.1950  3    0.00        
H  NH1  CT2 HA      0.00    3    0.00      
 
H  NH1  CT2  CT2    0.00    1    0.00     
CT2  CT2  CT2  HA   0.1950  3    0.00       
CT2  CT2  CC  O     0.050   6    0.00   
 
CT2  CT2  CC  NH2    0.020  6    180.00 
!CT2  CT2  CC  NH2   0.00   3    180.0 
 
HA   CT2  CT2  HA     0.1950  3    0.00    
HA   CT2  CT2  CC     0.1950  3    0.00   
CT2  CC    NH2  H     1.4     2    180.0   
HA   CT2  CC   O      0.00    3    0.00     
HA   CT2  CC   NH2    0.000   3    0.00    
O    CC   NH2  H      1.4     2    180.0   
CT2  CT2  CT2  CC     0.1950  3    0.00   
 
IMPROPER 
NH1  C   CT2  H     20.00    0    0.00 
C  CT3  NH1  O      120.0    0    0.00 
CC  CT2  NH2  O     45.0     0    0.00 
 
 
Topology for 6 (added to topology for DNA/proteins, top_all27_prot_na.inp) 
RESI BETA        0.00  !Beta alanine linker for polyamides  
GROUP                ! 
ATOM CL   CT3   -0.27!    HL2       H   HR1  HS1        H1 
ATOM HL1  HA     0.09!     \        |    |    |         / 
ATOM HL2  HA     0.09! HL1—CL---C---N---CR---CS---CT---NS 
ATOM HL3  HA     0.09!     /    ||       |    |   ||    \ 
                     !   HL3    O       HR3  HS2  OL     H2 
GROUP                ! 
ATOM C    C      0.51! 
ATOM O    O     -0.51! 
ATOM N    NH1   -0.47! 
ATOM H    H      0.47! 
ATOM CR   CT2   -0.18! 
ATOM HR1  HA     0.09! 
ATOM HR3  HA     0.09! 
 
GROUP 
ATOM CS   CT2    -0.18 
ATOM HS1  HA      0.09 
ATOM HS2  HA      0.09 
GROUP  
ATOM CT   CC       0.51 
ATOM OL   O      -0.51 
ATOM NS   NH2     -0.47 
ATOM H1   H       0.235 
ATOM H2   H       0.235 
 
BOND  HL1 CL  HL2 CL  HL3 CL           
BOND  CL C  C N  N CR        
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BOND  N H                   
BOND  HR1 CR  HR3 CR       
DOUBLE C O  CT OL 
BOND CR CS  CS CT  CT NS   
BOND NS H1  NS H2  CS HS1  CS HS2 
 
IMPR  N  C  CR H 
IMPR  C  CL N  O    
IC  O C N H      1.2233 122.84  180. 119.23 0.9933  
IC  H N C CL     0.9933 119.23    0. 116.25 1.5118  
IC  O C N CR     1.2233 122.84    0. 122.57 1.4488  
IC  N C CL HL1    1.3418 116.25  150. 109.3  1.109   
IC  N C CL HL2    1.3418 116.25   25. 109.3  1.109   
IC  N C CL HL3    1.3418 116.25  -95. 109.3  1.109   
IC  C N CR  CS     1.3418 122.57  90. 110.7  1.50   
IC  C N CR  HR1    1.3418 122.57  -150. 110.7  1.50   
IC  C N CR  hR3    1.3418 122.57  -30.0 110.7  1.50 
 
IC  N CR CS HS1    1.4488  110.7   60.0  109.5   1.10 
IC  N CR CS HS2    1.4488  110.7   -60.0  109.5   1.10 
IC  N CR CS CT     1.4488  110.7  -180.0 109.5   1.50 
IC  CR CS CT NS    1.50    109.5   150.0 115.0   1.40 
IC  CR CS CT OL    1.50    109.5   -36.50  123.1   1.24 
 
IC  OL CT NS H1    1.24    121.9   160.0  121.2  0.9933 
IC  OL CT NS H2    1.24    121.9    0.00  121.2  0.9933 
 
IMPR CT CS NS OL 
IMPR CT NS CS OL 
IMPR NS CT H2 H1 
IMPR NS CT H1 H2 
 
Parameters for 6 (added to parameters for DNA/proteins, par_all27_prot_na.inp) 
ANGLES 
!beta linker 
 
H  NH1  H     40.000     118.2      !A.E.L. 
 
DIHEDRALS  
 
CT3  C   NH1  H      2.5    2    180.0 
 
CT3  C   NH1  CT2    1.6    1     0.00 
CT3  C   NH1  CT2    2.5    2    180.0 
 
HA  CT3  C    O      0.00   3    180.0 
HA  CT3  C    NH1    0.00   3     0.00 
C   NH1  CT2  HA     0.00   3     0.00 
 
C   NH1  CT2  CT2    0.25   2      0.0  
C   NH1  CT2  CT2    0.3    1      0.0 
 
O   C    NH1   H     2.5    2     180.0 
O   C    NH1  CT2    2.5    2     180.0 
NH1  CT2 CT2  HA     0.1950 3      0.00 
NH1  CT2 CT2  CC     0.1950 3      0.00 
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H    NH1 CT2  HA     0.00   3      0.00 
H    NH1 CT2  CT2    0.000  1      0.00 
 
CT2  CT2 CC    O      0.0   2      0.00 
CT2  CT2 CC    NH2    1.0   1      0.0     
CT2  CT2 CC    NH2    0.3   3      0.00 
  
!CT2  CT2 CC    NH2    1.0  1      0.0 
 
HA   CT2 CT2  HA     0.1950 3      0.00 
HA   CT2 CT2  CC     0.1950 3      0.00 
CT2  CC   NH2  H     2.5    2     180.0 
HA   CT2 CC    O     0.00   3     180.0 
HA   CT2 CC    NH2   0.00   3     0.00 
O   CC   NH2   H     2.5    2     180.0 
 
 
Topology and parameters for netropsin and distamycin (streamed in; used with 
parameters for DNA/proteins, par_all27_prot_na.inp) 
 
RESI NETR    2.00  !netropsin 
!1st pyrrole ring 
GROUP    
ATOM HG   HP     0.115 !                    
ATOM CG   CY    -0.145 !                     
ATOM CD2  CPT   -0.020 !               
ATOM CD1  CA     0.035 !        
ATOM HD1  HP     0.115 !         
ATOM NE1  NY    -0.230 !          
!ATOM HE1  H      0.380 !          
ATOM CE2  CPT    0.130 !   
GROUP 
ATOM CH   CT3   -0.27  ! 
ATOM H1   HA     0.09 
ATOM H2   HA     0.09 
ATOM H3   HA     0.09 
GROUP  
ATOM N2    NH1    -0.47 
ATOM HM     H      0.235 
ATOM CB     C      0.745  
ATOM O2     O     -0.51 
!-----------------------------------------------  
!2nd pyrrole ring 
GROUP    
ATOM HG1   HP     0.115 !                    
ATOM CG1   CY    -0.145 !                     
ATOM CD3  CPT   -0.020 !               
ATOM CD4  CA     0.035 !        
ATOM HD4  HP     0.115 !         
ATOM NE2  NY    -0.230 !          
ATOM CE3  CPT    0.130 !   
GROUP 
ATOM CI   CT3   -0.27   
ATOM HI1   HA    0.09 
ATOM HI2   HA    0.09 
ATOM HI3   HA    0.09 
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GROUP  
ATOM NK    NH1    -0.47 
ATOM HN     H      0.235 
ATOM CK     C      0.745  
ATOM OK     O     -0.51 
GROUP  
ATOM NZ    NH1    -0.47 
ATOM HZ     H      0.235 
ATOM CZ     C      0.745  
ATOM OZ     O     -0.51 
!ATOM HZ     H      0.235  
!----------------------------------------- 
GROUP 
ATOM CV   CT2   -0.18 
ATOM HV1  HA     0.09 
!ATOM HR2  HA     0.09 
ATOM HV3  HA     0.09 
 
GROUP 
ATOM CC   CT2    -0.18 
ATOM HC1  HA      0.09 
ATOM HC2  HA      0.09 
!----------------------------------------- 
GROUP 
ATOM CZ2  C       0.64 
ATOM NH1  NC2     -0.74 
ATOM HH11 HC      0.46 
ATOM HH12 HC      0.46 
ATOM NH2  NC2     -0.74 
ATOM HH22 HC      0.46 
ATOM HH21 HC      0.46 
!----------------------------------------- 
GROUP  
ATOM CC2   CT2    -0.18 
ATOM HC12  HA      0.09 
ATOM HC14  HA      0.09 
ATOM NC    NC2    -0.47 
ATOM HC    HC       0.47 
ATOM CZ3  C       0.64 
ATOM NH4  NC2     -0.74 
ATOM HH14 HC      0.46 
ATOM HH16 HC      0.46 
ATOM NH5  NC2     -0.74 
ATOM HH25 HC      0.46 
ATOM HH27 HC      0.46 
 
!bonds for 1st pyrrole ring 
BOND CD2 HG  CD2 CG  NE1 CD1    
BOND NE1 CE2  
BOND CD1 HD1 
DOUBLE CD1 CG  CE2 CD2  
BOND CH NE1 
BOND CH H1  CH H2  CH H3 
BOND CE2 CK   
DOUBLE CB O2 
BOND N2 CG  N2 HM  N2 CB   
!------------------------------------------ 
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!bonds for 2nd pyrrole ring 
BOND CD3 HG1  CD3 CG1  NE2 CD4    
BOND NE2 CE3  
BOND CD4 HD4 
DOUBLE CD4 CG1  CE3 CD3  
BOND CI NE2 
BOND CI HI1  CI HI2  CI HI3 
BOND CZ CE3  
DOUBLE CK OK 
BOND NK CG1  NK HN  NK CK   
!-------------------------------------------- 
!1st tail amidino group 
DOUBLE CZ OZ  
BOND HV1 CV  HV3 CV  CV NZ  CZ NZ 
BOND CC CV  CC HC1  CC HC2  NZ HZ 
BOND CC CZ2  CZ2 NH2 
DOUBLE CZ2 NH1  
BOND NH1 HH12  NH1 HH11 
BOND NH2 HH22  NH2 HH21 
!-------------------------------------------- 
!2nd tail guanidino group 
BOND CB CC2  CC2 HC12  CC2 HC14 
BOND CC2 NC  NC HC 
BOND NC CZ3  CZ3 NH5 
DOUBLE CZ3 NH4 
BOND NH4 HH14  NH4 HH16 
BOND NH5 HH25  NH5 HH27 
 
!---------------------------------------------- 
!ic tables 
IC   CZ3   NC   CC2   CB       1.47  105.82  -180.0  109.5  1.54  
 
ic  HM  N2  CB  CC2    0.9933 119.23    0.  116.25  1.47 
ic  CG  N2  CB  CC2    1.40   119.23 -180.0 116.25  1.47 
ic  N2  CB  CC2 NC     1.3418 116.25 -180.  109.5   1.47   
ic  CG  N2  CB  O2     1.38   122.0   0.00  123.5   1.2233 
 
IC  CD2  CG  N2  CB    1.40   126.4  -180.0 130.3   1.46  
ic  CD1  CG  N2  CB    1.37   126.4     0.0 122.1   1.46  
ic  N2   CB  CC2 HC12  1.36   115.0  -60.0  109.5  1.07 
ic  N2   CB  CC2 HC14  1.36   115.0  60.0  109.5   1.07 
ic  O2   CB  CC2 HC12  1.22   123.0 -114.0 109.5   1.07 
ic  O2   CB  CC2 HC14  1.22   123.0  115.0 109.5   1.07 
  
!from arginine 
IC NC   CB   *CC2  HC14   1.5034 107.0900  120.6900 109.4100  1.1143 
IC NC   CB   *CC2  HC12   1.5034 107.0900 -119.0400 111.5200  1.1150 
IC CB   CC2   NC  CZ3    1.5384 107.0900  -180.0000 123.0500  1.3401 
IC CZ3  CC2   *NC  HC    1.3401 123.0500  -180.0000 113.1400  1.0065 
IC CC2   NC  CZ3   NH4   1.5034 123.0500     0.0000 118.0600  1.3311 
IC NC   CZ3   NH4  HH14  1.3401 118.0600  10.2800 120.6100  0.9903 
IC HH14 CZ3   *NH4 HH16  0.9903 120.6100  180.1900 116.2900  1.0023 
IC NH4  NC   *CZ3  NH5   1.3311 118.0600  160.6400 122.1400  1.3292 
IC NC   CZ3   NH5  HH25  1.3401 122.1400 170.1400 119.9100  0.9899 
IC HH25 CZ3   *NH5 HH27  0.9899 119.9100  70.1600 116.8800  0.9914 
IC CG   CD1  NE1  CE2   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD2  CB   *CG  CD1   0.0000  0.0000 180.0000  0.0000  0.0000 
 366
IC CD1  CG   CD2  CE2   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD2  CG   CD1  NE1   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD1  CE2  *NE1 CH    0.0000  0.0000 -180.0000  127.0  1.46 
IC CG   NE1  *CD1 HD1   0.0000  0.0000 180.0000  0.0000  0.0000 
IC CE2  CG   CD2  HG    0.0000  0.0000 -180.0000  126.9  1.08 
 
!ic's for methyl group  
IC  CD1 NE1 CH H1          1.37    123.2   0.00    109.5   1.08 
IC  CD1 NE1 CH H2          1.37    123.2  -120.0   109.5   1.08 
IC  CD1 ND1 CH H3          1.37    123.2   120.    109.5   1.08 
ic  CE2 NE1 CH H3          1.37    123.2   -60.0   109.5   1.08 
 
ic  HN  NK  CK  CE2    0.9933 119.23    0.  116.25  1.47   
ic  CG1 NK  CK  CE2    1.40   119.23 -180.0 116.25  1.47 
ic  NK  CK  CE2 NE1    1.3418 116.25  180.  122.1  1.38  
ic  NK  CK  CE2 CD2    1.3418 116.25    0.  130.3  1.40 
ic  NE1 CE2 CK  OK     1.38   122.0   0.00  123.5  1.2233 
ic  CD2 CE2 CK  OK     1.40   130.3   180.0 123.5  1.2233 
IC  CG  CD2 CE2 CK     1.40   107.1  -180.0 130.3  1.46  
ic  CD1 NE1 CE2 CK     1.37   109.8   180.0 122.1  1.46 
ic  CH  NE1 CE2 CK     1.46   127.0   0.00  122.1  1.46 
 
!ic's for amide group on CG 
ic  O2  CB  N2  HM      1.2233 122.84  180.  119.23  0.9933  
ic  HM  N2  CB  O2      0.9933 119.23  180.   112.25  1.23 
ic  O2  CB  N2  CG      1.2233 122.84    0.   125.57  1.40  
ic  CB  N2  CG  CD2     1.3418 122.57  180.   124.9  1.41  
ic  CB  N2  CG  CD1     1.3418 122.57    0.   127.2  1.40 
ic  N2  CG  CD2 CE2     1.40   124.9   180.   107.1  1.40 
ic  N2  CG  CD1 NE1     1.40   127.2  -180.0  107.6  1.37 
!------------------------------------------------------- 
!ic's for 2nd pyrrole ring 
IC CG1   CD4  NE2  CE3   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD4  CG1   CD3  CE3   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD3  CG1   CD4  NE2   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD4  CE3  *NE2 CI   0.0000  0.0000 -180.0000  127.0  1.46 
IC CG1   NE2  *CD4 HD4   0.0000  0.0000 180.0000  0.0000  0.0000 
IC CE3  CG1   CD3  HG1    0.0000  0.0000 -180.0000  126.9  1.08 
 
!ic's for methyl group  
IC  CD4 NE2 CI HI1          1.37    123.2   0.00    109.5   1.08 
IC  CD4 NE2 CI HI2          1.37    123.2  -120.0   109.5   1.08 
IC  CD4 NC1 CI HI3          1.37    123.2   120.    109.5   1.08 
ic  CE3 NE2 CI HI3          1.37    123.2   -60.0   109.5   1.08 
 
ic  HZ  NZ  CZ  CE3    0.9933 119.23    0.  116.25  1.47 
ic  CG2  NZ  CZ  CE3   1.40   119.23 -180.0 116.25  1.47 
ic  NZ  CZ  CE3 NE2    1.3418 116.25  180.  122.1  1.38  
ic  NZ  CZ  CE3 CD3    1.3418 116.25    0.  130.3  1.40 
ic  NE2 CE3 CZ  OZ     1.38   122.0   0.00  123.5  1.2233 
ic  CD3 CE3 CZ  OZ     1.40   130.3   180.0 123.5  1.2233 
IC  CG1  CD3 CE3 CZ     1.40   107.1  -180.0 130.3  1.46  
ic  CD4 NE2 CE3 CZ    1.37   109.8   180.0 122.1  1.46 
ic  CI  NE2 CE3 CZ     1.46   127.0   0.00  122.1  1.46 
 
ic  OK  CK  NK  HN      1.2233 122.84  -180.  119.23  0.9933  
ic  HN  NK  CK  CE2      0.9933 119.23    0.   112.25  1.47 !! 
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ic  OK  CK  NK  CG1      1.2233 122.84    0.   125.57  1.40  
ic  CK  NK  CG1  CD3     1.3418 122.57  180.   124.9  1.41  
ic  CK  NK  CG1  CD4     1.3418 122.57    0.   127.2  1.40 
IC  NK  CG1  CD3 CE3     1.40   124.9   180.   107.1  1.40 
ic  NK  CG1  CD4 NE2     1.40   127.2  -180.0  107.6  1.37 
 
!amide group and 1st tail 
ic  OZ  CZ  NZ  HZ      1.2233 122.84  -180.  119.23  0.9933  
ic  HZ  NZ  CZ  CE3      0.9933 119.23    0.   112.25  1.47 !! 
ic  CV  NZ  CZ  CE3     1.4700  120.0   -180.0 120.0   1.47 
ic  OZ  CZ  NZ  CV      1.2233 122.84    0.   125.57  1.40  
ic  CZ  NZ  CV  CC      1.3418 122.57  -180.   124.9  1.41 
ic  NZ  CV  CC  CZ2     1.40   124.9   60.   107.1  1.40 
ic  NZ  CV  CC  HC1     1.40   127.2  -60.0   107.6  1.07 
ic  NZ  CV  CC  HC2     1.40   127.2   60.0   107.6  1.07 
IC  CV  CC  CZ2 NH1     1.54   109.5  -120.0  120.0  1.33 
IC  CV  CC  CZ2 NH2     1.54   109.5   120.0   120.0  1.33 
IC  CZ  NZ  CV  HV1     1.47   120.6   100.0   109.5  1.07 
IC  CZ  NZ  CV  HV3     1.47   120.6  -18.0   109.5  1.07 
IC  CC  CZ2 NH2 HH21    1.54   120.0   170.0  109.5  0.99 
IC  CC  CZ2 NH2 HH22    1.54   120.0   -68.0  109.5  0.99 
IC  CC  CZ2 NH1 HH11    1.54   120.0   25.0   109.5  0.99 
IC  CC  CZ2 NH1 HH12    1.54   120.0  -145.0  109.5  0.99 
 
IMPR OK CG1 NK CK 
impr CZ3 NH4 NH5 NC 
impr O2 NC CC2 CB 
impr CZ2 NH2 NH1 CC 
 
RESI DIST        1.00 ! distamycin 
GROUP                  ! 
ATOM CB    CC     0.55 !    
ATOM N2    NH2   -0.55 !       
ATOM HM    H      0.25 !       
ATOM O2    O     -0.55 ! 
ATOM H     H      0.30 ! 
!1st pyrrole ring 
GROUP    
ATOM HG   HP     0.115 !                    
ATOM CG   CY    -0.145 !                     
ATOM CD2  CPT   -0.020 !               
ATOM CD1  CA     0.035 !        
ATOM HD1  HP     0.115 !         
ATOM NE1  NY    -0.230 !          
ATOM CE2  CPT    0.130 !   
GROUP 
ATOM CH   CT3   -0.27  ! 
ATOM H1   HA     0.09 
ATOM H2   HA     0.09 
ATOM H3   HA     0.09 
GROUP  
ATOM NK    NH1    -0.47 
ATOM HN     H      0.235 
ATOM CK     C      0.745  
ATOM OK     O     -0.51 
!2nd pyrrole ring 
GROUP    
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ATOM HG1   HP     0.115 !                    
ATOM CG1   CY    -0.145 !                     
ATOM CD3  CPT   -0.020 !               
ATOM CD4  CA     0.035 !        
ATOM HD4  HP     0.115 !         
ATOM NE2  NY    -0.230 !          
!ATOM HE1  H      0.380 !          
ATOM CE3  CPT    0.130 !   
GROUP 
ATOM CI   CT3    -0.27  ! 
ATOM HI1   HA     0.09 
ATOM HI2   HA     0.09 
ATOM HI3   HA     0.09 
 
GROUP  
ATOM NZ    NH1    -0.47 
ATOM HZ     H      0.235 
ATOM CZ     C      0.745  
ATOM OZ     O     -0.51 
!3rd pyrrole ring 
GROUP    
ATOM HG2   HP     0.115 !                    
ATOM CG2   CY    -0.145 !                     
ATOM CD5  CPT    -0.020 !               
ATOM CD6  CA      0.035 !        
ATOM HD6  HP      0.115 !         
ATOM NE3  NY     -0.230 !          
!ATOM HE1  H      0.380 !          
ATOM CE4  CPT     0.130 !   
GROUP 
ATOM CF   CT3     -0.27  ! 
ATOM HF1   HA     0.09 
ATOM HF2   HA     0.09 
ATOM HF3   HA     0.09 
ATOM CP    C      0.51 
ATOM OP    O     -0.51 
ATOM NP    NH1   -0.47 
ATOM HP    H      0.47 
ATOM CR   CT2    -0.18 
ATOM HR1  HA      0.09 
ATOM HR3  HA      0.09 
!GROUP 
ATOM CS  CT2     -0.18 
ATOM HS1  HA      0.09 
ATOM HS2  HA      0.09 
GROUP 
ATOM CZ2  C       0.64 
ATOM NH1  NC2     -0.74 
ATOM HH11 HC      0.46 
ATOM HH12 HC      0.46 
ATOM NH2  NC2     -0.74 
ATOM HH22 HC      0.46 
ATOM HH21 HC      0.46 
!bonds 
BOND  CB N2   N2 HM  CB H  N2 CG 
DOUBLE  CB O2 
!bonds for 1st pyrrole ring 
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BOND CD2 HG  CD2 CG  NE1 CD1    
BOND NE1 CE2  
BOND CD1 HD1 
DOUBLE CD1 CG  CE2 CD2  
BOND CH NE1 
BOND CH H1  CH H2  CH H3 
BOND CE2 CK   
   
!bonds for 2nd pyrrole ring 
BOND CD3 HG1  CD3 CG1  NE2 CD4    
BOND NE2 CE3  
BOND CD4 HD4 
DOUBLE CD4 CG1  CE3 CD3  
BOND CI NE2 
BOND CI HI1  CI HI2  CI HI3 
BOND CZ CE3   
DOUBLE CK OK 
BOND NK CG1  NK HN  NK CK   
 
!bonds for 3rd pyrrole ring 
BOND CD5 HG2  CD5 CG2  NE3 CD6    
BOND NE3 CE4  
BOND CD6 HD6 
DOUBLE CD6 CG2  CE4 CD5  
BOND CF NE3 
BOND CF HF1  CF HF2  CF HF3 
BOND CP CE4  
DOUBLE CZ OZ 
BOND NZ CG2  NZ HZ  NZ CZ  
 
!bonds for tail 
BOND CP NP  NP CR  NP HP 
BOND CR HR1   CR HR3  CR CS 
DOUBLE CP OP 
BOND CS HS1  CS HS2   
BOND CS CZ2  CZ2 NH2 
DOUBLE CZ2 NH1  
BOND NH1 HH12  NH1 HH11 
BOND NH2 HH22  NH2 HH21 
 
!ic table 
IMPR  CB H N2 O2   CB N2 H O2   
IMPR  N2 CB CG HM   N2 CB HM CG 
IC  O2   CB   N2   CG     1.2012 124.70  -18.0  118.63 1.40   !  
IC  O2   CB   N2   HM     1.2012 124.70  -162.  120.92  0.9930 !  
IC  CG   N2   CB   H      1.40   118.63   163.  115.65  1.34   !  
IC  HM   N2   CB   H      1.0015 118.63  19.7   115.54  1.34 
 
!ic's for 1st pyrrole ring 
IC CG   CD1  NE1  CE2   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD2  CB   *CG  CD1   0.0000  0.0000 180.0000  0.0000  0.0000 
IC CD1  CG   CD2  CE2   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD2  CG   CD1  NE1   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD1  CE2  *NE1 CH   0.0000  0.0000 -180.0000  127.0  1.46 
IC CG   NE1  *CD1 HD1   0.0000  0.0000 180.0000  0.0000  0.0000 
IC CE2  CG   CD2  HG    0.0000  0.0000 -180.0000  126.9  1.08 
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!ic's for methyl group  
IC  CD1 NE1 CH H1          1.37    123.2   0.00    109.5   1.08 
IC  CD1 NE1 CH H2          1.37    123.2  -120.0   109.5   1.08 
IC  CD1 ND1 CH H3          1.37    123.2   120.    109.5   1.08 
ic  CE2 NE1 CH H3          1.37    123.2   -60.0   109.5   1.08 
 
!ic's for amide group on CE2 
!ic  O1  CA  N1  HA     1.2233 122.84  180.  119.23  0.9933  
!ic  O1  CA  N1  HB     1.2233 122.84  0.00  119.23  0.9933 
ic  HN  NK  CK  CE2    0.9933 119.23    0.  116.25  1.47   
ic  CG1 NK  CK  CE2    1.40  119.23 -180.0 116.25  1.47 
ic  NK  CK  CE2 NE1    1.3418 116.25  180.  122.1  1.38  
ic  NK  CK  CE2 CD2    1.3418 116.25    0.  130.3  1.40 
ic  NE1 CE2 CK  OK     1.38   122.0   0.00  123.5  1.2233 
ic  CD2 CE2 CK  OK     1.40   130.3   180.0 123.5  1.2233 
IC  CG  CD2 CE2 CK     1.40   107.1  -180.0 130.3  1.46  
ic  CD1 NE1 CE2 CK     1.37   109.8   180.0 122.1  1.46 
ic  CH  NE1 CE2 CK     1.46   127.0   0.00  122.1  1.46 
 
!ic's for amide group on CG 
ic  O2  CB  N2  HM      1.2233 122.84  -180.  119.23  0.9933  
ic  HM  N2  CB  H       0.9933 119.23    0.   112.25  1.10  
ic  O2  CB  N2  CG      1.2233 122.84    0.   125.57  1.40  
ic  CB  N2  CG  CD2     1.3418 122.57  180.   124.9  1.41  
ic  CB  N2  CG  CD1     1.3418 122.57    0.   127.2  1.40 
IC  N2  CG  CD2 CE2     1.40   124.9   180.   107.1  1.40 
ic  N2  CG  CD1 NE1     1.40   127.2  -180.0  107.6  1.37 
 
!---------------------------------------------------- 
!ic's for 2nd pyrrole ring 
IC CG1   CD4  NE2  CE3   0.0000  0.0000  0.0000  0.0000  0.0000 
!IC CD2  CB   *CG  CD1   0.0000  0.0000 180.0000  0.0000  0.0000   
IC CD4  CG1   CD3  CE3   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD3  CG1   CD4  NE2   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD4  CE3  *NE2 CI   0.0000  0.0000 -180.0000  127.0  1.46 
IC CG1   NE2  *CD4 HD4   0.0000  0.0000 180.0000  0.0000  0.0000 
IC CE3  CG1   CD3  HG1    0.0000  0.0000 -180.0000  126.9  1.08 
 
!ic's for methyl group  
IC  CD4 NE2 CI HI1          1.37    123.2   0.00    109.5   1.08 
IC  CD4 NE2 CI HI2          1.37    123.2  -120.0   109.5   1.08 
IC  CD4 NC1 CI HI3          1.37    123.2   120.    109.5   1.08 
ic  CE3 NE2 CI HI3          1.37    123.2   -60.0   109.5   1.08 
 
!ic's for amide group on CE3 
!ic  OJ  CJ  NA  HC     1.2233 122.84  180.  119.23  0.9933  
!ic  OJ  CJ  NA  HD     1.2233 122.84  0.00  119.23  0.9933 
ic  HZ  NZ  CZ  CE3    0.9933 119.23    0.  116.25  1.47 
ic  CG2  NZ  CZ  CE3    1.40 119.23 -180.0 116.25  1.47 
ic  NZ  CZ  CE3 NE2    1.3418 116.25  180.  122.1  1.38  
ic  NZ  CZ  CE3 CD3    1.3418 116.25    0.  130.3  1.40 
ic  NE2 CE3 CZ  OZ     1.38   122.0   0.00  123.5  1.2233 
ic  CD4 CE3 CZ  OZ     1.40   130.3   180.0 123.5  1.2233 
IC  CG1  CD3 CE3 CZ     1.40   107.1  -180.0 130.3  1.46  
ic  CD4 NE2 CE3 CZ    1.37   109.8   180.0 122.1  1.46 
ic  CI  NE2 CE3 CZ     1.46   127.0   0.00  122.1  1.46 
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!ic's for amide group on CG1 
ic  OK  CK  NK  HN      1.2233 122.84  -180.  119.23  0.9933  
ic  HN  NK  CK  CE2      0.9933 119.23    0.   112.25  1.10 !! 
ic  OK  CK  NK  CG1      1.2233 122.84    0.   125.57  1.40  
ic  CK  NK  CG1  CD3     1.3418 122.57  180.   124.9  1.41  
ic  CK  NK  CG1  CD4     1.3418 122.57    0.   127.2  1.40 
IC  NK  CG1  CD3 CE3     1.40   124.9   180.   107.1  1.40 
ic  NK  CG1  CD4 NE2     1.40   127.2  -180.0  107.6  1.37 
!---------------------------------------------------------- 
!ic's for 3rd pyrrole ring 
IC CG2   CD6  NE3  CE4   0.0000  0.0000  0.0000  0.0000  0.0000 
!IC CD2  CB   *CG  CD1   0.0000  0.0000 180.0000  0.0000  0.0000   
IC CD6  CG2   CD5  CE4   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD5  CG2   CD6  NE3   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD6  CE4  *NE3 CF   0.0000  0.0000 -180.0000  127.0  1.46 
IC CG2   NE3  *CD6 HD6   0.0000  0.0000 180.0000  0.0000  0.0000 
IC CE4  CG2   CD5  HG2    0.0000  0.0000 -180.0000  126.9  1.08 
 
 
!ic's for methyl group  
IC  CD6 NE3 CF HF1          1.37    123.2   0.00    109.5   1.08 
IC  CD6 NE3 CF HF2          1.37    123.2  -120.0   109.5   1.08 
IC  CD6 NF1 CF HF3          1.37    123.2   120.    109.5   1.08 
ic  CE4 NE3 CF HF3          1.37    123.2   -60.0   109.5   1.08 
 
!ic's for amide group on CE4 
!ic  OL  CL  NB  HE     1.2233 122.84  180.  119.23  0.9933  
!ic  OL  CL  NB  HF     1.2233 122.84  0.00  119.23  0.9933 
ic  HP  NP  CP  CE4    0.9933 119.23    0.  116.25  1.47 
ic  CR  NP  CP  CE4    1.40  119.23 -180.0 116.25  1.47 
ic  NP  CP  CE4 NE3    1.3418 116.25  180.  122.1  1.38  
ic  NP  CP  CE4 CD5    1.3418 116.25    0.  130.3  1.40 
ic  NE3 CE5 CP  OP     1.38   122.0   0.00  123.5  1.2233 
ic  CD6 CE4 CP  OP     1.40   130.3   180.0 123.5  1.2233 
IC  CG2 CD5 CE4 CP     1.40   107.1  -180.0 130.3  1.46  
ic  CD6 NE3 CE4 CP    1.37   109.8   180.0 122.1  1.46 
ic  CF  NE3 CE4 CP     1.46   127.0   0.00  122.1  1.46 
!ic's for amide group on CG2 
ic  OZ  CZ  NZ  HZ      1.2233 122.84  -180.  119.23  0.9933  
ic  HZ  NZ  CZ  CE3      0.9933 119.23    0.   112.25  1.10 !! 
ic  OZ  CZ  NZ  CG2      1.2233 122.84    0.   125.57  1.40  
ic  CZ  NZ  CG2  CD5     1.3418 122.57  180.   124.9  1.41  
ic  CZ  NZ  CG2  CD6     1.3418 122.57    0.   127.2  1.40 
IC  NZ  CG2  CD5 CE4     1.40   124.9   180.   107.1  1.40 
ic  NZ  CG2  CD6 NE3     1.40   127.2  -180.0  107.6  1.37 
 
!ic's for cationic tail  
IMPR  NP  CP  CR HP 
IMPR  CP  CE4 NP  OP    
 
IC  OP   CP   NP   HP      1.2233 122.84  -166. 119.23 0.9933  
IC  HP   NP   CP   CE4     0.9933 119.23   14.  116.25 1.40 
IC  OP   CP   NP   CR     1.2233 122.84   -15.  117.57 1.4488  
IC  NP   CP   CE4  CD5    1.3418 116.25    0.  130.0  1.39   
IC  NP   CP   CE4  NE3    1.3418 116.25   180. 121.3  1.39   
!IC  NP   CP   CE4  HL3    1.3418 116.25  -87. 109.3  1.109   
IC  CP   NP   CR  HR1    1.3418 117.00    60.  110.7  1.113  !-180. 
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IC  CP   NP   CR  CS     1.3418 117.00   180.   110.7  1.50   
IC  CP   NP   CR  HR3    1.3418 117.00   -60.  110.7  1.113  !-150. 
IC  CE4  CP   NP  CR     1.40   115.9   164.8  117.17  1.47 
 
IC  NP  CR  CS CZ2       1.47   109.5   180.0  109.5  1.50 
IC  NP  CR  CS HS1      1.47   109.5   60.0  109.5  1.10 
IC  NP  CR  CS HS2      1.47   109.5   -60.0  109.5  1.10 
 
 
IC  CR  CS  CZ2 NH1     1.54   109.5  -120.0  120.0  1.33 
IC  CR  CS  CZ2 NH2     1.54   109.5   120.0   120.0  1.33 
IC  CS  CZ2 NH2 HH21    1.54   120.0   170.0  109.5  0.99 
IC  CS  CZ2 NH2 HH22    1.54   120.0   -68.0  109.5  0.99 
IC  CS  CZ2 NH1 HH11    1.54   120.0   25.0   109.5  0.99 
IC  CS  CZ2 NH1 HH12    1.54   120.0  -145.0  109.5  0.99 
!IMPR OK CG1 NK CK 
!impr CZ3 NH4 NH5 NC 
!impr O2 NC CC2 CB 
impr CZ2 NH2 NH1 CS 
 
impr CG2 CZ NZ HZ  
impr NZ CE3 CZ OZ 
 
impr CG1 CK NK HN 
impr NK CE2 CK OK 
 
impr NP CE4 CP OP 
impr CR CP NP HP 
 
impr CD1 CE2 NE1 CH 
impr CD4 CE3 NE2 CI 
impr CD6 CE4 NE3 CF 
impr NP CP CR HP 
impr CP CE4 NP OP 
impr OP CE4 CP NP 
impr OP NP CP CE4 
impr OP NE3 CE4 CP 
 
!parameters 
read parameter card append 
 
BONDS 
! 
!atom types  Kb          b0 
! 
 
!polyamide bonds 
NH2  CPT   500.000     1.41 !A.E.L. 
CD   CA    500.000     1.45 !A.E.L.  
CT3  NY    500.000     1.46 !A.E.L. 
CPT  HP    500.000     1.083 !A.E.L. 
NC2  CPT   500.000     1.41   !A.E.L. 
CD   NH2   500.00      1.36   !A.E.L. 
OS  CC     400.000      1.35   !a.E.L. 
OS  CT1    400.00       1.46   !A.E.L. 
 
NC2  H    500.000     1.00   !A.E.L. 
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CC   H    500.00      1.10 
NH2  CY   500.00      1.40 
!--------------------------------------------- 
!bonds for ipy drug 
!N-methyl-pyrrole 
CPT  HP    500.00     1.08   !A.E.L. 
CT3  NY    500.000    1.46 
C    CPT   500.00     1.47 
NH1  CY    500.00     1.40 
C    H     500.00     1.10 
OS  CT1    400.00     1.46   !A.E.L. 
OS  C     400.000      1.35   !a.E.L. 
 
!imidazole 
NR1 CT3   500.00      1.46   !A.E.L. 
CPH2 C    500.000     1.47 
CPH1 NH1  500.00      1.40 
C    H    500.00      1.10 
!-------------------------------------------------- 
 
ANGLES 
! 
!atom types     Ktheta    Theta0   Kub     S0 
! 
!polyamide angles 
!----------------------------------------- 
NH2  CC   H     50.000    120.00   ! 
O    CC   H     44.00     122.00 
CC   NH2  CY    40.       125.2 
H    NH2  CY    40.       117.2 
 
CA   CA   NY    40.00     120.0    !A.E.L. 
CA   CA   CT1   40.00     120.0    !A.E.L. 
CA   CT1  CT3   40.00     108.3    !A.E.L. 
CPT  CPT  NH2   40.00     126.440    !A.E.L. 
CPT  CT3  HA    40.00     109.50    !A.E.L. 
CY  CPT  NH2    40.00     126.370    !A.E.L. 
CY  CA  CD      40.00     130.110    !A.E.L. 
CA  CD  OH1     40.00     112.290   !A.E.L. 
CA  CD  OB      40.00      130.070  !A.E.L. 
CPT  NH2 HC     40.00      109.50  !A.E.L. 
NY  CPT  CT3    40.00      121.490  !A.E.L. 
CPT CPT CT3     40.00      130.090  !A.E.L. 
CA  NY CA       40.00      125.590  !A.E.L. 
NY  CA  CD      40.00      121.470  !A.E.L. 
CPT CY  CPT     40.00      35.915   !A.E.L. 
CA  NY  CT3     40.0       125.60   !A.E.L. 
CPT NY  CT3     40.00      125.60   !A.E.L. 
NY  CT3 HA      40.0       109.5    !A.E.L. 
CPT CY  NH2     40.00      126.320  !A.E.L. 
CA  CY  NH2     40.00      126.320  !A.E.L. 
CY  NH2 HC      40.00      109.50   !A.E.L. 
CPT CPT HP      40.00      130.110  !A.E.L. 
NY  CPT HP      40.00      121.470  !A.E.L. 
CT2 NH2 CT3     40.00      109.5    !A.E.L. 
CT3 NH2 CT3     40.00      105.970  !A.E.L. 
CPT NY CPT       40.000     108.8    !A.E.L. 
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CA  CD   NH2     40.000      115.0    !A.E.L. 
OB  CD   NH2    40.000      121.9    !A.E.L.  !!! 
CD  NH2  CPT    40.000      120.6    !A.E.L. 
CD  NH2  HC     40.000      121.2    !A.E.L. 
NH2  CC  OS    50.00    116.50   50.000   2.45000    
O    CC  OS    15.00    121.00   50.00    2.44000 
CC   OS  CT1   33.00    109.50   30.000   2.16300 
OS   CT1 CT3   34.500   110.10   22.53    2.17900  
CPT  NH2 CC    40.000   120.6        !A.E.L. 
HC   NH2 CC    40.000   121.2        !A.E.L. 
 
HA   CT2  NH2   40.000   115.0     !A.E.L. 
CT2  CT2  NH2   40.000   108.8     !A.E.L. 
CT3  NC2  CT3   40.000   109.5     !A.E.L. 
CT2  NC2  CT3   40.000   109.5     !A.E.L. 
CT2  NC2  H     40.000   109.5     !a.E.L. 
CT3  NC2  H     40.000   109.5     !A.E.L. 
CD   NH2  CT2    40.000   120.6     !A.E.L. 
CT2  C    NC2   40.00    120.0     !A.E.L. 
C    CT2  NC2   40.00    35.00     !A.E.L. 
!---------------------------------------------------- 
!angles for ipy drug 
!Boc group 
NH1  C  OS    50.00    116.50   50.000   2.45000    
O    C  OS    15.00    121.00   50.00    2.44000 
C   OS  CT1   33.00    109.50   30.000   2.16300 
OS   CT1 CT3   34.500   110.10   22.53    2.17900   
 
!N-methyl-pyrrole 
CPT  CY   NH1    40.000    124.9     !A.E.L. 
CA   CA   NH1    40.000    127.2  
HP   CPT  CY     40.000    126.9 
HP   CPT  CPT    40.000    125.9 
CA   NY   CT3    40.000    123.3 
CPT  NY   CT3    40.000    127. 
CPT  CPT  C      40.000    130.2 
NY   CPT  C      40.000    122.1 
NY   CT3  HA     40.000    109.5 
CPT  C    O      40.000    123.5 
CPT  C    NH1    40.000    114.4 
H   NH1   H      40.000    115.7 
CY  NH1   H      40.000    117.2 
CY  NH1   C      40.00     125.2 
NH1  C    H      40.00     112.0  
CA   CY   NH1    40.000    127.2 
CA   CY   C      40.00     100.3 
CPT  CY   C      40.000    151.9 
CPT  CY   CPT    40.000    36.3 
!imidazole 
CPH1 CPH1 NH1    40.000   129.3  !A.E.L. 
NR2  CPH1 NH1    40.000   120.0 
CPH1 NR1  CT3    40.000   124.7 
CPH2 NR1  CT3    40.000   127.8 
NR1  CPH2 C      40.000   123.8 
NR2  CPH2 C      40.000   124.8 
NR1  CT3  HA     40.000   107.4 
CPH2 C    O      40.000   122.6 
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CPH2 C    NH1    40.000   112.9 
H   NH1   H      40.000   121.1 
CPH1 NH1  H      40.000   115.7 
CPH1 NH1  C      40.000   124.5 
NH1  C    H      40.000   112.4  
 
!cationic tail 
CT2 NH3 CT3    40.000     109.5  !A.E.l. 
CT3 NH3 CT3    40.00      110.8  
 
CA  CY  CC     40.0       100.3 
CPT CY  CC     40.0       151.9 
!--------------------------------------------------- 
 
DIHEDRALS 
! 
!atom types             Kchi    n   delta 
! 
!polyamide dihedrals 
!-------------------------------------------------------- 
CA  CA  CT1 CT3     0.2000  1  169.040 !A.E.L. 
CA  NY  CA  CY      0.2000  1  180.00 !A.E.L. 
CA  NY  CA  CD      0.2000  1  0.000  !A.E.L. 
CA  NY  CPT CT3     0.2000  1  0.000 !A.E.L. 
CA  CA  CA  CT1     0.2000  1  180.0  !A.E.L. 
CA  CA  NY  CPT     0.2000  1  90.0   !A.E.L. 
CA  CA  CA  NY      0.2000  1  180.00 !A.E.L. 
HP  CA  CA  CT1     0.2000  1  0.000  !A.E.L. 
CT1 CA  CA  NY      0.2000  1  0.000  !A.E.L. 
HP  CY  CPT NH2     0.2000  1  0.000  !A.E.L. 
HP  CY  CA  CD      0.2000  1  0.000  !A.E.L. 
CY  CPT NH2 HC      0.2000  1  0.00 !A.E.L.  ! 
 
 
CPT CY  CA  CD      0.6     1  -180.00 !A.E.L.    !0.2000 1 -180.0 
CPT CPT CT3 HA      0.2000  1  0.000  !A.E.L. 
CA  CA  NY CA       0.2000  1  -90.0   !A.E.L. 
CA  CY  CPT  NH2    0.2000  1  180.00  !A.E.L. 
 
NY  CPT CT3  HA     0.0000  1 -180.00  !A.E.L. 
 
CPT  CPT  NH2  HC   0.00  1    -180.0  !A.E.L. !180 
CPT  CPT  NH2  HC   0.00  3     0.00 
      
 
CPT  NY CA  CD      0.6000  1    180.00  !A.E.L.   !0.200  1  180.0 
NH2  CPT CPT CT3    0.2000  1    0.000 !A.E.L. 
 
CY  CA NY CT3       0.2000  1   180.0  !A.E.L. 
CPT CPT NY CT3      0.2000  1   -180.0 !A.E.L. 
 
CA  NY CT3 HA       0.20000  1    120.0 !A.E.L. 
 
CPT NY CT3 HA       0.000   1    -60.0 !A.E.L.   
CPT NY CT3 HA       0.000   1    0.00  !A.E.L. 
CPT NY CT3 HA       0.000   1    -120.0 !A.E.L.   
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CPT CY NH2 HC       0.2000  1    -180.0 !A.E.L. 
CA  CY NH2 HC       0.2000  1    -180.00 !A.E.L. 
NY  CA  CY NH2      0.2000  1     180.0 !A.E.L. 
CPT CPT CY NH2      0.2000  1     180.0 !A.E.L. 
CA  NY  CPT HP      0.2000  1     180.0 !A.E.L. 
HP  CPT NY CT3      0.2000  1       0.0     !A.E.L. 
CT3 NY  CA CD       0.2000  1       0.0     !A.E.L. 
CT2 CT2 NH2 CT3     0.2000  1     180.0     !A.E.L. 
HA  CT2 NH2 CT3     0.2000  1      60.0     !A.E.L. 
 
 
CA  CD  NH2 CPT     1.6000   1       0.0     !A.E.L. 
CA  CD  NH2 CPT     2.5      2      180.0    !A.E.L.  
CA  CD  NH2 HC      1.4      2        0.0     !A.E.L.  !2.5 180.0 
 
!CY  CPT NH2 CD      0.2000   1     180.0     !A.E.L. 
CY  CPT NH2 CD      1.5      2     180.0 
 
CPT CPT NH2 CD      0.9650  1     180.00      !A.E.L.  
CPT CPT NH2 CD      3.8500  2     180.0 
!CPT CPT NH2 CD      .2     0      0.00      
 
  
CPT NH2 CD  OB      1.5      2     0.0     !A.E.L. 
HC  NH2 CD  OB      3.5      2     180.0     !A.E.L. 
!----------------------------------------------------------- 
NH2 CC  OS  CT1     0.20       1      -180.0  !A.E.L. 
 
O   CC  OS  CT1      0.9650      1    180.0 !A.E.L. 
O   CC  OS  CT1      2.8500      2    180.0 !A.E.L. 
 
CT3 CT1 OS CC        0.6        1     0.00  !A.E.L. 
 
CY  CPT NH2 CC       0.200      1    180.0  !A.E.L. 
 
CPT CPT NH2 CC       0.9650     1    180.0 
CPT CPT NH2 CC       3.8500     2    180.0  
 
CPT NH2 CC  O        1.5        2      0.0  !A.E.L. 
 
HC  NH2 CC  O        2.5        2    180.0  !A.E.L. 
HC  NH2 CC  OS       1.4        2      0.0  !a.E.L> 
 
CPT NH2 CC OS        1.600      1    0.00 
CPT NH2 CC OS        2.500      2   180.0  
!-------------------------------------------------------------------- 
HA  CT2 NH2 HC        0.200      1.5   -120.00   !!!! 
HA  CT2 NH2 HC        0.200      1     120.0  
 
CT2 CT2 NH2 HC         1.500       1      60.000 
 
CT2 CT2 NC2 H         0.9          3.7    0.00 
CT2 CT2 NC2 H         0.0           0     60.00 
 
NH2 CT2 CT2 CT2      1.0           1      180.0 
NH2 CT2 CT2 CT2      1.3          1.5    -180.0 
NH2 CT2 CT2 CT2      0.5          3       0.00 
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CA  CD  NH2  CT2     1.6    1    0.00 
CA  CD  NH2  CT2     2.5    2   180.0 
    
CD  NH2 CT2  HA     0.2000  1   60.0 
CD  NH2 CT2  CT2    0.200   1   180.0 
 
OB  CD  NH2  CT2    1.5     2   0.0 
 
 
CY  CA  CD   NH2    2.3   2    -180.00  !A.E.L. 
NY  CA  CD   NH2    2.3  2     -180.0   !A.E.L.   
CY  CA  CD   OB     2.3  2      180.00  !A.E.L.   
NY  CA  CD   OB     2.3  2       180.00  !A.E.L.   
!----------------------------------------------------------- 
!dihedrals for ipy drug 
!N-methyl-pyrrole 
 
!------------------------------------------------ 
CA  NY   CT3  HA     0.00     1       0.00   !methyl group 
CA  NY   CT3  HA     0.000    3     -120.0 
CA  NY   CT3  HA     0.000    2     -60.0 
!------------------------------------------------ 
!------------------------------------------ 
CPT NY   CT3  HA     0.055   3        0.0    !methyl group 
CPT NY   CT3  HA     0.00    1      -120. 
CPT NY   CT3  HA     0.00    2       -60.0 
!------------------------------------------ 
 
HP  CPT  CY   CA     2.0     1        180.0 
HP  CPT  CY   NH1    2.8     2        180.0 
 
CY  CA   NY   CT3    0.8    2        180.0 
CY  NH1  C     O     1.5    2        180.0 
CY  NH1  C     H     1.20   1        180.0 
CPT CY   NH1   H     0.000  1         0.00 
CPT CY   NH1   C     0.200  1        180.0 
 
CPT  CPT  NY   CT3   0.8    2        180.0 
 
CPT  CPT  C    O     2.5    2        180.0 
 
CPT  CPT  C    NH1   1.5    2        180.0 
 
CA   NY   CPT  C     2.00   1        180.0 
 
HP   CA   CY   NH1   1.00   2        180.0 
 
CA   CY   NH1  H     0.0    1        0.00 
 
CA   CY   NH1  C     2.5    2       180.0   
CA   CY   NH1  C     3.0    1       180.0    
 
HP   CA   NY   CT3   0.4000  2      180.0 
NY   CA   CY   NH1   2.0     2      180.0 
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NY   CPT  C    O     1.3   2      180.0   
NY   CPT  C    O     3.7    1      180.0   
 
 
NY   CPT  C    NH1   1.0     1     0.0 
 
CPT  CPT  CY   NH1   3.0    2      180.0 
CT3  NY   CPT  C     0.8     2      180.0 
 
H    NH1  C    H     1.4     2      180.0 
 
CPT  C    NH1   H      2.5     2      180.0 
!------------------------------------------------- 
!linking of boc and pyrrole 
OS   C    NH1  CY     1.20   1        180.0 
H    NH1  C    OS     1.4    2        180.0 
 
CT1  OS   C    NH1    0.20   1       -180.0  !A.E.L. 
 
O   C  OS  CT1       1.9650  1        180.0 !A.E.L.   
O   C  OS  CT1       3.8500  2        180.0 !A.E.L. 
 
CT3 CT1 OS  C         1.5     1         0.00 
!---------------------------------------------- 
CPT  C  NH1 CY      2.5     2     180.0 
CPT  C  NH1 CT2     2.5     2     180.0 
!--------------------------------------------- 
!N-methyl-imidazole 
!--------------------------------------------------- 
CPH1 NR1  CT3  HA      0.00  1     0.00 
CPH1 NR1  CT3  HA      0.000  3     -120.0     !methyl group 
CPH1 NR1  CT3  HA      0.000  2    -60.0 
!---------------------------------------------------- 
!-------------------------------------------------- 
CPH2 NR1 CT3 HA        0.000   3    0. 
CPH2 NR1 CT3 HA        0.0000   1   -120.0     !methyl group 
CPH2 NR1 CT3 HA        0.0000   2   -60.0 
!-------------------------------------------------- 
 
CPH1 CPH1 NH1 H        0.1   2   -180.0  !A.E.L. 
CPH1 CPH1 NH1 H        0.00  1    0.00 
 
CPH1 CPH1 NH1 C        1.5     1   180.0 
CPH1 CPH1 NH1 C        1.0    2      00.0 
 
HR3  CPH1 CPH1 NH1     0.5000  2    0.00 
 
CPH1 NH1  C    O       0.2000  2    0.00 
CPH1 NH1  C    O       3.000  1   180.0 
 
CPH1 NH1  C   H        0.80000  2   -180.0 
CPH1 NH1  C   H        0.5000   1     0.00 
NR1  CPH1 CPH1 NH1     1.0000   1   -180.0 
CPH2 NR2 CPH1 NH1      0.2000   1    -180.0 
NR2 CPH1 NH1  H        1.3      2   0.0 
NR2 CPH1 NH1  C        1.3      2  -180.0 
H   NH1  C   H         0.2000   2    0.00 
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CPH1 CPH1 NR1  CT3     0.2000  1   -180.0 
O  C  NH1  H           2.5000  2    180.0 
 
!---------------------------------------------------- 
 
CPH1 NR1  CPH2 C       0.2000  1     -180.0  ! 
HR3  CPH1 NR1  CT3     0.2000  1    0.00    ! 
CPH1 NR2  CPH2 C       0.2000  1    -180.0 
 
NR1  CPH2 C   O        5.000    2   180.0   !5.5  !5.0 
NR1  CPH2 C   O        4.500    1   180.0   !3.00 
 
NR1  CPH2 C  NH1       1.000    2   0.0  ! 
NR2 CPH2 C   O         1.0000   1    0.0    ! 
NR2 CPH2 C  NH1        0.0000   2   0.00    ! 
 
CPH2 C   NH1  H        0.2000   1    0.00 
CPH2 C   NH1  H        0.2000   2   180.0 
 
NR2 CPH2 NR1 CT3       0.2000   1  180.0 
CT3 NR1  CPH2 C        0.2000   1   0.00 
 
CPH2 C  NH1 CY         0.2000  1   0.00 
CPH2 C  NH1 CY         0.2000  2   180.0 
!-------------------------------------------------------- 
!netropsin 
!CY  NH1 C   CT2        0.2000  1   0.00    
CY  NH1 C   CT2        1.000  1   -180.0 
O   C   CT2 NC2        0.5000  1   0.000 
CT2 CT2 C   NC2        0.000   1   0.00 
NH1 C   CT2 NC2        0.6000  1   0.00 
HA  CT2 C   NC2        0.0000  3   0.00 
!--------------------------------------------------------- 
!distamycin 
CC  NH2  CY  CPT       0.2000  1   180.0 
CC  NH2  CY  CA        2.5     2   180.0 
CC  NH2  CY  CA        3.7     1   180.0 
 
NH2 CY   CPT HP        2.8     2   180.0 
NH2 CY   CA  HP        1.00    1   180.0 
 
H   NH2  CC  H         1.4     2   180.0 
H   NH2  CY  CPT       0.050   1   0.00 
 
H   NH2  CY  CA        0.05    1   0.00 
O   CC   NH2 CY        1.50    2   180.0 
H   CC   NH2 CY        1.20    1   180.0 
 
IMPROPER 
!atom types              Kpsi        psi0 
 
!polyamide impropers 
CA   CA   CA   NY     90.000          0     -180.00 !A.E.L. 
CPT  CA   NY   CA     90.000          0      180.00 !A.E.L. 
CY   CPT  CPT  NH2    90.000          0      180.00 !A.E.L. 
CA   CA   CA   CT1    90.000          0      180.00 !A.E.L. 
OH1  CA   CD   OB     90.000          0      180.0  !A.E.L. 
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CD   NY   CA   CY     90.000          0      180.0  !A.E.L. 
CT3  NY   CPT  CPT    90.000          0     -180.0  !A.E.L. 
CA  CPT   NY   CT3    90.000          0     -180.0  !A.E.L. 
CA  CPT   CY   NH2    90.000          0      180.00 !A.E.L. 
CPT CY    CPT  NH2    90.000          0     -180.0  !A.E.L. 
CPT NY    CPT  HP     90.000          0      180.0  !A.E.L. 
 
OB   CA   CD    OH1   90.00           0     -180.0  !A.E.L. 
 
OH1  OB   CD    CA    90.00           0     -180.0  !A.E.L. 
OB   OH1  CD    CA    90.00           0      180.0  !A.E.L. 
CY   CD   OH1   H     90.000          0      -180.0 !A.E.L. 
HP   CA   CD    OH1   90.00           0       0.00  !A.E.L. 
OH1  CA   CY   HP     90.000          0       0.00  !A.E.L. 
OB   CA   NY   CT3    90.000          0       0.00  !A.E.L. 
NH2  CT2  CT2  HA     90.000          0      -180.0 !A.E.L. 
OB   NH2  CT2  CT2    90.000          0       180.0 !A.E.L. 
CA  OB   CD    OH1    90.000          0       180.0 !A.E.L. 
NY  CD   OH1   H      90.000          0       180.0 !A.E.L. 
CY  CD   CA    NY     90.000          0      -180.0 !A.E.L. 
H   CD   CA    CA     90.000          0        0.000!A.E.L. 
H   CD   CA    NY     90.000          0       -180.0 !A.E.L. 
CD  CY   CA    NY     90.000          0        180.0 !A.E.L. 
CD  CA   CPT   CPT    90.000          0        0.00  !A.E.L. 
CA  CA   NY    CPT    90.000          0       -180.0 !A.E.L. 
CA  CA   CA    HP     90.000          0        180.0 !A.E.L. 
CT1 CA   CA    HP     90.000          0       -180.0 !A.E.L. 
HC  HC  NH2 CPT       90.000          0         -120.0 !A.E.L. 
HC  CPT NH2 HC        90.000          0          120.0 !A.E.L. 
CA  CPT NH2 HC        90.000          0           -20.33 !A.E.L. 
 
NY CD  NH2 CPT        90.00           0        180.0  !A.E.L. 
 
NH2  CD  CPT HC        20.000          0        0.00  !A.E.L. 
CD   CA  NH2 OB        45.000          0        0.00  !A.E.L. 
CA   CPT NH2 HC        90.000          0        0.00  !A.E.L. 
 
CC  OS   NH2   O      45.000          0      0.00  !A.E.L. 
CC  NH2  OS    O      45.000          0      0.00  !A.E.L.    
OS  NH2  CC    O      90.000          0     -180.0 !A.E.L. 
OS  O    CC    NH2    90.00           0      180.0 !A.E.L. 
CT3 OS   CT1   CT3    90.000         0      -120.0 !A.E.L. 
 
NH2 CC  CPT  HC       20.00          0       0.00  !A.e.L. 
 
NH2 CD  CT2  HC      20.000          0       0.00  !A.E.L. 
CPT CA  CY  HP       100.000         0       180.0     
NY  CPT CPT HP       100.000         0      -180.0 
HP  CPT CY  CA       100.000         0       180.0 
HP  CA  CY  CPT      100.000         0      -180.0 
 
CD  CA  NH2  OB       45.000         0         0.00 
CD  NH2 CA   OB       45.000         0         0.000 
!--------------------------------------------------------- 
!impropers for ipy drug  
!Boc Binder 
NH1  C   H   CY       4.00            0      0.00 
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!-------------------- 
!imid 
CT3 CPH1 NR1 CPH2    90.000          0      180.0   
NR1 CPH1 CPH2 CT3    90.000         0       0.00 
NR1 CPH2 CPH1 CT3    90.000         0       0.00 
CPH2 NR1 NR2  C      90.000         0       0.00 
CPH2 NR2 NR1  C      90.000         0       0.00 
O CPT C NH1          90.00          0       -180.0 
 
CPH1 CPH2 NR1 CT3    90.000         0       180.0 
O   CT2  C   NH1     90.000         0       -180.0 
O   NH1  C   CT2     90.000         0       180.0 
CY  C   NH1  H       90.00          0       180.0 
C  CA  CY  NH1       90.000         0       0.00 
H  C   NH1 CT2       90.000         0       180.0 
NC2 O  C   CT2       90.000         0       0.00 
C NC2 CT2  HA        90.000         0       120.0 
NH1 C CT2  CT2       90.0           0        0.00 
C NC2 NC2 CT2        90.00          0        0.00 
!-------------------------------------------------------- 
!distamycin 
NH2  CC  H   CY        4.0            0        0.000 
NH1  CPT C   O         90.0           0        180.0 
O    NH1 C   CPT       90.0           0        180.0 
CT2  C   NH1 H         90.0           0        180.0 
CC   H   NH2 O         120.0          0         0.00 
CC   NH2  H  O         120.0          0         0.00 
 
 
 
NONBONDED nbxmod  5 atom cdiel shift vatom vdistance vswitch - 
cutnb 14.0 ctofnb 12.0 ctonnb 10.0 eps 1.0 e14fac 1.0 wmin 1.5  
                !adm jr., 5/08/91, suggested cutoff scheme 
! 
!atom  ignored    epsilon      Rmin/2   ignored   eps,1-4       
Rmin/2,1-4 
! 
 
end 
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Topology and parameters for Dervan polyamides; IPY is the imidazole-pyrrole 
polyamide and HP2 is the hydroxypyrrole polyamide (streamed in; used with parameters 
for DNA/proteins, par_all27_prot_na.inp).  
 
!-------------------------------- 
RESI IPY       1.00 
GROUP  
ATOM CZ1   CPH1  0.06 !             
ATOM HE1   HR3    0.09 !         
ATOM CZ2  CPH1   0.22 !        
ATOM NZ1  NR1   -0.36 !   
ATOM CZ3  CPH2   0.25 !       
ATOM NZ2  NR2   -0.36 !    
ATOM HE2  HR3    0.10  
 
GROUP 
ATOM CZ4   CT3    -0.27 
ATOM HZ1   HA     0.09 
ATOM HZ2   HA     0.09 
ATOM HZ3   HA     0.09    
!----------------------------- 
!1st pyrrole ring 
GROUP    
ATOM HG   HP     0.115 !                    
ATOM CG   CY    -0.145 !                     
ATOM CD2  CPT   -0.020 !               
ATOM CD1  CA     0.035 !        
ATOM HD1  HP     0.115 !         
ATOM NE1  NY    -0.230 !          
!ATOM HE1  H      0.380 !          
ATOM CE2  CPT    0.130 !   
 
GROUP 
ATOM CH   CT3   -0.27  !change C1 to CH 
ATOM H1   HA     0.09 
ATOM H2   HA     0.09 
ATOM H3   HA     0.09 
GROUP  
ATOM N2    NH1    -0.47 
ATOM HM     H      0.235 
ATOM CB     C      0.745  
ATOM O2     O     -0.51 
!ATOM HZ     H      0.235  
!------------------------------------------- 
!2nd pyrrole ring 
GROUP    
ATOM HG1   HP     0.115 !                    
ATOM CG1   CY    -0.145 !                     
ATOM CD3  CPT   -0.020 !               
ATOM CD4  CA     0.035 !        
ATOM HD4  HP     0.115 !         
ATOM NE2  NY    -0.230 !          
!ATOM HE1  H      0.380 !          
ATOM CE3  CPT    0.130 !   
GROUP 
ATOM CI   CT3   -0.27  !change C1 to CH 
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ATOM HI1   HA     0.09 
ATOM HI2   HA     0.09 
ATOM HI3   HA     0.09 
 
GROUP  
ATOM NK    NH1    -0.47 
ATOM HN     H      0.235 
ATOM CK     C      0.745  
ATOM OK     O     -0.51 
!ATOM HZ     H      0.235  
!-------------------------------------------- 
!3rd pyrrole ring 
GROUP    
ATOM HG2   HP     0.115 !                    
ATOM CG2   CY    -0.145 !                     
ATOM CD5  CPT   -0.020 !               
ATOM CD6  CA     0.035 !        
ATOM HD6  HP     0.115 !         
ATOM NE3  NY    -0.230 !          
!ATOM HE1  H      0.380 !          
ATOM CE4  CPT    0.130 !   
 
GROUP 
ATOM CF   CT3   -0.27  !change C1 to CH 
ATOM HF1   HA     0.09 
ATOM HF2   HA     0.09 
ATOM HF3   HA     0.09 
 
GROUP  
ATOM CL    C      0.51 
ATOM OL    O     -0.51 
GROUP  
ATOM NZ    NH1    -0.47 
ATOM HZ     H      0.235 
ATOM CZ     C      0.745  
ATOM OZ     O     -0.51 
!ATOM HZ     H      0.235  
!------------------------------------------- 
!beta-alanine 
GROUP 
ATOM NB    NH1   -0.47 
ATOM HB    H      0.47 
ATOM CV   CT2   -0.18 
ATOM HV1  HA     0.09 
!ATOM HR2  HA     0.09 
ATOM HV3  HA     0.09 
 
GROUP 
ATOM CC   CT2    -0.18 
ATOM HC1  HA      0.09 
ATOM HC2  HA      0.09 
GROUP  
ATOM CT   C       0.51 
ATOM OT   O      -0.51 
!ATOM NS   NH1     -0.47 
!ATOM HS1   H       0.235 
!ATOM HS2   H       0.235 
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!----------------------------------------- 
!cationic tail 
GROUP 
ATOM NC    NH1   -0.47 
ATOM HC    H      0.47 
ATOM CE   CT2   -0.11 
ATOM HM1  HA     0.09 
ATOM HM3  HA     0.09 
 
GROUP 
ATOM CJ  CT2     -0.11 
ATOM HJ1  HA      0.09 
AtOM HJ2  HA      0.09 
ATOM CM   CT2    -0.11 
ATOM HN1  HA      0.09 
ATOM HN2  HA      0.09 
GROUP 
ATOM NN   NH3     -0.30     
ATOM HH   HC       0.33  
ATOM CX   CT3      0.23 
ATOM HX1  HA       0.05 
ATOM HX2  HA       0.05 
ATOM HX3  HA       0.05 
ATOM CY   CT3      0.23 
ATOM HY1  HA       0.05 
ATOM HY2  HA       0.05 
ATOM HY3  HA       0.05 
 
 
!---------------------------------------- 
!bonds for imidazole 
BOND NZ2 CZ2  NZ1 CZ1  CZ3 NZ1        
BOND CZ1 HE1  CZ2 HE2 
DOUBLE NZ2 CZ3  CZ2 CZ1 
BOND NZ1 CZ4  CZ4 HZ1  CZ4 HZ2  CZ4 HZ3 
BOND CZ3 CB   
!-------------------------------------- 
!bonds for 1st pyrrole ring 
BOND CD2 HG  CD2 CG  NE1 CD1    
BOND NE1 CE2  
BOND CD1 HD1 
DOUBLE CD1 CG  CE2 CD2  
BOND CH NE1 
BOND CH H1  CH H2  CH H3 
BOND CE2 CK   
DOUBLE CB O2 
BOND N2 CG  N2 HM  N2 CB   
!------------------------------------------ 
!bonds for 2nd pyrrole ring 
BOND CD3 HG1  CD3 CG1  NE2 CD4    
BOND NE2 CE3  
BOND CD4 HD4 
DOUBLE CD4 CG1  CE3 CD3  
BOND CI NE2 
BOND CI HI1  CI HI2  CI HI3 
BOND CZ CE3  !NA CJ  NA HC  NA HD 
DOUBLE CK OK 
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BOND NK CG1  NK HN  NK CK  !CB HZ 
!-------------------------------------------- 
!bonds for 3rd pyrrole ring 
BOND CD5 HG2  CD5 CG2  NE3 CD6    
BOND NE3 CE4  
BOND CD6 HD6 
DOUBLE CD6 CG2  CE4 CD5  
BOND CF NE3 
BOND CF HF1  CF HF2  CF HF3 
BOND CL CE4  CL NB  !NB HE  NB HF 
DOUBLE CZ OZ CL OL 
BOND NZ CG2  NZ HZ  NZ CZ  !CB HZ 
!-------------------------------------------- 
!bonds for beta-alanine 
BOND  NB CV        
BOND  NB HB         
BOND  HV1 CV  HV3 CV       
DOUBLE CT OT 
BOND CV CC  CC CT  !CT NS 
BOND CT NC   !NS HS1  NS HS2  
BOND CC HC1  CC HC2 
!------------------------------------------- 
!bonds for cationic tail 
BOND NC HC   NC CE 
!BOND CL HL1  CL HL2  CL HL3 
BOND CE HM1   CE HM3  CE CJ 
!DOUBLE C O 
BOND CJ HJ1  CJ HJ2  CJ CM 
BOND CM HN1  CM HN2  CM NN 
BOND NN HH  NN CX  NN CY 
BOND CX HX1  CX HX2  CX HX3 
BOND CY HY1  CY HY2  CY HY3 
 
!-------------------------------------------- 
!ic's for imidazole ring 
! KEEPS HYDROGENS IN RING PLANE 
!IMPH NZ1  CZ1  CZ3  CZ4       NZ1  CZ3  CZ1   CZ4 
IMPH CZ2  CZ1   NZ2  HE2       CZ2  NZ2  CZ1   HE2 
IMPH CZ3  NZ1  NZ2  CB       CZ3  NZ2  NZ1  CB  
IMPH CZ1   CZ2  NZ1  HE1        CZ1   NZ1  CZ2  HE1 
IC   HE1    CZ1    NZ1   CZ3    1.07    122.67  -173.67  109.79   
1.2987 
IC   CZ1    NZ1   CZ3   NZ2     1.2854  109.79    0.21   110.31   
1.3071 
IC   NZ1   CZ3   NZ2   CZ2      1.2987  110.31    0.03   105.82   
1.3165 
IC   CZ3   NZ2   CZ2   CZ1      1.3071  105.82   -0.23  108.68   1.3758 
IC   NZ2   CZ2   CZ1   NZ1      1.3165  108.68    0.35  105.39   1.2854 
IC   NZ2   CZ2   CZ1    HE1     1.3165  108.68  172.86  131.52   1.07 
IC   CZ2   CZ1    NZ1   CZ3     1.3758  105.39   -0.34  109.79   1.2987 
IC   CZ2   NZ2   CZ3   CB       1.3165  105.82  -180.0  124.7    1.46 
IC   NZ2   CZ3   NZ1   CZ4      1.34    110.31   180.0  127.8    1.46 
IC   HE1   CZ1   CZ2   HE2      1.07    131.52    0.00  129.3    1.07 
 
!ic's for methyl group  
IC  CZ1 NZ1 CZ4 HZ1          1.37    124.7   0.00    109.5   1.08 
IC  CZ1 NZ1 CZ4 HZ2          1.37    124.7  -120.0   109.5   1.08 
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IC  CZ1 NZ1 CZ4 HZ3          1.37    124.7   120.    109.5   1.08 
ic  CZ3 NZ1 CZ4 HZ3         1.37    124.7   -60.0   109.5   1.08 
 
impr CZ4 CZ1 NZ1 CZ3  !for now 
!impr CZ1 CZ3 NZ1 CZ4 
 
!ic's for amide group on CE1 
IMPR  CB CZ3 N2 O2   !for now 
 
!ic  O3  CC  N3  HC     1.2233 122.84  -180.  119.23  0.9933  
!ic  O3  CC  N3  HD     1.2233 122.84  0.00  119.23  0.9933 
ic  HM  N2  CB  CZ3    0.9933 119.23    0.  116.25  1.47 
ic  CG  N2  CB  CZ3    1.40   119.23  180.0 116.25  1.47 
ic  N2  CB  CZ3 NZ1    1.3418 116.25  180.  122.1   1.38   
ic  N2  CB  CZ3 NZ2    1.3418 116.25    0.  130.3   1.40 
ic  NZ1 CZ3 CB  O2     1.38   122.0   0.00  123.5   1.2233 
ic  NZ2 CZ3 CB  O2     1.40   130.3   180.0 123.5   1.2233 
IC  CZ2 NZ2 CZ3 CB     1.40   107.1  -180.0 130.3   1.46  
ic  CZ1  ND1 CZ3 CB    1.37   109.8   -180.0 122.1   1.46 
ic  CZ4  ND1 CZ3 CB    1.46   127.0   0.00  122.1   1.46 
 
!!impr O3 ND1 CE1 CC  !for now 
!impr CC ND1 CE1 NE2 
!------------------------------------------------- 
!ic's for 1st pyrrole ring 
IC CG   CD1  NE1  CE2   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD2  CB   *CG  CD1   0.0000  0.0000 180.0000  0.0000  0.0000 
IC CD1  CG   CD2  CE2   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD2  CG   CD1  NE1   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD1  CE2  *NE1 CH   0.0000  0.0000 -180.0000  127.0  1.46 
IC CG   NE1  *CD1 HD1   0.0000  0.0000 180.0000  0.0000  0.0000 
IC CE2  CG   CD2  HG    0.0000  0.0000 -180.0000  126.9  1.08 
 
!ic's for methyl group  
IC  CD1 NE1 CH H1          1.37    123.2   0.00    109.5   1.08 
IC  CD1 NE1 CH H2          1.37    123.2  -120.0   109.5   1.08 
IC  CD1 ND1 CH H3          1.37    123.2   120.    109.5   1.08 
ic  CE2 NE1 CH H3          1.37    123.2   -60.0   109.5   1.08 
 
!ic's for amide group on CE2 
!!ic  O1  CA  N1  HA     1.2233 122.84  180.  119.23  0.9933  
!!ic  O1  CA  N1  HB     1.2233 122.84  0.00  119.23  0.9933 
ic  HN  NK  CK  CE2    0.9933 119.23    0.  116.25  1.47   
ic  CG1 NK  CK  CE2    1.40   119.23 -180.0 116.25  1.47 
ic  NK  CK  CE2 NE1    1.3418 116.25  180.  122.1  1.38  
ic  NK  CK  CE2 CD2    1.3418 116.25    0.  130.3  1.40 
ic  NE1 CE2 CK  OK     1.38   122.0   0.00  123.5  1.2233 
ic  CD2 CE2 CK  OK     1.40   130.3   180.0 123.5  1.2233 
IC  CG  CD2 CE2 CK     1.40   107.1  -180.0 130.3  1.46  
ic  CD1 NE1 CE2 CK     1.37   109.8   180.0 122.1  1.46 
ic  CH  NE1 CE2 CK     1.46   127.0   0.00  122.1  1.46 
 
!ic's for amide group on CG 
ic  O2  CB  N2  HM      1.2233 122.84  -180.  119.23  0.9933  
ic  HM  N2  CB  O2      0.9933 119.23   180.   112.25  1.23 
ic  O2  CB  N2  CG      1.2233 122.84    0.   125.57  1.40  
ic  CB  N2  CG  CD2     1.3418 122.57  180.   124.9  1.41  
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ic  CB  N2  CG  CD1     1.3418 122.57    0.   127.2  1.40 
IC  N2  CG  CD2 CE2     1.40   124.9   180.   107.1  1.40 
ic  N2  CG  CD1 NE1     1.40   127.2  -180.0  107.6  1.37 
!------------------------------------------------------- 
!ic's for 2nd pyrrole ring 
IC CG1   CD4  NE2  CE3   0.0000  0.0000  0.0000  0.0000  0.0000 
!IC CD2  CB   *CG  CD1   0.0000  0.0000 180.0000  0.0000  0.0000   
IC CD4  CG1   CD3  CE3   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD3  CG1   CD4  NE2   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD4  CE3  *NE2 CI   0.0000  0.0000 -180.0000  127.0  1.46 
IC CG1   NE2  *CD4 HD4   0.0000  0.0000 180.0000  0.0000  0.0000 
IC CE3  CG1   CD3  HG1    0.0000  0.0000 -180.0000  126.9  1.08 
 
!ic's for methyl group  
IC  CD4 NE2 CI HI1          1.37    123.2   0.00    109.5   1.08 
IC  CD4 NE2 CI HI2          1.37    123.2  -120.0   109.5   1.08 
IC  CD4 NC1 CI HI3          1.37    123.2   120.    109.5   1.08 
ic  CE3 NE2 CI HI3          1.37    123.2   -60.0   109.5   1.08 
 
!ic's for amide group on CE3 
!!ic  OJ  CJ  NA  HC     1.2233 122.84  180.  119.23  0.9933  
!!ic  OJ  CJ  NA  HD     1.2233 122.84  0.00  119.23  0.9933 
ic  HZ  NZ  CZ  CE3    0.9933 119.23    0.  116.25  1.47 
ic  CG2  NZ  CZ  CE3   1.40   119.23 -180.0 116.25  1.47 
ic  NZ  CZ  CE3 NE2    1.3418 116.25  180.  122.1  1.38  
ic  NZ  CZ  CE3 CD3    1.3418 116.25    0.  130.3  1.40 
ic  NE2 CE3 CZ  OZ     1.38   122.0   0.00  123.5  1.2233 
ic  CD3 CE3 CZ  OZ     1.40   130.3   180.0 123.5  1.2233 
IC  CG1  CD3 CE3 CZ     1.40   107.1  -180.0 130.3  1.46  
ic  CD4 NE2 CE3 CZ    1.37   109.8   180.0 122.1  1.46 
ic  CI  NE2 CE3 CZ     1.46   127.0   0.00  122.1  1.46 
!ic's for amide group on CG1 
ic  OK  CK  NK  HN      1.2233 122.84  -180.  119.23  0.9933  
ic  HN  NK  CK  CE2      0.9933 119.23    0.   112.25  1.47 !! 
ic  OK  CK  NK  CG1      1.2233 122.84    0.   125.57  1.40  
ic  CK  NK  CG1  CD3     1.3418 122.57  180.   124.9  1.41  
ic  CK  NK  CG1  CD4     1.3418 122.57    0.   127.2  1.40 
IC  NK  CG1  CD3 CE3     1.40   124.9   180.   107.1  1.40 
ic  NK  CG1  CD4 NE2     1.40   127.2  -180.0  107.6  1.37 
!------------------------------------------------------ 
!ic's for 3rd pyrrole ring 
IC CG2   CD6  NE3  CE4   0.0000  0.0000  0.0000  0.0000  0.0000 
!IC CD2  CB   *CG  CD1   0.0000  0.0000 180.0000  0.0000  0.0000   
IC CD6  CG2   CD5  CE4   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD5  CG2   CD6  NE3   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD6  CE4  *NE3 CF   0.0000  0.0000 -180.0000  127.0  1.46 
IC CG2   NE3  *CD6 HD6   0.0000  0.0000 180.0000  0.0000  0.0000 
IC CE4  CG2   CD5  HG2    0.0000  0.0000 -180.0000  126.9  1.08 
!ic's for methyl group  
IC  CD6 NE3 CF HF1          1.37    123.2   0.00    109.5   1.08 
IC  CD6 NE3 CF HF2          1.37    123.2  -120.0   109.5   1.08 
IC  CD6 NF1 CF HF3          1.37    123.2   120.    109.5   1.08 
ic  CE4 NE3 CF HF3          1.37    123.2   -60.0   109.5   1.08 
 
!ic's for amide group on CE4 
!!ic  OL  CL  NB  HE     1.2233 122.84  180.  119.23  0.9933  
!!ic  OL  CL  NB  HF     1.2233 122.84  0.00  119.23  0.9933 
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ic  HB  NB  CL  CE4    0.9933 119.23    0.  116.25  1.47 
!ic  HF  NB  CL  CE4    0.9933 119.23  -180.  116.25  1.47 
ic  CV  NB  CL  CE4    1.40   119.23 -180.0 116.25  1.47 
ic  NB  CL  CE4 NE3    1.3418 116.25  180.  122.1  1.38  
ic  NB  CL  CE4 CD5    1.3418 116.25    0.  130.3  1.40 
ic  NE3 CE4 CL  OL     1.38   122.0   0.00  123.5  1.2233 
ic  CD5 CE4 CL  OL     1.40   130.3   180.0 123.5  1.2233 
IC  CG2 CD5 CE4 CL     1.40   107.1  -180.0 130.3  1.46  
ic  CD6 NE3 CE4 CL    1.37   109.8   180.0 122.1  1.46 
ic  CF  NE3 CE4 CL     1.46   127.0   0.00  122.1  1.46 
!ic's for amide group on CG2 
ic  OZ  CZ  NZ  HZ      1.2233 122.84  -180.  119.23  0.9933  
ic  HZ  NZ  CZ  CE3      0.9933 119.23    0.   112.25  1.47 !! 
ic  OZ  CZ  NZ  CG2      1.2233 122.84    0.   125.57  1.40  
ic  CZ  NZ  CG2  CD5     1.3418 122.57  180.   124.9  1.41  
ic  CZ  NZ  CG2  CD6     1.3418 122.57    0.   127.2  1.40 
IC  NZ  CG2  CD5 CE4     1.40   124.9   180.   107.1  1.40 
ic  NZ  CG2  CD6 NE3     1.40   127.2  -180.0  107.6  1.37 
 
!-------------------------------------------------------- 
!ic's for beta-alanine 
IMPR  NB  CL  CV HB 
IMPR  CL  CE4 NB OL    
IC  OL CL NB HB      1.2233 122.84  -180. 119.23 0.9933  
IC  HB NB CL CE4     0.9933 119.23    0. 116.25 1.47  
IC  OL CL NB CV     1.2233 122.84    0. 122.57 1.4488  
IC  NB CL CE4 CD5    1.3418 116.25   0. 109.3  1.40   
IC  NB CL CE4 NE3    1.3418 116.25  -180. 109.3  1.38   
IC  NB CL CE4 HL3    1.3418 116.25  -60. 109.3  1.109   
IC  CL NB CV  CC     1.3418 122.57  180. 110.7  1.50   
IC  CL NB CV  HV1    1.3418 122.57  -60. 110.7  1.50   
IC  CL NB CV  HV3    1.3418 122.57   60. 110.7  1.50 
 
IC  NB CV CC HC1    1.4488  110.7   60.0  109.5   1.10 
IC  NB CV CC HC2    1.4488  110.7   -60.0  109.5   1.10 
IC  NB CV CC CT     1.4488  110.7  180.0 109.5   1.50 
!IC  CV CC CT NS     1.50    109.5  180.0  115.0   1.40 
IC  CV CC CT NC    1.50    109.5   -180.0 115.0   1.40 
IC  CV CC CT OT    1.50    109.5    0.00  123.1   1.24 
 
IC  OT CT NC HC    1.24    121.9   180.0  121.2  0.9933 
IC  OT CT NC CE    1.24    121.9    0.00  121.2  1.47 
 
!IC  OT CT NS HS1    1.24    121.9   180.0  121.2  0.9933 
!IC  OT CT NS HS2    1.24    121.9    0.00  121.2  1.47 
 
!IMPR CT CC NS OT 
IMPR CT CC NC OT 
!--------------------------------------------------- 
!ic's for tail 
IMPR  NC  CT  CE HC 
IMPR  CT  CC NC  OT    
 
IC  OT   CT   NC   HC      1.2233 122.84  180. 119.23 0.9933  
IC  HC   NC   CT   CL     0.9933 119.23    0. 116.25 1.5118  
IC  OT   CT   NC   CE     1.2233 122.84    0. 122.57 1.4488  
IC  NC   CT   CC  HC1    1.3418 116.25   -60. 109.3  1.109   
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IC  NC   CT   CC  HC2    1.3418 116.25    60. 109.3  1.109   
IC  NC   CT   CC  CV    1.3418 116.25  -180. 109.3  1.50  
IC  CT   NC   CE  HM1    1.3418 122.57   60. 110.7  1.113   
IC  CT   NC   CE  CJ     1.3418 122.57  180. 110.7  1.50   
IC  CT   NC   CE  HM3    1.3418 122.57  -60.  110.7  1.113   
IC  NC  CE  CJ CM       1.47   109.5   180.0  109.5  1.50 
IC  NC  CE  CJ HJ1      1.47   109.5   -60.0  109.5  1.10 
IC  NC  CE  CJ HJ2      1.47   109.5    60.0  109.5  1.10 
IC  CE CJ  CM HN1      1.50   109.5    60.0  109.5  1.10 
IC  CE CJ  CM HN2      1.50   109.5    -60.0 109.5  1.10 
IC  CE CJ  CM NN       1.50   109.5    180.0 109.5  1.40 
IC  CJ CM NN HH         1.50   109.5   60.00   109.5  1.10 
IC  CJ CM NN CX        1.50   109.5  -60.0  109.5  1.47 
IC  CJ CM NN CY        1.50   109.5   180.0  109.5  1.47 
 
IC  CM NN CX HX1       1.47   109.5   -60.0  109.5  1.10 
IC  CM NN CX HX2       1.47   109.5    60.0  109.5  1.10 
IC  CM NN CX HX3       1.47   109.5   -180.  109.5  1.10 
IC  CM NN CY HY1       1.47   109.5    60.0  109.5  1.10 
IC  CM N1 CY HY2       1.47   109.5    180.0 109.5  1.10 
IC  CM N1 CY HY3       1.47   109.5   -60.0  109.5  1.10 
 
!IC  H1 N1 CX HX1       1.10   109.5    -180.0  109.5  1.10 
IC  HY2 CY NN HH        1.10   109.5    -60.0    109.5  1.10 
IC  HY3 CY NN HH        1.10   109.5     60.0    109.5  1.10 
 
!impr OL NE3 CE4 CL 
!impr OL CE4 CL NB 
impr OT CC CT NC 
impr OT CV CC CT 
impr OT NC CT CC 
!-------------------------------- 
 
RESI HP2      1.00 
!imidazole ring 
GROUP  
ATOM CZ1   CPH1  0.06 !             
ATOM HE1   HR3    0.09 !         
ATOM CZ2  CPH1   0.22 !        
ATOM NZ1  NR1   -0.36 !   
ATOM CZ3  CPH2   0.25 !       
ATOM NZ2  NR2   -0.36 !    
ATOM HE2  HR3    0.10  
 
GROUP 
ATOM CZ4   CT3    -0.27 
ATOM HZ1   HA     0.09 
ATOM HZ2   HA     0.09 
ATOM HZ3   HA     0.09    
!----------------------------- 
!1st pyrrole ring 
GROUP    
ATOM HG   HP     0.115 !                    
ATOM CG   CY    -0.145 !                     
ATOM CD2  CPT   -0.020 !               
ATOM CD1  CA     0.035 !        
ATOM HD1  HP     0.115 !         
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ATOM NE1  NY    -0.230 !          
!ATOM HE1  H      0.380 !          
ATOM CE2  CPT    0.130 !   
 
GROUP 
ATOM CH   CT3   -0.27   
ATOM H1   HA     0.09 
ATOM H2   HA     0.09 
ATOM H3   HA     0.09 
GROUP  
ATOM N2    NH1    -0.47 
ATOM HM     H      0.235 
ATOM CB     C      0.745  
ATOM O2     O     -0.51 
!ATOM HZ     H      0.235 
!------------------------------------------- 
!2nd pyrrole ring--hydroxypyrrole 
GROUP    
!ATOM HG1   HP     0.115 !  
ATOM OG1   OH1     -0.326 
ATOM HG1   H        0.397                 
ATOM CG1   CY     -0.140 !                     
ATOM CD3   CPT     0.020 !               
ATOM CD4   CA      0.014 !        
ATOM HD4   HP      0.115 !         
ATOM NE2   NY     -0.230 !          
!ATOM HE1  H       0.380 !          
ATOM CE3   CPT     0.150 !   
GROUP 
ATOM CI   CT3   -0.27  !change C1 to CH 
ATOM HI1   HA     0.09 
ATOM HI2   HA     0.09 
ATOM HI3   HA     0.09 
 
GROUP  
ATOM NK    NH1    -0.47 
ATOM HN     H      0.235 
ATOM CK     C      0.745  
ATOM OK     O     -0.51 
!ATOM HZ     H      0.235  
!-------------------------------------------- 
!3rd pyrrole ring 
GROUP    
ATOM HG2   HP     0.115 !                    
ATOM CG2   CY    -0.145 !                     
ATOM CD5  CPT    -0.020 !               
ATOM CD6  CA      0.035 !        
ATOM HD6  HP      0.115 !         
ATOM NE3  NY     -0.230 !          
!ATOM HE1  H      0.380 !          
ATOM CE4  CPT     0.130 !   
 
GROUP 
ATOM CF   CT3   -0.27  !change C1 to CH 
ATOM HF1   HA     0.09 
ATOM HF2   HA     0.09 
ATOM HF3   HA     0.09 
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GROUP  
ATOM CL    C      0.51 
ATOM OL    O     -0.51 
!ATOM NB    NH1   -0.62 
!ATOM HE     H     0.31 
!ATOM HF     H     0.31  
GROUP  
ATOM NZ    NH1    -0.47 
ATOM HZ     H      0.235 
ATOM CZ     C      0.745  
ATOM OZ     O     -0.51 
!ATOM HZ     H      0.235  
!------------------------------------------- 
!beta-alanine 
GROUP 
ATOM NB    NH1   -0.47 
ATOM HB    H      0.47 
ATOM CV   CT2   -0.18 
ATOM HV1  HA     0.09 
!ATOM HR2  HA     0.09 
ATOM HV3  HA     0.09 
 
GROUP 
ATOM CC   CT2    -0.18 
ATOM HC1  HA      0.09 
ATOM HC2  HA      0.09 
GROUP  
ATOM CT   C       0.51 
ATOM OT   O      -0.51 
!ATOM NS   NH1     -0.47 
!ATOM HS1   H       0.235 
!ATOM HS2   H       0.235 
!----------------------------------------- 
!cationic tail 
GROUP 
ATOM NC    NH1   -0.47 
ATOM HC    H      0.47 
ATOM CE   CT2   -0.11 
ATOM HM1  HA     0.09 
ATOM HM3  HA     0.09 
GROUP 
ATOM CJ  CT2     -0.11 
ATOM HJ1  HA      0.09 
AtOM HJ2  HA      0.09 
ATOM CM   CT2    -0.11 
ATOM HN1  HA      0.09 
ATOM HN2  HA      0.09 
GROUP 
ATOM NN   NH3     -0.30     
ATOM HH   HC       0.33  
ATOM CX   CT3      0.23 
ATOM HX1  HA       0.05 
ATOM HX2  HA       0.05 
ATOM HX3  HA       0.05 
ATOM CY   CT3      0.23 
ATOM HY1  HA       0.05 
ATOM HY2  HA       0.05 
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ATOM HY3  HA       0.05 
 
 
!---------------------------------------- 
!bonds for imidazole 
BOND NZ2 CZ2  NZ1 CZ1  CZ3 NZ1        
BOND CZ1 HE1  CZ2 HE2 
DOUBLE NZ2 CZ3  CZ2 CZ1 
BOND NZ1 CZ4  CZ4 HZ1  CZ4 HZ2  CZ4 HZ3 
BOND CZ3 CB   
!-------------------------------------- 
!bonds for 1st pyrrole ring 
BOND CD2 HG  CD2 CG  NE1 CD1    
BOND NE1 CE2  
BOND CD1 HD1 
DOUBLE CD1 CG  CE2 CD2  
BOND CH NE1 
BOND CH H1  CH H2  CH H3 
BOND CE2 CK   
DOUBLE CB O2 
BOND N2 CG  N2 HM  N2 CB   
!------------------------------------------ 
!bonds for 2nd pyrrole ring 
BOND CD3 OG1  OG1 HG1  CD3 CG1  NE2 CD4    
BOND NE2 CE3  
BOND CD4 HD4 
DOUBLE CD4 CG1  CE3 CD3  
BOND CI NE2 
BOND CI HI1  CI HI2  CI HI3 
BOND CZ CE3  !NA CJ  NA HC  NA HD 
DOUBLE CK OK 
BOND NK CG1  NK HN  NK CK  !CB HZ 
!-------------------------------------------- 
!bonds for 3rd pyrrole ring 
BOND CD5 HG2  CD5 CG2  NE3 CD6    
BOND NE3 CE4  
BOND CD6 HD6 
DOUBLE CD6 CG2  CE4 CD5  
BOND CF NE3 
BOND CF HF1  CF HF2  CF HF3 
BOND CL CE4  CL NB  !NB HE  NB HF 
DOUBLE CZ OZ CL OL 
BOND NZ CG2  NZ HZ  NZ CZ  !CB HZ 
!-------------------------------------------- 
!bonds for beta-alanine 
BOND  NB CV        
BOND  NB HB         
BOND  HV1 CV  HV3 CV       
DOUBLE CT OT 
BOND CV CC  CC CT  !CT NS 
BOND CT NC   !NS HS1  NS HS2  
BOND CC HC1  CC HC2 
!------------------------------------------- 
!bonds for cationic tail 
BOND NC HC   NC CE 
!BOND CL HL1  CL HL2  CL HL3 
BOND CE HM1   CE HM3  CE CJ 
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!DOUBLE C O 
BOND CJ HJ1  CJ HJ2  CJ CM 
BOND CM HN1  CM HN2  CM NN 
BOND NN HH  NN CX  NN CY 
BOND CX HX1  CX HX2  CX HX3 
BOND CY HY1  CY HY2  CY HY3 
 
!-------------------------------------------- 
!ic's for imidazole ring 
! KEEPS HYDROGENS IN RING PLANE 
!IMPH NZ1  CZ1  CZ3  CZ4       NZ1  CZ3  CZ1   CZ4 
IMPH CZ2  CZ1   NZ2  HE2       CZ2  NZ2  CZ1   HE2 
IMPH CZ3  NZ1  NZ2  CB       CZ3  NZ2  NZ1  CB   
IMPH CZ1   CZ2  NZ1  HE1        CZ1   NZ1  CZ2  HE1 
IC   HE1    CZ1    NZ1   CZ3    1.07    122.67  -173.67  109.79   
1.2987 
IC   CZ1    NZ1   CZ3   NZ2     1.2854  109.79    0.21   110.31   
1.3071 
IC   NZ1   CZ3   NZ2   CZ2      1.2987  110.31    0.03   105.82   
1.3165 
IC   CZ3   NZ2   CZ2   CZ1      1.3071  105.82   -0.23  108.68   1.3758 
IC   NZ2   CZ2   CZ1   NZ1      1.3165  108.68    0.35  105.39   1.2854 
IC   NZ2   CZ2   CZ1    HE1     1.3165  108.68  172.86  131.52   1.07 
IC   CZ2   CZ1    NZ1   CZ3     1.3758  105.39   -0.34  109.79   1.2987 
IC   CZ2   NZ2   CZ3   CB       1.3165  105.82  -180.0  124.7    1.46 
IC   NZ2   CZ3   NZ1   CZ4      1.34    110.31   180.0  127.8    1.46 
IC   HE1   CZ1   CZ2   HE2      1.07    131.52    0.00  129.3    1.07 
 
!ic's for methyl group  
IC  CZ1 NZ1 CZ4 HZ1          1.37    124.7   0.00    109.5   1.08 
IC  CZ1 NZ1 CZ4 HZ2          1.37    124.7  -120.0   109.5   1.08 
IC  CZ1 NZ1 CZ4 HZ3          1.37    124.7   120.    109.5   1.08 
ic  CZ3 NZ1 CZ4 HZ3         1.37    124.7   -60.0   109.5   1.08 
 
impr CZ4 CZ1 NZ1 CZ3   
 
 
!ic's for amide group on CE1 
IMPR  CB CZ3 N2 O2    
 
!ic  O3  CC  N3  HC     1.2233 122.84  -180.  119.23  0.9933  
!ic  O3  CC  N3  HD     1.2233 122.84  0.00  119.23  0.9933 
ic  HM  N2  CB  CZ3    0.9933 119.23    0.  116.25  1.47 
ic  CG  N2  CB  CZ3    1.40   119.23  180.0 116.25  1.47 
ic  N2  CB  CZ3 NZ1    1.3418 116.25  180.  122.1   1.38   
ic  N2  CB  CZ3 NZ2    1.3418 116.25    0.  130.3   1.40 
ic  NZ1 CZ3 CB  O2     1.38   122.0   0.00  123.5   1.2233 
ic  NZ2 CZ3 CB  O2     1.40   130.3   180.0 123.5   1.2233 
IC  CZ2 NZ2 CZ3 CB     1.40   107.1  -180.0 130.3   1.46  
ic  CZ1  NZ1 CZ3 CB    1.37   109.8   -180.0 122.1   1.46 
ic  CZ4  NZ1 CZ3 CB    1.46   127.0   0.00  122.1   1.46 
 
!------------------------------------------------- 
!ic's for 1st pyrrole ring 
IC CG   CD1  NE1  CE2   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD2  CB   *CG  CD1   0.0000  0.0000 180.0000  0.0000  0.0000 
IC CD1  CG   CD2  CE2   0.0000  0.0000  0.0000  0.0000  0.0000 
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IC CD2  CG   CD1  NE1   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD1  CE2  *NE1 CH   0.0000  0.0000 -180.0000  127.0  1.46 
IC CG   NE1  *CD1 HD1   0.0000  0.0000 180.0000  0.0000  0.0000 
IC CE2  CG   CD2  HG    0.0000  0.0000 -180.0000  126.9  1.08 
 
!ic's for methyl group  
IC  CD1 NE1 CH H1          1.37    123.2   0.00    109.5   1.08 
IC  CD1 NE1 CH H2          1.37    123.2  -120.0   109.5   1.08 
IC  CD1 ND1 CH H3          1.37    123.2   120.    109.5   1.08 
ic  CE2 NE1 CH H3          1.37    123.2   -60.0   109.5   1.08 
 
!ic's for amide group on CE2 
!!ic  O1  CA  N1  HA     1.2233 122.84  180.  119.23  0.9933  
!!ic  O1  CA  N1  HB     1.2233 122.84  0.00  119.23  0.9933 
ic  HN  NK  CK  CE2    0.9933 119.23    0.  116.25  1.47  !look at this 
section 
ic  CG1 NK  CK  CE2    1.40   119.23 -180.0 116.25  1.47 
ic  NK  CK  CE2 NE1    1.3418 116.25  180.  122.1  1.38  
ic  NK  CK  CE2 CD2    1.3418 116.25    0.  130.3  1.40 
ic  NE1 CE2 CK  OK     1.38   122.0   0.00  123.5  1.2233 
ic  CD2 CE2 CK  OK     1.40   130.3   180.0 123.5  1.2233 
IC  CG  CD2 CE2 CK     1.40   107.1  -180.0 130.3  1.46  
ic  CD1 NE1 CE2 CK     1.37   109.8   180.0 122.1  1.46 
ic  CH  NE1 CE2 CK     1.46   127.0   0.00  122.1  1.46 
 
!ic's for amide group on CG 
ic  O2  CB  N2  HM      1.2233 122.84  -180.  119.23  0.9933  
ic  HM  N2  CB  O2      0.9933 119.23   180.   112.25  1.23 
ic  O2  CB  N2  CG      1.2233 122.84    0.   125.57  1.40  
ic  CB  N2  CG  CD2     1.3418 122.57  180.   124.9  1.41  
ic  CB  N2  CG  CD1     1.3418 122.57    0.   127.2  1.40 
IC  N2  CG  CD2 CE2     1.40   124.9   180.   107.1  1.40 
ic  N2  CG  CD1 NE1     1.40   127.2  -180.0  107.6  1.37 
!------------------------------------------------------- 
!ic's for 2nd pyrrole ring 
IC CG1   CD4  NE2  CE3   0.0000  0.0000  0.0000  0.0000  0.0000 
!IC CD2  CB   *CG  CD1   0.0000  0.0000 180.0000  0.0000  0.0000   
IC CD4  CG1   CD3  CE3   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD3  CG1   CD4  NE2   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD4  CE3  *NE2 CI   0.0000  0.0000 -180.0000  127.0  1.46 
IC CG1   NE2  *CD4 HD4   0.0000  0.0000 180.0000  0.0000  0.0000 
IC CE3  CG1   CD3  OG1    0.0000  0.0000 -180.0000  126.9  1.08 
IC CE3  CD3   OG1  HG1   0.000    0.00   0.00     0.00    0.00 
 
!ic's for methyl group  
IC  CD4 NE2 CI HI1          1.37    123.2   0.00    109.5   1.08 
IC  CD4 NE2 CI HI2          1.37    123.2  -120.0   109.5   1.08 
IC  CD4 NC1 CI HI3          1.37    123.2   120.    109.5   1.08 
ic  CE3 NE2 CI HI3          1.37    123.2   -60.0   109.5   1.08 
 
!ic's for amide group on CE3 
!!ic  OJ  CJ  NA  HC     1.2233 122.84  180.  119.23  0.9933  
!!ic  OJ  CJ  NA  HD     1.2233 122.84  0.00  119.23  0.9933 
ic  HZ  NZ  CZ  CE3    0.9933 119.23    0.  116.25  1.47 
ic  CG2  NZ  CZ  CE3   1.40   119.23 -180.0 116.25  1.47 
ic  NZ  CZ  CE3 NE2    1.3418 116.25  180.  122.1  1.38  
ic  NZ  CZ  CE3 CD3    1.3418 116.25    0.  130.3  1.40 
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ic  NE2 CE3 CZ  OZ     1.38   122.0   0.00  123.5  1.2233 
ic  CD3 CE3 CZ  OZ     1.40   130.3   180.0 123.5  1.2233 
IC  CG1  CD3 CE3 CZ     1.40   107.1  -180.0 130.3  1.46  
ic  CD4 NE2 CE3 CZ    1.37   109.8   180.0 122.1  1.46 
ic  CI  NE2 CE3 CZ     1.46   127.0   0.00  122.1  1.46 
!ic's for amide group on CG1 
ic  OK  CK  NK  HN      1.2233 122.84  -180.  119.23  0.9933  
ic  HN  NK  CK  CE2      0.9933 119.23    0.   112.25  1.47 !! 
ic  OK  CK  NK  CG1      1.2233 122.84    0.   125.57  1.40  
ic  CK  NK  CG1  CD3     1.3418 122.57  180.   124.9  1.41  
ic  CK  NK  CG1  CD4     1.3418 122.57    0.   127.2  1.40 
IC  NK  CG1  CD3 CE3     1.40   124.9   180.   107.1  1.40 
ic  NK  CG1  CD4 NE2     1.40   127.2  -180.0  107.6  1.37 
!------------------------------------------------------ 
!ic's for 3rd pyrrole ring 
IC CG2   CD6  NE3  CE4   0.0000  0.0000  0.0000  0.0000  0.0000 
!IC CD2  CB   *CG  CD1   0.0000  0.0000 180.0000  0.0000  0.0000   
IC CD6  CG2   CD5  CE4   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD5  CG2   CD6  NE3   0.0000  0.0000  0.0000  0.0000  0.0000 
IC CD6  CE4  *NE3 CF   0.0000  0.0000 -180.0000  127.0  1.46 
IC CG2   NE3  *CD6 HD6   0.0000  0.0000 180.0000  0.0000  0.0000 
IC CE4  CG2   CD5  HG2    0.0000  0.0000 -180.0000  126.9  1.08 
!ic's for methyl group  
IC  CD6 NE3 CF HF1          1.37    123.2   0.00    109.5   1.08 
IC  CD6 NE3 CF HF2          1.37    123.2  -120.0   109.5   1.08 
IC  CD6 NF1 CF HF3          1.37    123.2   120.    109.5   1.08 
ic  CE4 NE3 CF HF3          1.37    123.2   -60.0   109.5   1.08 
 
!ic's for amide group on CE4 
!!ic  OL  CL  NB  HE     1.2233 122.84  180.  119.23  0.9933  
!!ic  OL  CL  NB  HF     1.2233 122.84  0.00  119.23  0.9933 
ic  HB  NB  CL  CE4    0.9933 119.23    0.  116.25  1.47 
!ic  HF  NB  CL  CE4    0.9933 119.23  -180.  116.25  1.47 
ic  CV  NB  CL  CE4    1.40   119.23 -180.0 116.25  1.47 
ic  NB  CL  CE4 NE3    1.3418 116.25  180.  122.1  1.38  
ic  NB  CL  CE4 CD5    1.3418 116.25    0.  130.3  1.40 
ic  NE3 CE4 CL  OL     1.38   122.0   0.00  123.5  1.2233 
ic  CD5 CE4 CL  OL     1.40   130.3   180.0 123.5  1.2233 
IC  CG2 CD5 CE4 CL     1.40   107.1  -180.0 130.3  1.46  
ic  CD6 NE3 CE4 CL    1.37   109.8   180.0 122.1  1.46 
ic  CF  NE3 CE4 CL     1.46   127.0   0.00  122.1  1.46 
!ic's for amide group on CG2 
ic  OZ  CZ  NZ  HZ      1.2233 122.84  -180.  119.23  0.9933  
ic  HZ  NZ  CZ  CE3      0.9933 119.23    0.   112.25  1.47 !! 
ic  OZ  CZ  NZ  CG2      1.2233 122.84    0.   125.57  1.40  
ic  CZ  NZ  CG2  CD5     1.3418 122.57  180.   124.9  1.41  
ic  CZ  NZ  CG2  CD6     1.3418 122.57    0.   127.2  1.40 
IC  NZ  CG2  CD5 CE4     1.40   124.9   180.   107.1  1.40 
ic  NZ  CG2  CD6 NE3     1.40   127.2  -180.0  107.6  1.37 
 
!-------------------------------------------------------- 
!ic's for beta-alanine 
IMPR  NB  CL  CV HB 
IMPR  CL  CE4 NB OL    
IC  OL CL NB HB      1.2233 122.84  -180. 119.23 0.9933  
IC  HB NB CL CE4     0.9933 119.23    0. 116.25 1.47  
IC  OL CL NB CV     1.2233 122.84    0. 122.57 1.4488  
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IC  NB CL CE4 CD5    1.3418 116.25   0. 109.3  1.40   
IC  NB CL CE4 NE3    1.3418 116.25  -180. 109.3  1.38   
IC  NB CL CE4 HL3    1.3418 116.25  -60. 109.3  1.109   
IC  CL NB CV  CC     1.3418 122.57  180. 110.7  1.50   
IC  CL NB CV  HV1    1.3418 122.57  -60. 110.7  1.50   
IC  CL NB CV  HV3    1.3418 122.57   60. 110.7  1.50 
 
IC  NB CV CC HC1    1.4488  110.7   60.0  109.5   1.10 
IC  NB CV CC HC2    1.4488  110.7   -60.0  109.5   1.10 
IC  NB CV CC CT     1.4488  110.7  180.0 109.5   1.50 
!IC  CV CC CT NS     1.50    109.5  180.0  115.0   1.40 
IC  CV CC CT NC    1.50    109.5   -180.0 115.0   1.40 
IC  CV CC CT OT    1.50    109.5    0.00  123.1   1.24 
 
IC  OT CT NC HC    1.24    121.9   180.0  121.2  0.9933 
IC  OT CT NC CE    1.24    121.9    0.00  121.2  1.47 
 
!IC  OT CT NS HS1    1.24    121.9   180.0  121.2  0.9933 
!IC  OT CT NS HS2    1.24    121.9    0.00  121.2  1.47 
 
!IMPR CT CC NS OT 
IMPR CT CC NC OT 
!--------------------------------------------------- 
!ic's for tail 
IMPR  NC  CT  CE HC 
IMPR  CT  CC NC  OT    
 
IC  OT   CT   NC   HC      1.2233 122.84  180. 119.23 0.9933  
IC  HC   NC   CT   CL     0.9933 119.23    0. 116.25 1.5118  
IC  OT   CT   NC   CE     1.2233 122.84    0. 122.57 1.4488  
IC  NC   CT   CC  HC1    1.3418 116.25   -60. 109.3  1.109   
IC  NC   CT   CC  HC2    1.3418 116.25    60. 109.3  1.109   
IC  NC   CT   CC  CV    1.3418 116.25  -180. 109.3  1.50  
IC  CT   NC   CE  HM1    1.3418 122.57   60. 110.7  1.113   
IC  CT   NC   CE  CJ     1.3418 122.57  180. 110.7  1.50   
IC  CT   NC   CE  HM3    1.3418 122.57  -60.  110.7  1.113   
IC  NC  CE  CJ CM       1.47   109.5   180.0  109.5  1.50 
IC  NC  CE  CJ HJ1      1.47   109.5   -60.0  109.5  1.10 
IC  NC  CE  CJ HJ2      1.47   109.5    60.0  109.5  1.10 
IC  CE CJ  CM HN1      1.50   109.5    60.0  109.5  1.10 
IC  CE CJ  CM HN2      1.50   109.5    -60.0 109.5  1.10 
IC  CE CJ  CM NN       1.50   109.5    180.0 109.5  1.40 
IC  CJ CM NN HH         1.50   109.5   60.00   109.5  1.10 
IC  CJ CM NN CX        1.50   109.5  -60.0  109.5  1.47 
IC  CJ CM NN CY        1.50   109.5   180.0  109.5  1.47 
 
IC  CM NN CX HX1       1.47   109.5   -60.0  109.5  1.10 
IC  CM NN CX HX2       1.47   109.5    60.0  109.5  1.10 
IC  CM NN CX HX3       1.47   109.5   -180.  109.5  1.10 
IC  CM NN CY HY1       1.47   109.5    60.0  109.5  1.10 
IC  CM N1 CY HY2       1.47   109.5    180.0 109.5  1.10 
IC  CM N1 CY HY3       1.47   109.5   -60.0  109.5  1.10 
 
!IC  H1 N1 CX HX1       1.10   109.5    -180.0  109.5  1.10 
IC  HY2 CY NN HH        1.10   109.5    -60.0    109.5  1.10 
IC  HY3 CY NN HH        1.10   109.5     60.0    109.5  1.10 
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impr OT CC CT NC 
impr OT CV CC CT 
impr OT NC CT CC 
 
 
end 
 
 
read parameter card append 
 
BONDS 
! 
!atom types  Kb          b0 
! 
 
!sulfate bond 
OC   S     400.000     1.43 
 
!polyamide bonds 
NH2  CPT   500.000     1.41 !A.E.L. 
CD   CA    500.000     1.45 !A.E.L.  
CT3  NY    500.000     1.46 !A.E.L. 
CPT  HP    500.000     1.083 !A.E.L. 
NC2  CPT   500.000     1.41   !A.E.L. 
CD   NH2   500.00      1.36   !A.E.L. 
OS  CC     400.000      1.35   !a.E.L. 
OS  CT1    400.00       1.46   !A.E.L. 
 
!NH2 CT2   500.000     1.46   !A.E.L. 
NC2  H    500.000     1.00   !A.E.L. 
CC   H    500.00      1.10 
NH2  CY   500.00      1.40 
!--------------------------------------------- 
!bonds for ipy drug 
!N-methyl-pyrrole 
 
CPT  HP    500.00     1.08   !A.E.L. 
CT3  NY    500.000    1.46 
C    CPT   500.00     1.47 
NH1  CY    500.00     1.40 
C    H     500.00     1.10 
OS  CT1    400.00     1.46   !A.E.L. 
OS  C     400.000      1.35   !a.E.L. 
CPT OH1   500.000     1.37   !ael; for hydroxypyrrole 
 
!imidazole 
NR1 CT3   500.00      1.46   !A.E.L. 
CPH2 C    500.000     1.47 
CPH1 NH1  500.00      1.40 
C    H    500.00      1.10 
!-------------------------------------------------- 
 
ANGLES 
! 
!atom types     Ktheta    Theta0   Kub     S0 
! 
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!sulfate angle 
OC   S    OC    40.00     109.5 
 
!polyamide angles 
!----------------------------------------- 
NH2  CC   H     50.000    120.00   !from formamide 
O    CC   H     44.00     122.00 
CC   NH2  CY    40.       125.2 
H    NH2  CY    40.       117.2 
H    OH1  CPT   40.0      106.4  
OH1  CPT  CY    40.0      123.1 
OH1  CPT  CPT   40.00     129.0 
 
CA   CA   NY    40.00     120.0    !A.E.L. 
CA   CA   CT1   40.00     120.0    !A.E.L. 
CA   CT1  CT3   40.00     108.3    !A.E.L. 
CPT  CPT  NH2   40.00     126.440    !A.E.L. 
CPT  CT3  HA    40.00     109.50    !A.E.L. 
CY  CPT  NH2    40.00     126.370    !A.E.L. 
CY  CA  CD      40.00     130.110    !A.E.L. 
CA  CD  OH1     40.00     112.290   !A.E.L. 
CA  CD  OB      40.00      130.070  !A.E.L. 
CPT  NH2 HC     40.00      109.50  !A.E.L. 
NY  CPT  CT3    40.00      121.490  !A.E.L. 
CPT CPT CT3     40.00      130.090  !A.E.L. 
CA  NY CA       40.00      125.590  !A.E.L. 
NY  CA  CD      40.00      121.470  !A.E.L. 
CPT CY  CPT     40.00      35.915   !A.E.L. 
CA  NY  CT3     40.0       125.60   !A.E.L. 
CPT NY  CT3     40.00      125.60   !A.E.L. 
NY  CT3 HA      40.0       109.5    !A.E.L. 
CPT CY  NH2     40.00      126.320  !A.E.L. 
CA  CY  NH2     40.00      126.320  !A.E.L. 
CY  NH2 HC      40.00      109.50   !A.E.L. 
CPT CPT HP      40.00      130.110  !A.E.L. 
NY  CPT HP      40.00      121.470  !A.E.L. 
!HA  CT2 NH2     40.00      109.5    !A.E.L. 
!CT2 CT2 NH2     40.00      109.5    !A.E.L. 
!CT2 NH2 HC      40.00      109.5    !A.E.L. 
CT2 NH2 CT3     40.00      109.5    !A.E.L. 
CT3 NH2 CT3     40.00      105.970  !A.E.L. 
CPT NY CPT       40.000     108.8    !A.E.L. 
CA  CD   NH2     40.000      115.0    !A.E.L. 
OB  CD   NH2    40.000      121.9    !A.E.L.  !!! 
CD  NH2  CPT    40.000      120.6    !A.E.L. 
CD  NH2  HC     40.000      121.2    !A.E.L. 
!NH2 CD   OB     40.000      121.9    !A.E.L. 
NH2  CC  OS    50.00    116.50   50.000   2.45000    
O    CC  OS    15.00    121.00   50.00    2.44000 
CC   OS  CT1   33.00    109.50   30.000   2.16300 
OS   CT1 CT3   34.500   110.10   22.53    2.17900  
CPT  NH2 CC    40.000   120.6        !A.E.L. 
HC   NH2 CC    40.000   121.2        !A.E.L. 
 
HA   CT2  NH2   40.000   115.0     !A.E.L. 
CT2  CT2  NH2   40.000   108.8     !A.E.L. 
CT3  NC2  CT3   40.000   109.5     !A.E.L. 
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CT2  NC2  CT3   40.000   109.5     !A.E.L. 
CT2  NC2  H     40.000   109.5     !a.E.L. 
CT3  NC2  H     40.000   109.5     !A.E.L. 
CD   NH2  CT2    40.000   120.6     !A.E.L. 
CT2  C    NC2   40.00    120.0     !A.E.L. 
C    CT2  NC2   40.00    35.00     !A.E.L. 
!---------------------------------------------------- 
!angles for ipy drug 
!Boc group 
NH1  C  OS    50.00    116.50   50.000   2.45000    
O    C  OS    15.00    121.00   50.00    2.44000 
C   OS  CT1   33.00    109.50   30.000   2.16300 
OS   CT1 CT3   34.500   110.10   22.53    2.17900   
 
!N-methyl-pyrrole 
CPT  CY   NH1    40.000    124.9     !A.E.L. 
CA   CA   NH1    40.000    127.2  
HP   CPT  CY     40.000    126.9 
HP   CPT  CPT    40.000    125.9 
CA   NY   CT3    40.000    123.3 
CPT  NY   CT3    40.000    127. 
CPT  CPT  C      40.000    130.2 
NY   CPT  C      40.000    122.1 
NY   CT3  HA     40.000    109.5 
CPT  C    O      40.000    123.5 
CPT  C    NH1    40.000    114.4 
H   NH1   H      40.000    115.7 
CY  NH1   H      40.000    117.2 
CY  NH1   C      40.00     125.2 
NH1  C    H      40.00     112.0  
CA   CY   NH1    40.000    127.2 
CA   CY   C      40.00     100.3 
CPT  CY   C      40.000    151.9 
CPT  CY   CPT    40.000    36.3 
 
!imidazole 
CPH1 CPH1 NH1    40.000   129.3  !A.E.L. 
NR2  CPH1 NH1    40.000   120.0 
CPH1 NR1  CT3    40.000   124.7 
CPH2 NR1  CT3    40.000   127.8 
NR1  CPH2 C      40.000   123.8 
NR2  CPH2 C      40.000   124.8 
NR1  CT3  HA     40.000   107.4 
CPH2 C    O      40.000   122.6 
CPH2 C    NH1    40.000   112.9 
H   NH1   H      40.000   121.1 
CPH1 NH1  H      40.000   115.7 
CPH1 NH1  C      40.000   124.5 
NH1  C    H      40.000   112.4  
 
!cationic tail 
CT2 NH3 CT3    40.000     109.5  !A.E.l. 
CT3 NH3 CT3    40.00      110.8  
 
CA  CY  CC     40.0       100.3 
CPT CY  CC     40.0       151.9 
!--------------------------------------------------- 
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DIHEDRALS 
! 
!atom types             Kchi    n   delta 
! 
!polyamide dihedrals 
!-------------------------------------------------------- 
CA  CA  CT1 CT3     0.2000  1  169.040 !A.E.L. 
CA  NY  CA  CY      0.2000  1  180.00 !A.E.L. 
CA  NY  CA  CD      0.2000  1  0.000  !A.E.L. 
CA  NY  CPT CT3     0.2000  1  0.000 !A.E.L. 
CA  CA  CA  CT1     0.2000  1  180.0  !A.E.L. 
CA  CA  NY  CPT     0.2000  1  90.0   !A.E.L. 
CA  CA  CA  NY      0.2000  1  180.00 !A.E.L. 
HP  CA  CA  CT1     0.2000  1  0.000  !A.E.L. 
CT1 CA  CA  NY      0.2000  1  0.000  !A.E.L. 
HP  CY  CPT NH2     0.2000  1  0.000  !A.E.L. 
HP  CY  CA  CD      0.2000  1  0.000  !A.E.L. 
CY  CPT NH2 HC      0.2000  1  0.00 !A.E.L.  ! 
 
 
CPT CY  CA  CD      0.6     1  -180.00 !A.E.L.     
CPT CPT CT3 HA      0.2000  1  0.000  !A.E.L. 
CA  CA  NY CA       0.2000  1  -90.0   !A.E.L. 
CA  CY  CPT  NH2    0.2000  1  180.00  !A.E.L. 
 
NY  CPT CT3  HA     0.0000  1 -180.00  !A.E.L. 
 
CPT  CPT  NH2  HC   0.00  1    -180.0  !A.E.L.  
CPT  CPT  NH2  HC   0.00  3     0.00 
      
 
CPT  NY CA  CD      0.6000  1    180.00  !A.E.L.    
NH2  CPT CPT CT3    0.2000  1    0.000 !A.E.L. 
 
CY  CA NY CT3       0.2000  1   180.0  !A.E.L. 
CPT CPT NY CT3      0.2000  1   -180.0 !A.E.L. 
 
CA  NY CT3 HA       0.20000  1    120.0 !A.E.L. 
 
CPT NY CT3 HA       0.000   1    -60.0 !A.E.L.   
CPT NY CT3 HA       0.000   1    0.00  !A.E.L. 
CPT NY CT3 HA       0.000   1    -120.0 !A.E.L.   
 
CPT CY NH2 HC       0.2000  1    -180.0 !A.E.L. 
CA  CY NH2 HC       0.2000  1    -180.00 !A.E.L. 
NY  CA  CY NH2      0.2000  1     180.0 !A.E.L. 
CPT CPT CY NH2      0.2000  1     180.0 !A.E.L. 
CA  NY  CPT HP      0.2000  1     180.0 !A.E.L. 
HP  CPT NY CT3      0.2000  1       0.0     !A.E.L. 
CT3 NY  CA CD       0.2000  1       0.0     !A.E.L. 
CT2 CT2 NH2 CT3     0.2000  1     180.0     !A.E.L. 
HA  CT2 NH2 CT3     0.2000  1      60.0     !A.E.L. 
 
 
CA  CD  NH2 CPT     1.6000   1       0.0     !A.E.L. 
CA  CD  NH2 CPT     2.5      2      180.0    !A.E.L.  
 401
CA  CD  NH2 HC      1.4      2        0.0     !A.E.L.  !2.5 180.0 
 
!CY  CPT NH2 CD      0.2000   1     180.0     !A.E.L. 
CY  CPT NH2 CD      1.5      2     180.0 
 
CPT CPT NH2 CD      0.9650  1     180.00      !A.E.L.  
CPT CPT NH2 CD      3.8500  2     180.0 
!CPT CPT NH2 CD      .2     0      0.00      
 
  
CPT NH2 CD  OB      1.5      2     0.0     !A.E.L. 
HC  NH2 CD  OB      3.5      2     180.0     !A.E.L. 
!----------------------------------------------------------- 
NH2 CC  OS  CT1     0.20       1      -180.0  !A.E.L. 
 
O   CC  OS  CT1      0.9650      1    180.0 !A.E.L. 
O   CC  OS  CT1      2.8500      2    180.0 !A.E.L. 
 
CT3 CT1 OS CC        0.6        1     0.00  !A.E.L. 
 
CY  CPT NH2 CC       0.200      1    180.0  !A.E.L. 
 
CPT CPT NH2 CC       0.9650     1    180.0 
CPT CPT NH2 CC       3.8500     2    180.0  
 
CPT NH2 CC  O        1.5        2      0.0  !A.E.L. 
 
HC  NH2 CC  O        2.5        2    180.0  !A.E.L. 
HC  NH2 CC  OS       1.4        2      0.0  !a.E.L> 
 
CPT NH2 CC OS        1.600      1    0.00 
CPT NH2 CC OS        2.500      2   180.0  
!-------------------------------------------------------------------- 
HA  CT2 NH2 HC        0.200      1.5   -120.00   !!!! 
HA  CT2 NH2 HC        0.200      1     120.0  
 
CT2 CT2 NH2 HC         1.500       1      60.000 
 
CT2 CT2 NC2 H         0.9          3.7    0.00 
CT2 CT2 NC2 H         0.0           0     60.00 
 
NH2 CT2 CT2 CT2      1.0           1      180.0 
NH2 CT2 CT2 CT2      1.3          1.5    -180.0 
NH2 CT2 CT2 CT2      0.5          3       0.00 
 
 
CA  CD  NH2  CT2     1.6    1    0.00 
CA  CD  NH2  CT2     2.5    2   180.0 
    
CD  NH2 CT2  HA     0.2000  1   60.0 
CD  NH2 CT2  CT2    0.200   1   180.0 
 
OB  CD  NH2  CT2    1.5     2   0.0 
 
 
CY  CA  CD   NH2    2.3   2    -180.00  !A.E.L. 
NY  CA  CD   NH2    2.3  2     -180.0   !A.E.L.   
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CY  CA  CD   OB     2.3  2      180.00  !A.E.L.   
NY  CA  CD   OB     2.3  2       180.00  !A.E.L.   
!----------------------------------------------------------- 
!dihedrals for ipy drug 
!N-methyl-pyrrole 
 
!------------------------------------------------ 
CA  NY   CT3  HA     0.00     1       0.00   !methyl group 
CA  NY   CT3  HA     0.000    3     -120.0 
CA  NY   CT3  HA     0.000    2     -60.0 
!------------------------------------------------ 
!------------------------------------------ 
CPT NY   CT3  HA     0.055   3        0.0    !methyl group 
CPT NY   CT3  HA     0.00    1      -120. 
CPT NY   CT3  HA     0.00    2       -60.0 
!------------------------------------------ 
 
HP  CPT  CY   CA     2.0     1        180.0 
 
HP  CPT  CY   NH1    2.8     2        180.0 
 
CY  CA   NY   CT3    0.8    2        180.0 
CY  NH1  C     O     1.5    2        180.0 
CY  NH1  C     H     1.20   1        180.0 
CPT CY   NH1   H     0.000  1         0.00 
CPT CY   NH1   C     0.200  1        180.0 
 
CPT  CPT  NY   CT3   0.8    2        180.0 
 
CPT  CPT  C    O     2.5    2        180.0 
 
CPT  CPT  C    NH1   1.5    2        180.0 
 
CA   NY   CPT  C     2.00   1        180.0 
 
HP   CA   CY   NH1   1.00   2        180.0 
 
CA   CY   NH1  H     0.0    1        0.00 
 
CA   CY   NH1  C     2.5    2       180.0   
CA   CY   NH1  C     3.0    1       180.0    
 
HP   CA   NY   CT3   0.4000  2      180.0 
NY   CA   CY   NH1   2.0     2      180.0 
 
NY   CPT  C    O     1.3   2      180.0   
NY   CPT  C    O     3.7    1      180.0  
 
 
NY   CPT  C    NH1   1.0     1     0.0 
 
CPT  CPT  CY   NH1   3.0    2      180.0 
CT3  NY   CPT  C     0.8     2      180.0 
 
H    NH1  C    H     1.4     2      180.0 
 
CPT  C    NH1   H      2.5     2      180.0 
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!------------------------------------------------- 
!---------------------------------------------- 
CPT  C  NH1 CY      2.5     2     180.0 
CPT  C  NH1 CT2     2.5     2     180.0 
!--------------------------------------------- 
!N-methyl-imidazole 
!--------------------------------------------------- 
CPH1 NR1  CT3  HA      0.00  1     0.00 
CPH1 NR1  CT3  HA      0.000  3     -120.0     !methyl group 
CPH1 NR1  CT3  HA      0.000  2    -60.0 
!---------------------------------------------------- 
!-------------------------------------------------- 
CPH2 NR1 CT3 HA        0.000   3    0. 
CPH2 NR1 CT3 HA        0.0000   1   -120.0     !methyl group 
CPH2 NR1 CT3 HA        0.0000   2   -60.0 
!-------------------------------------------------- 
 
CPH1 CPH1 NH1 H        0.1   2   -180.0  !A.E.L. 
CPH1 CPH1 NH1 H        0.00  1    0.00 
 
CPH1 CPH1 NH1 C        1.5     1   180.0 
CPH1 CPH1 NH1 C        1.0    2      00.0 
 
HR3  CPH1 CPH1 NH1     0.5000  2    0.00 
 
CPH1 NH1  C    O       0.2000  2    0.00 
CPH1 NH1  C    O       3.000  1   180.0 
 
CPH1 NH1  C   H        0.80000  2   -180.0 
CPH1 NH1  C   H        0.5000   1     0.00 
 
NR1  CPH1 CPH1 NH1     1.0000   1   -180.0 
CPH2 NR2 CPH1 NH1      0.2000   1    -180.0 
NR2 CPH1 NH1  H        1.3      2   0.0 
NR2 CPH1 NH1  C        1.3      2  -180.0 
H   NH1  C   H         0.2000   2    0.00 
CPH1 CPH1 NR1  CT3     0.2000  1   -180.0 
O  C  NH1  H           2.5000  2    180.0 
 
!---------------------------------------------------- 
 
CPH1 NR1  CPH2 C       0.2000  1     -180.0  ! 
HR3  CPH1 NR1  CT3     0.2000  1    0.00    ! 
CPH1 NR2  CPH2 C       0.2000  1    -180.0 
 
NR1  CPH2 C   O        5.000    2   180.0    
NR1  CPH2 C   O        4.500    1   180.0    
 
NR1  CPH2 C  NH1       1.000    2   0.0  ! 
NR2 CPH2 C   O         1.0000   1    0.0    ! 
NR2 CPH2 C  NH1        0.0000   2   0.00    ! 
 
CPH2 C   NH1  H        0.2000   1    0.00 
CPH2 C   NH1  H        0.2000   2   180.0 
 
NR2 CPH2 NR1 CT3       0.2000   1  180.0 
CT3 NR1  CPH2 C        0.2000   1   0.00 
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CPH2 C  NH1 CY         0.2000  1   0.00 
CPH2 C  NH1 CY         0.2000  2   180.0 
!-------------------------------------------------------- 
!netropsin 
!CY  NH1 C   CT2        0.2000  1   0.00    
CY  NH1 C   CT2        1.000  1   -180.0 
 
O   C   CT2 NC2        0.5000  1   0.000 
CT2 CT2 C   NC2        0.000   1   0.00 
NH1 C   CT2 NC2        0.6000  1   0.00 
HA  CT2 C   NC2        0.0000  3   0.00 
!--------------------------------------------------------- 
!distamycin 
CC  NH2  CY  CPT       0.2000  1   180.0 
CC  NH2  CY  CA        2.5     2   180.0 
CC  NH2  CY  CA        3.7     1   180.0 
 
NH2 CY   CPT HP        2.8     2   180.0 
NH2 CY   CA  HP        1.00    1   180.0 
 
H   NH2  CC  H         1.4     2   180.0 
H   NH2  CY  CPT       0.050   1   0.00 
 
H   NH2  CY  CA        0.05    1   0.00 
O   CC   NH2 CY        1.50    2   180.0 
H   CC   NH2 CY        1.20    1   180.0 
!hydroxypyrrole 
OH1 CPT  CY  CA        3.1     2   180.0 
 
OH1 CPT  CY  NH1       0.20    2   180.0 
 
H  OH1  CPT  CY        0.00    2   90.0 
H  OH1  CPT  CY        4.0     1   0.00 
 
H  OH1  CPT  CPT       0.50    2   180.0 
H  OH1  CPT  CPT       0.30    1    0.00 
 
IMPROPER 
!atom types              Kpsi        psi0 
!polyamide impropers 
CA   CA   CA   NY     90.000          0     -180.00 !A.E.L. 
CPT  CA   NY   CA     90.000          0      180.00 !A.E.L. 
CY   CPT  CPT  NH2    90.000          0      180.00 !A.E.L. 
CA   CA   CA   CT1    90.000          0      180.00 !A.E.L. 
OH1  CA   CD   OB     90.000          0      180.0  !A.E.L. 
CD   NY   CA   CY     90.000          0      180.0  !A.E.L. 
CT3  NY   CPT  CPT    90.000          0     -180.0  !A.E.L. 
CA  CPT   NY   CT3    90.000          0     -180.0  !A.E.L. 
CA  CPT   CY   NH2    90.000          0      180.00 !A.E.L. 
CPT CY    CPT  NH2    90.000          0     -180.0  !A.E.L. 
CPT NY    CPT  HP     90.000          0      180.0  !A.E.L. 
 
OB   CA   CD    OH1   90.00           0     -180.0  !A.E.L. 
 
OH1  OB   CD    CA    90.00           0     -180.0  !A.E.L. 
OB   OH1  CD    CA    90.00           0      180.0  !A.E.L. 
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CY   CD   OH1   H     90.000          0      -180.0 !A.E.L. 
HP   CA   CD    OH1   90.00           0       0.00  !A.E.L. 
OH1  CA   CY   HP     90.000          0       0.00  !A.E.L. 
OB   CA   NY   CT3    90.000          0       0.00  !A.E.L. 
NH2  CT2  CT2  HA     90.000          0      -180.0 !A.E.L. 
OB   NH2  CT2  CT2    90.000          0       180.0 !A.E.L. 
CA  OB   CD    OH1    90.000          0       180.0 !A.E.L. 
NY  CD   OH1   H      90.000          0       180.0 !A.E.L. 
CY  CD   CA    NY     90.000          0      -180.0 !A.E.L. 
H   CD   CA    CA     90.000          0        0.000!A.E.L. 
H   CD   CA    NY     90.000          0       -180.0 !A.E.L. 
CD  CY   CA    NY     90.000          0        180.0 !A.E.L. 
CD  CA   CPT   CPT    90.000          0        0.00  !A.E.L. 
CA  CA   NY    CPT    90.000          0       -180.0 !A.E.L. 
CA  CA   CA    HP     90.000          0        180.0 !A.E.L. 
CT1 CA   CA    HP     90.000          0       -180.0 !A.E.L. 
HC  HC  NH2 CPT       90.000          0       -120.0 !A.E.L. 
HC  CPT NH2 HC        90.000          0        120.0 !A.E.L. 
CA  CPT NH2 HC        90.000          0       -20.33 !A.E.L. 
 
NY CD  NH2 CPT        90.00           0        180.0  !A.E.L. 
 
NH2  CD  CPT HC        20.000          0        0.00  !A.E.L. 
CD   CA  NH2 OB        45.000          0        0.00  !A.E.L. 
CA   CPT NH2 HC        90.000          0        0.00  !A.E.L. 
 
CC  OS   NH2   O      45.000          0      0.00  !A.E.L. 
CC  NH2  OS    O      45.000          0      0.00  !A.E.L.    
OS  NH2  CC    O      90.000          0     -180.0 !A.E.L. 
OS  O    CC    NH2    90.00           0      180.0 !A.E.L. 
CT3 OS   CT1   CT3    90.000         0      -120.0 !A.E.L. 
 
NH2 CC  CPT  HC       20.00          0       0.00  !A.e.L. 
 
NH2 CD  CT2  HC      20.000          0       0.00  !A.E.L. 
CPT CA  CY  HP       100.000         0       180.0     
NY  CPT CPT HP       100.000         0      -180.0 
HP  CPT CY  CA       100.000         0       180.0 
HP  CA  CY  CPT      100.000         0      -180.0 
 
CD  CA  NH2  OB       45.000         0         0.00 
CD  NH2 CA   OB       45.000         0         0.000 
!--------------------------------------------------------- 
!impropers for ipy drug  
! 
NH1  C   H   CY       4.00            0      0.00 
!-------------------- 
!imid 
CT3 CPH1 NR1 CPH2    90.000          0      180.0   
NR1 CPH1 CPH2 CT3    90.000         0       0.00 
NR1 CPH2 CPH1 CT3    90.000         0       0.00 
CPH2 NR1 NR2  C      90.000         0       0.00 
CPH2 NR2 NR1  C      90.000         0       0.00 
O CPT C NH1          90.00          0       -180.0 
 
CPH1 CPH2 NR1 CT3    90.000         0       180.0 
O   CT2  C   NH1     90.000         0       -180.0 
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O   NH1  C   CT2     90.000         0       180.0 
CY  C   NH1  H       90.00          0       180.0 
C  CA  CY  NH1       90.000         0       0.00 
H  C   NH1 CT2       90.000         0       180.0 
NC2 O  C   CT2       90.000         0       0.00 
C NC2 CT2  HA        90.000         0       120.0 
NH1 C CT2  CT2       90.0           0        0.00 
C NC2 NC2 CT2        90.00          0        0.00 
!-------------------------------------------------------- 
!distamycin 
NH2  CC  H   CY        4.0            0        0.000 
NH1  CPT C   O         90.0           0        180.0 
O    NH1 C   CPT       90.0           0        180.0 
CT2  C   NH1 H         90.0           0        180.0 
CC   H   NH2 O         120.0          0         0.00 
CC   NH2  H  O         120.0          0         0.0 
 
 
NONBONDED nbxmod  5 atom cdiel shift vatom vdistance vswitch - 
cutnb 14.0 ctofnb 12.0 ctonnb 10.0 eps 1.0 e14fac 1.0 wmin 1.5  
                !adm jr., 5/08/91, suggested cutoff scheme 
! 
!atom  ignored    epsilon      Rmin/2   ignored   eps,1-4       
Rmin/2,1-4 
! 
!Butadiene  
CC1A   0.0   -0.0680     2.0900 ! 
CC1B   0.0   -0.0680     2.0900 ! 
CC2    0.0   -0.0640     2.0800 ! 
!sulfate 
!OC     2.1400  -0.6469   1.6000 
!S      0.3400   -0.0430  1.890 
!SCH1, SCH2 
NS1    0.000000  -0.200000     1.850000 !N for deprotonated Schiff's 
base 
NS2    0.000000  -0.200000     1.850000 !N for protonated Schiff's base 
 
end 
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Appendix B 
 
This appendix contains the initial CHARMM parameters for the retinoid model 
compounds, CHARMM atom names and numbering for the retinoids used in the 
protein/retinoid simulations, and distances measured from the protein/retinoid 
simulations.  The retinoid topology and parameters are at the end of this appendix.   
Initial CHARMM surfaces for retinoid model compounds 
 
 
 
 
 
 
Figure B.1 Model compounds and patch residues for retinoids (some hydrogens not shown for 
clarity).  Models 1-17 are the model compounds, and 18 and 19 are used to create patches for 
forming Schiff bases. 
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Figure B.2  Initial CHARMM surfaces for model compounds 1-4.   
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Figure B.3 Initial CHARMM surfaces for model compounds 5-8.  
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Figure B.4 Initial CHARMM surfaces for model compounds 9-12.  
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Additional tables for comparison of CHARMM energy minimized structures and 
experimental data 
 
Table B.1 Experimental, QM, and MM comparison of p-acetamide phenol (7)a 
 
Bond (Å) x-ray MP2 CHARMM Error (MP2 
& x-ray) 
Error 
(CHARMM 
& x-ray) 
Error (MP2 
& 
CHARMM) 
C22-C27 
1.39 1.40 1.41 0.01 0.02 0.01 
C27-C26 1.39 1.39                1.40 0 0.01 0.01 
C26-C25 1.38 1.40               1.40 0.02 0.02 0 
C25-C24 1.38 1.40 1.40 0.02 0.02 0 
C24-C23 1.39 1.40 1.41 0.01 0.02 0.01 
C25-O28 1.38 1.38 1.41 0 0.03 0.03 
C22-N21 1.42 1.41 1.42 0.01 0 0.01 
N21-C15 1.34 1.38 1.34 0.04 0 0.04 
C15-O29 1.22 1.23 1.22 0.01 0 0.01 
C15-C14 1.51 1.52 1.48 0.01 0.03 0.04 
Angle (º)       
C22-C27-C26 119.4 119.4 120.5 0 1.1 1.1 
C27-C26-C25 120.7 121 119.9 0.3 0.8 1.1 
C26-C25-C24 120.2 119.6 120 0.6 0.2 0.4 
C25-C24-C23 119.5 119.7 120 0.2 0.5 0.3 
C24-C23-C22 120.4 120.9 120.6 0.5 0.2 0.3 
C23-C22-C27 119.8 119.3 119 0.5 0.8 0.3 
C26-C25-O28 118.9 123.3 120.4 4.4 1.5 2.9 
C24-C25-O28 120.8 117.1 119.6 3.7 1.2 2.5 
C23-C22-N21 116.5 117.2 115.9 0.7 0.6 1.3 
C27-C22-N21 123.8 123.5 125.1 0.3 1.3 1.6 
C22-N21-C15 129.8 128.7 129.2 1.1 0.6 0.5 
N21-C15-O29 122.7 124.2 124.8 1.5 2.1 0.6 
N21-C15-C14 114.6 113.8 115.2 0.8 0.6 1.4 
O29-C15-C14 122.7 122 119.9 0.7 2.8 2.1 
Dihedral (º)       
C22-C27-C26-C25 0.45 0.09 0.26 0.36 0.19 0.17 
C27-C26-C5-C24 
2.23 0.13 0 2.1 2.23 0.13 
C26-C25-C24-C23 -2.65 -0.11 -0.04 2.54 2.61 0.07 
C25-C24-C23-C22 0.4 0.07 0.18 0.33 0.22 0.11 
C24-C23-C22-C27 2.27 0.03 0.43 2.24 1.84 0.4 
C23-C22-C27-C26 -2.68 -0.05 -0.48 2.63 2.2 0.43 
O28-C25-C26-C27 -178.2 -180 -179.9 1.8 1.7 0.1 
O28-C25-C24-C23 177.8 180 179.9 2.2 2.1 0.1 
C23-C22-N21-C15 -164.3 -179.7 -164.4 15.4 0.1 15.3 
C27-C22-N21-C15 17.7 0.2 14.2 17.5 3.5 14 
C22-N21-C15-O29 0.57 0.9 3.39 0.33 2.82 2.49 
C22-N21-C15-C14 -178.8 -177 -179.4 1.8 0.6 2.4 
aTable C.1 is continued from Table 4.5 in Chapter 4.  
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Table B.2 Comparison of CHARMM (energy-minimized structure) and x-ray data for 
retinal 
Bond (Å) x-ray CHARMM 
 
error 
C1-C2 1.55 1.55 0
C1-C6 1.54 1.53 0.01
C1-C17 1.51 1.55 0.04
C1-C18 1.54 1.55 0.01
C2-C3 1.42 1.53 0.11
C3-C4 1.49 1.53 0.04
C4-C5 1.51 1.51 0
C5-C6 1.33 1.37 0.04
C5-C16 1.51 1.51 0
C6-C7 1.48 1.5 0.02
C7-C8 1.32 1.35 0.03
C8-C9 1.47 1.48 0.01
C9-C10 1.35 1.35 0
C9-C19 1.49 1.51 0.02
C10-C11 1.44 1.48 0.04
C11-C12 1.34 1.35 0.01
C12-C13 1.45 1.48 0.03
C13-C14 1.34 1.35 0.01
C13-C20 1.5 1.51 0.01
C14-C15 1.46 1.48 0.02
C15-O 1.2 1.2 0
Angle (º)    
C2-C1-C6 110.2 112 1.8
C1-C6-C5 122.8 121 1.8
C6-C5-C4 122.6 122.8 0.2
C5-C4-C3 115.3 114.4 0.9
C4-C3-C2 115.5 109.9 5.6
C3-C2-C1 115.8 111.9 3.9
C4-C5-C16 113.1 113.9 0.8
C6-C5-C16 124.3 123.2 1.1
C2-C1-C18 104.7 107.1 2.4
C2-C1-C17 112 109.2 2.8
C6-C1-C18 110.3 110.8 0.5
C6-C1-C17 110.2 109.4 0.8
C1-C6-C7 115 116.1 1.1
C5-C6-C7 122.2 122 0.2
C6-C7-C8 124.5 127.2 2.7
C7-C8-C9 126.5 125.7 0.8
C8-C9-C10 118.3 121.6 3.3
C8-C9-C19 118.4 115 3.4
C10-C9-C19 123.3 123.3 0
C9-C10-C11 127.2 125.7 1.5
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Table B.2 (cont’d) 
C10-C11-C12 123.6 123.8 0.2
C11-C12-C13 126 124.9 1.1
C12-C13-C14 118.3 123.3 5
C12-C13-C20 118.3 112.7 5.6
C14-C13-C20 123.4 123.5 0.1
C13-C14-C15 125.9 121.9 4
C14-C15-O 123.2 122.8 0.4
Dihedral (º)    
C1-C2-C3-C4 50 59.9 9.9
C2-C3-C4-C5 -30.8 -45.4 14.6
C3-C4-C5-C6 6.83 21.3 14.47
C4-C5-C6-C1 -2.15 -9.54 7.39
C5-C6-C1-C2 18.7 22.6 3.9
C6-C1-C2-C3 -42.6 -48.2 5.6
C16-C5-C4-C3 -172.3 -162.8 9.5
C16-C5-C6-C1 176.9 175 1.9
C16-C5-C6-C7 -2.37 -6.5 4.13
C18-C1-C6-C5 133.9 142 8.1
C18-C1-C6-C7 -46.8 -48.9 2.1
C18-C1-C2-C3 -161.2 -169.8 8.6
C17-C1-C6-C5 -105.5 -98.7 6.8
C17-C1-C6-C7 73.9 70.5 3.4
C17-C1-C2-C3 80.5 73.2 7.3
C5-C6-C7-C8 -58.3 -58.7 0.4
C1-C6-C7-C8 122.4 132.3 9.9
C6-C7-C8-C9 -179.3 -179.7 0.4
C7-C8-C9-C10 175.8 134.2 41.6
C7-C8-C9-C19 -4.47 -43.1 38.63
C8-C9-C10-C11 179.1 178.5 0.6
C9-C10-C11-C12 -179.1 -177 2.1
C19-C9-C10-C11 -0.64 -1.46 0.82
C10-C11-C12-C13 175.5 174.6 0.9
C11-C12-C13-C14 -178.4 -63.4 115
C11-C12-C13-C20 -0.63 -124.9 124.27
C12-C13-C14-C15 177.7 179.5 1.8
C20-C13-C14-C15 0 -8.71 8.71
C13-C14-C15-O 179.3 178.4 0.9
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Table B.3 Comparison of CHARMM (energy-minimized structure) and x-ray data for 
retinoic acid (triclinic form) 
Bond (Å)            x-ray  CHARMM               error 
C1-C2 1.54 1.55 0.01
C1-C6 1.54 1.53 0.01
C1-C16 1.53 1.54 0.01
C1-C17 1.51 1.54 0.03
C2-C3 1.43 1.53 0.1
C3-C4 1.5 1.53 0.03
C4-C5 1.51 1.51 0
C5-C6 1.34 1.37 0.03
C5-C18 1.51 1.51 0
C6-C7 1.47 1.49 0.02
C7-C8 1.34 1.35 0.01
C8-C9 1.45 1.48 0.03
C9-C10 1.35 1.35 0
C9-C19 1.51 1.51 0
C10-C11 1.44 1.48 0.04
C11-C12 1.34 1.35 0.01
C12-C13 1.46 1.49 0.03
C13-C14 1.34 1.35 0.01
C13-C20 1.49 1.51 0.02
C14-C15 1.47 1.49 0.02
C15-O29 1.31 1.26 0.05
C15-O30 1.21 1.26 0.05
O29-O30 2.66 2.22 0.44
Angle (º)    
C2-C1-C6 110.2 112.5 2.3
C2-C1-C16 105.4 106.9 1.5
C2-C1-C17 110.9 109.1 1.8
C6-C1-C16 111.5 111.9 0.4
C6-C1-C17 109.1 108 1.1
C16-C1-C17 109.8 108.3 1.5
C1-C2-C3 116.3 112.4 3.9
C2-C3-C4 112.5 108.9 3.6
C3-C4-C5 113.6 113.5 0.1
C4-C5-C6 123 122.8 0.2
C4-C5-C18 112.3 114.5 2.2
C6-C5-C18 124.6 122.6 2
C1-C6-C5 122.1 121.9 0.2
C1-C6-C7 115 117.1 2.1
C5-C6-C7 122.9 121 1.9
C6-C7-C8 127.7 125.9 1.8
C7-C8-C9 125.6 124.8 0.8
C8-C9-C10 118.6 123.5 4.9
C8-C9-C19 118.3 112.7 5.6
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Table B.3 (cont’d). 
C10-C9-C19 123.2 123.7 0.5
C9-C10-C11 126.2 125.7 0.5
C10-C11-C12 124.5 123.9 0.6
C11-C12-C13 126.1 126.3 0.2
C12-C13-C14 118.4 121.2 2.8
C12-C13-C20 117.9 115.5 2.4
C14-C13-C20 123.7 123.4 0.3
C13-C14-C15 126.5 129.9 3.4
C14-C15-O30 112.3 114.8 2.5
C14-C15-O30 126 121.7 4.3
O29-C15-O30 121.7 123 1.3
Dihedral (º)    
C1-C2-C3-C4 -60 -60.8 0.8
C2-C3-C4-C5 -45 48.7 93.7
C3-C4-C5-C6 -11.5 -20.3 8.8
C4-C5-C6-C1 9.74 1.45 8.29
C5-C6-C1-C2 -11 -12.3 1.3
C6-C1-C2-C3 43.4 42.3 1.1
C18-C5-C4-C3 175 177.9 2.9
C18-C5-C6-C1 165.4 163 2.4
C18-C5-C6-C7 -4 -1.69 2.31
C16-C1-C6-C5 102.5 108.2 5.7
C16-C1-C6-C7 -108 -72.2 35.8
C16-C1-C2-C3 -77 -77.5 0.5
C17-C1-C6-C5 -126 -132.7 6.7
C17-C1-C6-C7 45.4 46.9 1.5
C17-C1-C2-C3 168.1 165.6 2.5
C1-C6-C7-C8 132.9 115.5 17.4
C5-C6-C7-C8 -63.7 -64.7 1
C6-C7-C8-C9 -180 -170.3 9.7
C7-C8-C9-C19 0 -38.3 38.3
C7-C8-C9-C10 178.5 140.3 38.2
C8-C9-C10-C11 -177.7 -178.1 0.4
C19-C9-C10-C11 0.66 -1.85 2.51
C9-C10-C11-C12 179.2 178.3 0.9
C10-C11-C12-C13 -179.5 -176.6 2.9
C11-C12-C13-C20 1.2 -33.8 35
C11-C12-C13-C14 -180 -146.4 33.6
C12-C13-C14-C15 -178 -179.4 1.4
C20-C13-C14-C15 0.68 0.3 0.38
C13-C14-C15-O29 -7.61 -11.7 4.09
C13-C14-C15-O30 176.4 175.5 0.9
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Table B.4 Comparison of CHARMM (energy-minimized structure) and x-ray data for 
retinoic acid (monoclinic form) 
Bond (Å)         x-ray         CHARMM                error
C1-C2 1.55 1.55 0
C1-C6 1.53 1.53 0
C1-C16 1.54 1.54 0
C1-C17 1.53 1.54 0.01
C2-C3 1.5 1.53 0.03
C3-C4 1.51 1.53 0.02
C4-C5 1.5 1.51 0.01
C5-C6 1.36 1.37 0.01
C5-C18 1.52 1.51 0.01
C6-C7 1.46 1.49 0.03
C7-C8 1.34 1.35 0.01
C8-C9 1.45 1.48 0.03
C9-C10 1.35 1.35 0
C9-C19 1.5 1.51 0.01
C10-C11 1.44 1.48 0.04
C11-C12 1.34 1.35 0.01
C12-C13 1.45 1.49 0.04
C13-C14 1.34 1.35 0.01
C13-C20 1.5 1.51 0.01
C14-C15 1.47 1.49 0.02
C15-O29 1.32 1.26 0.06
C15-O30 1.22 1.26 0.04
O29-O30 2.67 2.22 0.45
Angle (º)    
C2-C1-C6 110.1 112.5 2.4
C2-C1-C16 104.5 106.9 2.4
C2-C1-C17 110.1 109.1 1
C6-C1-C16 111.1 111.9 0.8
C6-C1-C17 111.3 108 3.3
C16-C1-C17 109.6 108.3 1.3
C1-C2-C3 112.2 112.4 0.2
C2-C3-C4 109.5 108.9 0.6
C3-C4-C5 113.6 113.5 0.1
C4-C5-C6 123.7 122.8 0.9
C4-C5-C18 112.5 114.5 2
C6-C5-C18 123.7 122.6 1.1
C1-C6-C5 121.6 121.9 0.3
C1-C6-C7 120.7 117.1 3.6
C5-C6-C7 117.7 121 3.3
C6-C7-C8 131.5 125.9 5.6
C7-C8-C9 125 124.8 0.2
C8-C9-C10 119.3 123.5 4.2
C8-C9-C19 118.4 112.7 5.7
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Table B.4 (cont’d)  
C10-C9-C19 122.3 123.7 1.4
C9-C10-C11 127.3 125.7 1.6
C10-C11-C12 123.4 123.9 0.5
C11-C12-C13 126.6 126.3 0.3
C12-C13-C14 117.4 121.2 3.8
C12-C13-C20 118.5 115.5 3
C14-C13-C20 124.1 123.4 0.7
C13-C14-C15 128.8 129.9 1.1
Dihedral (°)  
C14-C15-O29 112.1 114.8 2.7
C14-C15-O30 125.9 121.7 4.2
O29-C15-O30 122 123 1
C1-C2-C3-C4 -63.3 -60.8 2.5
C2-C3-C4-C5 43.2 48.7 5.5
C3-C4-C5-C6 -10.4 -20.3 9.9
C4-C5-C6-C1 -4.8 1.45 6.25
C5-C6-C1-C2 -13.4 -12.3 1.1
C6-C1-C2-C3 47.5 42.3 5.2
C18-C5-C6-C1 175.1 177.9 2.8
C18-C5-C4-C3 169.6 163 6.6
C18-C5-C6-C7 -3.1 -1.69 1.41
C16-C1-C6-C5 108.9 108.2 0.7
C16-C1-C6-C7 -72.9 -72.2 0.7
C16-C1-C2-C3 -75.5 -77.5 2
C17-C1-C6-C5 -128.7 -132.7 4
C17-C1-C6-C7 49.5 46.9 2.6
C17-C1-C2-C3 167 165.6 1.4
C1-C6-C7-C8 15.9 115.5 99.6
C5-C6-C7-C8 -165.8 -64.7 101.1
C6-C7-C8-C9 179.6 179.6 0
C7-C8-C9-C10 176.2 140.3 35.9
C7-C8-C9-C19 -1.9 -38.1 36.2
C8-C9-C10-C11 -178.2 -178.1 0.1
C19-C9-C10-C11 -0.13 -1.85 1.72
C9-C10-C11-C12 172 178.3 6.3
C10-C11-C12-C13 -177.8 -176.6 1.2
C11-C12-C13-C14 179.4 146 33.4
C11-C12-C13-C20 1.9 33.8 31.9
C12-C13-C14-C15 -179.8 -179.4 0.4
C15-C14-C13-C20 -2.5 0.3 2.8
O30-C15-C14-C13 -6.9 -11.7 4.8
O29-C15-C14-C13 173.7 175.5 1.8
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Additional information and plots for CRABPII/retinoic acid simulation 
 
 
Figure B.5 Overlay of cyclohexene rings (left) and overlay of chains (right).  X-ray 
structure is shown in red; average structure from the simulation is shown in blue.  
Bottom picture shows the CHARMM atom names of the carbons in the retinoic acid 
ligand, and it shows the dihedrals that contribute to the large average dihedral error.  
 
 
The chain rotates with respect to the cyclohexene ring during the simulation, which 
causes large deviations in the torsion angles that are involved around the connection of 
the ring to the chain (rotation about the C6-C7 bond).  The other sources of large RMSD 
differences involve parts of the chain (rotation about C8-C9, C10-C11, and C12-C13). 
These differences are seen during the simulation because these are single bonds, and the 
ligand will probably try to orient itself to optimize contacts with the protein side chains, 
and this does not appear to cause any major distortion of the surrounding protein 
residues.  The cyclohexene ring retains the C2’-endo conformation during the simulation. 
 The protein-ligand contact time series plots not shown in Chapter 4 are shown 
below in Figures B.6 and B.7.  
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Figure B.6 Retinoic acid-protein distances.  
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Figure B.7 Retinoic acid-protein distances. 
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The protein-protein contacts not shown in Chapter 4 are shown in Figure B.8.  
 
 
 
 
Figure B.8 Protein-protein distances from CRABPII/retinoic acid simulation.  
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Additional information and plots for CRBP/retinol simulation 
 The protein-ligand distance plots not shown in Chapter 4 are shown in Figures 
B.9-B.12.  
 
 
 
Figure B.9 Protein-ligand distances from CRBP/retinol simulation.  
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Figure B.10 Protein-ligand distances from CRBP/retinol simulation.  
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Figure B.11 Protein-ligand distances from CRBP/retinol simulation.  
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Figure B.12 Protein-ligand distances from CRBP/retinol simulation.  
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Additional information and plots for RBP/fenretinide simulation 
The plots shown are for the ligand-protein distances not shown in Chapter 4 (B.13-B.17).  
 
 
 
Figure B.13 Protein-ligand distances from RBP/fenretinide simulation.  
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Figure B.14 Protein-ligand distances from RBP/fenretinide simulation.  
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Figure B.15 Protein-ligand distances from RBP/fenretinide simulation.  
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Figure B.16 Protein-ligand distances from RBP/fenretinide simulation.  
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Figure B.17 Protein-ligand distances from RBP/fenretinide simulation.  
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Additional information and plots for SRII/retinal simulation 
 The plots below are the ligand-protein distances not shown in Chapter 4.  
 
 
 
Figure B.18 Protein-ligand distances from SRII/retinal simulation.  
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Figure B.19 Protein-ligand distances from SRII/retinal simulation.  
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Figure B.20 Protein-ligand distances from SRII/retinal simulation.  
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Figure B.21 Protein-ligand distances from SRII/retinal simulation.  
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Additional information and plots for BR/retinal simulation 
 The plots below are the ligand-protein distances not shown in Chapter 4 (B.22-
B.23).  
 
 
 
Figure B.22 Protein-ligand distances from BR/retinal simulation.  
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Figure B.23 Protein-ligand distances from BR/retinal simulation.  
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CHARMM Topology and Parameters for Retinoids and Retinoid Model Compounds 
 
Topology and parameters for retinoids were streamed into topology and parameters for 
proteins (top_all27_prot_na.inp and par_all27_prot_na.inp with CMAP backbone 
dihedral correction).  The CHARMM atom names and numbering used in plots and tables 
can also be found in the topology.  
 
Topology for 1 
 
RESI 13DB       0.00 ! 1,3-dibutene 
! 
GROUP                 
ATOM C1   CC2  -0.42 ! H11     H21 
ATOM H11  HE2   0.21 !   \    / 
ATOM H12  HE2   0.21 !    C1=C2      H41 
GROUP                !   /    \     / 
ATOM C2   CC1A -0.15 ! H12     C3=C4 
ATOM H21  HE1   0.15 !        /     \ 
ATOM C3   CC1B -0.15 !       H31     H42 
ATOM H31  HE1   0.15 ! 
GROUP                ! 
ATOM C4   CC2  -0.42 ! 
ATOM H41  HE2   0.21 ! 
ATOM H42  HE2   0.21 ! 
 
BOND C1   C2   C2   C3   C3   C4 
BOND C1   H11  C1   H12  C2   H21   C3   H31 
BOND C4   H41  C4   H42 
 
IC  C1   C2   C3   C4   0.00 0.00  180.0 0.00 0.00 
IC  C2   C3   C4   H41  0.00 0.00  180.0 0.00 0.00 
IC  C3   C2   C1   H11  0.00 0.00  180.0 0.00 0.00 
IC  C2   H11  *C1  H12  0.00 0.00  180.0 0.00 0.00 
IC  C3   H41  *C4  H42  0.00 0.00  180.0 0.00 0.00 
IC  C1   C3   *C2  H21  0.00 0.00  180.0 0.00 0.00 
IC  C2   C4   *C3  H31  0.00 0.00  180.0 0.00 0.00 
PATCH FIRST NONE LAST NONE 
 
Topology for 2 
 
RESI 13DP       0.00 ! 1,3-dipentene 
! 
GROUP                 
ATOM C1   CC2  -0.42 ! 
ATOM H11  HE2   0.21 ! H11     H21 
ATOM H12  HE2   0.21 !    \    /               
ATOM C2   CC1A -0.15 !    C1=C2      H41 
ATOM H21  HE1   0.15 !    /    \     / 
GROUP                ! H12      C3=C4   H51                 
ATOM C3   CC1B -0.15 !          /    \  /                              
ATOM H31  HE1   0.15 !        H31     C5-H52     
ATOM C4   CC1B -0.15 !                 \ 
ATOM H41  HE1   0.15 !                  H53 
GROUP                ! 
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ATOM C5   CT3  -0.27 ! 
ATOM H51  HA    0.09 ! 
ATOM H52  HA    0.09 ! 
ATOM H53  HA    0.09 ! 
 
BOND C1   C2   C2   C3   C3   C4    C4   C5 
BOND C1   H11  C1   H12  C2   H21   C3   H31 
BOND C4   H41  C5   H51  C5   H52   C5   H53 
 
IC  C1   C2   C3   C4   0.00 0.00  180.0 0.00 0.00 
IC  C2   C3   C4   C5   0.00 0.00  180.0 0.00 0.00 
IC  C3   C4   C5   H51  0.00 0.00  180.0 0.00 0.00 
IC  C3   C2   C1   H11  0.00 0.00  180.0 0.00 0.00 
IC  C2   H11  *C1  H12  0.00 0.00  180.0 0.00 0.00 
IC  C1   C3   *C2  H21  0.00 0.00  180.0 0.00 0.00 
IC  C2   C4   *C3  H31  0.00 0.00  180.0 0.00 0.00 
IC  C3   C5   *C4  H41  0.00 0.00  180.0 0.00 0.00 
IC  C4   H51  *C5  H52  0.00 0.00  120.0 0.00 0.00 
IC  C4   H51  *C5  H53  0.00 0.00 -120.0 0.00 0.00 
PATCH FIRST NONE LAST NONE 
 
Topology for 3 
 
RESI DMB1       0.00 ! 2-methyl-1,3-butadiene 
! 
GROUP  
ATOM C1   CC2  -0.42 ! 
ATOM H11  HE2   0.21 !     H2M1 H2M2 
ATOM H12  HE2   0.21 !        \  / 
GROUP                ! H11     C2M-H2M3 
ATOM C2   CC1A  0.00 !    \    / 
ATOM C2M  CT3  -0.27 !    C1=C2      H41 
ATOM H2M1 HA    0.09 !    /    \    / 
ATOM H2M2 HA    0.09 ! H12     C3=C4 
ATOM H2M3 HA    0.09 !         /    \                       
GROUP                !       H31     H42   
ATOM C3   CC1B -0.15 ! 
ATOM H31  HE1   0.15 ! 
GROUP                !                                     
ATOM C4   CC2  -0.42 ! 
ATOM H41  HE2   0.21 ! 
ATOM H42  HE2   0.21 ! 
 
BOND C1   C2   C2   C3   C3   C4    C2   C2M 
BOND C1   H11  C1   H12  C3   H31   C4   H41  C4   H42 
BOND C2M  H2M1 C2M  H2M2 C2M  H2M3 
IC  C1   C2   C3   C4   0.00 0.00  180.0 0.00 0.00 
IC  C2   C3   C4   H41  0.00 0.00  180.0 0.00 0.00 
IC  C3   C2   C1   H11  0.00 0.00  180.0 0.00 0.00 
IC  C2   H11  *C1  H12  0.00 0.00  180.0 0.00 0.00 
IC  C1   C3   *C2  C2M  0.00 0.00  180.0 0.00 0.00 
IC  C2   C4   *C3  H31  0.00 0.00  180.0 0.00 0.00 
IC  C3   H41  *C4  H42  0.00 0.00  180.0 0.00 0.00 
IC  C1   C2   C2M  H2M1 0.00 0.00  180.0 0.00 0.00 
IC  C2   H2M1 *C2M H2M2 0.00 0.00  120.0 0.00 0.00 
IC  C2   H2M1 *C2M H2M3 0.00 0.00 -120.0 0.00 0.00 
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PATCH FIRST NONE LAST NONE 
Topology for 4 
 
RESI DMP1       0.00 ! 4-methyl-1,3-pentadiene 
! 
GROUP  
ATOM C1   CC2  -0.42 ! 
ATOM H11  HE2   0.21 ! H11     H21 H4M1 H4M2 
ATOM H12  HE2   0.21 !    \    /    \   / 
GROUP                !    C1=C2      C4M-H4M3 
ATOM C2   CC1A -0.15 !    /    \     / 
ATOM H21  HE1   0.15 ! H12      C3=C4   H51 
ATOM C3   CC1B -0.15 !         /     \  / 
ATOM H31  HE1   0.15 !       H31      C5-H52 
GROUP                !                 \ 
ATOM C4   CC1B  0.00 !                 H53 
ATOM C4M  CT3  -0.27 ! 
ATOM H4M1 HA    0.09 ! 
ATOM H4M2 HA    0.09 ! 
ATOM H4M3 HA    0.09 ! 
GROUP 
ATOM C5   CT3  -0.27 ! 
ATOM H51  HA    0.09 ! 
ATOM H52  HA    0.09 ! 
ATOM H53  HA    0.09 ! 
 
BOND C1   C2   C2   C3   C3   C4    C4   C5   C4   C4M 
BOND C1   H11  C1   H12  C2   H21   C3   H31 
BOND C4M  H4M1 C4M  H4M2 C4M  H4M3 
BOND C5   H51  C5   H52  C5   H53 
 
IC  C1   C2   C3   C4   0.00 0.00  180.0 0.00 0.00 
IC  C2   C3   C4   C5   0.00 0.00  180.0 0.00 0.00 
IC  C3   C4   C5   H51  0.00 0.00  180.0 0.00 0.00 
IC  C3   C2   C1   H11  0.00 0.00  180.0 0.00 0.00 
IC  C2   H11  *C1  H12  0.00 0.00  180.0 0.00 0.00 
IC  C1   C3   *C2  H21  0.00 0.00  180.0 0.00 0.00 
IC  C2   C4   *C3  H31  0.00 0.00  180.0 0.00 0.00 
IC  C3   C5   *C4  C4M  0.00 0.00  180.0 0.00 0.00 
IC  C3   C4   C4M  H4M1 0.00 0.00  180.0 0.00 0.00 
IC  C4   H4M1 *C4M H4M2 0.00 0.00  120.0 0.00 0.00 
IC  C4   H4M1 *C4M H4M3 0.00 0.00 -120.0 0.00 0.00 
IC  C4   H51  *C5  H52  0.00 0.00  120.0 0.00 0.00 
IC  C4   H51  *C5  H53  0.00 0.00 -120.0 0.00 0.00 
PATCH FIRST NONE LAST NONE 
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Topology for 5 
 
RESI DMP2       0.00 ! 2-methyl-1,3-pentadiene  
! 
GROUP                !     H2M1 H2M2 
ATOM C1   CC2  -0.42 !        \  / 
ATOM H11  HE2   0.21 ! H11     C2M-H2M3 
ATOM H12  HE2   0.21 !    \    / 
GROUP                !    C1=C2      H41 
ATOM C2   CC1A  0.00 !    /    \     / 
ATOM C2M  CT3  -0.27 ! H12      C3=C4   H51 
ATOM H2M1 HA    0.09 !          /    \  / 
ATOM H2M2 HA    0.09 !         H31    C5-H52 
ATOM H2M3 HA    0.09 !                 \ 
ATOM C3   CC1B -0.15 !                  H53 
ATOM H31  HE1   0.15 !       
GROUP                !              
ATOM C4   CC1B -0.15 ! 
ATOM H41  HE1   0.15 ! 
ATOM C5   CT3  -0.27 ! 
ATOM H51  HA    0.09 ! 
ATOM H52  HA    0.09 ! 
ATOM H53  HA    0.09 ! 
 
BOND C1   C2   C2   C3   C3   C4    C4   C5   C2  C2M 
BOND C1   H11  C1   H12  C3   H31   C4   H41   
BOND C2M  H2M1 C2M  H2M2 C2M  H2M3 
BOND C5   H51  C5   H52  C5   H53 
 
IC  C1   C2   C3   C4   0.00 0.00  180.0 0.00 0.00 
IC  C2   C3   C4   C5   0.00 0.00  180.0 0.00 0.00 
IC  C3   C4   C5   H51  0.00 0.00  180.0 0.00 0.00 
IC  C3   C2   C1   H11  0.00 0.00  180.0 0.00 0.00 
IC  C2   H11  *C1  H12  0.00 0.00  180.0 0.00 0.00 
IC  C1   C3   *C2  C2M  0.00 0.00  180.0 0.00 0.00 
IC  C2   C4   *C3  H31  0.00 0.00  180.0 0.00 0.00 
IC  C3   C5   *C4  H41  0.00 0.00  180.0 0.00 0.00 
IC  C1   C2   C2M  H2M1 0.00 0.00  180.0 0.00 0.00 
IC  C2   H2M1 *C2M H2M2 0.00 0.00  120.0 0.00 0.00 
IC  C2   H2M1 *C2M H2M3 0.00 0.00 -120.0 0.00 0.00 
IC  C4   H51  *C5  H52  0.00 0.00  120.0 0.00 0.00 
IC  C4   H51  *C5  H53  0.00 0.00 -120.0 0.00 0.00 
PATCH FIRST NONE LAST NONE 
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Topology for 6 
 
RESI CROT       0.00 ! 2-buteneamide,N,3-dimethyl (crotonamide) 
                     ! numbering as in fennretinide 
! note different atom types for N21 and C15: this is consistent 
! with differences in NMA and acetamide 
GROUP 
ATOM C12  CT3  -0.27 !  
ATOM H121 HA    0.09 !       H202 H203 
ATOM H122 HA    0.09 !          \  / 
ATOM H123 HA    0.09 !     H201-C20 
GROUP                !           | 
ATOM C13  CC1A  0.00 !H121-C12--C13     O29 
ATOM C14  CC1A -0.15 !    /  |    \\     || 
ATOM H141 HE1   0.15 !H122 H123    C14--C15 
GROUP                !            /        \ 
ATOM C15  C     0.51 !         H141         N21-H211 (cis) 
ATOM O29  O    -0.51 !                       | 
GROUP                !                 H132-C16-H131 
ATOM N21  NH1  -0.47 !                       | 
ATOM H211 H     0.28 !                      H133 
ATOM C16  CT3  -0.08 
ATOM H131 HA    0.09 
ATOM H132 HA    0.09 
ATOM H133 HA    0.09 
GROUP                ! 
ATOM C20  CT3  -0.27 ! 
ATOM H201 HA    0.09 ! 
ATOM H202 HA    0.09 ! 
ATOM H203 HA    0.09 ! 
 
BOND C12  C13   C13  C14   C14  C15  C15   N21  N21  C16   
BOND C13  C20   C15  O29   C14  H141 N21  H211   
BOND C16  H131  C16  H132  C16  H133 
BOND C12  H121  C12  H122  C12  H123 
BOND C20  H201  C20  H202  C20  H203 
IC C12   C13   C14   C15    0.0000    0.00  180.00    0.00   0.0000 
IC C13   C14   C15   N21    0.0000    0.00  180.00    0.00   0.0000 
IC C14   C15   N21   C16    0.0000    0.00  180.00    0.00   0.0000 
IC H121  C13   *C12  H122   0.0000    0.00  120.00    0.00   0.0000 
IC H121  C13   *C12  H123   0.0000    0.00 -120.00    0.00   0.0000 
IC H121  C12   C13   C14    0.0000    0.00  180.00    0.00   0.0000 
IC C14   C12   *C13  C20    0.0000    0.00  180.00    0.00   0.0000 
IC C15   C13   *C14  H141   0.0000    0.00  180.00    0.00   0.0000 
IC N21   C14   *C15  O29    0.0000    0.00  180.00    0.00   0.0000 
IC C16   C15   *N21  H211   0.0000    0.00  180.00    0.00   0.0000 
IC C15   N21   C16   H131   0.0000    0.00  180.00    0.00   0.0000 
IC H131  N21   *C16  H132   0.0000    0.00  120.00    0.00   0.0000 
IC H131  N21   *C16  H133   0.0000    0.00 -120.00    0.00   0.0000 
IC C12   C13   C20   H201   0.0000    0.00  180.00    0.00   0.0000 
IC H201  C13   *C20  H202   0.0000    0.00  120.00    0.00   0.0000 
IC H201  C13   *C20  H203   0.0000    0.00 -120.00    0.00   0.0000 
 
PATCH FIRST NONE LAST NONE 
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Topology for 7  
 
RESI PACP       0.00 ! p-acetamide-phenol 
                     ! numbering as in fennretinide 
                     ! 
ATOM C14  CT3  -0.27 !           H142 
ATOM H141 HA    0.09 !            | 
ATOM H142 HA    0.09 !       H141-C14-H143 
ATOM H143 HA    0.09 !            | 
GROUP                !            C15=O29 
ATOM C15  C     0.52 !            | 
ATOM O29  O    -0.52 !            N21-H211 
GROUP                !            | 
ATOM N21  NH1  -0.47 !           C22                     
ATOM H211 H     0.33 !          //  \ 
ATOM C22  CA    0.14 !   H231-C23   C27-H271 
GROUP                !         |     || 
ATOM C23  CA   -0.115!   H241-C24   C26-H261 
ATOM H231 HP    0.115!         \\   / 
GROUP                !           C25 
ATOM C24  CA   -0.115!            | 
ATOM H241 HP    0.115!           O28 
GROUP                !             \ 
ATOM C26  CA   -0.115!              H281 
ATOM H261 HP    0.115 
GROUP 
ATOM C27  CA   -0.115 
ATOM H271 HP    0.115 
GROUP 
ATOM C25  CA    0.11 
ATOM O28  OH1  -0.54 
ATOM H281 H     0.43 
BOND C14  C15  C15  N21  N21  C22  C22  C23  C15  O29 
BOND C23  C24  C24  C25  C25  C26  C26  C27  C27  C22 
BOND C25  O28  O28  H281 N21  H211 
BOND C14  H141 C14  H142 C14  H143 
BOND C23  H231 C24  H241 C26  H261 C27  H271 
IC C14   C15   N21   C22    0.0000    0.00  180.00    0.00   0.0000 
IC C15   N21   C22   C27    0.0000    0.00    0.00    0.00   0.0000 
IC N21   C22   C23   C24    0.0000    0.00  180.00    0.00   0.0000 
IC C22   C23   C24   C25    0.0000    0.00    0.00    0.00   0.0000 
IC C23   C24   C25   O28    0.0000    0.00  180.00    0.00   0.0000 
IC H141  C15   *C14  H142   0.0000    0.00  120.00    0.00   0.0000 
IC H141  C15   *C14  H143   0.0000    0.00 -120.00    0.00   0.0000 
IC H141  C14   C15   N21    0.0000    0.00  180.00    0.00   0.0000 
IC N21   C14   *C15  O29    0.0000    0.00  180.00    0.00   0.0000 
IC C22   C15   *N21  H211   0.0000    0.00  180.00    0.00   0.0000 
IC C27   N21   *C22  C23    0.0000    0.00  180.00    0.00   0.0000 
IC C24   C22   *C23  H231   0.0000    0.00  180.00    0.00   0.0000 
IC C25   C23   *C24  H241   0.0000    0.00  180.00    0.00   0.0000 
IC O28   C24   *C25  C26    0.0000    0.00  180.00    0.00   0.0000 
IC C27   C25   *C26  H261   0.0000    0.00  180.00    0.00   0.0000 
IC C26   C22   *C27  H271   0.0000    0.00  180.00    0.00   0.0000 
IC C24   C25   O28   H281   0.0000    0.00  180.00    0.00   0.0000 
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PATCH FIRST NONE LAST NONE 
Topology for 8  
 
RESI MECH       0.00 ! 1,6,6-trimethyl-2-ethene-cyclohexene 
                     ! using retinol numbering 
GROUP 
ATOM C1   CT    0.00 !H162 H163  H171 H172 
ATOM C2   CT2  -0.18 !    \  |    |  / 
ATOM H21  HA    0.09 !H161-C16    C17-H173  H81 
ATOM H22  HA    0.09 !        \  /           | 
ATOM C3   CT2  -0.18 !  H21    C1           C8-H82 
ATOM H31  HA    0.09 !     \  /  \         // 
ATOM H32  HA    0.09 !  H22-C2    C6------C7 
ATOM C4   CT2  -0.18 !      |     ||        \ 
ATOM H41  HA    0.09 !  H31-C3    C5   H181  H71 
ATOM H42  HA    0.09 !     /  \  /  \  /     
ATOM C5   CC1A  0.00 !  H32    C4    C18-H18 
ATOM C6   CC1A  0.00 !        /  \     \     
GROUP                !      H41  H42   H183 
ATOM C7   CC1B -0.15 !  
ATOM H71  HE1   0.15 ! 
ATOM C8   CC2  -0.42 ! 
ATOM H81  HE2   0.21 ! 
ATOM H82  HE2   0.21 ! 
GROUP               ! 
ATOM C16  CT3  -0.27 ! 
ATOM H161 HA    0.09 ! 
ATOM H162 HA    0.09 ! 
ATOM H163 HA    0.09 ! 
GROUP                ! 
ATOM C17  CT3  -0.27 ! 
ATOM H171 HA    0.09 ! 
ATOM H172 HA    0.09 ! 
ATOM H173 HA    0.09 ! 
GROUP                ! 
ATOM C18  CT3  -0.27 ! 
ATOM H181 HA    0.09 ! 
ATOM H182 HA    0.09 ! 
ATOM H183 HA    0.09 ! 
 
BOND C1   C2   C2   C3   C3   C4   C4   C5   C5   C6   C6   C1 
BOND C6   C7   C7   C8   C1   C16  C1   C17  C5   C18 
BOND C2   H21  C2   H22  C3   H31  C3   H32  C4   H41  C4   H42 
BOND C16  H161 C16  H162 C16  H163 C17  H171 C17  H172 C17  H173 
BOND C7   H71  C8   H81  C8   H82  C18  H181 C18  H182 C18  H183 
 
!initial ring geometry is planar 
IC  C1   C2   C3   C4   0.00 0.00   63.0 0.00 0.00 
IC  C2   C3   C4   C5   0.00 0.00  -46.0 0.00 0.00 
IC  C3   C4   C5   C6   0.00 0.00   15.0 0.00 0.00 
IC  C1   C3   *C2  H21  0.00 0.00  120.0 0.00 0.00 
IC  C1   C3   *C2  H22  0.00 0.00 -120.0 0.00 0.00 
IC  C2   C4   *C3  H31  0.00 0.00  120.0 0.00 0.00 
IC  C2   C4   *C3  H32  0.00 0.00 -120.0 0.00 0.00 
IC  C3   C5   *C4  H41  0.00 0.00  120.0 0.00 0.00 
IC  C3   C5   *C4  H42  0.00 0.00 -120.0 0.00 0.00 
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IC  C1   C5   *C6  C7   0.00 0.00  180.0 0.00 0.00 
IC  C5   C6   C7   C8   0.00 0.00   60.0 0.00 0.00 
IC  C6   C8   *C7  H71  0.00 0.00  180.0 0.00 0.00 
IC  C6   C7   C8   H81  0.00 0.00  180.0 0.00 0.00 
IC  C7   H81  *C8  H82  0.00 0.00  180.0 0.00 0.00 
IC  C6   C2   *C1  C16  0.00 0.00  120.0 0.00 0.00 
IC  C6   C2   *C1  C17  0.00 0.00 -120.0 0.00 0.00 
IC  C2   C1   C16  H161 0.00 0.00  180.0 0.00 0.00 
IC  C1   H161 *C16 H162 0.00 0.00  120.0 0.00 0.00 
IC  C1   H161 *C16 H163 0.00 0.00 -120.0 0.00 0.00 
IC  C2   C1   C17  H171 0.00 0.00  180.0 0.00 0.00 
IC  C1   H171 *C17 H172 0.00 0.00  120.0 0.00 0.00 
IC  C1   H171 *C17 H173 0.00 0.00 -120.0 0.00 0.00 
IC  C4   C6   *C5  C18  0.00 0.00  180.0 0.00 0.00 
IC  C4   C5   C18  H181 0.00 0.00  180.0 0.00 0.00 
IC  C5   H181 *C18 H182 0.00 0.00  120.0 0.00 0.00 
IC  C5   H181 *C18 H183 0.00 0.00 -120.0 0.00 0.00 
PATCH FIRST NONE LAST NONE 
 
Topology for 9  
 
RESI TMCH       0.00 ! 1,2,6,6-tetramethylcyclohexene 
                     ! using retinol numbering 
GROUP 
ATOM C1   CT    0.00 !H162 H163  H171 H172 
ATOM C2   CT2  -0.18 !    \  |    |  / 
ATOM H21  HA    0.09 !H161-C16    C17-H173 
ATOM H22  HA    0.09 !        \  / 
ATOM C3   CT2  -0.18 !  H21    C1        H71 H72 
ATOM H31  HA    0.09 !     \  /  \        | / 
ATOM H32  HA    0.09 !  H22-C2    C6------C7-H73 
ATOM C4   CT2  -0.18 !      |     || 
ATOM H41  HA    0.09 !  H31-C3    C5   H181 
ATOM H42  HA    0.09 !     /  \  /  \  / 
ATOM C5   CC1A  0.00 !  H32    C4    C18-H18 
ATOM C6   CC1A  0.00 !        /  \     \ 
GROUP                !      H41  H42   H183 
ATOM C7   CT3  -0.27 ! 
ATOM H71  HA    0.09 ! 
ATOM H72  HA    0.09 ! 
ATOM H73  HA    0.09 ! 
GROUP                ! 
ATOM C16  CT3  -0.27 ! 
ATOM H161 HA    0.09 ! 
ATOM H162 HA    0.09 ! 
ATOM H163 HA    0.09 ! 
GROUP                ! 
ATOM C17  CT3  -0.27 ! 
ATOM H171 HA    0.09 ! 
ATOM H172 HA    0.09 ! 
ATOM H173 HA    0.09 ! 
GROUP                ! 
ATOM C18  CT3  -0.27 ! 
ATOM H181 HA    0.09 ! 
ATOM H182 HA    0.09 ! 
ATOM H183 HA    0.09 ! 
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BOND C1   C2   C2   C3   C3   C4   C4   C5   C5   C6   C6   C1 
BOND C6   C7   C1   C16  C1   C17  C5   C18 
BOND C2   H21  C2   H22  C3   H31  C3   H32  C4   H41  C4   H42 
BOND C16  H161 C16  H162 C16  H163 C17  H171 C17  H172 C17  H173 
BOND C7   H71  C7   H72  C7   H73  C18  H181 C18  H182 C18  H183 
 
!initial geometry is planar 
IC  C1   C2   C3   C4   0.00 0.00  -63.0 0.00 0.00 
IC  C2   C3   C4   C5   0.00 0.00   46.0 0.00 0.00 
IC  C3   C4   C5   C6   0.00 0.00  -13.0 0.00 0.00 
IC  C1   C3   *C2  H21  0.00 0.00  120.0 0.00 0.00 
IC  C1   C3   *C2  H22  0.00 0.00 -120.0 0.00 0.00 
IC  C2   C4   *C3  H31  0.00 0.00  120.0 0.00 0.00 
IC  C2   C4   *C3  H32  0.00 0.00 -120.0 0.00 0.00 
IC  C3   C5   *C4  H41  0.00 0.00  120.0 0.00 0.00 
IC  C3   C5   *C4  H42  0.00 0.00 -120.0 0.00 0.00 
IC  C1   C5   *C6  C7   0.00 0.00  180.0 0.00 0.00 
IC  C5   C6   C7   H71  0.00 0.00  180.0 0.00 0.00 
IC  C6   H71  *C7  H72  0.00 0.00  120.0 0.00 0.00 
IC  C6   H71  *C7  H73  0.00 0.00 -120.0 0.00 0.00 
IC  C6   C2   *C1  C16  0.00 0.00  120.0 0.00 0.00 
IC  C6   C2   *C1  C17  0.00 0.00 -120.0 0.00 0.00 
IC  C2   C1   C16  H161 0.00 0.00  180.0 0.00 0.00 
IC  C1   H161 *C16 H162 0.00 0.00  120.0 0.00 0.00 
IC  C1   H161 *C16 H163 0.00 0.00 -120.0 0.00 0.00 
IC  C2   C1   C17  H171 0.00 0.00  180.0 0.00 0.00 
IC  C1   H171 *C17 H172 0.00 0.00  120.0 0.00 0.00 
IC  C1   H171 *C17 H173 0.00 0.00 -120.0 0.00 0.00 
IC  C4   C6   *C5  C18  0.00 0.00  180.0 0.00 0.00 
IC  C4   C5   C18  H181 0.00 0.00  180.0 0.00 0.00 
IC  C5   H181 *C18 H182 0.00 0.00  120.0 0.00 0.00 
IC  C5   H181 *C18 H183 0.00 0.00 -120.0 0.00 0.00 
PATCH FIRST NONE LAST NONE 
 
Topology for 10 
 
RESI PRAC      -1.00 ! 2-propenoic acid 
GROUP 
ATOM C1  CC2   -0.42 ! 
ATOM H11 HE2    0.21 ! 
ATOM H12 HE2    0.21 !  H11    OD1  
GROUP               !   \     || 
ATOM C2  CC1A  -0.25 !   C1    CG 
ATOM H21 HE1    0.15 !   / \\ / \ 
ATOM CG  CC     0.62 ! H12  C2  OD2 (-) 
ATOM OD1 OC    -0.76 !      | 
ATOM OD2 OC    -0.76 !     H21 
            
BOND C1  H11  C1  H12  C1  C2   C2   H21 
BOND C2  CG   CG  OD1  CG  OD2 
IC C1    C2    CG    OD1    0.0000    0.00  180.00    0.00   0.0000 
IC OD1   C2    *CG   OD2    0.0000    0.00  180.00    0.00   0.0000 
IC H11   C1    C2    CG     0.0000    0.00  180.00    0.00   0.0000 
IC H11   C2    *C1   H12    0.0000    0.00  180.00    0.00   0.0000 
IC CG    C1    *C2   H21    0.0000    0.00  180.00    0.00   0.0000 
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PATCH FIRST NONE LAST NONE  
Topology for 11 
 
RESI PROL       0.00 ! 3-propenol (1-hydroxy-2-propene) 
! 
GROUP 
ATOM C1  CC2   -0.42 ! 
ATOM H11 HE2    0.21 !  H11    H31  
ATOM H12 HE2    0.21 !   \      | 
ATOM C2  CC1A  -0.15 !   C1    C3-OR 
ATOM H21 HE1    0.15 !   / \\ / |   \ 
GROUP               ! H12  C2 H32  HR 
ATOM C3  CT2    0.05 !       | 
ATOM H31 HA     0.09 !      H21 
ATOM H32 HA     0.09 
ATOM OR  OH1   -0.66 
ATOM HR  H      0.43 
BOND C1   C2   C2   C3   C3   OR   OR   HR 
BOND H11  C1   H12  C1   H21  C2   H31  C3 
BOND H32  C3    
 
IC C1    C2    C3    OR     0.0000    0.00    0.00    0.00   0.0000 
IC C2    C3    OR    HR     0.0000    0.00   60.00    0.00   0.0000 
IC H11   C1    C2    C3     0.0000    0.00  180.00    0.00   0.0000 
IC H11   C2    *C1   H12    0.0000    0.00  180.00    0.00   0.0000 
IC C3    C1    *C2   H21    0.0000    0.00  180.00    0.00   0.0000 
IC OR    C2    *C3   H31    0.0000    0.00  120.00    0.00   0.0000 
IC OR    C2    *C3   H32    0.0000    0.00 -120.00    0.00   0.0000 
 
PATCH FIRST NONE LAST NONE 
 
Topology for 12 
 
RESI PRAL       0.00 ! 1-propenal 
GROUP 
ATOM C1  CC2   -0.42 ! 
ATOM H11 HE2    0.21 !  H11    OD1  
ATOM H12 HE2    0.21 !   \     || 
ATOM C2  CC1A  -0.01 !   C1    CG 
ATOM H21 HE1    0.15 !   / \\ / \ 
ATOM CG  CD     0.19 ! H12  C2   H 
ATOM OD1 O     -0.43 !      | 
ATOM H   HR1    0.10 !     H21 
 
BOND C1  H11  C1  H12  C1  C2  C2  H21 
BOND C2  CG   CG  OD1  CG  H 
IMPR CG  C2   OD1 H 
 
IC C1    C2    CG    OD1    0.0000    0.00  180.00    0.00   0.0000 
IC H11   C1    C2    CG     0.0000    0.00  180.00    0.00   0.0000 
IC H11   C2    *C1   H12    0.0000    0.00  180.00    0.00   0.0000 
IC CG    C1    *C2   H21    0.0000    0.00  180.00    0.00   0.0000 
IC OD1   C2    *CG   H      0.0000    0.00  180.00    0.00   0.0000 
 
 
 447
 
Topology for 13 
 
RESI BTE2       0.00 ! 2-Butene, adm jr. 
GROUP 
ATOM C1  CT3  -0.27 !  H12 H13 
ATOM H11 HA    0.09 !    \ | 
ATOM H12 HA    0.09 ! H13-C1      H31 
ATOM H13 HA    0.09 !       \     / 
GROUP               !        C2=C3 
ATOM C2  CC1A -0.15 !       /     \ 
ATOM H21 HE1   0.15 !     H21      C4-H41 
GROUP               !              | \ 
ATOM C3  CC1A -0.15 !            H43 H42 
ATOM H31 HE1   0.15 ! 
GROUP 
ATOM C4  CT3  -0.27 
ATOM H41 HA    0.09 
ATOM H42 HA    0.09 
ATOM H43 HA    0.09 
 
BOND C1 H11  C1 H12  C1 H13 C1 C2   C2 H21 
DOUBLE C2 C3 
BOND C3 H31  C3 C4  C4 H41  C4 H42  C4 H43 
 
IC C1    C2    C3    C4     0.0000    0.00  180.00    0.00   0.0000 
IC H11   C2    *C1   H12    0.0000    0.00  120.00    0.00   0.0000 
IC H11   C2    *C1   H13    0.0000    0.00 -120.00    0.00   0.0000 
IC H11   C1    C2    C3     0.0000    0.00  180.00    0.00   0.0000 
IC C3    C1    *C2   H21    0.0000    0.00  180.00    0.00   0.0000 
IC C4    C2    *C3   H31    0.0000    0.00  180.00    0.00   0.0000 
IC C2    C3    C4    H41    0.0000    0.00  180.00    0.00   0.0000 
IC H41   C3    *C4   H42    0.0000    0.00  120.00    0.00   0.0000 
IC H41   C3    *C4   H43    0.0000    0.00 -120.00    0.00   0.0000 
 
PATCH FIRS NONE LAST NONE 
 
Topology for 14 
 
RESI HEP3       0.00 ! 1,3,5-heptatriene 
! 
GROUP                 
ATOM C1   CC2  -0.42 ! 
ATOM H11  HE2   0.21 ! H11     H21 
ATOM H12  HE2   0.21 !    \    /               
ATOM C2   CC1A -0.15 !    C1=C2      H41 
ATOM H21  HE1   0.15 !    /    \     / 
GROUP                ! H12      C3=C4      H61 
ATOM C3   CC1B -0.15 !          /    \    / 
ATOM H31  HE1   0.15 !        H31     C5=C6 
ATOM C4   CC1B -0.15 !               /    \  
ATOM H41  HE1   0.15 !             H51     H62 
GROUP                ! 
ATOM C5   CC1A -0.15 
ATOM H51  HE1   0.15 
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GROUP 
ATOM C6   CC2  -0.42 
ATOM H61  HE2   0.21 
ATOM H62  HE2   0.21 
 
BOND C1   C2   C2   C3   C3   C4    C4   C5   C5   C6 
BOND C1   H11  C1   H12  C2   H21   C3   H31 
BOND C4   H41  C5   H51  C6   H61   C6   H62 
 
IC C1    C2    C3    C4     0.0000    0.00  180.00    0.00   0.0000 
IC C2    C3    C4    C5     0.0000    0.00  180.00    0.00   0.0000 
IC C3    C4    C5    C6     0.0000    0.00  180.00    0.00   0.0000 
IC H11   C2    *C1   H12    0.0000    0.00  180.00    0.00   0.0000 
IC H11   C1    C2    C3     0.0000    0.00  180.00    0.00   0.0000 
IC C3    C1    *C2   H21    0.0000    0.00  180.00    0.00   0.0000 
IC C4    C2    *C3   H31    0.0000    0.00  180.00    0.00   0.0000 
IC C5    C3    *C4   H41    0.0000    0.00  180.00    0.00   0.0000 
IC C6    C4    *C5   H51    0.0000    0.00  180.00    0.00   0.0000 
IC C4    C5    C6    H61    0.0000    0.00  180.00    0.00   0.0000 
IC H61   C5    *C6   H62    0.0000    0.00  180.00    0.00   0.0000 
 
PATCH FIRST NONE LAST NONE 
 
Topology for 15 
 
RESI SCH1       0.00 ! Schiff's base model compound 1, deprotonated 
!                   ! new atom type NS1 
GROUP 
ATOM C1  CT3   -0.05 !   H11         H31 
ATOM H11 HA     0.09 !      \        / 
ATOM H12 HA     0.09 !  H12--C1-N2=C3    H41 
ATOM H13 HA     0.09 !      /        \  / 
ATOM N2  NS1   -0.60 !   H13          C4--H42 
ATOM C3  CC1B   0.23 !                  \ 
ATOM H31 HE1    0.15 !                   H43 
GROUP               ! 
ATOM C4  CT3   -0.27 ! 
ATOM H41 HA     0.09 ! 
ATOM H42 HA     0.09 
ATOM H43 HA     0.09 
 
BOND C1  H11  C1  H12  C1  H13   
BOND C1  N2   N2  C3   C3  H31 
BOND C3  C4   C4  H41  C4  H42  C4  H43 
 
IC C1    N2    C3    C4     0.0000    0.00  180.00    0.00   0.0000 
IC N2    C3    C4    H41    0.0000    0.00  180.00    0.00   0.0000 
IC C3    N2    C1    H11    0.0000    0.00    0.00    0.00   0.0000 
IC H11   N2    *C1   H12    0.0000    0.00  120.00    0.00   0.0000 
IC H11   N2    *C1   H13    0.0000    0.00 -120.00    0.00   0.0000 
IC C4    N2    *C3   H31    0.0000    0.00  180.00    0.00   0.0000 
IC H41   C3    *C4   H42    0.0000    0.00  120.00    0.00   0.0000 
IC H41   C3    *C4   H43    0.0000    0.00 -120.00    0.00   0.0000 
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Topology for 16 
 
RESI SCH2       1.00 ! Schiff's base model compound 2, protonated 
!                    ! new atom type, NS2 
GROUP 
ATOM C1  CT3    0.18 !   H11   H21    H31 
ATOM H11 HA     0.09 !      \   |    / 
ATOM H12 HA     0.09 !  H12--C1-N2=C3    H41 
ATOM H13 HA     0.09 !      /        \  / 
ATOM N2  NS2   -0.40 !   H13          C4--H42 
ATOM H21 HC     0.38 !                  \ 
ATOM C3  CC1B   0.37 !                   H43 
ATOM H31 HR1    0.20 ! hydrogen with intermediate VDW radius 
GROUP               ! 
ATOM C4  CT3   -0.27 ! 
ATOM H41 HA     0.09 ! 
ATOM H42 HA     0.09 
ATOM H43 HA     0.09 
 
BOND C1  H11  C1  H12  C1  H13   
BOND C1  N2   N2  H21  N2  C3   C3  H31 
BOND C3  C4   C4  H41  C4  H42  C4  H43 
 
IC C1    N2    C3    C4     0.0000    0.00  180.00    0.00   0.0000 
IC N2    C3    C4    H41    0.0000    0.00  180.00    0.00   0.0000 
IC C1    C3    *N2   H21    0.0000    0.00  180.00    0.00   0.0000 
IC C3    N2    C1    H11    0.0000    0.00    0.00    0.00   0.0000 
IC H11   N2    *C1   H12    0.0000    0.00  120.00    0.00   0.0000 
IC H11   N2    *C1   H13    0.0000    0.00 -120.00    0.00   0.0000 
IC C4    N2    *C3   H31    0.0000    0.00  180.00    0.00   0.0000 
IC H41   C3    *C4   H42    0.0000    0.00  120.00    0.00   0.0000 
IC H41   C3    *C4   H43    0.0000    0.00 -120.00    0.00   0.0000 
 
 
Topology for 17 
 
RESI SCH3       1.00 ! Schiff's base model compound 3, protonated 
!                   ! new atom type, NS2 
GROUP 
ATOM C1  CT3    0.18 !   H11   H21    H31 
ATOM H11 HA     0.09 !      \   |    / 
ATOM H12 HA     0.09 !  H12--C1-N2=C3      H51 
ATOM H13 HA     0.09 !      /        \     / 
ATOM N2  NS2   -0.40 !   H13          C4=C5 
ATOM H21 HC     0.38 !               /     \ 
ATOM C3  CC1B   0.37 !             H41     H52 
ATOM H31 HR1    0.20 ! hydrogen with intermediate VDW radius 
GROUP               ! 
ATOM C4  CC1A  -0.15 
ATOM H41 HE1    0.15 
ATOM C5  CC2   -0.42 
ATOM H51 HE2    0.21 
ATOM H52 HE2    0.21 
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BOND C1  H11  C1  H12  C1  H13 
BOND C1  N2   N2  H21  N2  C3   C3  H31 
BOND C3  C4   C4  H41   
BOND C4  C5   C5  H51  C5  H52 
 
IC C1    N2    C3    C4     0.0000    0.00  180.00    0.00   0.0000 
IC N2    C3    C4    C5     0.0000    0.00  180.00    0.00   0.0000 
IC H11   C1    N2    C3     0.0000    0.00  180.00    0.00   0.0000 
IC H11   N2    *C1   H12    0.0000    0.00  120.00    0.00   0.0000 
IC H11   N2    *C1   H13    0.0000    0.00 -120.00    0.00   0.0000 
IC C3    C1    *N2   H21    0.0000    0.00  180.00    0.00   0.0000 
IC C4    N2    *C3   H31    0.0000    0.00  180.00    0.00   0.0000 
IC C5    C3    *C4   H41    0.0000    0.00  180.00    0.00   0.0000 
IC C3    C4    C5    H51    0.0000    0.00  180.00    0.00   0.0000 
IC H51   C4    *C5   H52    0.0000    0.00  180.00    0.00   0.0000 
 
Topology for 18 
 
PRES SCK0       0.00 ! patch to link lysine with retinal to form a 
                     ! deprotonated schiff's base 
                     ! follow with AUTOgenerate ANGLes DIHEdrals 
command 
! residue 1: lysine 
! residue 2: retinal 
! 
DELETE ATOM 1HZ1 
DELETE ATOM 1HZ2 
DELETE ATOM 1HZ3 
DELETE ATOM 2O15 
GROUP                !  HE1 HE2 
ATOM 1CE  CT2   0.04 !    \ / 
ATOM 1HE1 HA    0.09 !  --1CE1       2H15 
ATOM 1HE2 HA    0.09 !        \       / 
ATOM 1NZ  NS1  -0.60 !        1NZ=2C15 
ATOM 2C15 CC1B  0.23 !        /       \ 
ATOM 2H15 HE1   0.15 !     2HZ1        2C14== 
GROUP                !                / 
ATOM 2C14 CC1A -0.15 !             2HE14 
ATOM 2H141 HE1  0.15 
 
BOND 1NZ 2C15  
 
IC 1CD    1CE    1NZ    2C15    0.0000    0.00  180.00    0.00   0.0000 
IC 1CE    1NZ    2C15   2C14    0.0000    0.00  180.00    0.00   0.0000 
IC 1NZ    2C15   2C14   2C13    0.0000    0.00  180.00    0.00   0.0000 
IC 2C14   1NZ    *2C15  2H15    0.0000    0.00  180.00    0.00   0.0000 
IC 2C5    2C6    2C1    2C2     0.0000    0.00    0.00    0.00   0.0000 
! required to build retinal 
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Topology for 19 
 
PRES SCK1       1.00 ! patch to link lysine with retinal to form a 
                     ! protonated schiff's base 
                     ! follow with AUTOgenerate ANGLes DIHEdrals 
command 
! residue 1: lysine 
! residue 2: retinal 
! 
DELETE ATOM 1HZ2 
DELETE ATOM 1HZ3 
DELETE ATOM 2O15 
GROUP                !  HE1 HE2 
ATOM 1CE  CT2   0.27 !    \ / 
ATOM 1HE1 HA    0.09 !  --1CE1       2H15 
ATOM 1HE2 HA    0.09 !        \       / 
ATOM 1NZ  NS2  -0.40 !        1NZ=2C15 
ATOM HZ1  HC    0.38 !        /       \ 
ATOM 2C15 CC1B  0.37 !     2HZ1        2C14== 
ATOM 2H15 HR1   0.20 !                / 
GROUP                !             2HE14 
ATOM 2C14 CC1A -0.15 
ATOM 2H141 HE1  0.15 
 
BOND 1NZ 2C15  
 
IC 1CD    1CE    1NZ    2C15    0.0000    0.00  180.00    0.00   0.0000 
IC 1CE    1NZ    2C15   2C14    0.0000    0.00  180.00    0.00   0.0000 
IC 1NZ    2C15   2C14   2C13    0.0000    0.00  180.00    0.00   0.0000 
IC 2C15   1CE    *1NZ   1HZ1    0.0000    0.00  180.00    0.00   0.0000 
IC 2C14   1NZ    *2C15  2H15    0.0000    0.00  180.00    0.00   0.0000 
IC 2C5    2C6    2C1    2C2     0.0000    0.00    0.00    0.00   0.0000 
! required to build retinal 
 
end 
 
Topology for fenretinide  
 
RESI FRET       0.00 ! fenretinide, nomenclature consistent with 
retinol 
! 
! 
!     
GROUP 
ATOM C1   CT    0.00  
ATOM C2   CT2  -0.18 
ATOM H21  HA    0.09 
ATOM H22  HA    0.09 
ATOM C3   CT2  -0.18 
ATOM H31  HA    0.09 
ATOM H32  HA    0.09 
ATOM C4   CT2  -0.18 
ATOM H41  HA    0.09 
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ATOM H42  HA    0.09 
ATOM C5   CC1A  0.00  
ATOM C6   CC1A  0.00 
GROUP 
ATOM C7   CC1B -0.15 
ATOM H71  HE1   0.15 
ATOM C8   CC1B -0.15 
ATOM H81  HE1   0.15 
ATOM C9   CC1A  0.00 
ATOM C10  CC1A -0.15 
ATOM H101 HE1   0.15 
GROUP 
ATOM C11  CC1B -0.15 !H162 H163  H171 H172 
ATOM H111 HE1   0.15 !    \  |    |  / 
ATOM C12  CC1B -0.15 !H161-C16    C17-H173            H191 H192 
ATOM H121 HE1   0.15 !        \  /                      \   / 
ATOM C13  CC1A  0.00 !  H21    C1        H71    H81      C19 
ATOM C14  CC1A -0.15 !     \  /  \        |      |       /  \ 
ATOM H141 HE1   0.15 !  H22-C2    C6------C7=====C8----C9    H193 
GROUP                !      |     ||                   || 
ATOM C16  CT3  -0.27 !  H31-C3    C5   H181            C10-H101  
ATOM H161 HA    0.09 !     /  \  /  \  /               | 
ATOM H162 HA    0.09 !  H32    C4    C18-H182          C11-H111 
ATOM H163 HA    0.09 !        /  \     \               || 
GROUP                !      H41  H42   H183            C12-H121 H201 
ATOM C17  CT3  -0.27 !                                 |       / 
ATOM H171 HA    0.09 !                                 C13---C20-H202 
ATOM H172 HA    0.09 !                                 ||      \ 
ATOM H173 HA    0.09 !                                 C14-H141 H203 
GROUP                !                                 | 
ATOM C18  CT3  -0.27 !                                 C15=O29 
ATOM H181 HA    0.09 !                                 | 
ATOM H182 HA    0.09 !                                 N21-H211 
ATOM H183 HA    0.09 !                                 | 
GROUP                !                                C22  
ATOM C19  CT3  -0.27 !                               //  \ 
ATOM H191 HA    0.09 !                        H231-C23   C27-H271 
ATOM H192 HA    0.09 !                              |     || 
ATOM H193 HA    0.09 !                        H241-C24   C26-H261 
GROUP                !                               \\  / 
ATOM C20  CT3  -0.27 !                                C25 
ATOM H201 HA    0.09 !                                 | 
ATOM H202 HA    0.09 !                                O28 
ATOM H203 HA    0.09 !                                  \ 
GROUP                !                                   H281 
ATOM C15  C     0.51 ! charges from CROT 
ATOM O29  O    -0.51 ! 
GROUP 
ATOM N21  NH1  -0.47 ! 
ATOM H211 H     0.33 ! charges from PACP 
ATOM C22  CA    0.14 ! 
GROUP  
ATOM C23  CA   -0.115 
ATOM H231 HP    0.115 
GROUP 
ATOM C24  CA   -0.115 
ATOM H241 HP    0.115 
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GROUP 
ATOM C26  CA   -0.115 
ATOM H261 HP    0.115 
GROUP 
ATOM C27  CA   -0.115 
ATOM H271 HP    0.115 
GROUP 
ATOM C25  CA    0.11 
ATOM O28  OH1  -0.54 
ATOM H281 H     0.43 
BOND C1   C2   C2   C3   C3   C4   C4   C5   C5   C6   C6   C1 
BOND C6   C7   C7   C8   C8   C9   C9   C10  C10  C11  C11  C12 
BOND C12  C13  C13  C14  C14  C15  C15  N21  N21  C22  C22  C23 
BOND C23  C24  C24  C25  C25  C26  C26  C27  C27  C22 
BOND C1   C16  C1   C17  C5   C18  C9   C19  C13  C20  C15  O29 
BOND C25  O28  O28  H281 N21  H211 
BOND C2   H21  C2   H22  C3   H31  C3   H32  C4   H41  C4   H42 
BOND C7   H71  C8   H81  C10  H101 C11  H111 C12  H121 C14  H141 
BOND C16  H161 C16  H162 C16  H163 C17  H171 C17  H172 C17  H173 
BOND C18  H181 C18  H182 C18  H183 C19  H191 C19  H192 C19  H193 
BOND C20  H201 C20  H202 C20  H203 
BOND C23  H231 C24  H241 C26  H261 C27  H271 
IC C1    C2    C3    C4     0.0000    0.00    0.00    0.00   0.0000 
IC C2    C3    C4    C5     0.0000    0.00    0.00    0.00   0.0000 
IC C6    C1    C2    C3     0.0000    0.00    0.00    0.00   0.0000 
IC C1    C6    C7    C8     0.0000    0.00  180.00    0.00   0.0000 
IC C6    C7    C8    C9     0.0000    0.00  180.00    0.00   0.0000 
IC C7    C8    C9    C10    0.0000    0.00  180.00    0.00   0.0000 
IC C2    C6    *C1   C16    0.0000    0.00  120.00    0.00   0.0000 
IC C2    C6    *C1   C17    0.0000    0.00 -120.00    0.00   0.0000 
IC C3    C1    *C2   H21    0.0000    0.00  120.00    0.00   0.0000 
IC C3    C1    *C2   H22    0.0000    0.00 -120.00    0.00   0.0000 
IC C4    C2    *C3   H31    0.0000    0.00  120.00    0.00   0.0000 
IC C4    C2    *C3   H32    0.0000    0.00 -120.00    0.00   0.0000 
IC C5    C3    *C4   H41    0.0000    0.00  120.00    0.00   0.0000 
IC C5    C3    *C4   H42    0.0000    0.00 -120.00    0.00   0.0000 
IC C5    C1    *C6   C7     0.0000    0.00  180.00    0.00   0.0000 
IC C8    C6    *C7   H71    0.0000    0.00  180.00    0.00   0.0000 
IC C9    C7    *C8   H81    0.0000    0.00  180.00    0.00   0.0000 
IC C10   C8    *C9   C19    0.0000    0.00  180.00    0.00   0.0000 
IC C8    C9    C10   C11    0.0000    0.00  180.00    0.00   0.0000 
IC C11   C9    *C10  H101   0.0000    0.00  180.00    0.00   0.0000 
IC C9    C10   C11   C12    0.0000    0.00  180.00    0.00   0.0000 
IC C12   C10   *C11  H111   0.0000    0.00  180.00    0.00   0.0000 
IC C10   C11   C12   C13    0.0000    0.00  180.00    0.00   0.0000 
IC C13   C11   *C12  H121   0.0000    0.00  180.00    0.00   0.0000 
IC C11   C12   C13   C14    0.0000    0.00  180.00    0.00   0.0000 
IC C14   C12   *C13  C20    0.0000    0.00  180.00    0.00   0.0000 
IC C12   C13   C14   C15    0.0000    0.00  180.00    0.00   0.0000 
IC C15   C13   *C14  H141   0.0000    0.00  180.00    0.00   0.0000 
IC C6    C1    C16   H161   0.0000    0.00  180.00    0.00   0.0000 
IC H161  C1    *C16  H162   0.0000    0.00  120.00    0.00   0.0000 
IC H161  C1    *C16  H163   0.0000    0.00 -120.00    0.00   0.0000 
IC C6    C1    C17   H171   0.0000    0.00  180.00    0.00   0.0000 
IC H171  C1    *C17  H172   0.0000    0.00  120.00    0.00   0.0000 
IC H171  C1    *C17  H173   0.0000    0.00 -120.00    0.00   0.0000 
IC C6    C4    *C5   C18    0.0000    0.00  180.00    0.00   0.0000 
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IC C4    C5    C18   H181   0.0000    0.00  180.00    0.00   0.0000 
IC H181  C5    *C18  H182   0.0000    0.00  120.00    0.00   0.0000 
IC H181  C5    *C18  H183   0.0000    0.00 -120.00    0.00   0.0000 
IC C8    C9    C19   H191   0.0000    0.00  180.00    0.00   0.0000 
IC H191  C9    *C19  H192   0.0000    0.00  120.00    0.00   0.0000 
IC H191  C9    *C19  H193   0.0000    0.00 -120.00    0.00   0.0000 
IC C12   C13   C20   H201   0.0000    0.00  180.00    0.00   0.0000 
IC H201  C13   *C20  H202   0.0000    0.00  120.00    0.00   0.0000 
IC H201  C13   *C20  H203   0.0000    0.00 -120.00    0.00   0.0000 
IC C13   C14   C15   N21    0.0000    0.00  180.00    0.00   0.0000 
IC N21   C14   *C15  O29    0.0000    0.00  180.00    0.00   0.0000 
IC C14   C15   N21   C22    0.0000    0.00  180.00    0.00   0.0000 
IC C22   C15   *N21  H211   0.0000    0.00  180.00    0.00   0.0000 
IC C15   N21   C22   C27    0.0000    0.00  180.00    0.00   0.0000 
IC C27   N21   *C22  C23    0.0000    0.00  180.00    0.00   0.0000 
IC N21   C22   C23   C24    0.0000    0.00  180.00    0.00   0.0000 
IC C24   C22   *C23  H231   0.0000    0.00  180.00    0.00   0.0000 
IC C22   C23   C24   C25    0.0000    0.00    0.00    0.00   0.0000 
IC C25   C23   *C24  H241   0.0000    0.00  180.00    0.00   0.0000 
IC C23   C24   C25   O28    0.0000    0.00  180.00    0.00   0.0000 
IC O28   C24   *C25  C26    0.0000    0.00  180.00    0.00   0.0000 
IC C27   C25   *C26  H261   0.0000    0.00  180.00    0.00   0.0000 
IC C26   C22   *C27  H271   0.0000    0.00  180.00    0.00   0.0000 
IC C24   C25   O28   H281   0.0000    0.00  180.00    0.00   0.0000 
 
PATCH FIRST NONE LAST NONE 
 
Topology for retinol 
 
RESI RTOL       0.00 ! retinol, nomenclature from PDB 
! 
GROUP 
ATOM C1   CT    0.00 
ATOM C2   CT2  -0.18 
ATOM H21  HA    0.09 
ATOM H22  HA    0.09 
GROUP 
ATOM C3   CT2  -0.18 
ATOM H31  HA    0.09 
ATOM H32  HA    0.09 
GROUP 
ATOM C4   CT2  -0.18 
ATOM H41  HA    0.09 
ATOM H42  HA    0.09 
ATOM C5   CC1A  0.00 
ATOM C6   CC1A  0.00 
GROUP 
ATOM C7   CC1B -0.15 
ATOM H71  HE1   0.15 
ATOM C8   CC1B -0.15 
ATOM H81  HE1   0.15 
GROUP 
ATOM C9   CC1A  0.00 
ATOM C10  CC1A -0.15 
ATOM H101 HE1   0.15 
GROUP 
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ATOM C11  CC1B -0.15 
ATOM H111 HE1   0.15 
GROUP 
ATOM C12  CC1B -0.15 
ATOM H121 HE1   0.15 
GROUP 
ATOM C13  CC1A  0.00 
ATOM C14  CC1A -0.15 ! 
ATOM H141 HE1   0.15 !H162 H163  H171 H172 
GROUP                !    \  |    |  / 
ATOM C15  CT2   0.05 !H161-C16    C17-H173            H191 H192 
ATOM H151 HA    0.09 !        \  /                      \   / 
ATOM H152 HA    0.09 !  H21    C1        H71    H81      C19 
ATOM OR   OH1  -0.66 !     \  /  \        |      |       /  \ 
ATOM HR   H     0.43 !  H22-C2    C6------C7=====C8----C9    H193 
GROUP                !      |     ||                   || 
ATOM C16  CT3  -0.27 !  H31-C3    C5   H181            C10-H101  
ATOM H161 HA    0.09 !     /  \  /  \  /               | 
ATOM H162 HA    0.09 !  H32    C4    C18-H182          C11-H111 
ATOM H163 HA    0.09 !        /  \     \               || 
GROUP                !      H41  H42   H183            C12-H121 H201 
ATOM C17  CT3  -0.27 !                                 |       / 
ATOM H171 HA    0.09 !                                 C13---C20-H202 
ATOM H172 HA    0.09 !                                 ||      \ 
ATOM H173 HA    0.09 !                                 C14-H141 H203 
GROUP                !                                 | 
ATOM C18  CT3  -0.27 !                            H151-C15-H152 
ATOM H181 HA    0.09 !                                 | 
ATOM H182 HA    0.09 !                                 OR    
ATOM H183 HA    0.09 !                                   \ 
GROUP                !                                    HR 
ATOM C19  CT3  -0.27 ! 
ATOM H191 HA    0.09 ! 
ATOM H192 HA    0.09 ! 
ATOM H193 HA    0.09 ! 
GROUP                ! 
ATOM C20  CT3  -0.27 ! 
ATOM H201 HA    0.09 ! 
ATOM H202 HA    0.09 ! 
ATOM H203 HA    0.09 ! 
 
BOND C1   C2   C2   C3   C3   C4   C4   C5   C5   C6   C6   C1 
BOND C6   C7   C7   C8   C8   C9   C9   C10  C10  C11  C11  C12 
BOND C12  C13  C13  C14  C14  C15  C15  OR 
BOND C1   C16  C1   C17  C5   C18  C9   C19  C13  C20 
BOND C2   H21  C2   H22  C3   H31  C3   H32  C4   H41  C4   H42 
BOND C7   H71  C8   H81  C10  H101 C11  H111 C12  H121 C14  H141 
BOND C15  H151 C15  H152 OR   HR 
BOND C16  H161 C16  H162 C16  H163 C17  H171 C17  H172 C17  H173 
BOND C18  H181 C18  H182 C18  H183 C19  H191 C19  H192 C19  H193 
BOND C20  H201 C20  H202 C20  H203 
IC C1    C2    C3    C4     0.0000    0.00    0.00    0.00   0.0000 
IC C6    C1    C2    C3     0.0000    0.00    0.00    0.00   0.0000 
IC C2    C3    C4    C5     0.0000    0.00    0.00    0.00   0.0000 
IC C1    C6    C7    C8     0.0000    0.00  180.00    0.00   0.0000 
IC C6    C7    C8    C9     0.0000    0.00  180.00    0.00   0.0000 
IC C7    C8    C9    C10    0.0000    0.00  180.00    0.00   0.0000 
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IC C2    C6    *C1   C16    0.0000    0.00  120.00    0.00   0.0000 
IC C2    C6    *C1   C17    0.0000    0.00 -120.00    0.00   0.0000 
IC C3    C1    *C2   H21    0.0000    0.00  120.00    0.00   0.0000 
IC C3    C1    *C2   H22    0.0000    0.00 -120.00    0.00   0.0000 
IC C4    C2    *C3   H31    0.0000    0.00  120.00    0.00   0.0000 
IC C4    C2    *C3   H32    0.0000    0.00 -120.00    0.00   0.0000 
IC C5    C3    *C4   H41    0.0000    0.00  120.00    0.00   0.0000 
IC C5    C3    *C4   H42    0.0000    0.00 -120.00    0.00   0.0000 
IC C5    C1    *C6   C7     0.0000    0.00  180.00    0.00   0.0000 
IC C8    C6    *C7   H71    0.0000    0.00  180.00    0.00   0.0000 
IC C9    C7    *C8   H81    0.0000    0.00  180.00    0.00   0.0000 
IC C10   C8    *C9   C19    0.0000    0.00  180.00    0.00   0.0000 
IC C8    C9    C10   C11    0.0000    0.00  180.00    0.00   0.0000 
IC C11   C9    *C10  H101   0.0000    0.00  180.00    0.00   0.0000 
IC C9    C10   C11   C12    0.0000    0.00  180.00    0.00   0.0000 
IC C12   C10   *C11  H111   0.0000    0.00  180.00    0.00   0.0000 
IC C10   C11   C12   C13    0.0000    0.00  180.00    0.00   0.0000 
IC C13   C11   *C12  H121   0.0000    0.00  180.00    0.00   0.0000 
IC C11   C12   C13   C14    0.0000    0.00  180.00    0.00   0.0000 
IC C14   C12   *C13  C20    0.0000    0.00  180.00    0.00   0.0000 
IC C12   C13   C14   C15    0.0000    0.00  180.00    0.00   0.0000 
IC C15   C13   *C14  H141   0.0000    0.00  180.00    0.00   0.0000 
IC C13   C14   C15   OR     0.0000    0.00  180.00    0.00   0.0000 
IC OR    C14   *C15  H151   0.0000    0.00  120.00    0.00   0.0000 
IC OR    C14   *C15  H152   0.0000    0.00 -120.00    0.00   0.0000 
IC C14   C15   OR    HR     0.0000    0.00  180.00    0.00   0.0000 
IC C6    C1    C16   H161   0.0000    0.00  180.00    0.00   0.0000 
IC H161  C1    *C16  H162   0.0000    0.00  120.00    0.00   0.0000 
IC H161  C1    *C16  H163   0.0000    0.00 -120.00    0.00   0.0000 
IC C6    C1    C17   H171   0.0000    0.00  180.00    0.00   0.0000 
IC H171  C1    *C17  H172   0.0000    0.00  120.00    0.00   0.0000 
IC H171  C1    *C17  H173   0.0000    0.00 -120.00    0.00   0.0000 
IC C6    C4    *C5   C18    0.0000    0.00  180.00    0.00   0.0000 
IC C4    C5    C18   H181   0.0000    0.00  180.00    0.00   0.0000 
IC H181  C5    *C18  H182   0.0000    0.00  120.00    0.00   0.0000 
IC H181  C5    *C18  H183   0.0000    0.00 -120.00    0.00   0.0000 
IC C8    C9    C19   H191   0.0000    0.00  180.00    0.00   0.0000 
IC H191  C9    *C19  H192   0.0000    0.00  120.00    0.00   0.0000 
IC H191  C9    *C19  H193   0.0000    0.00 -120.00    0.00   0.0000 
IC C12   C13   C20   H201   0.0000    0.00  180.00    0.00   0.0000 
IC H201  C13   *C20  H202   0.0000    0.00  120.00    0.00   0.0000 
IC H201  C13   *C20  H203   0.0000    0.00 -120.00    0.00   0.0000 
 
PATCH FIRST NONE LAST NONE 
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Topology for retinal 
 
RESI RTAL       0.00 ! retinal, nomenclature from PDB based on retinol 
! 
GROUP 
ATOM C1   CT    0.00 
ATOM C2   CT2  -0.18 
ATOM H21  HA    0.09 
ATOM H22  HA    0.09 
ATOM C3   CT2  -0.18 
ATOM H31  HA    0.09 
ATOM H32  HA    0.09 
ATOM C4   CT2  -0.18 
ATOM H41  HA    0.09 
ATOM H42  HA    0.09 
ATOM C5   CC1A  0.00 
ATOM C6   CC1A  0.00 
GROUP 
ATOM C7   CC1B -0.15 
ATOM H71  HE1   0.15 
ATOM C8   CC1B -0.15 
ATOM H81  HE1   0.15 
ATOM C9   CC1A  0.00 
ATOM C10  CC1A -0.15 
ATOM H101 HE1   0.15 
GROUP 
ATOM C11  CC1B -0.15 
ATOM H111 HE1   0.15 
ATOM C12  CC1B -0.15 
ATOM H121 HE1   0.15 ! 
ATOM C13  CC1A  0.00 !H162 H163  H171 H172 
GROUP                !    \  |    |  / 
ATOM C14  CC1A -0.01 !H161-C16    C17-H173            H191 H192 
ATOM H141 HE1   0.15 !        \  /                      \   / 
ATOM C15  CD    0.19 !  H21    C1        H71    H81      C19 
ATOM O15  O    -0.43 !     \  /  \        |      |       /  \ 
ATOM H15  HR1   0.10 !  H22-C2    C6------C7=====C8----C9    H193 
GROUP                !      |     ||                   || 
ATOM C16  CT3  -0.27 !  H31-C3    C5   H181            C10-H101  
ATOM H161 HA    0.09 !     /  \  /  \  /               | 
ATOM H162 HA    0.09 !  H32    C4    C18-H182          C11-H111 
ATOM H163 HA    0.09 !        /  \     \               || 
GROUP                !      H41  H42   H183            C12-H121 H201 
ATOM C17  CT3  -0.27 !                                 |       / 
ATOM H171 HA    0.09 !                                 C13---C20-H202 
ATOM H172 HA    0.09 !                                 ||      \ 
ATOM H173 HA    0.09 !                                 C14-H141 H203 
GROUP                !                                 | 
ATOM C18  CT3  -0.27 !                                 C15 
ATOM H181 HA    0.09 !                                /  \\ 
ATOM H182 HA    0.09 !                              H15   O15 
ATOM H183 HA    0.09 ! 
GROUP                ! 
ATOM C19  CT3  -0.27 ! 
ATOM H191 HA    0.09 ! 
ATOM H192 HA    0.09 ! 
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ATOM H193 HA    0.09 ! 
GROUP                ! 
ATOM C20  CT3  -0.27 ! 
ATOM H201 HA    0.09 ! 
ATOM H202 HA    0.09 ! 
ATOM H203 HA    0.09 ! 
 
BOND C1   C2   C2   C3   C3   C4   C4   C5   C5   C6   C6   C1 
BOND C6   C7   C7   C8   C8   C9   C9   C10  C10  C11  C11  C12 
BOND C12  C13  C13  C14  C14  C15  C15  O15  C15  H15 
BOND C1   C16  C1   C17  C5   C18  C9   C19  C13  C20 
BOND C2   H21  C2   H22  C3   H31  C3   H32  C4   H41  C4   H42 
BOND C7   H71  C8   H81  C10  H101 C11  H111 C12  H121 C14  H141 
BOND C16  H161 C16  H162 C16  H163 C17  H171 C17  H172 C17  H173 
BOND C18  H181 C18  H182 C18  H183 C19  H191 C19  H192 C19  H193 
BOND C20  H201 C20  H202 C20  H203 
IC C1    C2    C3    C4     0.0000    0.00    0.00    0.00   0.0000 
IC C2    C3    C4    C5     0.0000    0.00    0.00    0.00   0.0000 
IC C6    C1    C2    C3     0.0000    0.00    0.00    0.00   0.0000 
IC C1    C6    C7    C8     0.0000    0.00  180.00    0.00   0.0000 
IC C6    C7    C8    C9     0.0000    0.00  180.00    0.00   0.0000 
IC C7    C8    C9    C10    0.0000    0.00  180.00    0.00   0.0000 
IC C8    C9    C10   C11    0.0000    0.00  180.00    0.00   0.0000 
IC C2    C6    *C1   C16    0.0000    0.00  120.00    0.00   0.0000 
IC C2    C6    *C1   C17    0.0000    0.00 -120.00    0.00   0.0000 
IC C3    C1    *C2   H21    0.0000    0.00  120.00    0.00   0.0000 
IC C3    C1    *C2   H22    0.0000    0.00 -120.00    0.00   0.0000 
IC C4    C2    *C3   H31    0.0000    0.00  120.00    0.00   0.0000 
IC C4    C2    *C3   H32    0.0000    0.00 -120.00    0.00   0.0000 
IC C5    C3    *C4   H41    0.0000    0.00  120.00    0.00   0.0000 
IC C5    C3    *C4   H42    0.0000    0.00 -120.00    0.00   0.0000 
IC C5    C1    *C6   C7     0.0000    0.00  180.00    0.00   0.0000 
IC C8    C6    *C7   H71    0.0000    0.00  180.00    0.00   0.0000 
IC C9    C7    *C8   H81    0.0000    0.00  180.00    0.00   0.0000 
IC C10   C8    *C9   C19    0.0000    0.00  180.00    0.00   0.0000 
IC C11   C9    *C10  H101   0.0000    0.00  180.00    0.00   0.0000 
IC C9    C10   C11   C12    0.0000    0.00  180.00    0.00   0.0000 
IC C12   C10   *C11  H111   0.0000    0.00  180.00    0.00   0.0000 
IC C10   C11   C12   C13    0.0000    0.00  180.00    0.00   0.0000 
IC C13   C11   *C12  H121   0.0000    0.00  180.00    0.00   0.0000 
IC C11   C12   C13   C14    0.0000    0.00  180.00    0.00   0.0000 
IC C14   C12   *C13  C20    0.0000    0.00  180.00    0.00   0.0000 
IC C12   C13   C14   C15    0.0000    0.00  180.00    0.00   0.0000 
IC C15   C13   *C14  H141   0.0000    0.00  180.00    0.00   0.0000 
IC C13   C14   C15   O15    0.0000    0.00  180.00    0.00   0.0000 
IC O15   C14   *C15  H15    0.0000    0.00  180.00    0.00   0.0000 
IC C6    C1    C16   H161   0.0000    0.00  180.00    0.00   0.0000 
IC H161  C1    *C16  H162   0.0000    0.00  120.00    0.00   0.0000 
IC H161  C1    *C16  H163   0.0000    0.00 -120.00    0.00   0.0000 
IC C6    C1    C17   H171   0.0000    0.00  180.00    0.00   0.0000 
IC H171  C1    *C17  H172   0.0000    0.00  120.00    0.00   0.0000 
IC H171  C1    *C17  H173   0.0000    0.00 -120.00    0.00   0.0000 
IC C6    C4    *C5   C18    0.0000    0.00  180.00    0.00   0.0000 
IC C4    C5    C18   H181   0.0000    0.00  180.00    0.00   0.0000 
IC H181  C5    *C18  H182   0.0000    0.00  120.00    0.00   0.0000 
IC H181  C5    *C18  H183   0.0000    0.00 -120.00    0.00   0.0000 
IC C8    C9    C19   H191   0.0000    0.00  180.00    0.00   0.0000 
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IC H191  C9    *C19  H192   0.0000    0.00  120.00    0.00   0.0000 
IC H191  C9    *C19  H193   0.0000    0.00 -120.00    0.00   0.0000 
IC C12   C13   C20   H201   0.0000    0.00  180.00    0.00   0.0000 
IC H201  C13   *C20  H202   0.0000    0.00  120.00    0.00   0.0000 
IC H201  C13   *C20  H203   0.0000    0.00 -120.00    0.00   0.0000 
 
PATCH FIRST NONE LAST NONE 
 
Topology for retinoic acid 
 
RESI RTAC      -1.00 ! all-trans-retinoic acid, nomenclature from PDB 
! 
! retinoic acid is depronated form which exists at physiological pH 
GROUP 
ATOM C1   CT    0.00  
ATOM C16  CT3  -0.27 
ATOM H161 HA    0.09 
ATOM H162 HA    0.09 
ATOM H163 HA    0.09 
ATOM C17  CT3  -0.27 
ATOM H171 HA    0.09 
ATOM H172 HA    0.09 
ATOM H173 HA    0.09 
GROUP                
ATOM C2   CT2  -0.18 
ATOM H21  HA    0.09 
ATOM H22  HA    0.09 
ATOM C3   CT2  -0.18 
ATOM H31  HA    0.09 
ATOM H32  HA    0.09 
ATOM C4   CT2  -0.18 
ATOM H41  HA    0.09 
ATOM H42  HA    0.09 
GROUP                
ATOM C5   CC1A  0.00   
ATOM C6   CC1A  0.00 
GROUP 
ATOM C18  CT3  -0.27 
ATOM H181 HA    0.09 
ATOM H182 HA    0.09 
ATOM H183 HA    0.09 
GROUP 
ATOM C7   CC1B -0.15 
ATOM H71  HE1   0.15 
ATOM C8   CC1B -0.15 
ATOM H81  HE1   0.15 
GROUP 
ATOM C9   CC1A  0.00  
ATOM C19  CT3  -0.27 !H162 H163  H171 H172 
ATOM H191 HA    0.09 !    \  |    |  / 
ATOM H192 HA    0.09 !H161-C16    C17-H173            H191 H192 
ATOM H193 HA    0.09 !        \  /                      \   / 
ATOM C10  CC1A -0.15 !  H21    C1        H71    H81      C19 
ATOM H101 HE1   0.15 !     \  /  \        |      |       /  \ 
GROUP                !  H22-C2    C6------C7=====C8----C9    H193 
ATOM C11  CC1B -0.15 !      |     ||                   || 
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ATOM H111 HE1   0.15 !  H31-C3    C5   H181            C10-H101  
ATOM C12  CC1B -0.15 !     /  \  /  \  /               | 
ATOM H121 HE1   0.15 !  H32    C4    C18-H182          C11-H111 
GROUP                !        /  \     \               || 
ATOM C13  CC1A  0.00 !      H41  H42   H183            C12-H121 H201 
ATOM C20  CT3  -0.27 !                                 |       / 
ATOM H201 HA    0.09 !                                 C13---C20-H202 
ATOM H202 HA    0.09 !                                 ||      \ 
ATOM H203 HA    0.09 !                                 C14-H141 H203 
GROUP                !                                 | 
ATOM C14  CC1A -0.25 !                                 C15=O29 
ATOM H141 HE1   0.15 !                                 |   (-) 
ATOM C15  CC    0.62 !                                 O29B 
ATOM O29  OC   -0.76 ! 
ATOM O29B OC   -0.76 
 
BOND C1   C2   C2   C3   C3   C4   C4   C5   C5   C6   C6   C1 
BOND C6   C7   C7   C8   C8   C9   C9   C10  C10  C11  C11  C12 
BOND C12  C13  C13  C14  C14  C15  C15  O29  C15  O29B 
BOND C1   C16  C1   C17  C5   C18  C9   C19  C13  C20 
BOND C2   H21  C2   H22  C3   H31  C3   H32  C4   H41  C4   H42 
BOND C7   H71  C8   H81  C10  H101 C11  H111 C12  H121 C14  H141 
BOND C16  H161 C16  H162 C16  H163 C17  H171 C17  H172 C17  H173 
BOND C18  H181 C18  H182 C18  H183 C19  H191 C19  H192 C19  H193 
BOND C20  H201 C20  H202 C20  H203 
IC C1    C2    C3    C4     0.0000    0.00    0.00    0.00   0.0000 
IC C2    C3    C4    C5     0.0000    0.00    0.00    0.00   0.0000 
IC C6    C1    C2    C3     0.0000    0.00    0.00    0.00   0.0000 
IC C1    C6    C7    C8     0.0000    0.00  180.00    0.00   0.0000 
IC C6    C7    C8    C9     0.0000    0.00  180.00    0.00   0.0000 
IC C7    C8    C9    C10    0.0000    0.00  180.00    0.00   0.0000 
IC C2    C6    *C1   C16    0.0000    0.00  120.00    0.00   0.0000 
IC C2    C6    *C1   C17    0.0000    0.00 -120.00    0.00   0.0000 
IC C6    C1    C16   H161   0.0000    0.00  180.00    0.00   0.0000 
IC H161  C1    *C16  H162   0.0000    0.00  120.00    0.00   0.0000 
IC H161  C1    *C16  H163   0.0000    0.00 -120.00    0.00   0.0000 
IC C6    C1    C17   H171   0.0000    0.00  180.00    0.00   0.0000 
IC H171  C1    *C17  H172   0.0000    0.00  120.00    0.00   0.0000 
IC H171  C1    *C17  H173   0.0000    0.00 -120.00    0.00   0.0000 
IC C3    C1    *C2   H21    0.0000    0.00  120.00    0.00   0.0000 
IC C3    C1    *C2   H22    0.0000    0.00 -120.00    0.00   0.0000 
IC C4    C2    *C3   H31    0.0000    0.00  120.00    0.00   0.0000 
IC C4    C2    *C3   H32    0.0000    0.00 -120.00    0.00   0.0000 
IC C5    C3    *C4   H41    0.0000    0.00  120.00    0.00   0.0000 
IC C5    C3    *C4   H42    0.0000    0.00 -120.00    0.00   0.0000 
IC C6    C4    *C5   C18    0.0000    0.00  180.00    0.00   0.0000 
IC C4    C5    C18   H181   0.0000    0.00  180.00    0.00   0.0000 
IC H181  C5    *C18  H182   0.0000    0.00  120.00    0.00   0.0000 
IC H181  C5    *C18  H183   0.0000    0.00 -120.00    0.00   0.0000 
IC C5    C1    *C6   C7     0.0000    0.00  180.00    0.00   0.0000 
IC C8    C6    *C7   H71    0.0000    0.00  180.00    0.00   0.0000 
IC C9    C7    *C8   H81    0.0000    0.00  180.00    0.00   0.0000 
IC C10   C8    *C9   C19    0.0000    0.00  180.00    0.00   0.0000 
IC C8    C9    C19   H191   0.0000    0.00  180.00    0.00   0.0000 
IC H191  C9    *C19  H192   0.0000    0.00  120.00    0.00   0.0000 
IC H191  C9    *C19  H193   0.0000    0.00 -120.00    0.00   0.0000 
IC C8    C9    C10   C11    0.0000    0.00  180.00    0.00   0.0000 
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IC C11   C9    *C10  H101   0.0000    0.00  180.00    0.00   0.0000 
IC C9    C10   C11   C12    0.0000    0.00  180.00    0.00   0.0000 
IC C12   C10   *C11  H111   0.0000    0.00  180.00    0.00   0.0000 
IC C10   C11   C12   C13    0.0000    0.00  180.00    0.00   0.0000 
IC C13   C11   *C12  H121   0.0000    0.00  180.00    0.00   0.0000 
IC C11   C12   C13   C14    0.0000    0.00  180.00    0.00   0.0000 
IC C14   C12   *C13  C20    0.0000    0.00  180.00    0.00   0.0000 
IC C12   C13   C20   H201   0.0000    0.00  180.00    0.00   0.0000 
IC H201  C13   *C20  H202   0.0000    0.00  120.00    0.00   0.0000 
IC H201  C13   *C20  H203   0.0000    0.00 -120.00    0.00   0.0000 
IC C12   C13   C14   C15    0.0000    0.00  180.00    0.00   0.0000 
IC C15   C13   *C14  H141   0.0000    0.00  180.00    0.00   0.0000 
IC C13   C14   C15   O29    0.0000    0.00  180.00    0.00   0.0000 
IC O29   C14   *C15  O29B   0.0000    0.00  180.00    0.00   0.0000 
 
PATCH FIRST NONE LAST NONE 
 
 
Parameters for retinoids 
 
read parameter card append 
 
BONDS 
! 
!atom types  Kb          b0 
! 
!BTE2, 2-butene 
HE1   CC1A  360.500     1.100 
HE1   CC1B  360.500     1.100 
HE2   CC2   365.000     1.100 
CC1A  CC1A  440.000     1.340 
CC1B  CC1B  440.000     1.340 
!13DB, Butadiene 
CC1A  CC2   500.000     1.342 
CC1B  CC2   500.000     1.342 
CC1A  CC1B  300.000     1.470 
!13DP, 1,3-Pentadiene 
CC1B  CT3   383.000     1.504 
!MECH 
CC1A  CT2   365.000     1.502 
CC1A  CT    365.000     1.502 
CC1A  CT3   383.000     1.504 
!TMCH/MECH 
CT   CT2    222.500     1.538    
CT   CT3    222.500     1.538 
!PACP 
CA    NH1   305.000     1.414 
!PRAL 
CC1A  CD    300.000     1.4798 
CD    O     720.000     1.205 
CD    HR1   330.000     1.110 
!PRAC 
CC1A  CC    440.000     1.489 
!CROT 
CC1A  C     440.000     1.489 
!SCH1, Schiff's base model compound 1, deprotonated 
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CT3   NS1   310.000     1.440 
NS1   CC1B  500.000     1.276 
!SCH2, Schiff's base model compound 2, protonated 
HR1   CC1B  360.500     1.100 
CT3   NS2   300.000     1.453 
NS2   CC1B  470.000     1.283 
NS2   HC    455.000     1.000   
!SCK0, deprotonated Schiff's base, lysine retinal patch 
CT2   NS1   310.000     1.440 
!SCK1, , Schiff's base, lysine retinal patch 
CT2   NS2   300.000     1.453 
 
ANGLES 
! 
!atom types     Ktheta    Theta0   Kub     S0 
! 
!BTE2, 2-butene 
CC1A CC1A CT3    48.00     123.50 
HA   CT2  CC1A   45.00     111.50 
HA   CT3  CC1A   42.00     111.50 
HA   CT3  CC1B   42.00     111.50 
HE1  CC1A CC1A   42.00     119.00 
HE1  CC1B CC1B   42.00     119.00 
HE1  CC1A CT3    42.00     117.50 
HE1  CC1B CT3    22.00     117.50 
!13DB, 1,3-Butadiene 
HE1  CC1A CC2    42.00     118.00 
HE1  CC1B CC2    42.00     118.00 
HE2  CC2  CC1A   45.00     120.50  
HE2  CC2  CC1B   45.00     120.50  
HE1  CC1B CC1A   42.00     118.00  
HE1  CC1A CC1B   42.00     118.00  
CC1B CC1A CC2    48.00     123.50  
CC1A CC1B CC2    48.00     123.50  
HE2  CC2  HE2    19.00     119.00  
!13DP, Pentadiene 
CC1A CC1B CC1B   48.00     123.50  
CC1B CC1B CT3    48.00     123.50  
!MECH 
CC1A CT   CT3    32.00     112.20  
CC1A CT   CT2    32.00     112.20  
CC1A CT2  CT2    32.00     112.20  
CC1A CC1A CC1B   48.00     123.50  
CC1A CC1A CT     48.00     123.50  
CC1A CC1A CT2    48.00     123.50  
CC1B CC1A CT     48.00     123.50  
CT2  CC1A CT3    48.00     123.50  
!DMB1, 2-methyl-1,3-butadiene 
CC2  CC1A CT3    48.00     123.50 
CC1B CC1A CT3    48.00     113.00 
!DMP1, 4-methyl-1,3-pentadiene 
CT3  CC1B CT3    47.00     113.00 
!TMCH/MECH 
CT2  CT   CT3    58.35     113.50   11.16   2.561 
CT3  CT   CT3    58.35     113.50   11.16   2.561 
CT   CT2  CT2    58.35     113.50   11.16   2.561 
CT   CT2  HA     26.50     110.10   22.53   2.179 
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CT   CT3  HA     33.43     110.10   22.53   2.179 
CT   CC1A CT3    48.00     123.50 
!PACP 
CA   NH1  C      50.00     120.00  
H    NH1  CA     34.00     117.00  
NH1  CA   CA     40.00     120.00   35.00   2.4162 
!CROT 
CT3  CC1A CT3    47.00     125.20 
CC1A CC1A C      48.00     123.50 
HE1  CC1A C      52.00     119.50 
O    C    CC1A   80.00     122.50 
NH1  C    CC1A   80.00     116.50  
! PROL 
HE1  CC1A CT2    40.00     116.00  
OH1  CT2  CC1A   75.70     110.10  
CT2  CC1A CC2    28.00     126.00 
!PRAL 
CC2  CC1A CD     60.00     120.00 
CC1A CC1A CD     60.00     120.00 
HE1  CC1A CD     32.00     122.00 ! sum=242 
CC1A CD   O      75.00     124.00 
CC1A CD   HR1    15.00     115.00   
O    CD   HR1    75.00     121.00 ! fixed 
!PRAC 
HE1  CC1A CC     52.00     119.50 ! 
CC2  CC1A CC     40.00     119.00   35.00   2.5267 
CC1A CC   OC     40.00     118.00   50.00   2.3880 
CC1A CC1A CC     48.00     123.50 ! 
!SCH1, Schiff's base model compound 1, deprotonated 
CT3  NS1  CC1B   67.00     111.00 
NS1  CC1B CT3    52.00     123.00 !sum=242.5 
NS1  CC1B HE1    38.00     119.50 ! 
HA   CT3  NS1    42.00     113.50 
!SCH2, Schiff's base model compound 2, protonated 
CT3  NS2  CC1B   67.00     123.60 
CT3  NS2  HC     38.00     117.40 
CC1B NS2  HC     38.00     118.80 
NS2  CC1B CT3    40.00     125.60 
NS2  CC1B HR1    38.00     114.00 
CT3  CC1B HR1    42.00     120.40 
HA   CT3  NS2    42.00     110.10 
!SCH3, Schiff's base model compound 3, protonated 
NS2  CC1B CC1A   40.00     125.60 
HR1  CC1B CC1A   42.00     120.40 
!SCK0, deprotonated Schiff's base, lysine retinal patch 
CT2  CT2  NS1    67.70     110.00 !from lysine 
HA   CT2  NS1    42.00     113.50 
CT2  NS1  CC1B   67.00     111.00 
NS1  CC1B CC1A   40.00     123.00 
!SCK1, protonated Schiff's base, lysine retinal patch 
CT2  NS2  CC1B   67.00     123.60 
CT2  NS2  HC     38.00     117.40 
CT2  CT2  NS2    67.70     110.00 !from lysine 
HA   CT2  NS2    42.00     110.10 
 
DIHEDRALS 
! 
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!atom types             Kchi    n   delta 
! 
!BTE2, 2-butene 
HE1  CC1A CC1A HE1      5.2000  2   180.00 
CT3  CC1A CC1A HE1      5.2000  2   180.00 
CT3  CC1B CC1B HE1      5.2000  2   180.00 
CC1A CC1A CT3  HA       0.3000  3     0.00 
HE1  CC1A CT3  HA       0.3000  3     0.00 
HE1  CC1B CT3  HA       0.3000  3     0.00 
CT3  CC1A CC1A CT3     10.0000  2   180.00 !double bond 
CT2  CC1A CC1A CT3     10.0000  2   180.00 !double bond 
!13DB, 1,3-Butadiene 
CC2  CC1A CC1B CC2      0.4000  1   180.00 !  
CC2  CC1A CC1B CC2      0.4000  2   180.00 !  
CC2  CC1A CC1B CC2      1.3000  3     0.00 ! 
CC2  CC1A CC1B HE1      1.0000  2   180.00 ! 
HE1  CC1A CC1B CC2      1.0000  2   180.00 ! 
HE1  CC1A CC1B CC1B     1.0000  2   180.00 ! 
HE2  CC2  CC1A CC1B     5.0000  2   180.00 !double bond 
HE2  CC2  CC1B CC1A     5.0000  2   180.00 !double bond 
HE1  CC1B CC1B CC1A     5.2000  2   180.00 !double bond 
HE1  CC1B CC1A HE1      0.0000  2   180.00 ! 
!HEP3, 1,3,5-heptatriene 
CC1A CC1A CC1B CC2      0.5000  1   180.00 !  
CC1A CC1A CC1B CC2      2.0000  2     0.00 ! 
CC1A CC1A CC1B CC2      1.0000  3     0.00 ! 
CC1A CC1A CC1B CC1B     0.5000  1   180.00 ! 
CC1A CC1A CC1B CC1B     2.0000  2     0.00 ! 
CC1A CC1A CC1B CC1B     1.0000  3     0.00 ! 
CC1A CC1B CC1B CC1A     0.5600  1   180.00 !double bond 
CC1A CC1B CC1B CC1A     7.0000  2   180.00 !double bond 
CC1B CC1A CC1A CC1B     0.5600  1   180.00 !double bond 
CC1B CC1A CC1A CC1B     7.0000  2   180.00 !double bond 
HE1  CC1A CC2  HE2      5.2000  2   180.00 !double bond 
HE1  CC1B CC2  HE2      5.2000  2   180.00 !double bond 
HE1  CC1A CC1A CC1B     1.0000  2   180.00 !double bond 
!13DP, 1,3-Pentadiene 
CC1B CC1B CT3  HA       0.3000  3     0.00 
HE1  CC1B CC1B HE1      0.0000  2   180.00 ! 
CC1A CC1B CC1B CT3      0.5600  1   180.00 !double bond 
CC1A CC1B CC1B CT3      7.0000  2   180.00 !double bond 
CC2  CC1A CC1B CC1B     0.6000  1   180.00 ! also in DMB1, DMP1, DMP2 
CC2  CC1A CC1B CC1B     0.5000  2   180.00 ! comprise values obtained 
CC2  CC1A CC1B CC1B     1.0000  3     0.00 !  
!DMB1, 2-methyl-1,3-butadiene 
CC1B CC1A CT3  HA       0.3000  3   180.00 
CT3  CC1A CC2  HE2      1.0000  2   180.00 
CT3  CC1A CC1B HE1      1.0000  2   180.00 
CT3  CC1A CC1B CC2      1.1000  1   180.00 !see DMP1 
CT3  CC1A CC1B CC2      0.7000  2   180.00 
!DMP1, 4-methyl-1,3-pentadiene, no additional terms versus 13DP 
CT3  CC1B CT3  HA       0.3000  3     0.00 
!DMP2, 2-methyl-1,3-pentadiene 
CT3  CC1A CC1B CC1B     1.1000  1   180.00 !see DMP1 
CT3  CC1A CC1B CC1B     0.7000  2   180.00 
CC2  CC1A CT3  HA       0.3000  3     0.00 
!TMCH 
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CT   CC1A CC1A CT2     10.0000  2   180.00 ! double bond 
CT   CC1A CC1A CT3     10.0000  2   180.00 ! double bond 
CC1A CC1A CT   CT2      0.5000  2     0.00 ! c2-c1-c6=c5 
CC1A CC1A CT   CT2      0.3000  3     0.00 ! c2-c1-c6=c5 
CC1A CC1A CT   CT3      0.5000  2     0.00 ! c16/c17-c1-c6=c5 
CC1A CC1A CT   CT3      0.4000  3     0.00 ! c16/c17-c1-c6=c5 
CC1A CC1A CT2  CT2      0.5000  2     0.00 ! c3-c4-c5=c6 
CC1A CC1A CT2  CT2      0.3000  3     0.00 ! c3-c4-c5=c6 
CT2  CT2  CC1A CT3      0.1900  3     0.00 ! c3-c4-c5-c18 
CT2  CT   CC1A CT3      0.4000  3     0.00 ! c2-c1-c6-c7 
CT3  CT   CC1A CT3      0.4000  3     0.00 ! c16/c17-c1-c6-c7 
CC1A CT2  CT2  CT2      0.1900  3     0.00 ! 
CT2  CT2  CT   CC1A     0.2000  3     0.00 ! 
CT2  CT2  CT   CT3      0.2000  3     0.00 ! 
CT3  CC1A CT2  HA       0.1900  3     0.00 
CC1A CT   CT2  HA       0.1900  3     0.00 
CT3  CT   CT2  HA       0.1900  3     0.00 
CC1A CT2  CT2  HA       0.1900  3     0.00 
CT2  CC1A CT3  HA       0.1600  3     0.00 
CT   CC1A CT3  HA       0.1600  3     0.00 
CT2  CT   CT3  HA       0.1600  3     0.00 
CC1A CT   CT3  HA       0.1600  3     0.00 
CT3  CT   CT3  HA       0.1600  3     0.00 
!MECH  
CT   CC1A CC1B CC2      0.9000  1     0.00 
CT   CC1A CC1B CC2      2.1000  2   180.00 
CT   CC1A CC1B CC2      0.2200  3     0.00 
CT   CC1A CC1B CC2      0.2500  5   180.00 
CT   CC1A CC1B CC2      0.1000  6     0.00 
CT   CC1A CC1B CC1B     0.9000  1     0.00 
CT   CC1A CC1B CC1B     2.1000  2   180.00 
CT   CC1A CC1B CC1B     0.2200  3     0.00 
CT   CC1A CC1B CC1B     0.2500  5   180.00 
CT   CC1A CC1B CC1B     0.1000  6     0.00 
CC1B CC1A CT   CT2      0.3000  3     0.00 
CC1B CC1A CT   CT3      0.3000  3     0.00 
CC1B CC1A CC1A CT2      0.5600  1   180.00 ! double bond 
CC1B CC1A CC1A CT2      7.0000  2   180.00 ! double bond 
CC1B CC1A CC1A CT3      0.5600  1   180.00 ! double bond 
CC1B CC1A CC1A CT3      7.0000  2   180.00 ! double bond 
CT   CC1A CC1B HE1      1.0000  2   180.00 
CC1A CC1A CC1B HE1      1.0000  2   180.00 
!PACP 
O    C    NH1  CA       2.5000  2   180.00 ! 
HP   CA   CA   NH1      4.2000  2   180.00 ! 
CA   CA   CA   NH1      3.1000  2   180.00 ! 
C    NH1  CA   CA       1.2000  2   180.00 ! 
C    NH1  CA   CA       1.0000  3   180.00 ! 
H    NH1  CA   CA       0.5000  2   180.00 ! 
CA   NH1  C    CT3      2.5000  2   180.00 ! 
!CROT 
CT3  CC1A CT3  HA       0.3000  3     0.00 ! 
CC1B CC1A CC1A C        0.5600  1   180.00 !double bond 
CC1B CC1A CC1A C        7.0000  2   180.00 !double bond 
O    C    CC1A CC1A     0.7000  1   180.00 ! 
O    C    CC1A CC1A     1.2000  2   180.00 ! 
O    C    CC1A CC1A     0.1000  3   180.00 ! 
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O    C    CC1A CC1A     0.2000  4     0.00 ! 
NH1  C    CC1A CC1A     0.7000  1     0.00 ! 
NH1  C    CC1A CC1A     1.2000  2   180.00 ! 
NH1  C    CC1A CC1A     0.1000  3     0.00 ! 
NH1  C    CC1A CC1A     0.1500  4     0.00 ! 
HE1  CC1A C    NH1      0.3000  3   180.00 ! 
HE1  CC1A C    O        0.3000  3   180.00 ! 
CC1A C    NH1  H        2.5000  2   180.00 
CC1A C    NH1  CT3      1.6000  1     0.00 
CC1A C    NH1  CT3      2.5000  2   180.00  
CC1A C    NH1  CA       1.6000  1     0.00 !FRET 
CC1A C    NH1  CA       2.5000  2   180.00 !FRET 
C    CC1A CC1A CT3      0.5600  1   180.00 !double bond 
C    CC1A CC1A CT3      7.0000  2   180.00 !double bond 
!PROL  
CC2  CC1A CT2  OH1      1.9000  1   180.00 
CC2  CC1A CT2  OH1      0.4000  2   180.00 
CC2  CC1A CT2  OH1      0.6000  3   180.00 
CC1A CC1A CT2  OH1      1.9000  1   180.00 
CC1A CC1A CT2  OH1      0.4000  2   180.00 
CC1A CC1A CT2  OH1      0.6000  3   180.00 
CC1A CT2  OH1  H        1.3000  1     0.00 
CC1A CT2  OH1  H        0.7000  2     0.00 
CC1A CT2  OH1  H        0.5000  3     0.00 
HE1  CC1A CT2  OH1      0.2000  3     0.00 
HE1  CC1A CT2  HA       0.2000  3     0.00 
CC2  CC1A CT2  HA       0.0300  3     0.00 
CC1A CC1A CT2  HA       0.0300  3     0.00 
HE2  CC2  CC1A CT2      5.2000  2   180.00 
!PRAL 
CC2  CC1A CD   O        1.0000  2  180.00 ! 
CC1A CC1A CD   O        1.0000  2  180.00 ! 
CC2  CC1A CD   HR1      3.2000  2  180.00 
CC1A CC1A CD   HR1      3.2000  2  180.00 
HE1  CC1A CD   O        0.0000  2  180.00 
HE1  CC1A CD   HR1      0.0000  2  180.00 
HE2  CC2  CC1A CD       3.2000  2  180.00  
CT3  CC1A CC1A CD       0.5600  1  180.00 ! double bond 
CT3  CC1A CC1A CD       0.5000  2  180.00 ! db 
CC1B CC1A CC1A CD       0.5600  1  180.00 ! db 
CC1B CC1A CC1A CD       7.0000  2  180.00 ! db 
!PRAC 
CC2  CC1A CC   OC       1.3000  2  180.00 
CC1A CC1A CC   OC       1.3000  2  180.00 
HE2  CC2  CC1A CC       4.2000  2  180.00 
HE1  CC1A CC   OC       0.0000  2  180.00 
CC1B CC1A CC1A CC       0.5600  1  180.00 !double bond 
CC1B CC1A CC1A CC       7.0000  2  180.00 !double bond 
CC   CC1A CC1A CT3      0.5600  1  180.00 !double bond, rtac 
CC   CC1A CC1A CT3      7.0000  2  180.00 !double bond, rtac 
!SCH1, Schiff's base model compound 1, deprotonated 
CT3  NS1  CC1B HE1      8.5000  2   180.00 
CT3  NS1  CC1B CT3     12.0000  2   180.00 
NS1  CC1B CT3  HA       0.1000  3   180.00 
CC1B NS1  CT3  HA       0.3500  3   180.00 
!SCH2, Schiff's base model compound 2, protonated 
CT3  NS2  CC1B HR1      8.5000  2   180.00 
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CT3  NS2  CC1B CT3      7.0000  2   180.00 
NS2  CC1B CT3  HA       0.1500  3   180.00 
HR1  CC1B CT3  HA       0.1500  3     0.00 
CC1B NS2  CT3  HA       0.1500  3   180.00 
HA   CT3  NS2  HC       0.1100  3     0.00 
HC   NS2  CC1B HR1      5.0000  2   180.00 
HC   NS2  CC1B CT3      5.0000  2   180.00 
!SCH3, Schiff's base model compound 3, protonated 
CT3  NS2  CC1B CC1A     7.0000  2   180.00 
HC   NS2  CC1B CC1A     5.0000  2   180.00 
NS2  CC1B CC1A HE1      1.0000  2   180.00 
NS2  CC1B CC1A CC2      0.5000  1     0.00 !opt 
NS2  CC1B CC1A CC2      2.2000  2   180.00 !opt 
NS2  CC1B CC1A CC2      1.1000  3     0.00 !opt 
NS2  CC1B CC1A CC2      0.6000  4     0.00 !opt 
HR1  CC1B CC1A HE1      0.0000  2   180.00 
HR1  CC1B CC1A CC2      1.0000  2   180.00 
!SCK0, deprotonated Schiff's base, lysine retinal patch 
CT2  CT2  NS1  CC1B     0.1000  3     0.00 
CT2  NS1  CC1B CC1A    12.0000  2   180.00 !from CT3  NS1  CC1B CT3 
CT2  NS1  CC1B HE1      8.5000  2   180.00 !from CT3  NS1  CC1B HE1 
HA   CT2  NS1  CC1B     0.1000  3     0.00 
NS1  CC1B CC1A CC1A     0.5000  1     0.00 !from NS2  CC1B CC1A CC2 
NS1  CC1B CC1A CC1A     2.2000  2   180.00 !N=C-C=C dihedral not 
explicitly optimized 
NS1  CC1B CC1A CC1A     1.1000  3     0.00 ! 
NS1  CC1B CC1A CC1A     0.6000  4     0.00 ! 
NS1  CC1B CC1A HE1      1.0000  2   180.00 
!SCK1, Schiff's base, lysine retinal patch 
NS2  CC1B CC1A CC1A     0.5000  1     0.00 !from NS2  CC1B CC1A CC2 
NS2  CC1B CC1A CC1A     2.2000  2   180.00 ! 
NS2  CC1B CC1A CC1A     1.1000  3     0.00 ! 
NS2  CC1B CC1A CC1A     0.6000  4     0.00 ! 
HR1  CC1B CC1A CC1A     1.0000  2   180.00 
CT2  CT2  NS2  CC1B     0.1000  3     0.00 
CT2  NS2  CC1B CC1A     7.0000  2   180.00 
CT2  NS2  CC1B HR1      8.5000  2   180.00 
HA   CT2  NS2  CC1B     0.1000  3     0.00 
CT2  CT2  NS2  HC       0.1000  3     0.00 
HA   CT2  NS2  HC       0.1000  3     0.00 
 
IMPROPER 
!atom types              Kpsi        psi0 
!PRAL 
CD   CC1A O   HR1      14.0000  0     0.00 !  
 
NONBONDED nbxmod  5 atom cdiel shift vatom vdistance vswitch - 
cutnb 14.0 ctofnb 12.0 ctonnb 10.0 eps 1.0 e14fac 1.0 wmin 1.5  
                !adm jr., 5/08/91, suggested cutoff scheme 
! 
!atom  ignored    epsilon      Rmin/2   ignored   eps,1-4       
Rmin/2,1-4 
! 
!Butadiene  
CC1A   0.0   -0.0680     2.0900 ! 
CC1B   0.0   -0.0680     2.0900 ! 
CC2    0.0   -0.0640     2.0800 ! 
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!SCH1, SCH2 
NS1    0.000000  -0.200000     1.850000 !N for deprotonated Schiff's 
base 
NS2    0.000000  -0.200000     1.850000 !N for protonated Schiff's base 
 
end 
 
